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Summary  
The overall aim of these studies was to investigate selected aspects of psychopathology, 
neurobiological abnormalities and treatment in schizophrenia.   
The following topics were researched: 
1. Psychopathology: 
We explored the symptom structure of schizophrenia by means of principal 
components and factor analysis in two separate samples. 
a. The first study investigated the nature of symptoms in patients with a first-episode 
of schizophrenia, in a large cohort of patients who were participating in a 
multinational clinical trial. We compared our findings with similar analyses 
previously conducted in multi-episode schizophrenia patients.  
b. We then assessed the influence of culture on the symptom structure of 
schizophrenia by conducting a principal components and factor analysis of the 
symptom ratings in a large sample of South African Xhosa patients with 
schizophrenia, and comparing the results with those in other parts of the world. 
c. We investigated the occurrence of co-morbid depressive and anxiety symptoms, 
and their demographic and clinical correlates.  The sample for this study 
comprised acutely psychotic patients who were participants in clinical drug trials 
conducted at our centre.  
d. To explore the relationships between obsessive-compulsive disorder and 
schizophrenia, we conducted a review of the relevant literature. 
2. Neurobiological abnormalities: 
a. We performed a series of studies to investigate disorders of water homeostasis 
and vasopressin secretion in schizophrenia. To test the hypothesis that acutely 
psychotic patients have disordered regulation of water homeostasis, we applied a 
dynamic suppression test - a water loading test, with assessment of excretory 
capacity (including arginine vasopressin assay) in acutely psychotic patients. To 
evaluate whether a subset of patients with schizophrenia and co-morbid 
disordered water homeostasis sustained cerebral damage as a consequence of 
water intoxication we did the following experiment:  We identified a cohort of 
subjects with schizophrenia and disordered water homeostasis and compared 
them with patients with schizophrenia without disordered water homeostasis in 
terms of cerebral ventricular size and cognitive function. To assess the 
prevalence of disordered water homeostasis in a long-term inpatient sample of 
psychiatric patients we conducted serum sodium screening tests. Those subjects 
with dilutional hyponatraemia were then further investigated for dysregulation of 
water homeostatic mechanisms. 
b. We studied neurological soft signs in a sample of subjects with first-episode 
schizophrenia followed up over a two year period.  We investigated their 
occurrence, relationships to psychiatric symptoms and medication effects, their 
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temporal stability and their outcome correlates. We also investigated their 
potential to predict outcome in schizophrenia 
3. Treatment aspects 
A great deal of our work has focussed on the pharmacological treatment of schizophrenia. 
The following aspects of treatment are included in this thesis: 
a. Treatment effects on psychiatric symptoms: 
i. To assess the effects of ethnicity on treatment outcome in schizophrenia 
we compared the acute response to antipsychotic treatment in 3 ethnic 
groups, namely blacks, coloureds and whites.  We included patients in 
this analysis who had participated in clinical trials in our department as 
well as the Department of Psychiatry in the University of the Free Sate. 
Patients had been treated under blinded conditions over a 6-week period.  
ii. After discussions with the late Dr David Horrobin, who had pioneered 
possible applications of the omega-3 fatty acids in the treatment of 
various psychiatric disorders, we became interested in further 
investigating the potential of this group of compounds as an affordable 
adjunct to treating schizophrenia. We assessed the antipsychotic 
potential of the omega-3 fatty acid, ethyl-eicosapentaenoic-acid (e-EPA) 
supplementation versus placebo supplementation in a small sample of 
subjects with schizophrenia who had been only partially responsive to 
antipsychotic treatment previously.  We also conducted a review of the 
literature to evaluate the evidence for efficacy for the omega-3 fatty acids 
in schizophrenia according to published studies.    
b. Treatment effects on neurological abnormalities: 
i. In a single-blinded controlled study we compared a new generation 
antipsychotic to a conventional antipsychotic in the treatment of tardive 
dyskinesia (TD).  This was a long-term (1 yr) study in patients with 
chronic schizophrenia and established tardive dyskinesia.   
ii. We also assessed the effect of omega-3 fatty acid (e-EPA) 
supplementation in treating TD. This was conducted in a larger sample 
(n=84) of patients with chronic schizophrenia and established TD. The 
blinded, placebo-controlled phase was 12 weeks. This was followed by 
an open-label extension for 40 weeks. 
c. Conventional versus new generation antipsychotic agents. 
Several evidence-based literature reviews of the efficacy and tolerability of 
the new generation of antipsychotics compared to the conventional agents 
were conducted.  Some multinational, randomised, controlled clinical trials in 
which the author was principal investigator, are included in this thesis. Also, 
studies addressing patients with partial treatment refractoriness are included, 
as well as studies of the effects of antipsychotics on depressive symptoms, 
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body mass and glycaemic control.  Finally, we have included a pharmaco-
economic study comparing a conventional antipsychotic (haloperidol) with a 
new generation antipsychotic (quetiapine) in partially refractory patients in a 
South African setting. 
Findings and conclusions: 
1. Psychopathology: 
Our studies demonstrated that the factor structure for the symptoms of schizophrenia is 
replicable across samples, and is not greatly influenced by ethnic and cultural factors. 
However, changes in the factor structures do occur over time. There are symptom domains 
that are present in first-episode schizophrenia but disappear as a distinct entity as the illness 
becomes chronic.  Particularly, a motor component is evident in untreated patients, but 
disappears after initiation of treatment. We found that depression and anxiety are common 
co-morbid symptoms in schizophrenia, and have important clinical and outcome correlates. 
Depressive symptoms in the acute psychotic phase of schizophrenia are associated with a 
favourable prognosis and diminish as the symptoms of psychosis improve in response to 
antipsychotic treatment. However, persistent depressive symptoms are associated with a 
poorer prognosis, and require additional therapeutic intervention. 
2. Neurobiological abnormalities: 
We investigated the occurrence of disordered water regulation in a population of psychiatric 
inpatients, and conducted further investigations on those identified, in order to establish 
mechanisms involved. Polydipsia and the syndrome of inappropriate antidiuretic hormone 
secretion (SIADH) were found to occur in a subset of patients with schizophrenia, and are 
associated with acute psychosis, as well as with some psychotropic medications. These 
patients are characterised by more severe cognitive impairment and evidence of cerebral 
atrophy. The condition can become life-threatening in the presence of other factors impeding 
water excretion, particularly thiazide diuretics.  
Neurological soft signs were investigated in a sample of patients with a first-episode of 
schizophrenia. These soft signs appear to be trait-like (present early in the illness, and stable 
over time), except for a motor sequencing factor. Patients performing poorly on this latter 
group of tests have a longer duration of untreated psychosis, and are at significant risk for 
developing TD. 
3. Treatment aspects: 
Our studies suggest that there are important ethnic differences in antipsychotic treatment 
response, but that these differences could be explained by a number of environmental and 
biological factors. As was found with many studies worldwide, we found that the new 
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generation antipsychotics have important efficacy and safety advantages over their 
predecessors. Risperidone was as effective as haloperidol in first-episode psychosis, but with 
a more favourable side-effect profile in terms of reduced extrapyramidal symptoms. 
Quetiapine treatment in partially refractory patients resulted in more responders compared to 
haloperidol, and fewer extrapyramidal symptoms. However, evidence of a different side-effect 
profile is emerging. Of particular concern is the finding that some of the new antispychotics 
cause weight gain, glucose intolerance and dyslipidaemias. We found that one novel 
antipsychotic, quetiapine, was not associated with significantly more weight gain or 
disordered glucose metabolism that a conventional agent, haloperidol. The omega-3 fatty 
acids, particularly EPA may have a role in the treatment of various psychiatric disorders. Our 
studies provided mixed results – the first found a significant beneficial effect on psychotic 
symptoms and dyskinesia scores for EPA supplementation, while the second failed to 
demonstrate a beneficial effect on TD or psychotic symptoms. We explored the early 
treatment response in first-episode psychosis and found, unlike that reported in multi-episode 
patients, some patients took a long time to respond. We also found that early treatment 
response was a significant predictor of later remission, as was duration of untreated 
psychosis, educational level and baseline excitement factor scores.  Finally, our 
pharmacoeconomic study conducted for South African circumstances in patients with a partial 
response to conventional antipsychotic treatment showed cost-neutrality or cost-benefits for 
quetiapine compared with haloperidol treatment for direct costs.  
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Opsomming  
Die oorkoepelende doel van hierdie studies was om geselekteerde aspekte van 
psigopatologie, neurobiologiese abnormaliteite en behandeling in skisofrenie te ondersoek. 
Die volgende onderwerpe is nagevors: 
4. Psigopatologie: 
 Ons het die simptoomstruktuur van skisofrenie ondersoek deur middel van 
hoofkomponent- en faktoranalise in twee aparte steekproewe. 
a. Die eerste studie het die aard van simptome in pasiënte, met ŉ eerste-episode 
van skisofrenie, ondersoek in ŉ groot kohort van pasiënte wat deelgeneem het 
aan ŉ multi-nasionale kliniese proefneming. Ons het ons bevindinge vergelyk met 
soortgelyke analises wat voorheen gedoen is in multi-eposode skisofrenie 
pasiënte. 
b. Hierna het ons die invloed van kultuur op die simptoom struktuur van skisofrenie 
geassesseer deur ŉ hoofkomponent- en faktoranalise van die simptoomtellings 
uit te voer in ŉ groot steekproef van Suid-Afrikaanse Xhosa pasiënte met 
skisofrenie en die resultate te vergelyk met bevindinge in ander dele van die 
wêreld. 
c. Ons het die voorkoms van ko-morbiede depressiewe en angssimptome 
ondersoek, asook hul demografiese en kliniese korrelate. Die steekproef vir 
hierdie studie het bestaan uit akute psigotiese pasiënte wat deelnemers was in ŉ 
kliniese geneesmiddel proef wat uitgevoer is by ons sentrum. 
d. Om die verband tussen obsessief-kompulsiewe steurnis en skisofrenie te verken, 
het ons ŉ oorsig van die relevante literatuur gedoen. 
5. Neurobiologiese abnormaliteite: 
a. Ons het ŉ reeks studies uitgevoer om steurnisse in water homeostase en 
vasopressien sekresie in skisofrenie te ondersoek. Om die hipotese dat akute 
psigotiese pasiënte versteurde regulering van water homeostase het te 
ondersoek, het ons ŉ dinamiese onderdrukkingstoets toegepas – ŉ water 
ladingstoets, met assessering van ekskresiekapasiteit (insluitend arginien 
vasopressien essai) in akute psigotiese pasiënte. Om te evalueer of ŉ 
onderafdeling van skisofrenie pasiënte met ko-morbiede versteurde water 
homeostase serebrale skade opgedoen het as gevolg van water intoksikasie, het 
ons die volgende eksperiment uitgevoer: Ons het ŉ kohort deelnemers met 
skisofrenie en versteurde water homeostase geïdentifiseer en hulle vergelyk met 
skisofrenie pasiënte sonder versteurde water homeostase in terme van serebrale 
ventrikulêre grootte en kognitiewe funksionering. Om die voorkoms van 
versteurde water homeostase in ŉ langtermyn binne-pasiënt steekproef van 
psigiatriese pasiënte te bepaal, het ons serum natrium siftingstoetse uitgevoer. 
Deelnemers met hiponatremie is hierna verder ondersoek vir disregulering van 
water homeostatiese meganismes. 
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b. Ons het neurologiese sagte tekens in ŉ steekproef van deelnemers met eerste-
episode skisofrenie bestudeer en opgevolg oor ŉ twee jaar tydperk. Ons het hulle 
voorkoms, verwantskappe met psigiatriese simptome en medikasie effekte, hulle 
temporale stabiliteit en hul uitkoms korrelate ondersoek. Ons het ook hulle 
potensiaal om die uitkoms in skisofrenie te voorspel, ondersoek. 
 
6. Behandelings aspekte 
ŉ Groot meerderheid van ons werk het gefokus op die farmakologiese behandeling van 
skisofrenie. Die volgende aspekte van behandeling is ingesluit in hierdie tesis: 
a. Behandelingseffekte op psigiatriese simptome: 
i. Om die effek van etnisiteit op behandelingsuitkoms in skisofrenie te 
assesseer, het ons die akute respons op anti-psigotiese behandeling in 3 
etniese groepe vergelyk, naamlik swart, gekleurd, en wit. Ons het 
pasiënte wat deelgeneem het aan kliniese proefnemings in ons 
departement sowel as die Departement Psigiatrie van die Universiteit van 
die Vrystaan ingesluit in hierdie analise. Pasiënte is behadel onder 
geblinde toestande oor ŉ tydperk van 6 weke. 
ii. Na besprekings met wyle Dr David Horrobin, wie die moontlike 
toepassings van omega-3 vetsure in die behandeling van verskeie 
psigiatreise steurnisse gepionier het, het ons begin belangstel in verdere 
ondersoek na die potensiaal van hierdie groep samestellings as ŉ 
bekostigbare toevoeging in die behandeling van skisofrenie. Ons het die 
anti-psigotiese potensiaal van die omega-3 vetsuur, etiel-
eikosapentanoësuur (e-EPA) supplementasie versus plasebo 
supplementasie ondersoek in ŉ klein steekproef van deelnemers met 
skisofrenie wat slegs gedeeltelik responsief was op anti-psigotiese 
behandeling in die verlede. Ons het ook ŉ literatuuroorsig gedoen om die 
bewyse vir die effektiwiteit vir die omega-3 vetsure in skisofrenie te 
evalueer volgens gepubliseerde studies. 
b. Behandelingseffekte op neurologiese abnormaliteite: 
i. In ŉ enkelblinde kontrole studie het ons ŉ nuwe generasie anti-psigotiese 
medikasie vergelyk met ŉ konvensionele anti-psigotiese medikasie in die 
behandeling van tardiewe diskinesie (TD). Hierdie was ŉ langtermyn (1-
jaar) studie in pasiënte met chroniese skisofrenie en vasgestelde TD. 
ii. Ons het ook die effek van omega-3 vetsuur (e-EPA) suplementasie 
geassesseer in die behandeling van TD. Dit was gedoen in ŉ groter 
steekproef (n=84) van pasiënte met chroniese skisofrenie en vasgestelde 
TD. Die blinde, placebo kontrole fase was 12 weke. Dit is gevolg deur ŉ 
nie-geblinde ekstensie vir 40 weke. 
c. Konvensionele versus nuwe generasie anti-psigotiese agente.  
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Verskeie bewys-gebaseerde literatuuroorsigte oor die effektiwiteit en 
toleransie van die nuwe generasie anti-psigotiese agente in vergelyking met 
die konvensionele agente, is gedoen. Sommige multi-nasionale, ewekansige, 
kontole kliniese proefnemings waarin die outeur die hoofnavorser was, is 
ingesluit in hierdie tesis. Verder, studies wat die pasiënte met gedeeltelike 
behandelingsweerstandigheid aanspreek, is ingesluit, sowel as studies oor 
die effekte van anti-psigotiese agente op depressiewe simptome, 
liggaamsmassa en glisemiese kontrole. Laastens, het ons a farmako-
ekonomiese studie ingesluit wat die konvensionele anti-psigotiese 
behandeling (haloperidol) met ŉ nuwe generasie anti-psigotiese behandeling 
(quetiapien) in gedeeltelik weerstandige pasiënte in ŉ Suid-Afrikaanse ligging 
vergelyk. 
Bevindinge en gevolgtrekkings: 
4. Psigopatologie: 
Ons studies het gedemonstreer dat die faktor struktuur vir die simptome van skisofrenie 
herhaalbaar is oor steekproewe, en dat dit nie grootliks beïnvloed word deur etnisiteit en 
kulturele faktore nie. Veranderinge vind egter in die faktor strukture wel plaas met verloop van 
tyd. Daar is simptoom domeine wat teenwoordig is in eerste-episode skisofrenie, maar 
verdwyn as ŉ afsonderlike entiteit soos wat die toestand chronies word. Spesifiek, ŉ 
motoriese komponent is duidelik in onbehandelde pasiënte, maar verdwyn na die aanvang 
van behandeling. Ons het gevind dat depressie en angs algemene ko-morbiede simptome in 
skisofrenie is en het belangrike kliniese en uitkoms korrelate. Depressiewe simptome in die 
akute psigotiese fase van skisofrenie word geassosieer met ŉ gunstige prognose en 
verminder soos wat die simptome van psigose verbeter in repons op anti-psigotiese 
behandeling. Egter, volgehoue depressiewe simptome word geassosieer met ŉ swakker 
prognose en benodig addisionele terepeutiese intervensie. 
5. Neurobiologiese abnormaliteite: 
Ons het die voorkoms van versteurde water regulering ondersoek in ŉ populasie van 
psigiatriese binne-pasiënte en verdere ondersoek ingestel op dié wie geïdentifiseer is, om die 
betrokke meganismes vas te stel. Polidipsie en en die sindroom van onvoldoende anti-
diuretiese hormoon sekresie (SIADH) is gevind om voor te kom in ŉ onderafdeling van 
pasiënte met skisofrenie, en word geassosieer met akute psigose sowel as met somige 
psigotropiese medikasie. Hierdie pasiënte word gekenmerk deur meer ernstige kognitiewe 
beperking en bewyse van serebrale atrofie. Die toestand kan lewensbedreigend raak in die 
teenwoordigheid van ander faktore wat water ekskresie hinder, veral tiasied diuretikums. 
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Neurologiese sagte tekens is ondersoek in ŉ steekproef van pasiënte met eerste-episode 
skisofrenie. Hierdie sagte tekens blyk om kenmerkend (teenwoordig vroeg in die siekte, en 
stabiel oor tyd) te wees, behalwe vir ŉ motoriese volgorde faktor. Pasiënte wat swak vaar op 
die laasgenoemde groep toetse, het ŉ langer durasie van onbehandelde psigose, en het ŉ 
beduidende risko om TD te ontwikkel. 
6. Behandeling aspekte: 
Ons studies stel voor dat daar ŉ belangrigke etniese verskil is in anti-psigotiese 
behandelingsrespons, maar dat hierdie verskille verduidelik kan word deur ŉ aantal 
omgewings- en biologiese faktore. Soos wat gevind was vir verskeie studies wêreldwyd, het 
ons gevind dat die nuwe generasie anti-psigotiese agente belangrike effektiwiteit- en 
veiligheidsvoordele het bo hulle voorgangers. Risperidoon was net so effektief as haloperidol 
in eerste-episode psigose, maar met ŉ meer gunstige newe-effkte profiel in terme van 
verminderde ekstrapirimidale simptome. Quetiapien behandeling in veral refraktêre  pasiënte 
het gelei tot meer respondeerders vergeleke met haloperidol, en minder ekstra pirimidale 
simptome. Alhoewel, bewyse van ŉ verskillende newe-effekte profiel is besig om na vore te 
kom. Van spesifieke belang is die bevinding dat sommige van die nuwe anti-psigotiese 
agente gewigstoename, glukose intoleransie en dyslipidemie  veroorsaak. Ons het gevind dat 
een nuwe anti-psigotiese agent, quetiapien, nie geassosieer was met enige beduidende meer 
gewigstoename of versteurde glukose metabolisme as ŉ konvensionele agent, haloperidol, 
nie. Die omega-3 vetsure, spesifiek EPA mag moontlik ŉ rol in die behandeling van verskeie 
psigiatriese versteurings hê. Ons studies het gemengde resultate voorsien – die eerste het ŉ 
beduidende voordelige effek op psigotiese simptome en diskinesie tellings vir EPA 
supplementasie gevind, terwyl die tweede nie ŉ voordelige effek op TD of psigotiese 
simptome gevind het nie. Ons het die vroeë behandelingsrespons ondersoek in eerste-
episode pasiënte en het gevind, in teenstelling met dit wat gerapporteer word in multi-episode 
pasiënte, dat sommige pasiënte ŉ lang tyd geneem het om te reaggeer. Ons het ook gevind 
dat vroeë behandelingsrespons ŉ beduidende voorspeller was van latere remissie, so ook die 
durasie van onbehandelde psigose, opvoedingspeil, en basisvlak opwindings-faktor tellings. 
Laastens het ons farma-ekonomiese studie, wat uitgevoer is vir Suid-Afrikaanse 
omstandighede in pasiënte met ŉ gedeeltelike repons op konvensionele anti-psigotiese 
behandeling, koste-neutraliteit of koste-voordele aangetoon vir quetiapien vergeleke met 
haloperidol behandeling vir direkte onkostes. 
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Foreword 
This thesis comprises a collection of published studies that were conducted in patients with 
schizophrenia over the past 20 years. These studies focus on three major aspects of the 
illness, namely psychopathology, neurobiology and psychopharmacology. As a clinician-
researcher, all of the work has a strong clinical focus. I have only included studies in which I 
was the principal author.  Research in the field of schizophrenia, as is the case in most other 
areas, requires considerable collaboration. Almost all of my work has involved collaborations 
with various co-workers.  
 
Choosing schizophrenia as the subject of my research was not a difficult task. Being one of 
the major remaining challenges facing medical science, its peculiar complex of symptoms has 
fascinated and puzzled scientists for many years. There remain many unanswered 
fundamental questions regarding the illness. For example, no really plausible hypothesis has 
been forthcoming as to why the illness first overtly manifests itself around about late 
adolescence or early adulthood.  Also, no clearly defined anatomical or functional unit has 
been identified that can adequately explain the simultaneous occurrence of the apparently 
diverse symptoms that we have come to recognise as the psychopathology of schizophrenia.  
For example, how is emotional blunting linked to active auditory hallucinations, catatonic 
features and disorders of inferential thinking?  While some elegant hypotheses have been 
proposed (for example, "cognitive dysmetria" as consequence of a dysfunction in cortical-
subcortical-cerebellar circuitry [Andreasen et al., 1998] or psychosis as a state of aberrant 
salience [Kapur, 2003]) none have gained general acceptance.  Psychiatric disorders are an 
increasing part of the global health burden, and now rate as one of the largest causes of lost 
years of quality of life (Sadik, 1992).  Schizophrenia forms a significant part of this burden, 
being ranked the 9th most important cause of disability in the world (Murray & Lopez, 1997), 
and the most costly illness that psychiatrists treat (Andreasen, 1991). The illness imposes a 
disproportionately large emotional and economic burden on patients and their families, health 
care systems and society, because of its early onset, devastating effects, and usually chronic 
and unremitting course (Glazer and Johnstone, 1997). It has been referred to as youth’s 
greatest disabler, and has even been described as arguably the worst disease afflicting 
humankind (Aronson, 1997). 
 
To make matters worse, patients with schizophrenia have been stigmatised, marginalised and 
discriminated against possibly more than any persons, with or without illness. Throughout 
history misconceptions regarding the illness have prevailed. Sadly, many of these 
misconceptions are still widely prevalent today.  A lack of public awareness, as well as 
inadequate treatment and care facilities have resulted in the marginalisation of vast numbers 
of patients with schizophrenia. The costs both in terms of the economic burden and human 
suffering are staggering. Eighty percent of patients with schizophrenia are unemployed, 50% 
seriously contemplate suicide, and 10% successfully complete suicide (Weiden et al, 1996).   
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Direct (e.g. medication, hospitalisation) and indirect costs (eg. loss of earnings, time taken up 
by care-givers) are enormous, and in South Africa probably amount to billions of rands each 
year.  
 
The assessment and management of schizophrenia has undergone important new 
developments, with the emergence of enhanced diagnostic precision and more effective and 
better tolerated treatment options. Technological developments over the past decade and 
more have enabled us to study aspects of schizophrenia in more detail, and in a more 
sophisticated manner than previously. These developments have raised hopes for an 
improved outcome, including fewer residual symptoms, reduced functional impairment, better 
quality of life and reduced emotional distress for patients and their families.  Hopefully, 
important breakthroughs are just around the corner. 
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Abstract 
 
The PANSS is a widely used instrument for measuring severe psychopathology in 
adult patients with schizophrenia.  Data, primarily on chronic patients, have been used to 
define factors for the PANSS.   The present study examines the PANSS factor structure in a 
large sample of subjects with recent onset schizophrenia, schizophreniform disorder and 
schizo-affective disorder who had been exposed to very limited antipsychotic medication.   
Equamax factor analysis was conducted on PANSS baseline assessments from a 
multicenter, 11 country drug trial that enrolled 535 patients.   The forced five-factor solution 
essentially corresponds to the factors most frequently described previously, namely negative, 
positive, disorganized (or cognitive), excited and anxiety/depression.  In the exploratory 
analysis a seven-factor solution was obtained, with depression and anxiety symptoms 
separating and a motor component emerging.  The results of this study partially support the 
use of a five factor model for the PANSS, but suggest that scales for catatonia, depressive 
and anxiety syndromes should be included in future studies.   
 
1. Introduction 
 
Numerous attempts have been made to elucidate the complexities of schizophrenia by 
exploring relationships between its various symptoms.  The diversity of these symptoms has 
been difficult to explain, and has led to the proposal of pathophysiological heterogeneity as a 
conceptual model for the disorder (Buchanan and Carpenter, 1994).  A landmark change in 
our thinking entailed replacing the classical subtypes of schizophrenia with the division of 
symptoms into positive and negative components.  Although this distinction had long been 
considered (Reynolds, 1896; Jackson, 1931), it was only relatively recently that attention 
focussed on these two components as possibly representing separate pathological processes 
in schizophrenia. Strauss, Carpenter and Bartko (1974) described positive, or productive 
symptoms and negative, or deficit symptoms.  Based on this model, Crow (1980) 
hypothesised that the positive and negative symptoms represent different subtypes of 
schizophrenia, the former reflecting a hyperdopaminergic state, and the latter a consequence 
of structural brain-deficit.   
 
In order to investigate this distinction empirically, methods of phenomenologic description 
and nosologic categorisation were required. The Scale for the Assessment of Negative 
Symptoms (SANS), and the Scale for the Assessment of Positive Symptoms (SAPS), were 
developed according to Crow’s concept at the time, attempting to group all of the symptoms 
into positive and negative categories (Andreasen, 1983; Andreasen, 1984).  While the original 
factor analysis of the SANS and SAPS appeared to support the validity of the positive and 
negative dichotomy, most subsequent studies called the two-dimensional model into question, 
preferentially yielding a three-factor structure. These factors comprise a negative symptom 
factor and two positive symptom factors - a “psychosis” dimension and a “disorganisation” 
dimension (Andreasen and Olsen, 1982; Andreasen and Grove, 1986; Moscarelli et al., 1987; 
Liddle, 1987; Arndt et al., 1991; Miller et al., 1993; Bilder et al., 1985; Kulhara et al., 1986; 
Lenzenweger et al., 1989; Schuldberg et al., 1990; Gur et al., 1991; Minas et al., 1992; Brown 
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et al., 1992; Peralta et al., 1992).  Andreasen et al. (1995) summarised the results of the 
published factor analytic studies for the SANS and SAPS, noting strong similarities in the 
findings. These similarities were all the more striking considering that they included patients 
meeting various diagnostic criteria, at different stages of the illness, and with varying 
medication status. In addition, samples were often small and a variety of statistical techniques 
were employed. These factors have also been found to be stable over the course of time 
(Arndt et al, 1995), and to be resistant to cultural influences (Emsley et al, 2000). 
 
The Positive and Negative Syndrome Scale (PANSS) was later developed in an attempt 
to provide a more comprehensive assessment of the symptoms of schizophrenia  (Kay, 
Fisbein and Opler, 1987; Kay, Opler and Lindenmayer, 1988; Kay, Opler and Lindenmayer, 
1989). The scale comprises 30 items, and was designed to assess three main domains: the 
positive subscale (7 items), the negative subscale (7 items) and the general psychopathology 
subscale (14 items). The scale includes all of the items from the BPRS (Brief Psychiatric 
Rating Scale) (Overall and Gorham, 1988) and select items from the Psychopathology Rating 
Scale (Singh and  Kay, 1987) The PANSS is widely used in clinical and research settings, 
and is regarded as a reliable means of symptom assessment (Bell, et al 1992; Muller, et al 
1998).  To assess the factorial validity of the PANSS, the authors conducted a principal 
component analysis with equamax rotation on 240 schizophrenic inpatients (Kay and Sevy, 
1990). The two main components to emerge were the negative and positive syndromes. 
These two factors were very robust, with eigenvalues of 7.08 and 3.74 respectively, and 
together accounted for 36.1% of the total variance. They also found five additional 
components of significance: excitement, depression, cognitive dysfunction, 
suspiciousness/persecution, and stereotyped thinking. Of the 7 components, the first four had 
eigenvalues > 2 and explained 52.3% of the total variance. They were clearly distinct, and 
statistically unrelated. Also, these 4 components embraced 5 or more items each, while the 
other 3 components together had only 5 items. For these reasons, they decided to retain only 
the first 4 components.  However, subsequent studies (Lepine et al, 1989; Dolfus et al, 1991; 
Lindstrom and von Knorring, 1993; Bell et al, 1994; Lindenmeyer et al, 1994; Kawasaki et al, 
1994; Lindenmeyer et al, 1995; Marder et al, 1997; White et al, 1997; Lancon et al, 1998; 
Lancon et al, 1999; Lancon et al, 2000; Lykouras et al, 2000; Mass et al, 2000; Wolthaus et al 
2000), as well as a re-analysis of the original sample of Kay and Savy  (Lindenmeyer et al, 
1995) overwhelmingly favoured a five-factor solution – i.e. negative, positive, disorganised (or 
cognitive), excited and depression/anxiety factors. As was the case with the SANS and 
SAPS, the PANSS factor structure does not appear to be affected by age, severity of 
symptoms, chronicity of illness (White et al, 1997), or by short-term medication withdrawal 
(Lindenmayer et al, 1995). However, all but one (Wolthaus et al 2000) of the published 
analyses were conducted in subjects who were mostly medicated and in a chronic phase of 
the illness. The present study examines the PANSS factor structure in a large sample of 
subjects with recent-onset schizophrenia, schizophreniform disorder and schizo-affective 
disorder who had been exposed to very limited antipsychotic medication, and compares the 
results with previously published studies. 
 
Methods 
The RIS-INT-35 is a randomized, double-blind, multicenter, international trial comparing 
the effect of treatment with risperidone or haloperidol on the long-term outcome of early 
psychotic patients. Subjects are receiving trial medication for at least one year and are 
followed-up for a minimum of two and a maximum of four years.  The key inclusion criteria 
were: aged < 45 years, having a DSM-IV diagnosis of schizophrenia, schizophreniform 
disorder or schizoaffective disorder for at most 12 months, having had a maximum of two life-
time psychiatric hospitalizations for psychosis, having persistent current psychotic symptoms 
requiring long-term neuroleptic treatment, and having had 12 weeks or less of cumulative 
lifetime exposure to neuroleptic medications.  
 
Recruitment started in November 1996 and ended in December 1999. The study is being 
conducted according to Good Clinical Practice.  Investigators (N=49) underwent training and 
inter-rater reliability testing at an investigator meeting prior to the start of the study, and 
further training was provided at follow-up meetings.  Before enrolling patients into the study, 
raters were trained to administer the PANSS and achieved an inter-rater reliability of 0.80 or 
greater. Blinded follow-up of the remaining subjects in the trial is still ongoing. This article 
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presents (blinded for treatment) baseline data. The total study sample includes randomized 
subjects from 11 countries.   Approval was obtained from Institutional Review Boards, and 
subjects provided informed, written consent to participate in the study.  
 
2.1  Sample 
The sample comprised 535 subjects (380 men and 155 women) after excluding two 
persons who left the trial before treatment but after randomisation, and 21 patients from a 
centre removed from the trial in the early stages of the trial due to inconsistent data reporting. 
The mean (±SD) age was 26.0 ( ± 6.9) yrs, and duration of illness  435.1 (±1136) days.  The 
sample was composed of patients assigned the following diagnoses: schizophrenia (n=270), 
schizophreniform disorder (n=243) and schizoaffective disorder (n=43).   Thirty-one percent 
(n=167) had no previous exposure to antipsychotic medication.  Most patients were 
Caucasian (n=400) and the rest Black (n=40), Hispanic (n=17), Oriental (n=11) or members of 
other groups (n=43).    
 
 
2.2  Statistical analysis  
 A principal components factor analysis using equamax rotation was performed.  The 
equamax rotation was chosen to be consistent with many previous studies of the PANSS.  
The first round of analysis did not limit the number of factors.  A second round limited the 
number of factors to five. Items were allocated to factors according to their highest loading. 
Internal consistency for each of the components was determined by calculating Cronbach’s 
alpha coefficients (Cronbach, 1951). A further five-factor analysis was performed on the 167 
subjects who had never been exposed to antipsychotic medication. 
 
3.  Results 
 
The mean (±SD) PANSS scores for the sample were as follows: PANSS total 82.5 
(±20.2); PANSS positive subscale 20.3 (± 6.2); PANSS negative subscale 21.5 (±7.1); and 
PANSS general psychopathology subscale 40.7 (±10.5).   In two cases the PANSS was not 
completed thus results are presented on 533 persons.   Table 1 presents the results of the 
rotated principal component matrix with the factor loadings for the analysis limited to five 
factors for the 533 subjects.  Descriptive names have been assigned to each of the factors.  
Our factor loadings are compared with those of other published studies in Table 2.  While 
many items have strong loadings and are consistently related to a particular factor across 
studies, others are less specific, loading with more than one factor in the same analysis, or 
loading with different factors in different studies. The following items are inconsistently 
associated with specific factors. In the negative factor: disturbance of volition (G13); in the 
disorganized factor: stereotyped thinking (N7), mannerisms (G5), preoccupation (G15); in the 
positive factor: suspiciousness (P6); and in the depressive/anxiety factor: somatic concern 
(G1), and tension (G4).  We repeated the forced five-factor analysis after removing these 
items in order to examine whether their exclusion affected the specificity of the PANSS 
factors. Alpha values and percentage variance were almost identical to what they had been 
when these variables were included in the analysis, these results are as follows: Negative 
factor 0.88 and 17.1%; disorganized factor 0.72 and 11.5%; positive factor 0.75 and 11.4%; 
excited factor 0.71 and 10.7%; and anxiety/depression factor 0.64 and 8.7%.  
 
The five-factor analysis for the 167 neuroleptic-naïve subjects produced a solution similar 
to the entire sample that explained 53.7% of the total variance and identified the following 
factors: Negative factor: N4, N2, N1, N3, N6, G16 and G7 (alpha= .87 , % variance 14.6); 
disorganized factor: G11, P2, N5, G10, G15, N7 and G13 (alpha=.79, % variance=11.8); 
excited factor: P7, P4, G14, G8 and G1 (alpha=.68  ,% variance=9.4%); positive factor: P1, 
G9, P5, P6 and P3 (alpha=.70  , % variance= 9.1); and anxiety/depression: G2, G4, G3, G6, 
G12 and G5 (alpha=.66  ,% variance=8.8). 
 
     Table 3 presents the results of the exploratory factor analysis for the entire sample.  The 7 
components shown had eigenvalues greater than unity, and accounted for 61.7% of the 
variance. The forced five-factor solution essentially corresponds to the five factors most 
frequently described previously, namely negative, positive, disorganized (or cognitive), 
excited and anxiety/depression.  However, in the exploratory seven-factor solution depression 
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and anxiety symptoms have separated, and a motor component has emerged.  
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 4   Discussion 
 
The forced five-factor solution provides an adequate model insofar as it accounts for 
54.7% of the total variance, and the internal consistency for each factor is good, with the 
exception of the depression/anxiety component, which is modest. As shown in Table 4, most 
published studies favour a five-factor solution. The factors identified in our study are 
essentially the same as those described in the majority of other studies, namely negative, 
positive, disorganized (or cognitive), excited and depression/anxiety.  As was the case in the 
majority of the chronic schizophrenia samples, we found that the negative factor was the most 
robust, accounting for 15.4% of the total variance. This was somewhat surprising, considering 
that negative symptoms, although present, are less prominent in first-episode schizophrenia 
than in chronic samples (Mayerhof et al, 1994; Emsley et al, 1999). The disorganized and 
positive dimensions formed the second and third factors respectively. Once again this 
corresponds with the findings in the majority of chronic schizophrenia samples where the 
negative, positive and disorganized components accounted for most of the variance. These 3 
factors also match the 3 factors identified by the SANS and SAPS global item analyses.   
 
While 14 of the 16 reported PANSS factor analytical studies (Table 4) reported a five-
factor solution, the criteria used to select the number of factors differed from study to study, 
and in fact 4 of the studies only reported a forced five-factor model (Marder et al, 1997; 
Lancon et al, 1998; Lancon et al, 1999; Lancon et al, 2000).  Other studies, using the 
conventional method of selecting factors with eigenvalues > 1, actually obtained more than 5 
factors, and then discarded the additional factors for various reasons (Lindstrom and von 
Knorring, 1993 Bell et al, 1994 Kawasaki et al, 1994 Lykouras et al, 2000). Thus, the choice 
of the number of factors is arbitrary, and the apparent uniformity of the findings somewhat 
misleading.  Some PANSS items do not appear to contribute significantly to the symptom 
structure of schizophrenia.  Exclusion of the less specific items (P6, N7, G1, G4, G5, G13, 
and G15) does not substantially affect alpha values and percentage variance of the five 
factors, indicating that omission of these items in future studies is not likely to significantly 
alter the PANSS factor structure.  
 
 The seven factors with eigenvalues greater than unity that were obtained from the 
exploratory factor analysis are of considerable interest. The emergence of a motor component 
was unanticipated, and to our knowledge, has not been described in previous PANSS factor 
analytical studies. Although comprising only two items, with an internal consistency of 0.55, it 
accounts for 7.6% of the total variance. The items making up this factor, mannerisms and 
posturing (G5) and motor retardation (G7) are characteristic of catatonic symptoms. Although 
once thought to have dramatically decreased in prevalence (Magrinat et al, 1983), catatonic 
symptoms are now recognized with increasing frequency in clinical practice (Johnson, 1993). 
The decline in catatonic symptoms is likely to have been related to the advent of antipsychotic 
agents – either as part of the response to treatment, or alternatively due to extrapyramidal 
side-effects masking these symptoms. This would explain why previous PANSS factor 
analyses did not identify a catatonic or motor component, as they were conducted largely in 
medicated samples. 
 
Motor symptoms have been well documented in neuroleptic-naïve patients with first-
episode schizophrenia (Puri et al, 1999), as well as in elderly never-medicated subjects with 
schizophrenia (McCreadie et al, 1996), suggesting that these symptoms are an integral part 
of the illness, rather than just medication side-effects. In previous PANSS factor analyses 
conducted in medicated and chronic samples, catatonic items loaded with either the negative 
or disorganized factor (Table2). In the only other PANSS factor analysis of a first-episode 
psychosis sample (Wolthaus et al, 2000), the motor retardation item (G7) loaded with the 
negative factor, while the mannerisms and posturing item (G5) was excluded because it did 
not load by ≥0.50 on any of the components. However, other studies using rating scales 
covering a broader range of symptoms have reported a catatonic factor (Andreasen and 
Olsen, 1982; Kitamura et al, 1995; McGorry et al, 1998). Indeed, a recent article examining 
the complexities of the symptom structure of schizophrenia argues for the inclusion of 
catatonia as an additional symptom dimension (Peralta and Cuesta, 2001(a)), and a set of 
empirical diagnostic criteria for catatonia have been proposed (Peralta and Cuesta, 2001(b)). 
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The other finding of interest with the 7-factor solution was that depressive and anxiety 
symptoms separated into ‘purer’ components. Depression and anxiety symptoms loaded as a 
single factor in the original PANSS analysis of Kay and Sevy (1991), as well as in the majority 
of subsequent studies. However separate anxiety and depression factors were also reported 
by Peralta and Cuesta (1994) when they reported an 8 factor solution, and Dollfus et al (1991) 
found an anxiety factor without a depressive factor. It is not clear how clinically meaningful 
this separation of anxiety and depression items is. Depressive symptoms are common in first-
episode schizophrenia (Koreen et al, 1993; Emsley et al, 1999) and when present, are usually 
associated with a full depressive syndrome (Barnes et al, 1989). There is considerable 
evidence that depression may in fact be a core feature of the illness (Koreen et al, 1993). 
Anxiety symptoms are also frequently encountered. There are many possible explanations for 
symptoms of depression and anxiety in schizophrenia, including the following: Response to 
adverse life events (e.g. involuntary hospitalisation, unemployment, broken relationships); 
reaction to terrifying psychotic experiences; substance intoxication or withdrawal; neuroleptic-
induced (either directly, e.g. akathisia, or indirectly e.g. in reaction to the distressing 
experience of developing acute dystonia); or co-morbid major depression or anxiety disorders 
(Emsley et al, 2001).  
Interpretation of our findings is subject to certain limitations.  The sample was selected 
according to specific criteria for a randomised clinical trial, and may not accurately represent 
subjects encountered in clinical practice.  Further, many subjects had been exposed to small 
quantities of antipsychotics, so that the sample cannot be regarded as medication-naïve. 
Also, because of the large number of sites, many investigators were involved in PANSS 
assessments, subjects differed widely in terms of language and culture, and the different 
versions of the PANSS were not validated. Finally, the inherent limitations of factor-analysis 
(Peralta and Cuesta, 2001a) need to be kept in mind. 
 
The symptom structure of schizophrenia and other psychoses appears to be more 
influenced by the measurement instrument than any other factor (Peralta and Cuesta, 2001a). 
Also, many studies are flawed by research designs orientated towards confirmation rather 
than exploration ((McGorry et al, 1998). Finally, the symptom domains of schizophrenia and 
other psychoses that have been described so far have yet to be externally validated by 
means of neurobiological and other strategies. Our results suggest that future assessments of 
symptom domains in schizophrenia should, in addition to the PANSS, include an assessment 
scale for catatonic symptoms, as well as instruments to identify specific anxiety and 
depressive syndromes.  
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Table1.  Factors and factor loadings (the factor on which each item had its highest loading) of 
PANNS items for 533 subjects, for the forced five factor solution using the equamax method. 
 
 
Factor and Items Variable Factor Loadings 
1: Negative  Alpha=.89  
Passive social withdrawal   N4 .80 
Emotional withdrawal      N2 .78 
Blunted Affect        N1 .74 
Lack of spontaneity N6 .71 
Poor rapport N3 .69 
Active social avoidance G16 .67 
Motor retardation G7 .62 
Disturbance of Volition G13 .51 
      % of variance (rotation sums of squares)  15.4% 
2:  Disorganized  Alpha=.80  
Poor attention G11 .74 
Stereotyped thinking N7 .63 
Conceptual disorganization P2 .62 
Difficulty in abstract thinking N5 .56 
Preoccupation G15 .50 
Disorientation G10 .40 
Mannerisms and posturing G5 .38 
      % of variance (rotation sums of squares)  11.4% 
3: Positive  Alpha=.78  
Delusions P1 .84 
Unusual thought content G9 .74 
Hallucinatory behavior P3 .65 
Suspiciousness P6 .63 
Grandiosity P5 .45 
Lack of judgment and insight G12 .41 
      % of variance (rotation sums of squares)  10.8% 
4: Excited Alpha=.71  
Hostility P7 .80 
Poor impulse control G14 .69 
Excitement P4 .63 
Uncooperativeness G8 .57 
      % of variance (rotation sums of squares)  9.0% 
5: Anxiety & Depression Alpha=.66  
Anxiety G2 .81 
Tension G4 .67 
Depression G6 .59 
Guilt feelings G3 .56 
Somatic concern G1 .43 
      % of variance (rotation sums of squares)  8.4% (cumulative 54.7%) 
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Table 2. Comparison of component loadings for the 30 PANSS items for the present study 
with other published studies*.  
 
Factor and Item Study 
Present study 
 
1.  Negative factor: 
Kay 
& 
Sevy, 
1990 
Lindenma
yer et al, 
1994 
White 
et al, 
1997 
Marder 
et al, 
1997 
Lancon 
et al, 
1999 
Lancon 
et al, 
2000 
Mass 
et al, 
2000 
Lykour
as et al, 
2000 
N1 blunted affect 1 1 1 1 1 1 1 1 
N2 emotional withdrawal 1 1 1 1 1 1 1 1 
N3 poor rapport 1 1 1 1 1 1 1 1 
N4 passive social 
withdrawal 
1 1 1 1 1 1 1 1 
N6 lack of spontaneity 1 1 1 1 1 1 1 1 
G7 motor retardation 1 1 1 1 1 1  1 
G13 disturbance of volition 1 2 2 2 1   1 
G16 active social 
avoidance 
1 1  1 1 1 1 4 
2.  Disorganised  factor:         
P2 conceptual 
disorganisation 
2 2  2 2 2 2 2 
N5 difficulty in abstract 
thinking 
2 2 2 2 2 2 2 2 
N7 stereotyped thinking  4 2 3 4   2 
G5 mannerisms 1 2 1 2 2  4 1/2 
G10 disorientation 2 2  2 2 2  2 
G11 poor attention 1 2 2 2 2 2 2 2 
G15 preoccupation 5 5 2 2 1   1 
3.  Positive factor:         
P1 delusions 3 3 3 3 3 3 3 3 
P3 hallucinations 3 3 3 3 3 3 3 3 
P5 grandiosity 3 3 3 3 3 3 4 3 
P6 suspiciousness  3  3 3 3  3 
G9 unusual thought 
content 
3 3 3 3 3 3 3 3 
G12 Lack of judgement 3 3  3 3 3  3/5 
4.  Excited factor:         
P4 excitation 4 4 4 4 4 4 4 4 
P7 hostility 4 4 4 4 4 4 4 4 
G8 uncooperativeness 4 4 4 4 4  4 4 
G14 poor impulse control 4 4 4 4 4 4 4 4 
5.  Depressive & anxiety 
factor: 
        
G1 somatic concern 5 5 5 3 3   4 
G2 anxiety 5 5 5 5 5 5 5 5 
G3 guilt feelings 5 5 5 5 5 5 5 5 
G4 tension 4 4 5 5 4 4 4 4 
G6 depression 5 5 5 5 5 5 5 5 
 
*Published studies with samples ≥ 240 and where component loadings are reported are 
included. 
Numbers depict the factor in which that item had its highest loading in the study in question. 
(1=negative factor; 2=disorganised factor; 3=positive factor; 4=excited factor; 
5=depressive/anxiety factor.) 
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Table 3.  Factors and factor loadings (the factor on which each item had its highest loading) of 
PANNS items for 533 subjects, for the unlimited factor solution using the equamax method. 
 
Factor and Items Variable Factor Loadings 
1: Negative  Alpha=.88  
Passive social withdrawal   N4 .77 
Emotional withdrawal      N2 .73 
Poor rapport N3 .68 
Active social avoidance G16 .68 
Lack of spontaneity N6 .68 
Blunted Affect        N1 .62 
Disturbance of Volition G13 .41 
      % of variance (rotation sums of squares)  12.4% 
2: Positive Alpha=.80  
Delusions P1 .83 
Unusual thought content G9 .75 
Hallucinatory behavior P3 .63 
Suspiciousness P6 .59 
Grandiosity P5 .50 
Lack of judgement and insight G12 .41 
Preoccupation G15 .38 
      % of variance (rotation sums of squares)  10.0% 
3. Disorganized Alpha=.77  
Disorientation G10 .75 
Poor attention G11 .64 
Difficulty in abstract thinking N5 .59 
Conceptual disorganization P2 .56 
Stereotyped thinking N7 .54 
      % of variance (rotation sums of squares)  9.8% 
4. Excited  Alpha=.71  
Hostility P7 .80 
Poor impulse control G14 .72 
Excitement P4 .64 
Uncooperativeness G8 .52 
      % of variance  8.4% 
5. Motor Alpha=.55  
Mannerisms and posturing G5 .72 
Motor retardation G7 .55 
      % of variance (rotation sums of squares)  7.6% 
6. Depression Alpha=.53  
Depression G6 .77 
Guilt feelings G3 .68 
      % of variance  6.8% 
7. Anxiety  Alpha=.62  
Somatic concern G1 .72 
Anxiety G2 .60 
Tension G4 .57 
      % of variance (rotation sums of squares)  6.7% (cumulative 61.7%) 
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Table 4. Details of published PANSS factor analytical studies.  
 
Authors 
 
N Sample  Medication 
status 
Statistical 
methods 
No. of 
factors 
Criteria for 
choosing no. of 
factors 
% 
variance 
Kay & Sevy, 
1990 
240 Schizophrenia, with 
psychotic symptoms 
All but 2 
medicated 
PCA, equamax 
rotation 
4  Eigenvalues>1 
gave 7 factors: 3 
discarded 
52% 
Dollfus et al, 
1991 
70 Schizophrenia, 
acute or stabilised.  
All but 1 
medicated 
PCA, varimax 
rotation 
5 Eigenvalues>1 56% 
Lindstrom & von 
Knorring, 1993 
120 Schizophrenia, 
chronic. 
Not specified PCA, varimax 
rotation 
5 Eigenvalues>1 
gave 9 factors: 4 
discarded 
70% 
Peralta & 
Cuesta, 1994 
100 Schizophrenia, 
exacerbation, 20% 
first-admission. 
All medicated PCA, varimax 
rotation, CFA 
8 Eigenvalues>1 69.9% 
Lindenmeyer et 
al, 1994 
240 Re-analysis of Kay 
& Sevy, 1990 
sample 
All but 2 
medicated 
PCA, 
orthogonal 
rotation 
5 Eigenvalues>1 57.5% 
Bell et al, 1994 146 Schizophrenia, 
schizo-affective 
mostly outpatients 
Not specified PCA, equamax 
rotation 
5 Eigenvalues>1 
gave 8 factors: 3 
discarded 
52.3% 
Kawasaki et al, 
1994 
70 Schizophrenia, 
active symptoms.  
All but one 
medicated 
PCA, varimax 
rotation 
5 Eigenvalues>1 
gave 6 factors: 1 
discarded 
68.7% 
Lindenmeyer et 
al, 1995 
517 Schizophrenia, 
chronic in-patients 
Medicated, 
then after 1 
week washout  
PCA, equamax 
rotation 
5 Scree plot 
examination 
51.7% 
White et al, 
1997 
1233 Schizophrenia or 
schizo-affective, 
diverse  
Not specified PCA, varimax 
rotation and 
CFA 
5 Eigenvalues>1 51% 
Marder et al, 
1997 
513 Schizophrenia, 
chronic, PANSS 
score 60 to 120 
Medicated, 
washout up to  
7 days 
PCA, equamax 
rotation 
5 Forced 5 factors Not 
reported 
Lancon et al, 
1998 
205 Schizophrenia, 
long-term 
maintenance.  
All medicated  PCA, varimax 
rotation 
5 Forced 5 factors 57% 
Lancon et al, 
1999 
342 Schizophrenia, 217 
acute relapse, 125 
chronic.  
All medicated PCA, varimax 
rotation 
5 Forced 5 factors 57.5% 
Lancon et al, 
2000 
342 Schizophrenia, 118 
acute relapse, 224 
chronic.  
All medicated PCA, varimax 
rotation 
5 Forced 5 factors 64.3%acute 
62.1%chr 
Lykouras et al, 
2000 
258 Schizophrenia, 
acute or stable.  
All medicated PCA, varimax 
rotation, CFA 
5 Eigenvalues>1 
gave 7 factors: 
scree plot gave 5 
factors 
59.85% 
Mass et al, 2000 253 Schizophrenia, 
mainly multi-
episode 
94.5% 
medicated 
PCA, varimax 
rotation 
5 Eigenvalues>1 72.3% 
Wolthaus et al, 
2000 
138 Schizophrenia, 
recent onset and 
spectrum disorders 
Not specified PCA, varimax 
and equamax 
5 Scree plot Not 
reported 
 
 
 
PCA = principal-component analysis 
CFA = confirmatory factor analysis 
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Abstract 
Most studies investigating the symptom dimensions of schizophrenia utilising the Scale for the 
Assessment of Negative Symptoms (SANS) and the Scale for the Assessment of Positive 
Symptoms (SAPS) favour a three factor model. This study sought to investigate the factor 
structure of both the global and individual items of the SANS and SAPS in a large sample of 
South African Xhosa patients with schizophrenia. A total of 422 subjects participated. Both 
principal components and factor analytical procedures were applied. For the global items, a 
two-factor solution representing positive and negative symptoms accounted for 59.9% of the 
variance. Alternatively, the three dimensional model of negative, psychotic and 
disorganisation factors was supported by a five factor solution if the more heterogeneous 
items of attention and alogia were ignored. Analysis of the individual items yielded a five-
factor solution with the negative symptoms splitting into diminished expression and disordered 
relating, and the positive symptoms separating into factors for psychosis, thought disorder 
and bizarre behaviour. Our findings are very similar to those in other parts of the world, 
providing evidence that the factor structure for the symptoms of schizophrenia is relatively 
resistant to cultural influences. This is particularly true for negative symptoms. 
 
 
 
1. Introduction 
 
Considerable attempts have been made to elucidate the heterogeneity of schizophrenia by 
exploring the relationships between its various symptoms. The Scale for the Assessment of 
Negative Symptoms (SANS) and the Scale for the Assessment of Positive Symptoms (SAPS) 
were developed specifically for this purpose (Andreasen, 1983; Andreasen, 1984), and have 
been extensively used in research settings. The SANS contains 20 items that are 
summarised in five global ratings: affective flattening, alogia, avolition/apathy, 
anhedonia/asociality and attention. The SAPS comprises 30 items that are summarised in 
four global ratings: hallucinations, delusions, bizarre behaviour and positive formal thought 
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disorder. Taken together, these two scales provide a comprehensive assessment of the 
symptoms of schizophrenia (Andreasen, 1989). The scales were organised according to 
Crow’s (1980) concept at that time of two broad dimensions - positive and negative symptoms 
- that represented different subtypes of schizophrenia. However, most subsequent studies 
have called this model into question and preferentially yielded a three-factor structure. These 
factors comprise a negative symptom factor (SANS global ratings for avolition/apathy, 
anhedonia/asociality and affective flattening) and two positive symptom factors (a “psychosis” 
dimension consisting of SAPS global ratings for hallucinations and delusions and a 
“disorganisation dimension” comprising SAPS global ratings for bizarre behaviour and formal 
thought disorder) (Andreasen and Olsen, 1982; Andreasen and Grove, 1986; Moscarelli et al., 
1987; Liddle, 1987; Arndt et al., 1991; Miller et al., 1993; Bilder et al., 1985; Kulhara et al., 
1986; Lenzenweger et al., 1989; Schuldberg et al., 1990; Gur et al., 1991; Minas et al., 1992; 
Brown et al., 1992; Peralta et al., 1992). 
 
Andreasen et al. (1995) summarised the results of the published factor analytic studies, and 
noted the strong convergence towards a three dimensional model. The similarities in the 
findings are all the more striking considering that these studies included patients from various 
parts of the world, often with small sample sizes, and using a variety of factor analytic 
techniques. Also, study samples varied considerably regarding the stage of the illness and 
medication status. Although commonly reproduced, the validity of the three factor model has 
been questioned, largely due to inadequate measurement at the symptom level (Stuart et al., 
1999). The majority of these studies analysed the global ratings of the two scales - a practice 
that runs the risk of missing relationships between individual symptoms. Indeed, two studies 
that analysed the individual items rather than the global scores found evidence that the 
dimensionality could be increased to five factors. In the first of these studies, Minas et al. 
(1994), utilising a principal components analysis of individual items on a sample of 114 
patients with psychotic disorders, found that the structure could be summarised by three 
major components labeled negative symptoms, thought disorder and delusions/hallucinations. 
However, they also found that dimensionality could meaningfully be increased to five 
components - the negative symptoms factor was found to separate into two components that 
they labeled negative signs and social dysfunctions, and the delusions/hallucinations factor 
separated into two components, delusions and hallucinations, with “loss of boundary 
delusions” being related to both factors. In the second study, Toomey et al. (1997) applied 
factor analysis to the item-level ratings to a heterogeneous sample of 549 psychiatric patients. 
This revealed two negative symptom factors (diminished expression and disordered relating), 
two positive symptom factors (bizarre delusions and auditory hallucinations), and a 
disorganisation factor. Thus, the findings of these two studies analysing individual items are 
also remarkably similar. 
 
It is not clear whether ethnicity and culture have any influence on these factor structures. 
Although previous studies included patients from different language and cultural groups 
(United States, Spain, Italy, England, Australia), all but one (India) (Kulhara et al., 1986) 
studied Caucasian populations. Other cross-cultural studies, although not looking specifically 
at factor structures, have reported varying degrees of inter-ethnic variation in the symptoms of 
schizophrenia. Some studies found Schneiderian first-rank or core symptoms to be similar 
across cultures (Ndetei and Singh, 1983 A; Sartorius et al., 1986; Gureje, 1987; Malik et al., 
1990; Ensink et al., 1998) and negative symptoms also to be similar (Dassori et al., 1998). 
However, others report cross-cultural differences: A lower prevalence of first-rank or core 
symptoms has been found in developing countries (Chandrasena et al., 1987), in subjects 
less proficient in English (Coffey et al., 1993), and in minority groups (Breke and Barrio, 
1997), while a higher prevalence of visual hallucinations has been reported in Kenyans 
(Ndetei and Singh 1983 B). To effectively address the question of whether the factor structure 
for the symptoms of schizophrenia is influenced by culture and ethnicity, it would be important 
to investigate subjects from a very different background and in a relatively non-acculturated 
setting.  African subjects are an appropriate group to study as they are culturally and 
genetically distinct (Cavalli-Sforza et al., 1994). Symptoms of schizophrenia have been 
investigated in African subjects, with no differences in core symptoms being found in Kenyans 
(Ndetei and Singh., 1983 A), Nigerians (Gureje, 1987) and South African Xhosas (Ensink et 
al., 1998) while one study reported visual hallucinations to be more common in Kenyans 
(Ndetei and Singh 1983 B).  
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This study investigated the factor structure of the symptoms of schizophrenia in South African 
Xhosa patients. To our knowledge such a study has not previously been undertaken in 
African patients. The large sample allowed us to analyse not only the global items, but also 
the individual items of the SANS and SAPS scales. Both principal components and factor 
analytical procedures were applied. 
 
 
2. Methods 
2.1 Subjects  
Subjects were recruited from in-patient and out-patient hospital services and community 
clinics throughout the Western and Eastern Cape Provinces of South Africa. Potential 
participants had to be of Xhosa ethnicity, and have a diagnosis of schizophrenia. The Xhosas 
are the southernmost indigenous African population. Belonging to the Nguni language group, 
the characteristic clicking sounds attest to their ancestral links with the Khoisan people 
(Cavalli-Sforza et al., 1994). Particularly the rural Xhosa people have maintained purity of 
language and traditional custom including ancestor worship and traditional medicine 
(Cheetham and Cheetham, 1976). The study protocol was presented to the local mental 
health workers, who were then asked to identify possible participants. All candidates were 
then screened by one of us (DJHN or NIM) for suitability. The study group included subjects 
at various stages of the illness, and with various levels of symptoms. Patients were diagnosed 
according to DSM IV criteria (A.P.A., 1994). Subjects with known organic aetiology were 
excluded. Patients were included in the study if they met the criteria and approval for 
participation was obtained from the treating mental health workers and their care-givers. In 
addition, all patients provided written, informed consent. These procedures yielded 422 
patients. Because of missing observations, 396 patients were included in the global ratings 
analysis and 347 patients were included in the item ratings analysis.  
 
2.2 Ratings 
The ratings of positive and negative symptoms used for analysis in this study were taken from 
the SANS and SAPS scales in the Diagnostic Interview for Genetic Studies (DIGS), version 
2.0 (Nurnberger et al., 1994). The DIGS is a comprehensive clinical interview designed for the 
assessment of major mood and psychotic disorders and their spectrum conditions. Ratings 
were performed by either a psychiatrist (DJHN) or a trained Xhosa psychiatric nurse with 
extensive experience in an academic psychiatric hospital (IM). For patients who were not 
fluent in English, interviews were conducted in Xhosa – either by the interviewer (NIM) or 
through an interpreter (DJHN). Interviewers rated individual items and also made global 
ratings to reflect the overall impairment in each area. Patients were recruited over a two-year 
period. In order to attain optimal rating consistency all subjects were assessed by both raters 
together during the first year of the study. Thereafter the raters partook in regular calibration 
meetings.  
 
A study of the inter-rater reliability for the global and individual items was made in which 18 
subjects were assessed by both of the raters. In the case of the SANS items the mean, 
minimum and maximum correlation coefficients were, respectively 0.826; 0.539; and 0.958, 
and for the SAPS items 0.828; 0.314; and 1.000. The question of relative bias of the raters 
was also examined. While in some items there were significant differences in mean scores, 
overall there was no detectable tendency for the raters to assign significantly different scores.  
 
2.3 Data analysis 
Various analyses of the data were undertaken. Factor analysis of the global ratings, and of 
the individual items, was performed by the method of maximum likelihood. This is a well 
established, standard statistical procedure. It requires the number of factors to be specified, 
and principal component analysis was performed as a guide for choosing the number of 
factors. We chose to use two criteria for the global items – that eigenvalues should be greater 
than unity (Andreasen et al, 1995), and that the number of factors specified should account 
for at least 60% of the total variation. The initial maximum likelihood factor solution was 
rotated using the varimax procedure.
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3. Results 
The sample comprised 317 men and 105 women with a mean (±SD) age of 38.2 (9.43) yrs.  
Their mean (±SD)  educational status was 7.4 (3.1) yrs and the duration of illness 13.5 (9.4) 
yrs. 
3.1 Global items: 
The mean (±SD) scores for the global items were as follows: Affective flattening 2.22 (±1.25); 
alogia 2.16 (±1.55); avolition 2.77 (±1.28); anhedonia 2.94 (±1.25); attention 0.44(± 0.95); 
hallucinations 1.22 (±1.62); delusions 1.30 (±1.68); bizarre behaviour 0.91 (±1.48); and 
thought disorder 0.86 (±1.38). The results of the principal components analysis are given in 
Table 1. The first two factors had eigenvalues greater than unity and accounted for 60% of the 
variation. The first five principal components accounted for 85% of the total variation. Table 2 
gives the results of the two-factor analysis for the global ratings after the factors were rotated 
using the varimax rotation procedure. The first factor reflects the negative symptom dimension 
and accounts for 26.7% of the variance. Anhedonia, avolition, alogia and affective flattening 
all load highly with this factor, while attentional impairment loads almost equally on both 
factors. The second factor comprises a positive symptom dimension, with hallucinations, 
delusions, bizarre behaviour and to a lesser extent thought disorder loading here. The second 
factor accounts for 23.2% of the variance.  The results of the five-factor analysis are given in 
Table 3. The first two factors – i.e. negative and positive symptoms - are substantially the 
same as in the two-factor analysis. Factors three and four are largely determined by global 
items attentional impairment and alogia. Factor five, a disorganisational factor, comprises 
largely the global items bizarre behaviour and to a lesser extent thought disorder. 
 
3.2 Individual items: 
The first five principal components accounted for 55% of the total variation, and the first 20 
principal components for 85%. The first 10 components had eigenvalues of greater than one. 
We chose to report a five-factor model because the two previous analyses of individual items 
(Minas et al., 1994; Toomey et al., 1997) had favoured such a model. Table 4 gives details of 
a maximum likelihood five-factor analysis. Hallucinations and delusions form a single factor 
with the exception of delusions of jealousy. The second factor essentially corresponds with 
the “diminished expression” factor of Toomey et al. (1997) except that the items impersistence 
at work or school and physical anergia also load here in our analysis. The third factor 
comprises the items for positive formal thought disorder, as well as inappropriate affect, 
blocking and aggressive and agitated behaviour. The fourth factor corresponds with the  
“disordered relating” factor of Toomey et al. (1997), with the addition of poverty of content of 
speech. The fifth factor consists of the bizarre behaviour items (excluding aggressive and 
agitated behaviour) plus grooming and hygiene and delusions of jealousy. 
 
 
4. Discussion 
Global ratings: 
As was the case in the study of Toomey et al. (1997), our factor analysis of the SANS and 
SAPS global ratings did not obviously replicate the three factor solution most frequently 
reported in the literature.  This may be due to differences in the statistical methods that were 
applied. As pointed out by Toomey et al. (1997), previous studies favoured principal 
component analysis rather than factor analysis, with the former method running the risk of 
measurement error contributing to the findings. Our analysis yielded a two factor solution 
representing positive and negative symptoms that together accounted for a large portion of 
the variance, namely 59.9%. Attention was the only global item not to fit clearly into one of 
these two categories - a finding in keeping with previous studies indicating that this item has 
the least robust correlation and may in fact be heterogeneous (Andreasen et al., 1995). 
 
However, while the two factor model appeared to fit well, the five factor model was also of 
interest, and yielded a solution that is consistent with previous work. Thus, the first two factors 
of the five factor analysis are essentially the same as with the two factor analysis (negative 
and positive dimensions) while factors three and four are largely determined by global items 
attentional impairment and alogia respectively. If, as was the case with Andreasen et al. 
(1994), these latter two factors are excluded, then our results are similar to those authors and 
to the majority of other studies in favouring a three factor solution comprising psychoticism, 
negative symptoms and disorganisation. Considering the diversity of the patient samples in 
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the various published studies as well as the existence of other methodological differences 
mentioned previously, the consistency of these findings with the previous studies is striking.  
Individual items: 
When comparing our individual item analysis with the two previously published studies (Minas 
et al., 1994; Toomey et al., 1997) there are once again strong similarities. The two negative 
symptom factors and a thought disorder (or disorganisation) factor were common to all three 
studies. The five factor item-level model split the negative symptom factor into two separate 
factors reflecting diminished expression and disordered relating. This latter term was coined 
by Toomey et al. (1997), who proposed that deficits in personal relationships constitute a 
dimension that is independent from the other negative symptoms.  The positive symptoms 
were split in the item-level analysis into factors for psychosis (hallucinations and delusions), 
thought disorder and bizarre behaviour. Thus, the disorganisation factor reported in the 3 
factor solution for the global items has split into thought disorder and bizarre behaviour factors 
in the individual item analysis. The thought disorder factor corresponds to the one reported by 
Minas et al. (1994) and Toomey et al. (1997). As was the case with these authors, as well as 
with Miller et al.(1993), we found that inappropriate affect loaded with this thought disorder 
factor. However, unlike them, we did not find that hallucinations separated from delusions, or 
that delusions differentiated into those that were bizarre and those that were non-bizarre. 
Also, our fifth factor, "bizarre behaviour", has not previously been reported as a separate 
factor, although the possibility was raised in one study (Andreasen et al., 1986). 
 
There are various possible explanations for these observed differences. For example, both of 
the previous studies examined a much more heterogeneous sample than ours. Also, there 
may have been important treatment-related differences between the samples such as 
duration of symptoms prior to treatment, duration of treatment and current medication status. 
Another possibility is that cultural factors are responsible for these differences. Thus, the 
three factors of diminished expression, disordered relating and disorganisation may be 
relatively resistant to cultural influences, whereas the positive symptoms of delusions and 
hallucinations and in particular bizarre behaviour may be more susceptible to such influences. 
In this regard it is interesting to note that black Xhosa patients with schizophrenia have 
previously been reported by their relatives to have more bizarre behaviour than that reported 
by the relatives of their white English-speaking counterparts (Ensink et al., 1998). 
 
If diminished expression, disordered relating, and disorganisation are more resistant to 
cultural influences, this may also argue for these symptoms of the illness being more 
genetically mediated than the other symptoms. With this in mind it would have been of 
interest to compare our findings with the studies conducted in Kenyan samples (Ndetei and 
Singh, 1983 A and 1983 B). While linguistically distinct from each other, the genetic distance 
between the Xhosa (south-east bantu) and the predominant Kenyan ethnic groups (other 
bantus and nilotics) is very small (Cavalli-Sforza et al., 1994). Unfortunately, comparisons are 
not possible as different methods of assessment were used and negative and disorganised 
symptoms were not reported in the Kenyan studies. 
 
Interpretation of the results of this study is subject to a number of limitations: First, the patient 
ratings were cross-sectional, and important historical information may have been missed. 
Second, the assessment instruments were not translated into Xhosa. Third, the sample was 
of low education. Fourth, patients were not assessed at the same stage of their illness. This 
could have influenced our results, as the symptom dimensions of schizophrenia have been 
shown to have different patterns of exacerbation and remission during the course of the 
illness (Arndt et al., 1995). And fifth, the sample size was less than optimal for analysing the 
individual items. In spite of these limitations our solutions explained a high percentage of the 
variance in this study, suggesting that the results are indeed valid. 
 
Previous studies of cultural differences in the symptoms of schizophrenia have often been 
limited by small samples, lack of specific diagnostic criteria and non-standardised symptom 
assessment. The present study addressed these issues. We found close similarities between 
the factor structures of Xhosa patients with schizophrenia and those from other parts of the 
world. The results are very similar to previously reported studies regarding negative 
symptoms – i.e. a single negative factor for the global items that separated into factors for 
diminished expression and disordered relating in the individual item analysis. However, the 
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positive symptoms did not show the same degree of stability at the individual item level – 
delusions and hallucinations did not split, while bizarre behaviour emerged as a separate 
factor. Our findings provide compelling evidence that the symptom dimensions of 
schizophrenia are relatively resistant to cultural influences. This is particularly true for 
negative symptoms, and provides further support for their inclusion in international cross-
cultural studies (Dassori et al., 1998). 
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Table 1 Principal component analysis for the SANS and SAPS global ratings* 
 
Symptom                      PC1       PC2       PC3       PC4       PC5 
Affective flattening       -0.381     0.224     0.156     0.316    -0.010     
Alogia                          -0.337     0.382     0.076    -0.305    -0.373     
Avolition                       -0.374     0.296    -0.227     0.147     0.363      
Anhedonia                   -0.346     0.390    -0.311     0.153     0.002      
Attention                      -0.252    -0.077     0.811     0.261    -0.158      
Hallucinations              -0.292    -0.476    -0.242     0.274    -0.360      
Delusions                     -0.328    -0.445    -0.286     0.094    -0.201     
Bizarre behaviour         -0.325    -0.343     0.141    -0.106     0.725     
Thought disorder          -0.345    -0.128     0.063    -0.774    -0.092      
Eigenvalue                    3.7356    1.6516   0.9392   0.7088   0.5858 
Proportion                     0.415      0.184      0.104      0.079      0.065      
Cumulative                  0.415     0.599     0.703     0.782     0.847 
 
* The first five components are reported 
SANS indicates Scale for the Assessment of Negative Symptoms 
SAPS indicates Scale for the Assessment of Positive Symptoms 
 
 
 
 
Table 2 Two factor structure for SANS and SAPS global ratings. 
 
Symptom                    Negative   Positive  Communality 
                                 Symptoms   Symptoms 
Affective flattening         0.668     -0.255      0.512 
Alogia                            0.712     -0.083      0.513 
Avolition                         0.757     -0.200      0.613 
Anhedonia                     0.781     -0.118      0.624 
Attention                        0.264     -0.260      0.137 
Hallucinations               0.059     -0.788      0.625 
Delusions                      0.121     -0.853      0.743 
Bizarre behaviour          0.216     -0.582      0.386 
Thought disorder           0.369     -0.450      0.338 
 
Variance                        2.4059     2.0842     4.4902 
% Variance                  26.7       23.2       49.9 
 
The strongest correlations on a factor for a given item are given in bold face 
SANS indicates Scale for the Assessment of Negative Symptoms 
SAPS indicates Scale for the Assessment of Positive Symptoms 
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Table 3 Five factor structure for SANS and SAPS global ratings. 
 
Variable                      Negative   Positive   Attention   Alogia Disorganisation Commnlty 
                                Symptoms   Symptoms 
Affective flattening        0.573     -0.171     -0.260      0.244      0.155            0.509 
Alogia                           0.474     -0.013     -0.119      0.871      0.045            1.000 
Avolition                        0.788     -0.117     -0.051      0.129      0.187            0.689 
Anhedonia                    0.800     -0.105     -0.005      0.210      0.001            0.695 
Attention                       0.113     -0.119     -0.969      0.105      0.151            1.000 
Hallucinations               0.111     -0.766     -0.114     -0.011      0.146            0.633 
Delusions                      0.131     -0.843     -0.030      0.088      0.229           0.788 
Bizarre behaviour          0.149     -0.367     -0.164      0.035      0.775           0.786 
Thought disorder           0.228     -0.335     -0.125      0.319      0.337           0.396 
 
Variance                        1.9302     1.6124     1.0802     1.0011     0.8723       6.4962 
% Variance                  21.4       17.9       12.0       11.1        9.7       72.2 
 
The strongest correlations on a factor for a given item are given in bold face 
SANS indicates Scale for the Assessment of Negative Symptoms 
SAPS indicates Scale for the Assessment of Positive Symptoms 
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Table 4   Five factor analysis for SANS and SAPS individual items. 
 
SANS Item                       Psychotic  Diminished  Thought-   Disordered  Bizarre    Commnlty 
                                    Symptoms   Expression  disorder   Relating    Behaviour  
1  unchanging facial expression   0.013     0.845    -0.009     0.007     0.148     0.737 
2  decreased spont. movements     0.064     0.882    -0.035     0.086    -0.032     0.792 
3  paucity of expressive gestures 0.046     0.933    -0.041     0.055     0.033     0.879 
4  poor eye contact               0.034     0.732     0.132     0.258     0.074     0.625 
5  affective nonresponsivity      0.100     0.849     0.006     0.238     0.013     0.787 
6  inappropriate affect           0.079     0.028     0.511     0.071     0.228     0.325 
7  lack of vocal inflections      0.066     0.844    -0.026     0.169     0.102     0.756 
9  poverty of speech             -0.027     0.677     0.050     0.277    -0.053     0.541 
10 poverty of content of speech   0.113     0.388     0.348     0.455    -0.149     0.514 
11 blocking                       0.135     0.201     0.210     0.128    -0.034     0.121 
12 increased latency of response  0.010     0.255     0.132     0.202    -0.054     0.126 
14 grooming and hygiene          -0.098     0.318     0.123     0.264     0.350     0.318 
15 impersistance                  0.004     0.454     0.136     0.421     0.246     0.463 
16 physical anergia               0.070     0.508    -0.005     0.460     0.103     0.485 
18 recreational interests         0.041     0.460     0.101     0.681     0.122     0.703 
20 intimacy and closeness         0.158     0.432     0.201     0.736     0.031     0.794 
21 relationships                  0.079     0.437     0.120     0.726     0.087     0.747 
23 social inattentiveness         0.037     0.302     0.170    -0.034     0.231     0.176 
SAPS Item 
1  auditory hallucinations        0.627     0.064     0.093     0.026     0.572     0.733 
2  voices commenting              0.590     0.077     0.165     0.078     0.524     0.662 
3  voices conversing              0.591     0.052     0.106     0.077     0.572     0.696 
4  somatic/tactile hallucinations 0.567    -0.010     0.035     0.040     0.394     0.479 
5  olfactory hallucinations       0.563     0.042     0.144     0.106     0.239     0.408 
6  visual hallucinations          0.491    -0.034     0.285     0.010     0.327     0.430 
8  persecutory delusions          0.472     0.150     0.237     0.067     0.446     0.505 
9  delusions of jealousy          0.096    -0.074     0.108    -0.110     0.175     0.069 
10 delusions of guilt or sin      0.673     0.050     0.031    -0.043    -0.096     0.468 
11 grandiose delusions            0.476    -0.061     0.187     0.114     0.205     0.321 
12 religious delusions            0.391     0.037     0.237     0.054     0.268     0.285 
13 somatic delusions              0.570     0.012     0.147     0.074     0.180     0.384 
14 delusions of reference         0.549     0.102     0.248     0.082     0.299     0.470 
15 delusions of being controlled  0.689     0.073     0.145     0.043     0.150     0.526 
16 delusions of mind reading      0.796     0.101     0.139     0.020     0.026     0.664 
17 thought broadcasting           0.809     0.044     0.078    -0.007    -0.104     0.673 
18 thought insertion              0.761     0.015     0.169    -0.041    -0.202     0.651 
19 thought withdrawal             0.731     0.014     0.155    -0.005    -0.076     0.564 
21 clothing and appearance        0.073     0.187     0.218     0.199     0.306     0.221 
22 social and sexual behaviour    0.008     0.048     0.264    -0.012     0.339     0.187 
23 aggressive, agitated behaviour 0.176     0.025     0.273    -0.015     0.217     0.154 
24 repetitive behaviour           0.074     0.063     0.091     0.044     0.129     0.036 
26 derailment                     0.182     0.056     0.819     0.096     0.178     0.748 
27 tangentiality                  0.137     0.140     0.866     0.104     0.208     0.843 
28 incoherence                    0.213     0.169     0.779     0.193     0.064     0.723 
29 illogicality                   0.212     0.126     0.840     0.137     0.163     0.811 
30 circumstantiality              0.220     0.133     0.657     0.236    -0.000     0.553 
31 pressure of speech             0.035    -0.054     0.314     0.056     0.168     0.134 
32 distractible speech            0.216     0.005     0.506    -0.038     0.055     0.307 
33 clanging                       0.050    -0.042     0.214    -0.031    -0.002     0.051 
 
Variance                          6.9285    6.5031    4.8526    2.7582    2.6037   23.6462 
% Variance                       14.4      13.5      10.1       5.7       5.4      49.3 
 
The highest correlations on a factor for each item are given in bold face 
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ABSTRACT 
Background:  Symptoms of depression and anxiety are frequently encountered in 
the course of schizophrenia, and are of considerable clinical importance. They may 
compromise social and vocational functioning, and are associated with an increased risk of 
relapse and suicide. Various treatment approaches have been reported to be successful.  
 
Methods:  The sample comprised 177 patients with schizophrenia or 
schizophreniform disorder who were participants in multinational clinical drug trials at our 
academic psychiatric unit over a 7 year period and who were assessed by means of the 
Positive and Negative Syndrome Scale (PANSS). Analysis was performed on baseline 
PANSS scores. The depression/anxiety score was compared in the men and women, first-
episode and multiple episode patients, and those with predominantly positive and negative 
syndromes. Correlations were sought between depression/anxiety scores and age, total 
PANSS score, positive score, negative score, general psychopathology score and treatment 
outcome. Multivariate analysis was applied to determine contributions of individual variables 
toward depression/anxiety and outcome scores. 
Results:  Depression and anxiety symptoms were more severe in women (p = 
0.007), first-episode patients (p = 0.02), and those with predominantly positive symptoms (p < 
0.0001). Depression/anxiety scores were significantly correlated to age (r = -0.31, p< 0.0001), 
PANSS positive scores (r = 0.39, p < 0.0001) and treatment outcome (r = 0.25, p = 0.006). 
Multivariate analysis bore out these results, with the exception that first episode was not a 
significant predictor of depression and anxiety scores.  
Conclusions: Depressive/anxiety scores were generally low in our sample, perhaps 
because patients with schizoaffective disorder were excluded. The finding that these 
symptoms were more prominent in women and first-episode patients is in keeping with 
previous literature. The higher scores in first-episode patients are likely due to the higher 
positive symptom scores in these patients. The association between depressive/anxiety 
scores and positive symptoms but not with negative symptoms points to a specific 
relationship between affective symptoms and the positive symptom domain of schizophrenia.  
The presence of depressive and anxiety symptoms may predict a more favorable outcome to 
treatment, although this may only apply to the acute exacerbations of  the illness.   
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INTRODUCTION 
Symptoms of depression and anxiety are frequently encountered during the course of 
schizophrenia. They may occur during any phase of the illness, and are not always easy to 
recognize. Depressive symptoms may mimic the negative symptoms of schizophrenia1 and 
neuroleptic-induced akinesia, while anxiety symptoms may be indistinguishable from 
akathisia.2,3  Possible causes of depression and anxiety in schizophrenia include response to 
adverse life events4, substance abuse,1 co-morbid major depression or anxiety disorders, 
neuroleptic-induced dysphoria5or the possibility that these symptoms are a core feature of the 
schizophrenic illness.6 The prevalence of depressive symptoms in schizophrenia has been 
reported as between 7% and 70%, depending on the criteria applied and populations 
studied.7 Depressive symptoms are very common in first-episode schizophrenia,6 the majority 
occurring concurrently with the psychotic symptoms and resolving as the psychosis remits. 
The majority of depressive symptoms appear to be related to the psychotic symptoms.  
Although not clear-cut, the presence of depressive symptoms in the acute phase of the illness 
may be associated with a favorable outcome,7,8 while in the chronic course they may be 
negative prognostic indicators.9,10 Koreen et al6 found that depressive symptoms in their first-
episode patients did not significantly affect the prognosis. 
Anxiety symptoms in schizophrenia have been less well studied, although reports of 
co-morbid anxiety disorders and syndromes including obsessive-compulsive disorder,11 panic 
attacks,12  social anxiety13 and posttraumatic stress disorder14 have appeared in the literature. 
Kay15 found that depressive and anxiety symptoms clustered together as a distinct factor in 
patients with schizophrenia. Whatever their origins, depressive and anxiety symptoms in 
schizophrenia are of considerable clinical relevance. They may compromise social and 
vocational functioning, and are associated with an increased risk of relapse16 and suicide.17 
The importance of recognizing these symptoms is further underlined by the fact that they may 
be responsive to various therapeutic interventions. Most depressive symptoms accompanying 
an acute psychosis resolve with neuroleptic treatment of the psychosis.6 Tricyclic 
antidepressants, although not effective in treating depressive symptoms in actively psychotic 
patients,18 were successful in treating post-psychotic depression, 19,20 as was lithium 
carbonate.20 Decreased depression and suicidality was reported with clozapine treatment of 
neuroleptic-resistant schizophrenia.21 More recently, olanzapine was found to be superior to 
haloperidol in reducing depressive signs and symptoms in schizophrenia, and this effect was 
independent of reduction of psychotic symptoms.1 Alprazolam has been reported to be 
effective in schizophrenia with panic anxiety,22 as has cognitive-behavioral therapy.23  
 
This study further investigates depressive and anxiety symptoms in a large sample of 
patients with schizophrenia and schizophreniform disorder. The patients comprise participants 
in multinational clinical drug trials at our academic psychiatric unit who were assessed by 
means of the Positive and Negative Syndrome Scale (PANSS)15 over a 7 year period. 
 
PATIENTS AND METHODS 
Patients meeting DSM-III-R24 or DSM-IV25 criteria for schizophrenia or 
schizophreniform disorder who had participated in multinational clinical trials within our 
department and in whom the PANSS had been used to assess symptom severity were 
included. All patients had provided informed, written consent to participate in the trials, and 
the studies were approved by the Ethics Committee of the University of Stellenbosch. The 
trials took place between 1991 and 1998 at an academic psychiatric hospital under a single 
principal investigator (RAE). The other investigators were experienced psychiatrists who had 
undergone training and inter-rater reliability testing for using the PANSS. Subjects were aged 
between 18 and 65 years, had no concomitant significant medical conditions and did not meet 
criteria for substance abuse. Schizoaffective disorder was an exclusion criterion for all of the 
trials. Analysis was performed on baseline PANSS scores of all of the patients who had been 
randomized to one of the trials. The following PANSS groups were selected, according to 
previously specified criteria:15 Total PANSS score (30 items); positive scale (items P1-P7); 
negative scale (items N1-N7); composite score (positive scale score minus negative scale 
score); and general psychopathology scale (items G1-G14). Patients were also divided into 
those with predominantly positive syndromes (score of 4 or more on at least three of the 
positive items and on fewer than three on the negative scale) and those with predominantly 
negative syndromes (score of 4 or more on at least three of the negative items and on fewer 
than three on the positive scale), and into those suffering from their first psychotic episode 
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and those suffering from recurrent psychotic episodes. Depressive and anxiety symptoms 
were examined in these different groups. The depression/anxiety factor comprised the sum of 
the scores from PANSS items G1 (somatic concern), G2 (anxiety), G3 (guilt feelings) and G6 
(depression).  Finally, correlations were sought between depression/anxiety scores and the 
following variables: Age, total PANSS score; positive score; negative score; composite score; 
and treatment outcome as assessed by the change from baseline in total PANSS scores 
(minus depression/anxiety items) at 6 weeks (or the closest assessment to 6 weeks, ranging 
from 5 – 9 weeks). 
 
Statistical analysis: 
Student’s t-test (2-tailed) and Pearson’s Product Moment Correlation Coefficient were 
used for differences and correlations between numeric variables. To determine the 
contributions of individual variables toward depression/anxiety and outcome scores, 
significant univariate results were followed with regression analysis with simultaneous entry, 
using the method  of least squares. The significance level was set at 0.05. 
 
 
RESULTS 
The sample comprised 177 subjects of whom 113 (64%) were men and 64 (36%) 
women. The mean ± sd age was 35.6 ± 13.36 years. Sixty (34%) were first-episode patients. 
The median (interquartile range) number of psychotic episodes in the multiple episode group 
was 2 (3).  DSM diagnoses were as follows: Paranoid schizophrenia (n=41), disorganized 
schizophrenia (n=28), catatonic schizophrenia (n=2), undifferentiated schizophrenia (n=48), 
residual schizophrenia (n=27) and schizophreniform disorder (n=29). For the entire sample 
mean PANSS scores were as follows: positive scale 20.5 ± 6.82; negative scale 24.5 ± 6.71; 
general psychopathology scale 38.6 ± 9.06; total PANSS score 83.6 ± 17.61; composite score 
–4 ± 9.66; and depression/anxiety factor 7.8 ± 3.05. 
 
We were initially interested in looking at anxiety and depressive symptoms separately.  
To determine whether these were in fact separate entities we selected the items that we 
considered to represent “pure” anxiety (G2. Anxiety + G4. Tension) and depressive (G3. Guilt 
feelings + G6. Depression) symptoms and correlated them. A highly significant correlation (r = 
0.5, p < 0.0001) was found between these factors, indicating that depression and anxiety 
symptoms largely occurred together in our sample of patients. This is in keeping with the 
original principal component analysis of Kay, in which the depressive and anxiety symptoms 
of the PANSS scale formed a single component. 15 We therefore examined depression and 
anxiety symptoms as one factor, using the items identified by Kay15 (G1, G2, G3 and G6). 
Figure 1 shows the various PANSS scores for men and women, and Figure 2 shows the 
various PANSS scores for first-episode and multiple episode patients. Thirty-four patients met 
criteria for a predominantly positive syndrome, and 59 for a predominantly negative 
syndrome. The depression/anxiety scores for these two groups were, respectively, 8.2 ± 2.5 
and 6.3 ± 2.45. The difference between these groups was highly significant (p = 0.0004).  The 
depression/anxiety score was found to correlate significantly with age (r = - 0.31, p < 0.0001), 
PANSS positive score (r = 0.39, p < 0.0001), treatment outcome (r = 0.25, p = 0.006) but not 
with the PANSS negative score (r = - 0.07, p = 0.4).  
Because the depression/anxiety factor was related to both first-episode and positive 
symptom scores, and first-episode patients had significantly higher positive symptom scores, 
multiple regression, using the method of least squares was performed. The 
depression/anxiety score was the dependent variable and age, sex, first episode, positive 
score, negative score and the interaction of positive score and first-episode were the 
independent variables. The overall regression was significant [F(6,168) = 8.54, p < 0.0001, 
adjusted R2 = 0.21], suggesting that 21% of the variance in depression/anxiety scores was 
associated with the model. Significant predictors were younger age (p = 0.02), female gender 
(p =  0.005) and positive symptoms (p = 0.04). 
 
To identify the contributions of age, sex, first-episode and depression/anxiety score to 
predicting outcome, multiple regression was performed with outcome as the dependent 
variable and the other variables as predictor variables. The symptoms included in the 
depression/anxiety factor (G1, G2, G3 and  G6) were excluded from the total PANSS scores. 
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The overall regression was significant [F(4,117) = 4.46, p < 0.002, adjusted R2 = 0.10], 
suggesting that 10% of the variance in outcome could be explained by these variables. The 
only significant predictor was anxiety/depression score (p = 0.04).  
 
 
 
DISCUSSION 
The major findings of this study were that depressive and anxiety symptoms were 
more prominent in women, those with predominantly positive symptoms and those suffering 
from their first psychotic episode. There was a significant negative association with age, and a 
significant positive association with positive symptoms. Generally, symptoms of depression 
and anxiety were present only to a moderate degree, even in the first-episode patients. This is 
in contrast to the findings of Koreen et al6 (although direct comparisons are not possible 
because different scales were used to assess symptom severity). This discrepancy could be 
due to the fact that patients with schizoaffective disorder were excluded from our sample. 
 
The finding that depressive and anxiety symptoms are more prominent in women is in 
keeping with previously reported gender differences in schizophrenia.26  Bardenstein and 
McGlashan,27 after reviewing the literature, concluded that women with schizophrenia are 
more likely to experience affective symptoms, while men are likely to have more prominent 
negative symptoms. Häfner et al28 found more depressive symptoms in women than in men in 
first-admission patients with schizophrenia. However, it is possible that these results could 
reflect differences in men and women that are not related to schizophrenia.28 Also, the 
differences, although significant are small, and may not be clinically meaningful.   
  
As with the studies of House et al29 and Koreen et al,6 our study showed that 
depressive and anxiety symptoms were more prominent in patients experiencing their first-
episode of schizophrenia. Again however, the differences although significant are small, and 
may not have clinical relevance. On the other hand, the additional clear-cut differences 
between first-episode and multiple-episode patients regarding positive symptoms, negative 
symptoms and general psychopathology scores indicate that the psychopathology of first-
episode schizophrenia is different from multiple-episode schizophrenia. Multivariate analyses 
indicate that the higher positive symptom scores in first-episode patients are likely to account 
also for the higher levels of depressive and anxiety symptoms encountered in first-episode 
compared to multiple-episode patients. 
Whereas Koreen et al6 found depression to be significantly correlated with both 
positive and negative symptoms, we found a significant correlation with positive symptoms 
only. Our findings are thus consistent with other studies30,31 indicating an association between 
depression/anxiety and positive symptoms, with independence of negative symptoms. This 
points to a specific association between these affective symptoms and the positive symptom 
domain of schizophrenia. There are several possible explanations for this association. First, it 
could be that depressive and anxiety symptoms are secondary to the positive symptoms. 
Second, in the stress-diathesis context, these affective symptoms may themselves constitute 
a stressor that triggers a psychotic episode.32 Third, affective symptoms and positive 
symptoms may represent common clinical manifestations of the same underlying pathological 
process. This latter possibility is consistent with the proposal that depression is a core part of 
schizophrenia that occurs at the height of psychosis and decreases over the course of 
treatment.6 
 
The finding that depression and anxiety scores correlated with treatment response is 
consistent with that reported by Kay,15  who found that this factor emerged as the only clinical 
variable to reliably predict good outcome. This is particularly interesting considering that both 
our study and that of Kay excluded patients with schizoaffective disorder. Thus, the better 
prognosis in patients with schizophrenia with affective symptoms cannot be explained on the 
basis that these patients were actually suffering from schizoaffective disorder.  However, the 
fact that most of our patients were experiencing acute exacerbations of their illness is 
consistent with other studies indicating that the favourable outcome associated with 
depressive symptoms may only apply to the acute phase of the illness.7,8    
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There are a number of limitations to this study.  Firstly, we only looked at symptoms of 
depression and anxiety, and not at specific co-morbid mood and anxiety disorders. Secondly, 
side-effects of medication taken prior to the onset of the trials were not assessed. Although 
patients had undergone a washout period of 3 to 7 days before the PANSS assessment was 
done, extrapyramidal or other side-effects from previously taken medication could have 
influenced the results. However, medication effects are unlikely to have played a major role, 
considering that  previous studies failed to show a strong association between depression 
and extrapyramidal symptoms.6,29 Thirdly, the various investigators may have rated symptoms 
differently. The fact that regular inter-rater reliability training took place, and the same principle 
investigator was present for all of the studies, decreases the likelihood of this possibility. 
Finally, the correlations with treatment outcome need to be interpreted with caution, as 
patients obviously received different treatments. Details of medication were not available to 
us, as a number of the studies had not been unblinded at the time of our analysis. 
 
In conclusion, the assessment of depressive and anxiety symptoms in patients with 
schizophrenia is of considerable importance. These symptoms may be core features of the 
illness, and may be of value in predicting the treatment outcome in patients suffering acute 
exacerbations of the illness.  
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Table 1.  Mean ± SD PANSS Scores for Men and Women With Schizophrenia or 
Schizophreniform Disorder. 
 Men (n=113) Women (n=64) p value 
Depression/anxiety score 7.29 ±2.95 8.6 ± 3.09 0.007 
Positive score 20.4 ± 6.70 20.8 ± 7.08 NS 
Negative score 24.7 ± 7.25 24.2 ± 5.68 NS 
GPS 38.3 ± 8.75 39.1 ± 9.62 NS 
PANSS total score 83.4 ± 17.07 84.1 ± 18.65 NS 
Composite score -4.3 ± 10.45 -3.4 ± 8.14 NS 
  
GPS = General psychopathology score 
NS = not significant 
 
 
 
 
Table 2. Mean ± SD PANSS Scores for First Episode and Multiple Episode Patients With 
Schizophrenia or Schizophreniform Disorder. 
 First episode (n=60) Multiple episode (n=115) p value 
Depression/anxiety score 8.5 ± 3.32 7.4 ± 2.84 0.02 
Positive score 23.7 ± 5.15 18.7 ± 6.94 < 0.0001 
Negative score 23.3 ± 8.06 25.3 ± 5.79 0.05 
GPS 41.4 ± 10.19 37.2 ± 8.08 0.003 
PANSS total score 88.4 ± 19.2 81.2 ± 16.33 0.01 
Composite score 0.42 ±9.24 -6.5 ± 8.89 < 0.00001 
 
GPS = General psychopathology score 
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Introduction 
Similarities between schizophrenia and obsessive-compulsive disorder (OCD) have long been 
recognised.  Obsessive-compulsive symptoms in patients with schizophrenia were first 
described by Westphal over 100 years ago.1  The disorder was considered to be a variant of 
schizophrenia.  Since that time the relationship of OCD to schizophrenia and psychosis has 
been the subject of considerable debate.  Unfortunately, only a few methodologically sound 
studies have investigated this relationship.  Associations between the two disorders have 
been investigated in two ways – on the one hand the frequency of obsessions and 
compulsions in patients with schizophrenia has been assessed, and on the other hand the 
occurrence of psychotic symptoms in patients with OCD has been investigated.  This article 
reviews the literature concerning the co-occurrence of schizophrenia and OCD.  Clinical 
implications are highlighted, and avenues for further research are suggested. 
 
OCD IN PATIENTS WITH SCHIZOPHRENIA 
Several studies have investigated the occurrence of OCD symptoms in patients with 
schizophrenia, with the reported frequency ranging from 3.5% to 25%.2-4  In a retrospective 
chart review, Rosen2 found prominent features of OCD in 30 (3.5%) of 848 patients with 
schizophrenia.  These symptoms either preceded or coincided with the onset of the 
schizophrenic symptoms.  He emphasised the depressive and paranoid features of these 
patients, and considered them to have a good prognosis.  In another retrospective chart 
review Fenton and McGlashan3 found that 21 (12.9%) of 163 DSM-III-diagnosed 
schizophrenic patients had prominent OCD symptoms.  Berman et al.4 interviewed the 
treating physicians of 108 patients with chronic schizophrenia and found prominent OCD 
symptoms in 27 (25%).  However, in a well-designed study on 77 patients with schizophrenia 
or schizo-affective disorder, Eisen et al.5 found that only 6 (7.8%) also met DSM-III-R criteria 
for OCD.  This prospective study employed the Structured Clinical Interview for DSM-III-R and 
the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), as well as chart review and contact 
with the treating clinicians.  Of the above studies, the latter is most likely to reflect the true 
incidence of OCD in patients with schizophrenia.  The occurrence of OC symptoms in patients 
with schizophrenia is likely to be considerably higher.  In a study limited by ?is small sample 
size, Yaryura-Tobias et al.6 reported unexpectedly high scores on the Y-BOCS and the Self-
Rated Symptom Scale for OCD in 13 patients with schizophrenia, and found great similarities 
in thought process impairment and perceptual deficits when compared with 22 OCD patients.  
Little is known about the clinical, neurobiological and treatment aspects of these patients.  
The need for further carefully planned prospective studies is obvious. 
 
OCD WITH PSYCHOTIC FEATURES 
Clinical observations indicate that not all OCD patients recognise their obsessions as being 
irrational or excessive.  Their ideas have usually been described as overvalued or delusional.  
Kozak and Foa7 have examined the matter of insight in OCD and conclude that OCD ideas 
cannot be dichotomised into those with and those without insight.  They suggest that a 
continuum of strength of OC beliefs is more appropriate, and emphasise that the relationship 
between the degree of OC conviction and outcome of treatment remains unclear.  In 1875 du 
Saulle8 reported psychotic symptoms in some of the 27 OCD patients he described.  The 
patients with psychotic features also had poor insight and severe psychopathology.  Janet9 
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found psychotic symptoms in 7.7% of patients with OCD.  In a review of the literature of OCD 
with psychotic features, Insel and Akiskal10 list 9 studies11-19 of patients who were initially 
diagnosed as OCD and in whom a relatively high incidence of psychosis was found.  
Incidence rates for schizophrenia in these studies range from 0.7% to 12.3%.  The authors 
point out that these findings should be interpreted with caution, as these were all retrospective 
studies, with the diagnoses being made by chart review.  Also, standardised criteria for 
diagnosing schizophrenia were not used.  Rudin12 and Muller13 found that a relatively high 
percentage of their patients had schizophrenia, while other studies considered their OCD 
patients to be psychotic only in the presence of paranoid thinking, or transient loss of insight.  
Interestingly, many of the OCD patients with psychotic features reportedly had a relatively 
good outcome. 
 
Insel and Akiskal10 emphasise that the deterioration often seen in patients with schizophrenia 
is extremely rare in OCD patients with psychotic features.  The literature suggests that 
psychotic features in OCD patients may often be due to a paranoid state or a mood disorder 
rather than a schizophrenic illness.  More recently, Eisen and Rasmussen20 assessed 475 
patients with DSM-III-R OCD.  Sixty-seven (14%) were identified as having ‘psychotic’ 
symptoms.  However, the only psychotic symptom in 27 (6%) was lack of insight, and 14 (3%) 
were actually diagnosed as schizotypal personality disorder.  The remainder of the patients 
met criteria for specific psychotic disorders.  Eighteen (4%) met criteria for schizophrenia, and 
8 (2%) had a delusional disorder.  OCD patients with psychotic features were more likely to 
be male, single, to have received treatment earlier, and to have had a deteriorating course.  In 
contrast to some earlier studies, therefore, these authors found that OCD patients with 
features of schizophrenia had a poor outcome.  Clearly, there is considerable heterogeneity 
among OCD patients with psychotic symptoms. 
 
The co-occurrence of OCD and schizophrenia appears to be greater than would be expected 
by chance.  Taken together, the evidence points to a small but significant subset of patients 
sharing OCD and schizophrenia symptoms.  Whether this represents a distinct clinical entity, 
or the extremes of a continuum, is not clear.  Further prospective studies are required to 
clarify this issue as well as to determine such matters as whether these patients have other 
distinctive features, whether they respond differentially to standard treatment, and whether 
other treatment options – e.g. serotonin reuptake inhibitors (SRIs) combined with 
antipsychotics – may be effective.21 
 
SEROTONIN AND DOPAMINE  
There is considerable evidence suggesting that serotonergic and dopaminergic pathways 
may have particular relevance both for patients with OCD and for those with schizophrenia.  
SRIs are the first-line treatment for OCD,21 and dopamine-blocking agents have been the 
mainstay of the treatment of schizophrenia for many years.22  Furthermore, preclinical and 
clinical findings have reported that dopamine plays a role in OCD and possibly related 
disorders such as Tourette’s syndrome.23,24  Also, in treatment-resistant OCD augmentation 
with haloperidol has been successful, particularly if tics are present.25  The advent of the new 
antipsychotics has brought renewed interest because of their combined dopaminergic and 
serotonergic blocking properties.  In this regard several studies, although uncontrolled, have 
reported a favourable augmentative effect with the new antipsychotic risperidone in treatment-
resistant OCD.26-30  Paradoxically, several anecdotal reports have arisen of OCD symptoms 
emerging in patients with schizophrenia during treatment with both clozapine31-36 and 
risperidone.37-39  The frequency of this occurrence is unknown and it may be extremely rare, 
as a retrospective review of hospital files in 142 randomly selected patients on clozapine 
treatment failed to identify a single case of OCD symptoms worsening or emerging during 
treatment.40  Also, in a prospective study of patients with schizophrenia those taking another 
new antipsychotic, olanzapine, did not experience more OC symptoms than those taking 
placebo.41 
 
These findings again point to a complex interrelationship between serotonin and dopamine in 
the pathogenesis of OCD and schizophrenia.  It may be that the emergence of OCD 
symptoms during treatment with the new antipsychotics is a coincidental occurrence, or it may 
represent a rare idiosyncratic reaction.  On the other hand it may be that patients with 
coexisting psychosis and OCD and patients with resistant OCD represent two distinct 
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subgroups with different underlying disorders of serotonergic and dopaminergic function.  
Patients with OCD and psychosis may therefore experience exacerbation of OCD symptoms 
with combined dopamine and serotonin blockade, while patients with refractory OCD may 
respond favourably to this intervention.  The differential response for symptoms of OCD and 
schizophrenia in patients with both disorders is not entirely unexpected, as functional brain-
imaging studies have suggested an opposite pattern of frontal lobe activity,42 and 
neuropsychological investigations report a double dissociation of frontal lobe functioning in 
OCD and schizophrenia.43  Whatever the underlying mechanisms, increasing evidence points 
to the involvement of serotonergic and dopaminergic neurotransmitter systems in patients 
with coexisting OCD and schizophrenia.21  Future controlled trials with drugs acting on these 
two systems in different ways may shed more light on the underlying mechanisms, and may 
offer better therapeutic options for these patients.  The new antipsychotics in particular may 
have a role to play and may deserve exploration – not only in schizophrenia, but also in OCD 
and related disorders such as Tourette’s syndrome. 
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Abstract 
To investigate the pathogenesis of water intoxication in psychotic disorders, a standard water 
load test was given to 23 unmedicated patients with schizophrenic or schizoaffective 
disorders.  Levels of plasma arginine vasopressin were measured concurrently.  Compared 
with 28 healthy volunteers, the psychotic patients had significantly smaller cumulative urine 
output and higher minimum urine osmolalities.  Patients whose current illness had lasted less 
than 24 weeks exhibited the most severe antidiuretic state and also had the highest plasma 
arginine vasopressin levels.  Water intoxication in acute exacerbations of psychosis may 
develop as a result of impaired excretory mechanisms. 
 
 
 
Self-induced water intoxication is a well-recognized complication in certain patients with 
psychotic disorders, particularly of the schizophrenic type (1-3).  Initially, polydipsia was 
emphasized in the pathogenesis (4), but it was later recognized that impaired excretory 
mechanisms may also play a role.  Lack of maximal urinary diluting capacity in the presence 
of serum hypotonicity in some cases suggested an excessive secretion of arginine 
vasopressin.  In fact, the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 
has subsequently been documented by direct assay of arginine vasopressin in a number of 
psychotic patients with water intoxication (5,6).  In a further development, Raskind et al. (7) 
reported elevated plasma arginine vasopressin levels in unmedicated, acutely psychotic 
patients without water intoxication.  This led us to investigate the existence of an antidiuretic 
state in psychotic patients by measuring their responses to a standard water load test (8) and 
estimating concurrent levels of plasma arginine vasopressin.  Reference data were obtained 
by simultaneously studying a group of healthy volunteers. 
 
METHOD 
 
The psychotic patients consisted of 16 men and seven women between the ages of 18 and 
42 years (median=27 years) who met the Research Diagnostic Criteria (9) for a schizophrenic 
(N=15) or schizoaffective (N=8) disorder.  All of them manifested features of active psychosis, 
had been free of psychotropic medication for at least 4 months, and were tested within 4 days 
of admission to a psychiatric ward.  At the time of the study, each patient was rated on the 
Brief Psychiatric Rating Scale (BPRS) (10).  The healthy volunteers were recruited from 
hospital staff and their families;  there were 21 men and seven women between the ages of 
18 and 55 years (median=25.5 years).  Subjects in both groups were in good physical health, 
did not display polydipsia, and had no other disorders associated with an abnormal fluid 
balance or with SIADH.  None gave a history of excessive alcohol consumption or drug abuse 
or was taking any medication.  All subjects gave informed consent. 
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The subjects fasted and abstained from smoking from the previous evening until completion 
of the test, during which they remained recumbent.  Blood and urine samples were obtained 
before the administration of a standard water load test.  Blood was analyzed for sodium, 
potassium, creatinine, urea, osmolality, glucose, albumin, globulin, conjugated and 
unconjugated bilirubin, γ-glutamyltransferase, hematocrit, thyroid-stimulating hormone, T3, T4, 
9-hour cortisol, plasma renin activity, and β2 microglobulin (as an indicator of glomerular 
function).  Urine was analyzed for osmolality and β2 microglobulin (as an indicator of renal 
tubular function). 
 
For the water load test, subjects consumed 20 ml/kg of body weight of cool tap water within 
15 minutes.  Each hour during the next 4 hours, blood pressure was recorded and samples of 
blood and total urine output were collected.  These were analyzed for electrolyte and 
osmolality concentrations.  Blood for arginine vasopressin assay was drawn at 0, 2, and 4 
hours and was collected in ice-cooled EDTA Vacutainer tubes.  These were immediately 
transported on ice to the laboratory, and the plasma was separated in a cold centrifuge at 
4oC.  The separated plasma was stored at –20oC.  Arginine vasopressin was measured by 
means of a radio-immunoassay kit (Immuno Nuclear Corp.).  Interassay and intra-assay 
coefficients of variation were 12.5% and 11.2%, respectively. 
 
To determine the relationships between the variables of anxiety, psychotic symptoms, and 
response to the water load test, the following procedure was followed.  A total anxiety factor, 
consisting of the sum of the scores from the BPRS scales of anxiety, agitation, and 
excitement, and a psychosis factor, consisting of the sum of the scores from the BPRS scales 
of suspiciousness, hallucinations, unusual thought content, and conceptual disorganization 
(7), were calculated.  Correlations were then sought between these scores and the 
percentage water load excreted, the minimum urine osmolality obtained, and plasma arginine 
vasopressin values at 0, 2, and 4 hours. 
 
Because of small sample sizes, the median and interquartile ranges were used to summarize 
the continuous measurements within the groups.  Pairwise comparisons were done with the 
Mann-Whitney U test or, when there were many tied values, the Median test (11).  Spearman 
correlation coefficients (rho) for selected continuous variables were calculated within each 
group.  A significance level of 0.05 was used throughout. 
 
RESULTS 
 
Values for baseline blood and urine studies were within normal limits in all of the subjects.  
The percentage water load excreted and the minimum urine osmolalities obtained in the two 
groups of subjects are shown in figures 1 and 2.  Compared with healthy volunteers, the 
psychotic patients excreted a significantly lower cumulative volume (for healthy volunteers, 
median=115% and interquartile range=32;  for psychotic patients, median=86% and 
interquartile range=44).  The psychotic patients also had significantly higher minimum urine 
osmolalities (for healthy volunteers, median=72 mmol/kg of water and interquartile range=18;  
for psychotic patients, median=112 mmol/lkg and interquartile range=161).  Figure 3 shows 
plasma arginine vasopressin levels measured at 0, 2, and 4 hours.  Median and interquartile 
range values at 0, 2, and 4 hours for the psychotic patients were 1.30 and 1.80 pg/ml, 0.90 
and 0.70 pg/ml, and 1.00 and 0.90 pg/ml, respectively;  for the healthy volunteers, they were 
1.15 and 0.58 pg/ml, 0.90 and 0.63 pg/ml, and 0.99 and 0.84 pg/ml, respectively.  There were 
no significant differences between the two groups. 
 
Baseline serum sodium levels for the psychotic patients (median=142 mmol/liter and 
interquartile range=3) were similar to those of the healthy volunteers (median=142 mmol/liter 
and interquartile range=5).  At 4 hours, serum sodium values had reverted to baseline levels 
in the healthy volunteers (median=142 mmol/liter and interquartile range=5) but remained 
significantly lower (median test, χ2=8.64, df=1, p=0.003) in the psychotic patients 
(median=139 mmol/liter and interquartile range=4).  The median value and interquartile range 
for serum osmolality before loading for the psychotic patients were 284 and 14 mmol/kg of 
water, and for the healthy volunteers, 285.5 and 6 mmol/kg.  At 4 hours, the medians and 
interquartile ranges were 279 and 8 mmol/kg of water for the psychotic patients and 281.5 
and 7 mmol/kg for the healthy volunteers. 
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The only significant correlations were between total anxiety scores and plasma arginine 
vasopressin at 0 hours (rho=0.54, N=23, p=0.007) and at 2 hours (rho=0.51, N=23, p=0.01). 
 
On separating the psychotic patients according to duration of the current illness, those with a 
duration of less than 24 weeks (N=12) showed the most pronounced antidiuretic state.  Thus, 
compared with the healthy volunteers, all 12 were below the 0.25 centile of 104% for 
cumulative urine output, 10 were above the 0.75 centile of 81.5 mmol/kg of water for minimum 
urine osmolality, and seven were above the 0.75 centile of 1.40 pg/ml for baseline arginine 
vasopressin levels. 
 
 
Figure 1. Percentage Water Load Excreted for 23 Psychotic Patients (group A) and 28 
Healthy Volunteers (group B)a 
 
 
 
 
 55
Figure 2. Minimum Urine Osmolalities After Water Loading for 23 Psychotic Patients 
(group A) and 28 Healthy Volunteers (group B)a 
 
 
 
Figure 3. Plasma Arginine Vasopressin Levels at 0, 2, and 4 Hours During Water 
Loading for 23 Psychotic Patients (group A) and 28 Healthy Volunteers 
(group B)a 
  
 
 
 
 56
 
 
DISCUSSION 
 
The results of this study indicate that an antidiuretic state exists in some patients with 
schizophrenic and schizoaffective disorders and that this is most pronounced in those whose 
current illness is of less than 24 weeks’ duration.  We attribute this abnormality to an arginine 
vasopressin mediated effect, since other, recognized causes of water excretion, such as 
renal, hepatic, or cardiac failure, hypothyroidism, and adrenal insufficiency (8), were not 
evident.  Arginine vasopressin hypersecretion is suggested by the fact that the highest 
baseline plasma arginine vasopressin levels were found in the patients with the most 
pronounced antidiuretic state.  However, the possibility of enhanced renal sensitivity to 
arginine vasopressin cannot be excluded, because levels of the hormone did not differ 
significantly between the psychotic patients and the healthy volunteers.  In a study of water 
metabolism in medicated psychotic patients with polydipsia and hyponatremia (12), similar 
findings in conjunction with a shift in the relation between urine osmolality and plasma 
arginine vasopressin levels led the authors to suggest the existence in their patients of 
enhanced renal sensitivity to arginine vasopressin.  The cause was not readily apparent.  Our 
patients did not have polydipsia or hyponatremia and were not receiving neuroleptics.  
Nevertheless, enhanced renal sensitivity to arginine vasopressin remains a possible 
explanation for their antidiuretic state. 
 
Seven of the 12 patients whose current illness had lasted less than 24 weeks had baseline 
arginine vasopressin levels above the 0.75 centile for the control subjects.  Hyperosmolality, 
the normally overriding physiological stimulus to arginine vasopressin release, cannot be 
implicated because serum sodium levels were not raised.  (The use in this context of serum 
sodium values rather than values for serum osmolality is in accordance with 
recommendations (8) when, as in our case, the method for determining osmolality uses 
serum rather than plasma and vapor pressure osmometry rather than freezing point 
depression).  The recognized nonosmolar stimuli of hypovolemia, hypotension, nausea, and 
hypoglycemia (8) were not present, while the activity of plasma renin – implicated in the 
control of arginine vasopressin release (13) – was not elevated.  Pathways subserving 
osmoregulation may have been deranged.  Thus, although preservation of osmoreceptor 
control was indicated by a fall in plasma arginine vasopressin levels at 2 and 4 hours that was 
appropriate to the reduced concentration of serum sodium (figure 3), the higher baseline 
plasma arginine vasopressin levels could be explained by a resetting of osmoreceptors, with 
a downward shifting of the threshold at which arginine vasopressin is released (14).  In this 
regard, it is noteworthy that in the psychotic patients with polydipsia and hyponatremia studied 
by Goldman et al. (12), the osmotic threshold for arginine vasopressin release was shown to 
be lowered. 
 
Nonspecific emotional stress has been proposed as a stimulus to arginine vasopressin 
release (15).  Whereas the evidence is tenuous and may depend on the development of 
hypotension (16), our findings of significant correlations between total anxiety scores and 
plasma arginine vasopressin levels at 0 and 2 hours suggest that emotional stress may have 
been relevant in this instance.  Finally, some process other than the recognized osmolar and 
nonosmolar regulatory mechanisms may have been responsible.  Raskind et al. (7) have 
suggested that a disturbance of CNS function may produce the symptoms of a psychotic 
disorder and simultaneously alter central arginine vasopressin regulation. 
 
The finding of higher baseline plasma arginine vasopressin levels in patients with an illness of 
short duration accords with the fact that many reported cases of water intoxication occurred at 
the time of an acute psychotic episode.  It could be that excessive release of arginine 
vasopressin is a necessary factor.  Occurring during acute exacerbations and thereby 
rendering such individuals susceptible, the actual development of water intoxication may 
depend on the presence of additional factors that compromise water homeostasis.  Factors 
that may be particularly relevant include increased fluid intake (primary polydipsia) (1), defects 
in urinary dilution (12), and drugs considered to be causative agents in SIADH, such as the 
nicotine from tobacco smoking (17), carbamazepine (18), thiazide diuretics (19), and, 
possibly, neuroleptic drugs (20). 
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2.b Disordered water homeostasis in schizophrenia and cerebral ventricular size 
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Summary 
Background:  A possible association between disordered water homeostasis and cerebral 
ventricular size in patients with schizophrenia was investigated. 
Method:  In a cross-sectional study of hospitalised patients, cerebral ventricular size was 
measured in 16 schizophrenic patients with disordered water homeostasis and 16 matched 
schizophrenic controls by magnetic resonance imaging. 
Results:  Ventricle to brain ratio, third ventricular index, bicaudate index and bifrontal index 
tended to be greater in those with schizophrenia with disordered water homeostasis, although 
differences were significant only for the bifrontal index (P<0.05).  Strong negative correlations 
were found between ventricular size and performance on neuropsychological testing in the 
disordered water homeostasis group. 
Conclusion:  These results provide evidence for an association between structural brain 
abnormality and disordered water homeostasis in a subset of schizophrenic patients. 
 
 
 
Disordered water homeostasis is a well-recognised complication of schizophrenia (Ferrier, 
1985), its estimated prevalence in state psychiatric hospitals being between 7% and 18% 
(Jose & Perez Cruet, 1979; Blum & Friedland, 1983).  The disorder comprises polydipsia 
and/or impaired urinary excretion due to the syndrome of inappropriate antidiuretic hormone 
secretion (Riggs et al, 1991).  In approximately 50% of cases the disorder is severe enough to 
cause periodic episodes of water intoxication (Jose & Perez Cruet, 1979) – a potentially lethal 
and under-recognised medical emergency. 
 
Recent studies provide evidence to suggest that disordered water homeostasis in 
schizophrenia is associated with structural brain abnormality.  Kirch et al (1985) reported that 
eight polydipsic schizophrenics who had developed hyponatraemia showed brain scan 
evidence of ventricular enlargement, and cognitive impairment on IQ testing.  Lawson et al 
(1985) found that although schizophrenics with polydipsia and polyuria were more likely to 
have good premorbid histories and positive treatment responses, those who developed 
hyponatraemia showed tardive dyskinesia and enlarged ventricles on CT scanning.  Schnur 
et al (1993) found that schizophrenic patients with polydipsia and hyponatraemia performed 
significantly worse on the Mini-Mental State examination than did a schizophrenic comparison 
group.  They suggested that their findings could be explained by repeated episodes of 
hyponatraemia causing brain damage in these patients.  We recently reported the findings of 
a study of 16 schizophrenics with severely disordered water homeostasis and 16 carefully 
matched schizophrenic controls, where neuropsychological tests were applied to each subject 
(Emsley et al, 1993).   Significantly more cognitive impairment was found in the patients with 
disordered water homeostasis relative to the control group.  We now report results of 
measurement of the cerebral ventricular size in these subjects by magnetic resonance 
imaging (MRI). 
 
Method 
 
Subjects 
 
The patients with severely deranged water homeostasis (Group A) were all long-term in-
patients of a state psychiatric hospital who met DSM-III-R criteria (American Psychiatric 
Association, 1987) for schizophrenia.  All displayed profound polydipsia and/or hyponatraemia 
(serum sodium < 130 mmol/l).  The polydipsic patients were identified by an experienced 
psychiatric nurse who visited the wards and interviewed staff members with daily contact with 
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the patients.  We included only patients who had been noticed to consume volumes of fluid 
obviously much above normal.  The patients with hyponatraemia were identified from a survey 
in which serum sodium levels of all adult patients at the hospital were determined.  For those 
whose levels were below 130 mmol/l, other causes of hyponatraemia were excluded 
(Robertson, 1987).  Excretory capacity was regarded as impaired if concomitant urine 
samples showed non-maximal urinary dilution – i.e. urine osmolality > 100 mmol/kg H2O 
(Robertson, 1987). 
 
The control group (Group B) comprised long-term-care in-patients from the same state 
psychiatric hospital who met DSM-III-R criteria for schizophrenia, but had never shown 
evidence of polydipsia or polyuria or had previous episodes of hyponatraemia.  Their clinical 
files were scrutinised, ward staff were interviewed and serum sodium levels measured.  
These patients were matched with the Group A patients for age, sex, educational status, 
socio-demographic background and duration of schizophrenic illness.  Subjects in both 
groups were in good physical health, and all provided informed consent. 
 
Magnetic resonance imaging 
 
MR images were acquired with the South African Medical Research Council’s Elscint 0.5 T 
Gyrex V imager.  All measurements were performed by one of us (RS) without knowledge of 
the subject’s identity.  Routine spin-echo technique protocols were used to demonstrate the 
brain parenchyma (T1-weighted) and cerebrospinal fluid spaces (T2-weighted).  The following 
multislice sequences were performed:  a T1-weighted coronal study  (TR500/TE30 ms, slice 
width 6 mm, slice gap 3 mm) and a T2-weighted axial study (TR2000/TE30, 90 ms, slice width 
4.7 mm, slice gap 1.6 mm).  The coronal slices were planned at 90o to the orbito-meatal line.  
The ventricular size was then determined by the following measures. 
 
Ventricle to brain ratio (VBR) 
 
From the T2-weighted axial sequence, we chose the two consecutive slices visually judged to 
show the largest lateral ventricular area.  The margins of the lateral ventricles were defined on 
the screen by a manual tracing technique and the area was computed using standard in-built 
image analysis software.  The area of the brain was calculated similarly, from the same slices.  
The VBR was taken as the average of the two measures of the ratio of the area of ventricle to 
area of brain. 
 
Third ventricular index (TVI) 
 
From the coronal plane T1-weighted image, the slice visually judged to display the maximum 
width of the third ventricle was chosen.  The TV1 was obtained by dividing the width of the 
third ventricle by the transverse distance between the inner tables of the skull at the same 
level. 
 
Bicaudate index (BCI) 
 
From the coronal slice with the most medially placed caudate heads, the bicaudate distance 
was measured from the maximum convexity of the caudate nuclei, and this was expressed as 
a percentage of the internal diameter of the calvarium at the same level. 
 
Bifrontal index (BFI) 
 
In the same coronal slice as the BCI, the greatest transverse distance between the frontal 
horns of the lateral ventricles was measured and expressed as a percentage of the diameter 
of the inner skull table at the same level. 
 
The BCI, BFI and TVI measures were adapted from Geremia & Huckman (1992).  For the 
various measures the test/retest reliability was: VBR 0.97, BCI 0.98, BFI 0.98 and TVI 0.97. 
 
Neuropsychological evaluation 
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The following tests were applied to each subject:  Wechsler Adult Intelligence Scale (WAIS); 
Wechsler Memory Scale (WMS) (logical memory, visual reproduction and associate learning 
subtests); Rey Complex Figure Test (RCFT) (with delayed recall after 30 min); Trail Making 
Test (TMT); Auditory Verbal Learning Test (AVLT).  Testing and scoring were done in a blind 
fashion. Because some subjects were unable to understand properly the instructions for Part 
B of the TMT, these results were excluded.  For the AVLT the totals of Trials 1 to 5 were used.  
Premorbid IQ was estimated by averaging the three highest subtest standard scores of the 
WAIS (Lezak, 1983). 
To assess whether the groups differed in the severity or the nature of their symptoms, the 
Positive and Negative Syndrome Scale for Schizophrenia (PANSS) (Kay et al, 1987) was 
applied to each subject.  This scale yields separate scores along a Positive Scale, Negative 
Scale, Composite Index (Positive score minus Negative score) and General Psychopathology 
Scale. 
 
Neuropsychological testing took place in the mornings only, and patients were prevented from 
drinking fluids before and during testing.  The MRI studies were, as far as possible, performed 
in the mornings only, after an overnight fast and a light breakfast.  Because of difficulties in 
obtaining MRI bookings, two Group A and five Group B patients were scanned in the early 
afternoon (12.30 p.m.).  These patients were given a light lunch, including beverage, 
beforehand.  No other fluids were allowed.  None of the subjects exhibited impairment of 
consciousness or any other symptoms of acute water intoxication (Arieff et al, 1976) at the 
time of neuropsychological testing or MRI.  Thus, although serum sodium levels were not 
determined at the time, we consider it unlikely that our results were influenced by the acute 
effects of water intoxication.   
 
 
Statistical methods 
 
Results were expressed as the mean (standard deviation).  Since the size of the sample was 
large enough for the assumptions of the t-test to be satisfied and measurements were 
unimodal and continuous, Student’s t-test was chosen for comparisons between groups.  
Correlations for selected variables within groups were performed using the Pearson product 
moment correlation coefficient.  Because of the known effects of age on the size of the 
cerebral ventricles, partial correlations were computed between MRI measures and 
neuropsychological tests, adjusting for age. 
 
 
 
Results 
 
Relevant demographic and clinical data are given in Table 1.  The groups did not differ 
significantly regarding age, sex, highest school grade obtained, duration of illness, estimated 
premorbid IQ, dosage of neuroleptics, number receiving anticholinergic medication, previous 
electroconvulsive therapy, number with tardive dyskinesia, or number of smokers.  Serum 
sodium levels for the hyponatraemia patients (n = 10) ranged from 115 to 129 mmol/l (mean 
124 mmol/l), and for Group B patients (n = 16) from 136 to 145 mmol/l (mean 141 mmol/l).  
Eight hyponatraemic patients had concomitant urine osmolalities over 100 mmol/kg H2O 
(urine samples could not be obtained from the other two).  Five Group A patients (and none of 
the Group B patients) had documented evidence in their files of previous unexplained 
seizures or episodes of loss or clouding of consciousness.  When the ventricular size of these 
five was compared to the other eleven Group A patients, none of the measurements differed 
significantly. 
 
There were no significant differences in any of the PANSS scores between the two groups 
(Table 2).   
 
The measures of ventricular size are given in Table 3.  For all four measures the ventricular 
size tended to be greater in Group A subjects, although this reached significance only for the 
bifrontal index.  Table 4 indicates the partial correlations of individual neuropsychological test 
scores with the measures of ventricular size for the two groups after adjusting for age.  In both 
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groups there was an inverse relationship between cognitive function and ventricular size, but 
the correlations were much stronger in Group A.  Of the 40 correlations performed, 20 were 
significant in Group A, while only one was significant in Group B. 
 
 
Table 1 
Demographic and clinical data for the schizophrenics with disordered water 
homeostasis (Group A) and those without (Group B) 
 
     Group A Group B 
________________________________________________________________ 
n       16  16 
Age (years)      51.9 (11.5) 52.1 (11.7) 
Sex – M:F      14 : 2  14 : 2 
Duration of illness (years)    30.9 (11.2) 31.2 (11.8) 
Polydipsia (n)     10  - 
Hyponatraemia (n)     10  - 
School grade (years)    7.0 (3.1) 7.0 (3.1) 
Premorbid IQ      76.3 (20.9) 82.9 (21.6) 
Dosage of neuroleptics (mg)1   317 (284) 213 (162) 
Anticholinergic medication (n)   9  4 
Previous ECT (n)     8  10 
Tardive dyskinesia (n)    2  3 
Smokers (n)      13  13 
 
______________________________________________________________ 
Values are expressed as the group mean (standard deviation). 
1. Chlorpromazine equivalents. 
ECT = electro-convulsive therapy. 
Table 2 
Test scores : mean values (s.d.) 
 
Test     Group A Group B P Max. score 
__________________________________________________________________________ 
Positive & Negative syndrome Scale 
for Schizophrenics (PANSS)     
 
Positive syndrome   13 (4)  13 (4)   -  
Negative syndrome   26 (11)  27 (13)   - 
Composite score   -13 (9)  -14 (11)   - 
General Psychopathology  80 (28)  78 (28)   - 
Wechsler Adult Intelligence Scale       
(WAIS): total score   61.8 (29.7) 69.2 (19.7) 0.32 - 
Wechsler Memory Scale (WMS)   
Logical memory    2.4 (2.6) 4 (3.3)  0.04 14 
Visual reproduction   2.4 (2.7) 4.6 (3.2) 0.04 21 
Associate learning   4.1 (4.6) 7.3 (5.5) 0.08 36 
Rey Complex Figure Test (RCFT)  
Copy score    14.2 (12.6) 21.9 (10.5) 0.07  
Recall score    3.2 (3.8) 5.5 (3.6) 0.08 36 
Trail Making Test (TMT) Part A  
(seconds to complete test)  180.7 (97.8) 94.0 (55.6) 0.009 
Auditory Verbal Learning Test (AVLT) 16.9 (15.0) 23.4 (15.8) 0.24 75  
__________________________________________________________________________ 
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Table 3 
Measures of ventricular size for the schizophrenics with disordered water homeostasis 
(Group A, n = 16) and those without (Group B, n = 16) 
 
Measure    Group A Group B  P 
________________________________________________________________ 
 
TVI     4.75 (2.02) 3.72 (1.85)  0.144 
BCI     15.52 (3.86) 14.04 (4.51)  0.329  
BFI     29.02 (4.83) 25.62 (4.42)  0.046 
VBR     9.41 (4.27) 7.86 (2.79)  0.239  
______________________________________________________________ 
Results are expressed as the mean (standard deviation). 
TVI = third ventricular index; BCI – bicaudate index; BFI = bifrontal index; VBR = ventricle-to-
brain ratio 
 
 
 
 
Table 4 
Partial correlations of ventricular size measures with psychometric indices (controlling 
for age) for 16 schizophrenic patients with disordered water homeostasis (Group A) 
and 16 schizophrenics without (Group B) 
   TVI  BCI  BFI  VBR 
__________________________________________________________________________ 
   A B A B A B A B  
VIQ   -0.56* -0.15 -0.42 -0.09 -0.62** -0.31 -0.45 -0.26 
PIQ   -0.54* -0.10 -0.39 -0.11 -0.59* -0.28 -0.35 -0.30 
TIQ   -0.55* -0.12 -0.41 -0.09 -0.61* -0.30 -0.40 -0.29 
RCFT   -0.63** 0.05 -0.42 -0.07 -0.61* -0.28 -0.40 -0.21 
RCFTREC  -0.54* 0.08 -0.30 -0.01 -0.33 0.05 -0.20 -0.01 
WMLOG  -0.58* -0.28 -0.49 -0.38 -0.58* -0.24 -0.54* -0.26 
WMVIS   -0.53* -0.33 -0.26 -0.15 -0.48 -0.45 -0.34 -0.35 
WMASS  -0.56* 0.09 -0.31 0.22 -0.47 0.20 -0.33 -0.11 
TMTA   0.86*** 0.33 0.64* 0.29 0.78*** 0.53 0.81*** 0.69** 
AVLT   -0.59* 0.03 -0.45 0.24 -0.52* 0.19 -0.43 -0.12  
_________________________________________________________________________ 
*P<0.05; **P<0.01; ***P<0.005 
TVI = third ventricular index; BCI – bicaudate index; BFI = bifrontal index; VBR = ventricle-to-
brain ratio; VIQ = verbal intelligence quotient; PIQ = performance intelligence quotient; TIQ = 
total  intelligence quotient; RCFT = Rey Complex Figure Test; RCFTREC = Rey Complex 
Figure Test with delayed recall after 30 minutes; WMLOG = Wechsler Memory Scale, logical 
memory subtest; WMVIS = Wechsler Memory Scale, visual reproduction; WMASS = 
Wechsler Memory Scale, associate learning; TMTA = Trail Making Test, Part A; AVLT = 
Auditory Verbal Learning Test. 
 
Discussion 
 
In this study, evidence of enlarged ventricles was found in brains of schizophrenic patients 
with deranged water homeostatic mechanisms, compared with a control group of 
schizophrenic patients without such derangement.  Although only one of the four measures of 
ventricular size showed a statistically significant difference between the groups, we consider it 
unlikely that this is a chance finding, for two reasons.  First, ventricular size was greater in 
Group A patients for the other three measures as well, although not significantly so.  The 
relatively small samples may account for the lack of significant differences for these 
measures.  Second, the stronger correlations found between ventricular size and cognition 
function in Group A patients suggest that these results are functionally significant.  These 
results provide the first quantitative radiological evidence of structural brain disorder in 
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schizophrenic patients with co-existing disordered water homeostasis.  Together with the 
findings of our previous study (Emsley et al, 1993), they provide compelling evidence for an 
association between disordered water homeostasis and structural brain disorder in 
schizophrenic patients. 
 
Although the nature of this association is unclear, three possibilities need to be considered.  
The first is that the co-existence of disordered water homeostasis and structural brain 
disorder in schizophrenic patients is a coincidental finding.  The second is that disordered 
water homeostasis may be a consequence of the disease process underlying the 
schizophrenic disorder.  This would be consistent with a proposal by Raskind et al (1975) that 
an underlying cerebral disorder simultaneously produces the symptoms of a psychotic 
disorder, alters the thirst threshold and stimulates vasopressin secretion.  It also accords with 
the suggestion that the ventricular enlargement observed in schizophrenics with disordered 
water homeostasis by Kirch et al (1985) and Lawson et al (1985) might be due to a structural 
defect involving the hypothalamus (Illowsky & Kirch, 1988).  More specifically, Ferrier (1985) 
has suggested that the dilatation of the third ventricle seen in some chronic schizophrenics 
might indicate a destructive or degenerative process in the hypothalamus in these patients.  
The finding in our study that the TVI did not differ significantly between the groups does not 
support the existence of structural pathology specifically in the hypothalamic area.  However, 
TVI is at best a rough measure of diencephalic structures, so that our findings do not rule out 
the possibility of a less obvious structural lesion in this region. 
 
The third possibility is that brain damage develops in these patients as a consequence of their 
disordered water regulation, by way of one or more episodes of water intoxication.  The 
hyponatraemic encephalopathy itself may directly cause irreversible brain damage (Arieff et 
al, 1976), or this could occur by way of hypoxaemia and even head trauma associated with 
the seizures and coma that commonly accompany the condition.  Our finding that patients 
with previous seizures or episodes of impairment of consciousness did not have larger 
ventricles than other Group A patients is an argument against this.  However, the number of 
patients with previous water intoxication episodes is likely to have been underestimated, as 
full clinical records were not always available, and previous episodes of water intoxication 
may have gone unrecognised.  Future longitudinal studies will need to assess whether these 
factors are important. 
 
The possibility that brain damage results from disordered water homeostasis raises an 
important question: can this mechanism account for some of the ventriculomegaly reported in 
schizophrenia (Weinberger et al, 1983)?  If this were so, one would expect the ventricular 
dilatation to develop after the onset of the schizophrenic illness, and become progressively 
worse.   While it is thought that ventriculomegaly in schizophrenics is static and actually 
antedates the illness (Weinberger et al, 1982), there is in fact evidence to suggest that in a 
subgroup of schizophrenic patients this may not be so.  Haug (1962) reported progressive 
cerebral atrophy in four of 31 schizophrenics who underwent pneumoencephalography.  More 
recently, Nasrallah et al (1986) reported the results of a CT scan follow-up study of ventricular 
size in schizophrenia.  Although no significant change was found in the mean VBR after three 
years, 4 of 11 patients showed increases of over 50% in individual ratios.  We suggest that 
some of these cases could be explained on the basis of water intoxication, and that this 
possibility needs to be kept in mind in future studies of ventricular size in schizophrenia. 
 
The limitations of this study include the relatively small sample sizes and the low level of 
education of the patients.  The possibility that differences in hydration between the two groups 
could have influenced the results cannot be excluded.  However, overhydration is unlikely in 
the group with disordered water homeostasis, as precautions were taken to prevent fluid 
overload during the MRI studies.  Furthermore, overhydration is associated with a decrease in 
ventricular size, with a return to normal after water restriction (Berginer et al, 1985).  The 
possibility of water restriction causing dehydration in the patients with disordered water 
homeostasis, with resultant cerebral shrinkage, is also unlikely, because of their impaired 
excretory capacity.  Further studies need to address the question of whether the structural 
brain disorder in these patients is static or progressive, and whether it is related to episodes 
of actual water intoxication.  The need for heightened clinical awareness to the possibility of 
water intoxication occurring in schizophrenic patients is obvious, as the condition can be 
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effectively treated, and future episodes prevented.  Treatment modalities include fluid 
restriction, removal of exacerbating factors such as thiazide diuretics or carbamazepine, the 
use of medications such as demeclocycline (Illowsky & Kirch, 1988) and group therapy 
(Millson et al, 1993). 
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To investigate a possible association between disordered water homeostasis and cognitive 
impairment in schizophrenia, neuropsychological tests were applied to 16 schizophrenic 
patients with severely deranged water homeostasis and to 16 matched schizophrenic 
controls.  The patients with disordered water homeostasis tended to obtain poorer scores 
than the controls throughout, the differences being statistically significant for two of the tests 
(Wechsler Memory Scale Visual Reproduction and Trail Marking Test part A).  These results 
were not ascribable to differences in the duration of the illness, premorbid IQ, medication, or 
electroconvulsive therapy received, or prominence of any particular symptoms.  The results 
suggest the co-existence of disordered water homeostasis and cognitive impairment in a 
subset of schizophrenic patients. 
 
 
Introduction 
 
Polydipsia and polyuria were first reported in psychiatric patients 60 years ago (Hoskins and 
Sleeper 1933).  Since then an association between schizophrenia and disorders of water 
homeostasis has been well established (Riggs et al 1991).  Although schizophrenics generally 
exhibit increased fluid intake and urine output (Lawson et al 1985), and impaired excretory 
capacity (Emsley et al 1989) compared to controls, 6.6% have a more profound derangement 
of fluid homeostatic mechanisms (Jose and Perez-Cruet 1979).  This latter group is 
characterized by frank polydipsia and/or inappropriate secretion of antidiuretic hormone, 
which may periodically lead to episodes of water intoxication (Riggs et al 1991).  The 
pathogenesis of the disorder remains essentially conjectural.  One possibility is that both the 
psychotic illness and the deranged water homeostasis are manifestations of an underlying 
disturbance of central nervous system function (Raskind et al 1975). 
 
Sleeper and Jellinek (1936), in comparing 12 polyuric schizophrenics with 12 schizophrenic 
patients with a normal urinary output, reported higher IQs and less emotional deterioration in 
the polyuric group, and considered the cause to be psychological rather than biological.  
However, two recent studies provide evidence to suggest that deranged water homeostasis in 
schizophrenia, if severe, is associated with structural brain damage.  Kirch et al (1985) found 
that the clinical profile in eight polydipsic schizophrenic patients who had developed 
hyponatremia conformed to type II schizophrenia as described by Crow (1985), which has 
been associated with structural brain damage.  Also, their patients showed computed 
tomography (CT) brain scan evidence of ventricular enlargement, and cognitive impairment 
on IQ testing.  Similarly, Lawson et al (1985) found that although schizophrenic patients with 
polydipsia and polyuria were more likely to have good premorbid histories and positive 
neuroleptic responses, those who developed hyponatremia showed tardive dyskinesia and 
enlarged ventricles on CT scanning – again conforming to type II schizophrenia (Crow 1985).  
Although the limited size of the samples in these studies precludes any definitive conclusions, 
it may be that schizophrenic patients with mild polydipsia and polyuria conform to type I 
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schizophrenia, whereas those with a more severe disorder of water homeostasis who develop 
hyponatremia correspond to type II schizophrenia. 
 
Cognitive impairment has been described in a subset of patients with schizophrenia (Watson 
et al 1987).  The present study investigates the possibility that disordered water homeostasis 
is associated with cognitive impairment in schizophrenia.  We have applied a battery of 
standard neuropsychological tests to schizophrenic patients with severely disordered water 
homeostasis and compared them with carefully matched schizophrenic patients without any 
evidence of such derangement. 
 
Methods 
 
The patients with severely deranged water homeostasis (Group A) were selected as follows:  
All were long-term care inpatients from a State Psychiatric Hospital who met DSM-III-R criteria 
(American Psychiatric Association 1987) for a schizophrenic disorder.  All displayed either 
profound polydipsia or an impaired excretory capacity, or both.  Patients with polydipsia were 
identified by an experienced psychiatric nurse who visited each ward and interviewed at least 
one staff member with day-to-day patient contact.  Only patients who had been observed to 
consume vastly excessive volumes of fluid were included.  The patients with an impaired 
excretory capacity were identified as follows:  Serum sodium levels of all long-term care adult 
inpatients were determined.  In patients with levels < 130 mmol/L, other causes of 
hyponatremia were excluded and an impaired excretory capacity was confirmed by 
demonstration of concomitant nonmaximal urinary diluting capacity (Robertson 1987). 
 
The control group (Group B) comprised long-term care inpatients from the same State 
Psychiatric Hospital who met DSM-III-R criteria for a schizophrenic disorder, but had never 
displayed polydipsia, polyuria, or had any previous episodes of hyponatremia, and who were 
found on testing to have a normal serum sodium.  These patients were matched with Group A 
patients for age, gender, education status, sociodemographic background, and duration of 
schizophrenic illness.  Subjects in both groups were in good physical health, and all provided 
informed consent. 
 
The following neuropsychological tests were applied to each subject:  Wechsler Adult 
Intelligence Scale (WAIS); Wechsler Memory Scale (WMS) (logical memory, visual 
reproduction and associate learning subtests); Rey Complex Figure Test (RCFT) (with 
delayed recall after 30 min); Trail Making Test (TMT); Auditory Verbal Learning Test (AVLT).  
Testing and scoring were done in a blind fashion.  Patients were tested in the morning only, 
and were prevented from drinking prior to and during testing.  None of the subjects exhibited 
impairment of consciousness or any other symptoms of acute water intoxication (Arieff et al 
1976) at the time of testing.  Thus, although serum sodium levels were not determined at the 
time, we consider it unlikely that test performances were influenced by water intoxication.  
Because some subjects were unable to adequately understand the instructions for part B of 
the TMT these results were excluded.  For the AVLT the totals of trials 1 to 5 were used.  
Premorbid IQ was estimated by averaging the three highest subtest standard scores of the 
WAIS (Lezak 1983).  To assess whether any differences in test performance between the two 
groups could be ascribed to differences in the severity or nature of symptoms, the Positive 
and Negative Syndrome Scale for Schizophrenia (PANSS) (Kay et al 1987) was applied to all 
subjects.   This scale yields separate scores along a Positive Scale, Negative Scale, 
Composite Index (Positive score minus Negative score) and General Psychopathology Scale. 
 
Because of small sample sizes and skewed data, the median (and interquartile range) were 
used to summarize the measurements within the groups.  Comparisons between groups were 
performed using the Wilcoxon-Mann-Whitney U test. 
 
Results 
 
The patients with disordered water homeostasis (Group A) consisted of 14 men and 2 women 
between the ages of 23 and 61 years (median 55.0 years).  All had either polydipsia (n=5), or 
dilutional hyponatremia with evidence of impaired excretory capacity (n=6), or both (n=5).  
The highest school grade obtained ranged from 1 to 10 (median 6) and the duration of the 
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schizophrenic illness ranged from 3 to 44 years (median 33.5 years).  The control group 
(Group B) comprised 14 men and 2 women aged 23 to 67 years (median 55.5 years).  The 
highest school grade obtained ranged from 0 to 10 (median 6) and the duration of the 
schizophrenic illness ranged from 2 to 44 years (median 32 years). 
Group A and Group B did not differ significantly regarding premorbid IQ [71(31) versus 
76(36)], the dosage of neuroleptics [258(400) mg versus 175(200) mg chlorpromazine 
equivalents], as well as the number receiving anticholinergic medication (9 versus 4) or 
previous electroconvulsive therapy (8 versus 10), showing evidence of tardive dyskinesia (2 
versus 3), or smoking (13 versus 13).  None of the subjects were receiving benzodiazepines.  
An attempt to estimate the number of patients with previous episodes of water intoxication 
was made by searching their files for previous unexplained seizures, delirium, or documented 
serum sodium values < 120 mmol/L.  Evidence of such episodes was found in 5 of the Group 
A patients.  When these 5 patients were compared to the other 11 patients in Group A they did 
not show significantly more cognitive impairment, negative symptomatology, or tardive 
dyskinesia.  Results of the neuropsychological tests for the two groups are given in Table 1.  
Group A patients obtained significantly poorer scores than the Group B controls for the WMS 
visual reproduction (a test of immediate visual memory) and TMT part A (a test involving 
visual scanning and visuomotor integration).  Although there were no other significant 
differences between the groups, Group A patients obtained poorer scores than the Group B 
controls for all of the other tests. 
 
There were no significant differences in any of the PANSS scores between the two groups.  
These scores – expressed as group median (and interquartile range) – were as follows:  
Positive Syndrome scores:  Group A 11(6), Group B 11(5);  Negative Syndrome scores:  
Group A 21(11), Group B 25(19);  Composite scores:  Group A -9(13), Group B -11(21);  
General Psychopathology scores:  Group A 34(14), Group B 36(9). 
 
 
 
 
Table 1. Neuropsychological Test Scores for the Schizophrenics with Disordered 
Water Homeostasis (Group A, n = 16) and those without (Group B, n = 
16)a 
________________________________________________________ 
Test   Group A  Group B  p  value    
 _______________________________________________________ 
WAIS    
VIQ  56 (35)  64 (34)  NS 
PIQ  62 (31)  72 (29)  NS 
TIQ  57 (35)  64 (31)  NS 
WMS 
LM  2 (4)   4 (4)   NS  
VR  1 (4)   4 (5)   0.04 
AL  3 (8)   8 (6)   NS 
RCFT 
Copy score 11 (24)  23 (16)  NS 
Recall score 2 (6)   5 (6)   NS 
TMT (Part A)  170 (123)  64 (43)  0.004 
AVLT   14 (27)  23 (20)  NS 
________________________________________________________  
aValues are expressed as the group median (and interquartile range). 
WAIS = Wechsler Adult Intelligence Scale; VIQ = verbal intelligence quotient; 
PIQ = performance intelligence quotient; TIQ = total intelligence quotient; 
WMS = Wechsler Memory Scale;  LM = logical memory (maximum score = 23);  VR = visual 
reproduction (maximum score = 14); AL = associate learning (maximum score = 21);  RCFT = 
Rey Complex Figure Test (maximum score = 36);  TMT = Trail Making Test (seconds taken to 
complete the test); 
AVLT = Auditory Verbal Learning Test (maximum score = 75). (NS = not significant.) 
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Discussion 
 
This study suggests that deranged water homeostasis is associated with cognitive impairment 
in schizophrenic patients.  This finding cannot be explained on the basis of differences 
between the two groups regarding education status, premorbid IQ, duration of illness, 
medications or electroconvulsive therapy received.  Further, the similar PANSS scores 
indicate that the groups did not differ regarding severity of illness, or prominence of any 
particular symptoms that could effect their performance on neuropsychological testing.  
Finally, as far as possible, precautions were taken to avoid the possibility that acute water 
intoxication could affect test performances. 
 
Our findings of cognitive impairment, together with the findings of Kirch et al (1985) and 
Lawson et al (1985), provide evidence that in patients with schizophrenia, severely disordered 
water homeostasis is associated with structural brain damage.  To attribute the cognitive 
deficits demonstrated in this study to lesions in a discrete area is not warranted by the results.  
Although the significantly lower scores of group A patients for the WMS visual reproduction 
subtest and the TMT part A may indicate visual information input dysfunction as associated 
with right hemisphere pathology (Golden et al 1981; Lezak 1983), the trend toward poorer 
performance throughout in group A patients points rather to a more global impairment of 
function.  Whether the cognitive impairment is static or progressive in these patients remains 
to be determined in future longitudinal studies.  Our study was not designed to investigate 
whether these patients form a distinct subset of schizophrenics.  However, the fact that the 
PANSS scores were similar for the two groups suggests that they do not constitute a group 
that is easily distinguishable on clinical grounds.  In particular, and contrary to the findings of 
Kirch et al (1985) and Lawson et al (1985), we did not find that negative symptoms were more 
common in our patients with water dysregulation.  In addition, within the group of patients with 
disordered water homeostasis, those with previous episodes of water intoxication did not 
display more negative symptomatology, cognitive impairment, or tardive dyskinesia.  This 
finding needs to be interpreted cautiously, however, because of the possibility of a type II error 
caused by the small sample.  Also, the actual incidence of water intoxication in the group A 
patients is likely to have been underestimated because of the unavailability of full clinical 
records together with the possibility of previous episodes of water intoxication having gone 
unrecognized. 
 
Another possible explanation for our findings is that the cognitive impairment may be a 
consequence of the disordered water homeostasis, by way of previous episodes of water 
intoxication.  Thus, dilutional hyponatremia may intermittently develop in these patients as the 
result of gross polydipsia, impaired excretory capacity, or most likely, both of these 
mechanisms (Cheng et al 1990).  Rapid development of hyponatremia does not allow for 
adaptive changes to take place in the brain, and cerebral edema may ensue (Cluitmans and 
Meinders 1990).  The resultant encephalopathy is associated with profound neurological 
disturbance, which may lead to irreversible brain damage (Arieff et al 1976).  Additional 
mechanisms that could contribute to cerebral damage in these patients include hypoxemia 
and even head trauma associated with seizures and coma, which often accompany water 
intoxication.  The relative importance of these factors could not be assessed in our study, and 
needs to be addressed in future longitudinal studies.  It is likely that cognitive impairment in 
schizophrenia is multidetermined, with factors such as premorbid cognitive deficits, symptoms 
of the illness itself and effects of medication possibly playing a role.  However, the 
implications of our findings are considerable, as they suggest that a potentially preventable 
condition may contribute to cognitive impairment in schizophrenia.  Once diagnosed, water 
intoxication can be effectively treated and further episodes prevented by restricting fluid 
intake, removing exacerbating factors and, if necessary, prescribing specific medications 
(Illowsky and Kirch 1988). 
 
The results of this study need to be interpreted with the relatively small sample sizes as well 
as the limited educational status of the subjects kept in mind.  Further studies to investigate 
the nature of any underlying structural brain damage in these patients are currently under 
way. 
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2.d  Inappropriate antidiuretic state in long-term psychiatric inpatients 
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Summary 
 
To investigate the occurrence of an inappropriate antidiuretic state in a long-term psychiatric 
inpatient population, 690 patients underwent serum sodium determination.  Forty-four patients 
(6,4%) had levels < 133 mmol/l.  Fifteen of these patients could be investigated further and 
the biochemical findings in all were consistent with an inappropriate antidiuretic state.  
Evidence of previous episodes of water intoxication was found in 80% of these patients.  
Although more than one possible cause was present in most patients, the two factors most 
strongly incriminated in the pathogenesis of the inappropriate antidiuretic state were the drugs 
carbamazepine and hydrochlorothiazide. 
 
 
 
 
Water intoxication is a well-recognised complication in certain patients with psychiatric 
disorders.  The condition is characterised by seizures and confusion, and may progress to 
coma and death.1  Most of the cases appear to be ‘self-induced’, i.e. associated with 
polydipsia.2  However, polydipsia alone does not usually appreciably dilute body fluids 
because of the great excretory capacity of the kidneys,3 and it is now increasingly recognised 
that impairment of excretory capacity may be an additional necessary factor for the 
development of water intoxication.  In this regard, an inappropriate antidiuretic state, most 
probably due to vasopressin hypersecretion, has been documented in a number of such 
patients.4  Factors incriminated in the pathogenesis of the antidiuretic state in psychiatric 
patients include psychosis,5 alcohol withdrawal,6 psychotropic medication,7 carbamazepine,8 
thiazide diuretics9 and smoking.10 
 
A study was undertaken to investigate the occurrence of an inappropriate antidiuretic state in 
long-term psychiatric inpatients, and to identify factors of pathogenic significance. 
 
 
Patients and methods 
 
All long-term inpatients at Stikland Psychiatric Hospital between the ages of 18 years and 70 
years were screened for possible dilutional hyponatraemia.  Blood samples for serum sodium 
estimation were obtained between 14h00 and 17h00, for one ward (containing usually 
between 30 and 50 patients) at a time.  Serum sodium levels were determined on the same 
day using a Beckman Klina flame photometer. 
 
Patients with hyponatraemia, i.e. serum sodium levels < 133 mmol/l, were kept recumbent, 
given nothing by mouth and abstained from smoking overnight. 
 
The next morning the hyponatraemic patients were assessed clinically.  A detailed 
examination of the files was undertaken and a physical examination performed.  In particular, 
the following information was noted:  psychiatric and associated medical diagnoses; all 
psychotropic and other medications being taken at the time; and previous episodes of 
possible water intoxication, as indicated by unexplained seizures or delirium or a previously 
documented serum sodium value < 120 mmol/l.  The ward staff were also questioned about 
the presence of polydipsia and the smoking habits of the patients. 
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All patients unable to provide consent or co-operate sufficiently or who had severe medical 
illness were excluded from further study.  For the others, an 18-gauge indwelling catheter was 
inserted into the anterior cubital fossa, after which the patient was kept recumbent for 30 
minutes.  Blood samples were then collected for estimation of serum sodium, potassium, 
urea, creatinine, glucose, thyroid stimulating hormone, tri-iodothyronine, tetra-iodothyronine, 
cortisol and aldosterone levels and plasma renin activity.  Concomitant urine samples were 
analysed for osmolality.  Osmolality was determined by freezing point depression with an 
Osmomat 030 cryoscopic osmometer. 
 
The following criteria3 were used as indicative of an inappropriate antidiuretic state:  (i) body 
fluid hypotonicity, as indicated by a serum sodium value < 133 mmol/l; (ii) concomitant non-
maximal dilution of urine, i.e. urine osmolality > 100 mmol/kg H2O; and (iii) no evidence of 
oedema, hypovolaemia, hypotension, hypoglycaemia, nausea or abnormal cardiac, renal, 
hepatic, adrenal or thyroid function. 
 
 
Results 
 
Of 690 patients who underwent serum sodium determination, 44 (6,4%) had levels < 133 
mmol/l.  Twenty-nine of the 44 were excluded from further study for the following reasons:  (i) 
inability to provide informed consent or to co-operate sufficiently (N = 14); (ii) concomitant 
physical illness (N = 4); and (iii) resolution of hyponatraemia before further studies could be 
carried out (N = 11).  The remaining 15 patients, or 2,2% of the total population screened for 
hyponatraemia, had biochemical findings consistent with the diagnosis of an antidiuretic state 
(Table 1).  Other blood investigations indicated that no other recognised causes of impaired 
excretory capacity were present. 
 
In order to establish whether factors implicated in the pathogenesis of the inappropriate 
antidiuretic state occurred more frequently in these patients, the following comparisons were 
made:  using a chi-square test the 15 patients with an inappropriate antidiuretic state were 
compared with the 646 patients with normal serum sodium values for the following factors:  
diagnosis of schizophrenia, smoking, and the taking of psychotropic medication, 
carbamazepine or hydrochlorothiazide.  The only significant differences found were that the 
patients with an inappropriate antidiuretic state were more often receiving the drugs 
carbamazepine (chi-square 8,40; df = 1; P < 0.005) and hydrochlorothiazide (chi-square 3,92; 
df = 1; P < 0.05).  These two drugs were then discontinued in the 13 patients with an 
inappropriate antidiuretic state who had been taking them, and their serum sodium levels 
returned to normal within 2 weeks 
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TABLE 1. DETAILS OF THE 15 PATIENTS WITH BIOCHEMICAL EVIDENCE OF AN 
INAPPROPRIATE ANTIDIURETIC STATE 
_____________________________________________________ 
            Urine 
            osmo-  
    Factors   Evidence of Serum   lality 
Age    Psychiatric associated   previous water sodium   (mm/kg  
 (yrs) Sex diagnosis with IAS     Polydipsia  intoxication (mmol/l)   H2O) 
__________________________________________________________________________ 
67 F MR  N,C  -  + 124   569 
31 F MR  N,C  +  + 125   476 
53 F MR  N,C  -  + 129   148 
34 M MR  N,C  -  + 125   451 
52 M MR  N,C,S  +  + 127   249 
41 M MR  N,H,S  -  + 127   507 
66 M MR  H  -  + 129   508 
48 M MR  N,C,S  -  + 125   370 
33 F MR  N,C,S  -  + 128   445 
54 M Schiz.  N,S  -  - 128   517 
58 M Schiz.  S  +  + 129   255 
65 M Schiz.  N,H,S  -  - 129   455 
68 M Schiz.  N,H,S  -  + 129   226 
61 M Schiz.  H,S  -  - 128   315 
56 F Schiz.  N,C  -  + 129   276  
__________________________________________________________________________ 
IAS = inappropriate antidiuretic state; MR = mental retardation; schiz. = schizophrenia; N = 
neuroleptic medication; C = carbamazepine; H = hydrochlorothiazide; S = smoking. 
 
 
 
Discussion 
 
In this study, evidence of an inappropriate antidiuretic state was found in 2,2% of long-term 
psychiatric inpatients.  The actual incidence is likely to be considerably higher, however, since 
it was not possible to investigate almost two-thirds of the hyponatraemic patients. 
 
In most of the patients more than one possible cause of an inappropriate antidiuretic state 
was present, suggesting the possibility of a multifactorial aetiology.  Cigarette smoking has 
been associated with vasopressin hypersecretion,10 as have neuroleptic drugs7 and 
schizophrenic psychosis.5  However, the two factors disproportionately over-represented in 
these patients compared with other long-term psychiatric patients were the drugs 
carbamazepine and hydrochlorothiazide.  Furthermore, the fact that serum sodium levels 
returned to normal soon after their discontinuation indicates an important pathogenic role for 
these drugs. 
 
Various mechanisms whereby these drugs induce an inappropriate antidiuretic state have 
been proposed.  Carbamazepine may stimulate vasopressin release,11 enhance renal 
sensitivity to the hormone8 or have a direct effect on the renal tubule.12  Hydrochlorothiazide 
may cause an antidiuresis by reducing free-water clearance as a direct consequence of 
natriuresis13 or by stimulating the release of vasopressin.14 
 
Patients with an inappropriate antidiuretic state are at serious risk for the development of 
water intoxication – as demonstrated by the fact that 80% of cases in this study had evidence 
in their clinical files of previous episodes of water intoxication.  While previous studies have 
highlighted the risk of water intoxication in patients with polydipsia,2,4,15 in this study 12 of the 
15 patients did not display excessive fluid intake.  This would indicate that even more patients 
are at risk for developing water intoxication than was previously recognised.  Considering the 
possible consequences (water intoxication may cause irreversible brain damage16 and was 
found to be responsible for nearly one-fifth of deaths in schizophrenics aged < 53 years in a 
state hospital17), the implications for clinical psychiatry would seem considerable. 
 75
 
Identification of these patients is important, since water intoxication, once diagnosed, can be 
effectively treated simply by restricting fluid intake.18  We suggest, therefore, that all long-term 
psychiatric inpatients at risk for the development of water intoxication be periodically screened 
for hyponatraemia. 
 
This work was supported by the South African Medical Research Council. 
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Abstract 
Objective: Neurological abnormalities in subjects with schizophrenia have been 
regarded as diagnostically non-specific and non-localising. This study assessed the temporal 
stability of neurological abnormalities in subjects with first-episode schizophrenia over the 
course of 12 months. We also examined their relationships with psychiatric symptoms, 
medication effects and treatment outcome. Method:  The sample comprised 66 largely 
medication-naïve subjects who were treated according to a fixed protocol. We performed a 
factor analysis of the Neurological Evaluation Scale (NES) items, and relationships between 
the NES factors and various clinical and outcome measures were explored. Results:  Five 
NES factors were identified, explaining 68.4% of the variance. While the NES total scores did 
not change significantly over time, poor performance on motor sequencing tests was related 
to longer duration of untreated psychosis, and showed a tendency to improve as psychiatric 
symptoms resolved. The most interesting finding was that high scores on the motor 
sequencing factor predicted the emergence of persistent dyskinesia at 24 months (ANCOVAR  
F(1, 20)=19.287, p=0.0002). Conclusions: Two NES factors (motor sequencing and attention) 
are reasonably replicable across samples, and have potential relevance for the further 
exploration of the pathogenesis of schizophrenia, as well as possible clinical applications.   
 
 
1. Introduction 
Subtle neurological abnormalities are found more frequently in patients with 
schizophrenia than in healthy controls (Heinrichs and Buchanan 1988;Buchanan and 
Heinrichs 1989;Mohr et al. 1996;Egan et al. 2001;Yazici et al. 2002;Shibre et al. 
2002;Keshavan et al. 2003) and other psychotic disorders (Keshavan et al. 2003).  These so 
called ‘soft’ neurological signs are thought most likely to be non-specific markers of 
neurodevelopmental abnormality, possibly as a consequence of a failure in the integration 
between sensory and motor systems (Griffiths et al. 1998), or alternatively reflecting deficits in 
neuronal circuits involving structures such as the basal ganglia and brain-stem (Heinrichs and 
Buchanan 1988). A recent study has reported associated regional grey matter volume 
changes, suggestive of perturbed cortical-subcortical connectivity (Dazzan et al. 2004). On 
the other hand, it has been proposed that they could be secondary to psychiatric symptoms 
(e.g. impaired attention), or to the side-effects of antipsychotic medication (Lawrie et al. 2001).  
 
Support for the neurodevelopmental marker hypothesis is based on the finding that 
they are present early in the illness (in medication-naive first-episode samples) (Gupta et al. 
1995;Venkatasubramanian et al. 2003;Shibre et al. 2002;Keshavan et al. 2003;Whitty et al. 
2003) and have been reported to be stable over time (Chen et al. 1996;Marcus et al. 1985). 
However, the temporal stability of neurological signs has been poorly studied.  One of these 
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studies assessed the association between age and neurological signs in a cross-sectional 
design only (Chen et al. 1996) and the other followed up a cohort of siblings of schizophrenics 
with neurological abnormalities (Marcus et al. 1985).  In fact, another study found that 
neurological soft signs varied with the clinical course (Schroder et al. 1991), and two others 
reported progression of neurological dysfunction (Madsen et al. 1999;Chen et al. 2000). A 
recent prospective study in fist-episode schizophrenia reported improvement in motor-related 
and cortical neurological soft signs at 6 months, which was associated with improvement in 
psychopathology. At the same time, ‘harder’ signs tended to worsen (Whitty et al. 2003). 
 
Studies investigating relationships between neurological abnormalities and psychiatric 
symptoms have similarly reported conflicting results. While neurological signs have been 
associated with prominent negative symptoms (Flashman et al. 1996;Merriam et al. 
1990;Wong et al. 1997) and positive symptoms (Browne et al. 2000), other workers have 
reported no association with positive and negative symptoms (Flyckt et al. 1999) or with 
global measures of psychopathology (Sanders et al. 1994). A study investigating the 
relationship between neurological abnormalities and three dimensions of schizophrenia 
(psychomotor poverty, disorganization and reality distortion) found no significant correlations 
between neurological abnormalities and either reality distortion or disorganization dimensions, 
while an extrapyramidal factor was modestly related to psychomotor poverty in males. In 
female subjects there was a significant relationship between psychomotor poverty and a 
neurological factor reflecting attention and initiative (Malla et al. 1997). Another study 
examined the relationships between neurological abnormalities and the symptom domains of 
hallucinations/delusions, disorganization and the deficit syndrome. Each of the three 
syndromes was found to have a distinctive relationship pattern to neurological signs. 
Disorganization was significantly related to the global abnormalities, to sensory integration, 
and to sequencing of complex motor acts; the deficit syndrome was significantly related only 
to sensory integration deficits; while negative symptoms (primary and secondary) and 
hallucinations/delusions were not related to any neurological abnormalities (Arango et al. 
2000). 
 
Very few longitudinal studies have investigated the effect of antipsychotic medication 
on neurological abnormalities. Most studies comparing medicated and unmedicated patients, 
or patients with and without extrapyramidal symptoms (EPS), report no association between 
neurological abnormalities and antipsychotic medication or EPS (Ismail et al. 1998b;King et 
al. 1991b;Mohr et al. 1996;Griffiths et al. 1998;Flyckt et al. 1999;Browne et al. 2000;Arango et 
al. 2000), although one study suggests that antipsychotics may, directly or indirectly, improve 
baseline neurological dysfunction (Madsen et al. 1999).  Also, King et al (King et al. 1991a) 
reported an association between neurological abnormalities and TD, and suggested that the 
former may predict vulnerability to the later development of TD.  Neurological abnormalities 
are not related to cannabis use (Bersani et al. 2002), but they may be influenced by alcohol 
dependence (Mohr et al. 1996).  Neurological signs in schizophrenia have been associated 
with a poorer outcome, greater cognitive impairment (Arango et al. 2000;Flashman et al. 
1996) ventricular enlargement (Mohr et al. 1996) and reduced cortical volumes (Rubin et al. 
1994;Arango et al. 2000;Mohr et al. 1996;Wong et al. 1997;Ismail et al. 1998b). The 
possibility that neurological signs have a genetic origin is suggested by the finding that they 
are present in non-affected family members of patients with schizophrenia (Ismail et al. 
1998a;Niethammer et al. 2000;Egan et al. 2001). However, one study found no association 
between neurological signs and a positive family-history in patients with schizophrenia 
(Lawrie et al. 2001), and another found such an association in females while in males 
neurological signs were associated with obstetric complications but not with a positive family 
history (Lane et al. 1996). 
 
Another area of uncertainty relates to the validity of the scales used to assess 
neurological dysfunction. One widely used scale, the Neurological Evaluation Scale (NES) 
(Buchanan and Heinrichs 1989), was developed to standardize the assessment of 
neurological abnormalities in schizophrenia.  Some of the items were grouped into three 
putative functional areas of interest, namely sensory integration, motor co-ordination and 
sequencing of complex motor acts. However, subsequent factor analyses have failed to 
provide empirical validation for these groupings, although some similarities were found. A 
study conducted in medicated schizophrenic patients yielded five factors (Malla et al. 1997), 
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while two later analyses (in unmedicated subjects and treatment-naive first-episode samples 
respectively) reported four factor solutions (Sanders et al. 2000;Keshavan et al. 2003).  
 
It has been suggested that neurological signs may be useful in differentiating 
schizophrenia from other psychotic disorders, on the basis that abnormal scores in cognitively 
demanding and perceptual tasks from the Neurological Evaluation Scale (NES) were 
markedly higher in patients with schizophrenia than in subjects with other psychoses and 
healthy controls. These abnormalities could possibly reflect discrete neuroanatomical 
alterations in schizophrenia and may have a localizing value, as higher scores for the 
cognitive-perceptual abnormalities factor were significantly correlated with smaller volumes of 
the left heteromedial association cortex as assessed by magnetic resonance imaging 
(Keshavan et al. 2003). 
 
The interpretation of many of the previous studies is complicated by the use of 
different (and unvalidated) assessment methods of neurological signs, different stages of the 
illness of samples, varying antipsychotic medication status, small samples and cross-
sectional designs. Also, relatively few studies have explored neurological abnormalities in 
first-episode patients (Rubin 1997;Rubin et al. 1994;Gupta et al. 1995;Sanders et al. 
1994;Keshavan et al. 2003). 
 
Thus although neurological abnormalities have been consistently reported in subjects 
with schizophrenia, little is known about their origins and significance, and findings regarding 
their relationships to psychiatric symptoms, medication effects and outcome are inconsistent.  
This study attempts to address these uncertainties by investigating neurological abnormalities 
over the course of 12 months in a sample of largely medication-naïve subjects with a first-
episode of schizophrenia who were treated over a two-year period according to a fixed 
protocol. 
 
 
2.  Methods 
2.1 Subjects. 
Subjects were recruited from our Early Psychosis Unit at Stikland Psychiatric 
Hospital, Cape Town. Inclusion criteria were: In- and out-patients; aged between 16 and 55 
years; a DSM-IV diagnosis of schizophreniform disorder, schizophrenia or schizo-affective 
disorder; and prior antipsychotic exposure of 4 weeks or less. Exclusion criteria were an 
additional DSM-IV axis I diagnosis other than schizophreniform disorder, schizophrenia or 
schizoaffective disorder; alcohol or other substance abuse or dependence; prior depot 
antipsychotic treatment; significant medical illness; and mental handicap. Ethical approval 
was obtained from the Stellenbosch University Ethics Committee, and patients and/or their 
families provided written, informed consent to participate in the trial.  
2.2  Ratings 
Baseline evaluations were performed as far as possible before antipsychotic 
medication was prescribed. In the few cases where patients were unable to be assessed 
because of the severity of their illness, the evaluations were conducted as soon as they were 
deemed well enough to co-operate for the examination. A structured evaluation was 
performed by means of the Structured Clinical Interview for DSM-IV Axis I Disorders, Patient 
Edition (SCID-P) (First et al. 1994). Neurological signs were assessed by means of the NES 
(Buchanan and Heinrichs 1989). An experienced psychiatrist (HJT) performed all of the NES 
assessments after undergoing training with the instrument. Additional assessments included 
the Positive and Negative Symptom Scale (PANSS) (Kay et al. 1987), Simpson-Angus Rating 
Scale (SAS)(Simpson and Angus 1970), Abnormal Involuntary Movement Scale (AIMS) (Guy 
1976) and Barnes Akathisia Scale (BAS) (Barnes 1989). A physical examination was also 
performed. Investigators participated in regular inter-rater-reliability training sessions. 
Concordance coefficients for the PANSS, SAS, AIMS and BAS were above 0.8. The NES 
assessments were conducted at 0, 3, 6 and 12 months. All of the other assessments took 
place at three monthly intervals for the full 24 months.  
2.3 Treatment 
Subjects were treated with very low doses of haloperidol in an open label design 
according to a fixed protocol which has been fully described elsewhere (Oosthuizen et al. 
2001). Lorazepam was permitted for sedation, and orphenadrine and benzhexol were 
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prescribed for treatment of EPS. Eighty-one percent of the subjects were still taking 
haloperidol at endpoint, at a mean ± SD daily dose of 1.68±1.02 mg/day. Generally, the 
treatment was effective and well tolerated, although a high incidence of 12.3% of probable or 
definite tardive dyskinesia was found at 12 months (Oosthuizen et al. 2003).  
2.4 Data analysis 
Various analyses of the data were undertaken. Factor analysis was performed by the 
method of maximum likelihood. It requires the number of factors to be specified, and a 
principal component analysis was performed as a guide for choosing the number of factors. 
The criterion chosen to select the number of factors was that eigenvalues should be greater 
than unity (Andreasen et al, 1995). The maximum likelihood factor solution was rotated using 
the varimax procedure. The first analysis was performed on the individual items of the NES. A 
further analysis was conducted on the PANSS items, this time using a forced five factor 
analysis. To explore relationships between neurological abnormalities and psychiatric 
symptoms we conducted Pearson Product Moment Correlation tests between the NES factors 
and the PANSS factors.  Multiple regression analysis was performed to determine the 
significance of the relationships between the PANSS factors 1 to 5 (independent variables) 
and the NES factors 1 to 5 each as dependent variables. NES factors were correlated with 
demographic variables, EPS rating scale scores and DUP. Analysis of covariance was 
preformed for binary variables.  Student’s t-test was used to compare independent variables. 
A significance level of 0.05 was mainly used except where otherwise stated.   Corrections for 
multiple comparisons were not applied because of the exploratory nature of the study.  To 
examine the stability of the neurological abnormalities over time we conducted an observed 
cases (OC) analysis at each timepoint, and a repeated measures analysis of variance 
(RANOVA).  Results are reported as the mean±SD. Analyses were performed using Statistica 
version 6 (Statsoft, Inc.) software. 
 
 
3.  Results 
The sample comprised 66 subjects (53% women) aged 28.1±8.5 yrs, with an illness 
duration of 371±787 days and baseline PANSS total scores of 92.1±16.2. Six subjects were 
not naïve to psychotropic medication at the start of the study. Five had received small doses 
of antipsychotic medication, and one an antidepressant.  The ethnicity of our sample reflected 
that of our catchment area, with 47 being of mixed descent, 5 black and 14 white. For the 
initial factor analysis (conducted on baseline NES scores), we followed the procedure of Malla 
et al (Malla et al. 1997) and Keshaven et al (Keshavan et al. 2003)  by discarding items that 
were abnormal in <10% of the sample (items 2, 3, 4, 7, 18, 19, 21, 22, 23, 24, 25, 26), as well 
as the cerebral dominance items (handedness, footedness, eyedness).  We were left with 13 
items for the analysis. These items were similar, but not identical to the 13 items selected by 
Keshaven et al (Keshavan et al. 2003). The first five NES factors had eigenvalues greater 
than unity and accounted for 68.4% of the variance.  Table 1 presents the results of the 
rotated principal component matrix with the factor loadings for the analysis. Descriptive 
names have been assigned to each of the factors. Baseline scores for the NES items, factors 
and total scores are given in Table 2.  We found the following significant correlations between 
NES factors  age, level of education and race: Age and NES factor 4 (motor sequencing) 
(r=0.333, p=0.04); level of education and factor 3 (attention) (r=0.457, p=0.005) and factor 5 
(rhythmicity) (r=0.337, p=0.04). The number of subjects who underwent NES re-assessment 
at 3, 6 and 12 months, was 35, 31 and 20, respectively.   
 
3.1 Stability of the neurological abnormalities over time 
The NES total scores did not change significantly over time, although compared with 
baseline scores (OC analysis), the motor sequencing factor score was significantly reduced at 
3 months (p=0.01), but not at 6 and 12 months. However, the repeated measures analysis of 
variance revealed no significant changes in NES factor scores over time. 
 
3.2 Relationships between neurological abnormalities and psychiatric symptoms 
We conducted a forced 5 factor analysis of individual PANSS item scores after 
omitting the items that were previously shown to load inconsistently (Emsley et al. 2003). This 
solution explained 64.3% of the variance and comprised the following factors: Negative (items 
N1, 2, 3, 4, 6 and G 7); disorganised (items P 3, 4, N 5, G 10, 11 and 14); depression/anxiety 
(items G 2, 3, 6, 16); excitement (items P 7 and G 8) and positive (items P 1, 5 and G 9) 
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factors.  The only significant correlations between NES and PANSS factors were between 
NES factor 1 (balance) and PANSS factor 5 (positive) (r=0.298, p=0.04) and NES factor 2 
(rapid movements, convergence) and PANSS factor 3 (depression/anxiety) (r=0.286, p=0.05). 
However, the R2 values in the regression analysis were low (0.097 and 0.11, respectively), 
indicating that relatively little variance is shared between PANSS and NESS factors.  
 
3.3 Relationships between baseline neurological abnormalities and emergent acute EPS and 
dyskinesia 
When correlations were sought between NES factors and SAS, AIMS and BAS 
scores at 3, 6, 9, 12, 15, 18, 21 and 24 months, we found that the NES balance factor was 
significantly correlated with SAS total scores at 6 (r=0.58, p=0.03) and 24 months (r=0.59, 
p=0.02). Analysis of covariance of NES factors and AIMS scores controlling for age and level 
of education revealed a highly significant association between the NES motor sequencing 
factor and the emergence of TD at 24 months (F(1, 20)=19.287, p=0.0002). The patients with 
emergent dyskinesia met Schooler and Kane criteria (Schooler and Kane 1982) for TD.  
When the NES factor scores were compared in patients with and without TD, significantly 
higher scores were found in the TD patients for the motor sequencing factor (3.2±2.0 vs 
1.6±1.9) (p=0.01). While many individual NES items showed significant correlations with EPS 
at the 0.05 level, the only highly significant correlation was that of item 14 (rapid alternating 
movements) with baseline Simpson Angus scores (r=0.77, p=0.001) 
 
3.4 Relationships between baseline neurological abnormalities and duration of untreated 
psychosis 
None of the NES factors were significantly correlated with DUP. However, when 
subjects with a DUP > 1month were compared to those with DUP ≤ 1 month, the former had 
significantly higher NES motor sequencing factor scores (p=0.02).  
 
3.5 Relationships between baseline neurological abnormalities and outcome 
No significant correlations were found between the NES factors and outcome as 
assessed by percentage change in PANSS total and subscale scores at 12 months, response 
rates (>50% improvement in PANSS total score) at 12 and 24 months, and relapse rates 
(defined as hospitalization, or an unscheduled visit due to increase in PANSS score ) at 12 
and 24 months. 
 
 
4. Discussion 
A five-factor model provided the best solution for the NES item factor structure in our 
sample, accounting for 68.4% of the variance. Substantial similarities were found between our 
factor analysis and some of the other studies, indicating reproducibility of certain factors 
across samples. Our results were quite similar to those of Sanders et al (Sanders et al. 2000) 
and Keshaven et al (Keshavan et al. 2003) insofar as we also identified factors for balance, 
attention and motor-sequencing.  Three of the motor sequencing items (fist-ring test, fist-
edge-palm test, Ozeretski test) factored together in all three of the other published NES factor 
analyses (Malla et al. 1997;Sanders et al. 2000;Keshavan et al. 2003), and two attentional 
items (memory, extinction) in two others (Sanders et al. 2000;Keshavan et al. 2003). 
Interestingly, it was these motor sequencing and attentional abnormalities that have been 
reported to be more specific to schizophrenia (Keshavan et al. 2003).  Impairment on motor-
sequencing tasks is indicative of problems with the initiation and organization of action, 
specifically suggestive of perseveration, and is a cardinal feature of frontal dysfunction 
(Ovsiew 1994).  While not reported in previous studies, the association of rapid alternating 
movements and convergence to form the second factor can be understood from a neuro-
anatomical point of view.  Impairment of rapid alternating movements is a feature of abnormal 
coordination, typically as a result of disturbance in corticospinal or cerebellar pathways. 
Supranuclear control of vergence is likely to be influenced by widely distributed networks, 
similar to those controlling pursuit eye movements (Leigh and Zee 1991). Additional deficits or 
dysfunction in control of vergence may result from dysfunction in cerebellar-brainstem 
pathways (Gamlin 1999). 
 
The neurological abnormalities displayed considerable temporal stability, suggesting 
a trait-like nature (Lawrie et al. 2001). However, the fact that some variation occurred over 
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time, suggests that factors such as psychiatric symptom changes and the effects of 
medication may play a role.  The significant improvements observed in the motor sequencing 
factor in the OC analysis suggest that these abnormalities may at least in part be secondary 
to psychiatric symptoms, with improvement occurring as the psychiatric symptoms resolve.  
To further explore this possibility we searched for correlations between PANSS individual 
items and NES factors. The NES rhythmicity factor was significantly correlated with PANSS 
items P2 (conceptual disorganization) (r=0.45, p=0.003) and G11 (poor attention) (r=0.43, 
p=0.006).  These findings suggest that impairment on some NES tests (motor sequencing 
and rhythmicity) may be secondary to psychiatric symptoms. The only item score to worsen 
over time was item 14 (rapid alternating movements), at 3 months. Together with the finding 
of a strong correlation between this item and symptoms of parkinsonism, this strongly 
suggests that this is a secondary effect of antipsychotic medication. 
 
It is also possible that the improved performance on the motor sequencing tests could 
be due to a direct beneficial effect of treatment, particularly considering that impairment on 
this factor was greater in subjects with a longer DUP.  Both of these findings are consistent 
with the ‘toxic psychosis’ hypothesis proposing that ongoing psychotic symptoms are 
indicative of a progressive underlying morbid process, and that antipsychotic medication acts 
as a neuroprotective factor (Lieberman et al. 1993).  (This hypothesis is based on a reported 
association between longer DUP and poorer overall outcome in patients with schizophrenia 
(McGlashan 1999;Malla et al. 2002).) Of further interest in this regard is that Madsen et al 
(Madsen et al. 1999) reported an increase in neurological abnormalities in patients with 
schizophrenia 5 years after their first presentation that was more marked in those patients 
who had not received antipsychotic medication over this period. These authors proposed a 
hypothetical protective effect of antipsychotics on neurological dysfunction.  Little shared 
variance was observed between neurological signs and psychiatric symptoms, counting 
against the possibility of common biological underpinnings.   
 
A striking finding in our study was the relationship between motor sequencing 
abnormalities at baseline and the later development of TD. This was unanticipated, although it 
had previously been suggested that the presence of neurological abnormalities may predict 
vulnerability to the later development of TD (King et al. 1991). This finding may be of clinical 
relevance insofar as it could represent a clinical marker for predicting those at risk of 
developing TD. Such a marker would indeed be helpful, as to date no reliable baseline clinical 
features have been identified that predict TD in first-episode schizophrenia (Chakos et al. 
1996a;Oosthuizen et al. 2003). Thus, the presence of motor sequencing abnormalities, 
particularly in the presence of additional putative risk factors, should alert the clinician to the 
risk of TD, and prescribing an antipsychotic with the lowest risk of producing EPS in such 
cases would seem prudent. Other reported risk factors for TD include poor treatment 
response (Chakos et al. 1996b), medication-free intervals (Jeste et al. 1979), being of African 
descent (Glazer et al. 1994), increasing age (Morgenstern and Glazer 1993;Kane and Smith 
1982), female gender (Chakos et al. 1996b) and the development of EPS during the acute 
treatment phase (Chatterjee et al. 1995). It is also of interest to note that motor sequencing 
abnormalities have been found to be significantly correlated with smaller right and left caudate 
volumes (Keshavan et al. 2003). This raises the possibility that a neuroanatomical basis 
exists for a subset of patients with schizophrenia who may be identifiable by motor 
abnormalities and who are at risk for developing TD. 
 
The attentional factor may represent a stable marker for schizophrenia. While the two 
items of this factor, the memory and extinction tests, cannot be regarded as highly specific, 
the factor remained stable over time. Scores did not improve as the psychosis remitted, and 
they were not influenced by medication-effects. That this factor is a stable characterstic of 
some individuals with schizophrenia is further supported by the recent finding of Keshavan et 
al (Keshavan et al. 2003) who identified a similar factor that was found to be specific for 
schizophrenia insofar as scores were markedly higher in patients with schizophrenia 
compared to other psychoses and healthy volunteers, and were correlated with smaller 
volumes of the left heteromedial association cortex.   
 
Similar to a previous report (Johnstone et al. 1990), we were not able to identify any 
associations between neurological abnormalities and treatment outcome. 
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Generalization of our findings may be limited by the sample size, particularly at 
follow-up, and by the inherent limitations of factor analysis (McGorry et al. 1998). The 
unexplained negative loading on some of the factors in a sense shows inconsistency of the 
data. Also, improvement on some of the tests could be ascribed to a learning effect. 
Nevertheless, when taken in conjunction with previously published studies, certain tentative 
inferences may be drawn.  It would appear that two NES factors are reasonably replicable 
across samples, and have potential relevance for the further exploration of the pathogenesis 
of schizophrenia, as well as possible clinical applications.  Impairment on the motor 
sequencing factor may be progressive while psychotic symptoms remain untreated, and 
improve as the symptoms resolve with treatment. Also, impairment on this factor may be an 
important predictor of vulnerability to TD. The cognitive/perceptual or attentional factor 
appears to be stable over time, diagnosis specific, and possibly reflects a stable characteristic 
of schizophrenia with specific neuroanatomical underpinnings. 
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Table 1. The factor structure for the NES items. 
 Factor 
Item number and 
description 
1 
Balance 
2 
Rapid 
movements, 
convergence 
3 
Attention 
4 
Motor 
sequencing 
5 
Rhythmicity 
1   Tandem walk 0.827094 0.027646 0.260490 0.160499 -0.089155
6   Audio-visual 
integration 
-0.055468 0.078780 0.272793 0.280807 0.776058
8   Graphesthesia -0.621741 -0.016411 0.324952 0.048104 -0.119486
9   Fist-ring test 0.209653 0.052447 0.379532 0.731771 -0.004955
10 Fist-edge-palm test  0.130619 -0.554852 -0.163520 0.589595 0.084821
11 Ozeretski test -0.080285 0.111193 -0.092655 0.816276 0.152403
12 Memory 0.019871 -0.026882 0.736503 -0.117030 0.127643
13 Ryhthm tapping test -0.010556 0.021590 0.017907 -0.011399 0.905431
14 Rapid alternating 
movements 
-0.171688 0.728850 -0.069402 0.167228 0.116818
15 Finger-thumb 
opposition 
0.267354 0.477651 -0.245194 0.265210 0.372777
16 Mirror movements -0.510251 0.245081 0.197664 0.560421 0.256501
17 Extinction -0.076806 -0.034127 0.811045 0.234276 0.064696
20 Convergence 0.471211 0.651951 0.032437 -0.071837 -0.071125
Explained Variance 1.730941 1.577047 1.732846 2.142588 1.718682
Proportion of Total 0.133149 0.121311 0.133296 0.164814 0.132206
 
The strongest correlations on a factor for a given item are given in bold face and italics. 
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Table 2. Baseline scores for the NES individual items, factors and total scores 
 
 
NES Item  Mean Std.Dev. 
1   Tandem walk 0.3208 0.51041 
6   Audio-visual integration 0.7222 0.85598 
8   Graphesthesia 1.2778 0.85598 
9   Fist-ring test 0.5660 0.72083 
10 Fist-edge-palm test  0.8302 0.82592 
11 Ozeretski test 0.3922 0.66569 
12 Memory 0.6000 0.83299 
13 Ryhthm tapping test 0.9811 0.93007 
14 Rapid alternating movements 0.1481 0.45172 
15 Finger-thumb opposition 0.1111 0.37197 
16 Mirror movements 0.3333 0.58277 
17 Extinction 0.1698 0.42679 
20 Convergence 0.3962 0.59935 
Factor 1 0.3208 0.51041 
Factor 2 0.5472 0.79822 
Factor 3 0.7959 1.06026 
Factor 4 2.0800 1.79387 
Factor 5 1.7170 1.53645 
TOTAL NES  Score 6.7222 3.74376 
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ABSTRACT 
Background:  Numerous cultural and ethnic factors may directly and indirectly 
influence treatment outcome in schizophrenia. The present study compared the response to 
antipsychotic treatment in three ethnic groups of patients with schizophrenia. 
Methods:  Fifty Black, 63 Coloured (mixed descent) and 79 White patients with 
schizophrenia or schizophreniform disorder who were participants in multinational clinical 
drug trials were assessed by means of the Positive and Negative Syndrome Scale (PANSS). 
Treatment response was measured by the change in PANSS total scores, and the change in 
positive, negative and general psychopathology subscale scores from baseline to 6 weeks. 
Also, the percentage of responders (defined as ≥ 40% reduction in PANSS total scores) was 
calculated for each group.  
Results:  Baseline PANSS scores differed significantly, being higher for Blacks and 
Coloureds. Coloureds showed the greatest mean ± SD percentage reduction in PANSS total 
score (29.4 ± 21.6) followed by Blacks (28.4 ± 14.7) and Whites (11.4 ±27.6). Analysis of 
covariance revealed a significant effect of ethnicity on the reduction in PANSS total scores 
(p<0.0001). The numbers of responders were: Coloureds 20 (32%), Blacks 12 (24%) and 
Whites 7 (9%) (p=0.002). 
Conclusions: Significant ethnic differences in acute antipsychotic treatment 
response are demonstrated by this study. Factors such as diet, nutritional status, body mass, 
and substance use could be important, as well as genetically determined ethnospecific 
pharmacokinetic and pharmacodynamic differences. Delayed help-seeking may account for 
the higher baseline scores in the Blacks and Coloureds.  
 
 
Introduction 
The field of ethnopsychopharmacology has become a focus of considerable attention. While 
psychotropic drugs appear to be effective across cultural and ethnic boundaries,1,2 it is 
increasingly recognised that cross-cultural or cross-ethnic variations in responses to 
psychotropic agents do occur.3,4 The discovery of widespread ethno-specific polymorphisms 
in genes governing pharmacokinetic and pharmacodynamic aspects of psychotropic drugs 
may explain some of these variations.2,5 However, numerous other factors that are either 
directly or indirectly related to culture and ethnicity may be equally important. These include 
diet and nutritional status, exposure to various substances (eg. alcohol, tobacco), body mass, 
accessibility of services, compliance, social support, and co-morbid medical conditions.6 
 
Differences in the doses of antipsychotics prescribed for the treatment of psychotic disorders 
in different ethnic groups have been consistently reported. African Americans are more likely 
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than Caucasians to receive higher doses.7-13 This may in part be due to delayed help-seeking, 
greater body weight, or biased therapist attitudes.11 Several retrospective studies have 
reported that Asian patients receive lower doses of antipsychotics than Caucasians, 14 -16 
although one study17 failed to find such differences. Also, Asians have been found to have 
higher plasma concentrations of antipsychotics than Caucasians.18,19  Ruiz et al20 examined a 
sample of 58 Caucasian, 135 African American, and 11 Hispanic patients who received 
conventional antipsychotics. The mean dose of antipsychotics was similar for the Caucasian 
and African American groups (16.2 and 15.5 mg haloperidol equivalents/day, respectively), 
while for the Hispanic patients it was considerably lower (7.6 mg haloperidol equivalents/day). 
In a similar study involving the atypical antipsychotics (clozapine, risperidone and 
olanzapine), African Americans were prescribed the highest mean doses, followed by 
Hispanics and Caucasians. The doses prescribed for Asian Americans were much lower than 
for the other groups. These results may have been confounded by large differences that were 
found in mean body weights between the groups.21 
 
While previous studies comparing ethnic differences in antipsychotic treatment  have 
concentrated on examining the doses of antipsychotics prescribed, there is little information 
regarding the actual treatment responses of different ethnic groups.  The present study 
compares the response to antipsychotic treatment in three ethnic groups of patients with 
schizophrenia, and considers some factors that may contribute to differences in outcome. 
 
 
Methods 
Subjects  
Subjects were recruited from in-patient and out-patient hospital services. They comprised 
patients who had participated in multinational randomised clinical trials from two academic 
psychiatric hospitals in South Africa (Stikland Hospital, Cape Town, and Oranje Hospital, 
Bloemfontein) where the Positive and Negative Syndrome Scale (PANSS)22 had been used to 
assess symptom severity. They all met DSM-IV23 criteria for schizophrenia or 
schizophreniform disorder, and belonged to one of three ethnic groups: Blacks, Whites or 
Coloureds. The Blacks were mainly from the Sotho (Sesotho and Setswana) ethnic group, 
with the rest from the Nguni group (Zulu and Xhosa). The Coloureds have developed from 
indigenous people living in the tip of Africa (San and Khoi), from slaves from Malaya and 
Madagascar, and from White European settlers.24 The Whites were largely of European 
descent. The trials were undertaken between 1991 and 2000. Subjects were men and women 
aged between 18 and 65 years, with no concomitant significant medical conditions, and who 
did not meet criteria for substance abuse. All participants provided written, informed consent 
to participate in the clinical trials. Approval was obtained from the Ethics Committees of the 
Universities of Stellenbosch and Free State. The trials compared novel with conventional 
antipsychotics, and none had a placebo arm.  
 
Ratings 
All of the investigators were experienced psychiatrists who had undergone training and inter-
rater reliability testing for the PANSS.   Analyses were performed on the PANSS scores at 
baseline, and at 6 weeks (or the closest assessment to 6 weeks that was performed, ranging 
from 5 to 9 weeks). The following PANSS scores were selected, according to previously 
specified criteria22: Total PANSS score (30 items); positive subscale score (items P1to P7); 
negative subscale score (items N1 to N7); and general psychopathology subscale score 
(items G1-G14). Treatment response was assessed by the following means: Change from 
baseline to 6 weeks for PANSS total, positive subscale, negative subscale, and general 
psychopathology subscale scores. Also, the percentage of responders was calculated for 
each group. Responders were defined as those showing a 40% or greater reduction in 
PANSS total scores between baseline and 6 weeks. 
 
Data analysis 
The Chi square test was used for comparing categorical variables. All tests were 2-tailed. For 
differences between groups, one-way ANOVA or a chi-square test were performed where 
appropriate. To control for effects due to gender and age differences between the groups, 
ANCOVA was employed, with ethnicity and gender as categorical predictors and age as 
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covariate. Tukey’s HSD for unequal group sizes was used for post-hoc pairwise comparisons. 
The significance level was set at 0.05. 
 
Results 
The sample comprised 50 Blacks, 63 Coloureds and 79 Whites. The mean ±SD age of the 
Coloureds (29.3 ±10.7 years) was significantly lower than that of the Blacks (36.9 ±9.9 years) 
(p=0.005) and the Whites (38.6 ±13.2 years) (p < 0.0001). The baseline PANSS scores for 
the three groups are given in Table 1. There were significant differences among the groups for 
all of the PANSS scores. After controlling for age and gender, there was still a significant 
effect (p<0.001) of ethnicity on baseline PANSS total scores (F2,189=17.53), PANSS positive 
scores (F2,189=11.3) and PANSS General Psychopathology scores (F2,189=21.04), but not the 
PANSS negative scores. Pairwise comparisons of PANSS total scores revealed significant 
differences between all ethnic groups (p<0.009). The PANSS positive subscale scores for the 
Whites differed significantly from those for the Coloureds and Blacks (p<0.0001), and PANSS 
General Psychopathology subscale scores differed significantly between all three groups 
(Black vs. White p<0.0001; Black vs. Coloured p=0.004; and Coloured vs. White p=0.03). 
 
Figures 1 to 4 depict the change in PANSS total, positive, negative and general 
psychopathology subscale scores between baseline and week 6. Although the Blacks and 
Coloureds had significantly higher baseline PANSS total, positive and general 
psychopathology subscale scores, their endpoint scores were similar to, and in some cases 
lower than, those for the Whites. Coloureds showed the greatest percentage reduction in 
PANSS total scores (29.4±21.6), followed by Blacks (28.4±14.7) and Whites (11.4±27.6). 
Analysis of covariance, with ethnicity and age as categorical predictors and age as covariate 
revealed a significant effect of ethnicity on percentage reduction in PANSS total scores 
(F2,189=9.55;p<0.0001). Pairwise comparisons showed that Whites differed significantly from 
Coloureds (p<0.0001) and from Blacks (p=0.008), but that Blacks and Coloureds did not 
(p=0.96). The response rates (≥ 40% reduction in PANSS total scores) for each group were: 
Coloured 20 (32%), Black 12 (24%) and White 7 (9%) (chi-square 12.2; df 2; p=0.002). 
 
 
Discussion  
 
This study demonstrates important ethnic differences in the acute response to antipsychotic 
treatment in patients with schizophrenia and schizophreniform disorder. Compared to Whites, 
the Coloured and Black subjects showed a much greater reduction in symptoms and had 
significantly better response rates. Whether these differences in acute treatment response are 
maintained in the longer term and result in better overall outcome remains to be determined. 
This would appear to be likely though, as responsiveness to biological treatments is reported 
to be predictive of good outcome.25 Also, initial reductions in positive, and particularly negative 
symptoms are independently associated with reduced service use and improved quality of life 
after two years of treatment.26  
 
There is considerable evidence to suggest that the clinical course of schizophrenia varies 
across cultures - the outcome in developing countries being generally more favourable,27 
although the evidence is not conclusive.28 The reasons for these variations in outcome are not 
clear. While personal dynamics within the patient’s family have been suggested as a major 
factor,29 this is unlikely to account for the differences in acute treatment response that were 
observed in our study. Another possibility is that patients from certain cultural settings have a 
better outcome because they have fewer negative symptoms, which are less responsive to 
antipsychotic drugs. Once again, our findings do not support this hypothesis – the Whites, 
who had the poorest outcome, did not have higher negative symptom scores. In fact, the 
baseline negative symptom scores of the Blacks were higher than, and those of the 
Coloureds similar to those of the Whites, while the response for negative symptoms tended to 
be better in both Blacks and Coloureds compared to Whites.  
 
The differences in treatment response could be partly explained by the differences in baseline 
PANSS scores, which in turn may be due to age differences - younger patients have been 
reported to have higher positive scores and a better response to antipsychotic treatment.30 On 
the other hand, another study reported that high scores on both negative and positive 
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subscales at index admission were significantly correlated with a poor outcome 5 years 
later.31 Even after controlling for age in our study, the Black and Coloured patients had 
significantly higher baseline positive scores and better response to treatment than the Whites.  
Our findings therefore support previous work suggesting that there are real differences in 
responses to antipsychotics between ethnic groups.7-11,12,16,20,21 
 
In addition to age differences, there are other factors that could explain the higher baseline 
symptom scores for the Coloured and Black patients. For example, the illness may express 
itself differently across cultures, being less severe in some. We do not consider this likely, 
however, as most studies report the core symptoms of schizophrenia to be similar across 
cultures,32-37 although a lower prevalence of first-rank or core symptoms has been found in 
developing countries,38 in subjects less proficient in English,39 and in minority groups,40 while 
a higher prevalence of visual hallucinations has been reported in Kenyans.41 Also, in a large 
sample of indigenous Africans the factor structure for the symptoms of schizophrenia was 
found to be very similar to that previously described in Caucasian subjects.42 
 
A more likely explanation for the differences in baseline scores is that there was a longer 
delay in help-seeking in the Black and Coloured subjects. Generally, treatment facilities are 
less accessible, and the level of community awareness of mental health matters is lower for 
Blacks and Coloureds than it is for Whites.43 This is not a problem that is specific to South 
Africa – for example, in the United States, African Americans have limited access to the 
mental health system, and a variety of socio-economic, cultural, attitudinal and biologic 
factors interact to preclude them from optimal care.44 These patients are often treated 
differently – they are more likely to be hospitalised, involuntarily committed, placed in 
seclusion and given depot antipsychotics. These factors are thought to contribute to the 
reluctance of African Americans to utilise the mental health services. 
 
There are a number of factors that could contribute to the observed differences in outcome 
between the ethnic groups, other than the already mentioned differences in baseline PANSS 
scores. For example, environmental factors such as differences in diet, nutritional status, body 
mass, and substance use and abuse may be important. These factors are known to affect the 
pharmacokinetics and pharmacodynamics of psychotropic drugs, and may differ considerably 
between ethnic groups.3,6  Apart from excluding substance abusers, none of these factors 
were investigated in this study. Finally, the possibility exists that genetically determined 
pharmacokinetic and pharmacodynamic differences exist between the ethnic groups. Further 
research will hopefully shed more light on this issue. 
 
There are certain limitations to our study.  First, there is a possibility of clinician bias, as the 
majority of investigators were White. Research has shown that the cultural and linguistic bias 
of the clinician has a significant influence upon the diagnosis and further management of the 
patient.45 Clinicians, when dealing with patients from a different cultural background to their 
own, run the risk of unwittingly applying an ethnocentric bias to their evaluation and treatment 
of these patients. This has been demonstrated to lead to inaccurate assessment and 
inadequate treatment.10,46 It could be argued, for example, that the Black and Coloured 
groups contained some cases of ‘atypical psychoses’, or bouffee delirante, known to be 
common in developing countries47 and to have a favourable prognosis.48 However, we 
consider this unlikely to be a major factor in our study, as the use of standard diagnostic 
procedures and rating scales has been shown to largely eliminate the possibility of cultural 
bias.49 
 
Second, the study design did not make provision for examining the possible contributory 
effects of aspects such as diet, nutritional status, body mass and duration of untreated 
psychosis. Third, the fact that patients received different antipsychotic drugs should be borne 
in mind, although the possibility of a treatment bias is minimised by the fact that the trials 
were randomised. Details of medication were not available to us, as some of the studies had 
not been unblinded at the time of our analysis. Fourth, possible differences in chronicity and 
past treatment history could be important in explaining both baseline 
and outcome differences between the groups. Finally, it is not clear to what degree our 
findings can be generalised to other cultural settings.  
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This study confirms and extends previous work indicating ethnic differences in response to 
antipsychotic treatment. Substantial adjustments may be required in the prescribing habits of 
clinicians when dealing with patients of an ethnic group other than their own. Clinicians need 
to be alert to the many factors that may contribute directly and indirectly to cultural and ethnic 
variations in the response of patients to treatment. It may be that groups such as Blacks and 
Coloureds require lower doses of antipsychotics than Whites. It is of concern therefore that 
Black patients generally receive higher doses than Whites, considering that they not only 
respond better, but may be more at risk for developing side-effects such as tardive 
dyskinesia.50 Future studies need to investigate factors such as body-mass, nutritional status 
and duration of symptoms before seeking help, and include assessments of blood levels of 
antipsychotics, as well as the genetic structure of the drug-metabolising enzymes in different 
ethnic groups. Although there are understandable sensitivities regarding research comparing 
different ethnic groups,51 further such studies are clearly indicated.2 Not only do differences in 
efficacy and tolerability need to be defined, but so too do inequities in service provision and 
social circumstances.    
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Table 1. Mean ±SD baseline PANSS scores for the Black, Coloured and White subjects. 
  
 Blacks  
(N=50) 
Coloureds 
(N=63) 
Whites 
(N=79) 
  
 Mean SD Mean SD Mean SD F2,189 P 
PANSS total 102.3 14.5 90.7 19.0 82.3 16.5 21.4 <0.0001 
PANSS positive 24.4 5.5 23.1 5.5 18.6 6.8 16.9 =0.0001 
PANSS negative 27.6 4.8 24.8 7.8 24.8 5.8 3.56 =0.034 
General 
psychopathology 
50.3 8.5 42.8 10.3 38.9 8.7 23.6 <0.0001 
Composite score -3.12 7.1 -1.7 9.1 -6.2 8.9 5.3 =0.006 
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Figure 1. Mean (and standard error) PANSS total scores for the 50 Black, 63 Coloured and 79 
White subjects at baseline and after 6 weeks of treatment. 
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Figure 2. Mean (and standard error) PANSS positive subscale scores for the 50 Black, 63 
Coloured and 79 White subjects at baseline and after 6 weeks of treatment. 
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Figure 3. Mean (and standard error) PANSS negative subscale scores for the 50 Black, 63 
Coloured and 79 White subjects at baseline and after 6 weeks of treatment. 
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Figure 4. Mean (and standard error) PANSS general psychopathology subscale scores for the 
50 Black, 63 Coloured and 79 White subjects at baseline and after 6 weeks of treatment. 
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Objective: The study investigated the efficacy and tolerability of ethyl-
eicosapentaenoic acid (E-EPA) as add-on treatment in chronic, severe schizophrenia. 
Method: A randomized, parallel-group, double-blind, placebo-controlled, fixed-dose, 
add-on study was conducted over 12 weeks. Forty patients with persistent symptoms after at 
least 6 months of stable antipsychotic treatment received E-EPA or placebo, in addition to 
their existing treatment. 
Results: At 12 weeks, the E-EPA group had significantly greater reduction of 
Positive and Negative Syndrome Scale total scores and of dyskinesia scores than the 
placebo group. 
Conclusions: EPA may be an effective and well-tolerated add-on treatment in 
schizophrenia. 
 
 
Extrapyrimadal symptoms and limited efficacy are serious limitations of conventional 
antipsychotics, while high acquisition costs have put the novel antipsychotics beyond the 
reach of patients in lower-income countries (1). Omega-3 polyunsaturated fatty acids may 
offer an affordable treatment alternative. Supportive findings include low levels of omega-3 
polyunsaturated fatty acids in red blood cells (2) and the brain (3) in schizophrenia. Open-
label supplemental studies have suggested a beneficial effect for omega-3 polyunsaturated 
fatty acids in schizophrenia. A pilot study found that eicosapentaenoic acid (EPA) was 
superior to docohexaenoic acid and placebo when added to standard antipsychotic treatment 
(4), although another double-blind study of EPA versus placebo found no improvement of 
symptoms with EPA (5). In a dose-ranging study, ethyl-EPA (E-EPA) doses of 1, 2, and 4 
g/day were no better than placebo, although subjects taking clozapine with E-EPA improved 
significantly, the effect being greatest with a 2 g/day dose of E-EPA (6). Recent reviews of the 
treatment of schizophrenia with omega-3 polyunsaturated fatty acids found results to be 
encouraging but preliminary (7), somewhat conflicting (8), and requiring independent 
replication (9). 
 
 
Method 
Forty subjects aged 18 to 55 years who met DSM-IV criteria for schizophrenia were 
recruited. All had received fixed doses of antipsychotics for at least 6 months and had a 
Positive and Negative Syndrome Scale (10) total score 50. Exclusion criteria comprised 
substance abuse and significant medical conditions. The University of Stellenbosch ethics 
committee approved the study, and subjects provided informed, written consent. 
This was a randomized, parallel-group, double-blind, placebo-controlled, add-on 
study conducted over 12 weeks. Patients were assessed at baseline and at weeks 3, 6, 9, 
and 12 by means of the Positive and Negative Syndrome Scale and the Extrapyramidal 
Symptom Rating Scale (11). Subjects were randomly assigned to receive either 3 g/day of E-
EPA supplement in encapsulated form (three 500-mg capsules twice daily) (Laxdale Ltd., 
Stirling, Scotland) or placebo (3 g/day of medicinal liquid paraffin BP) in addition to the 
medication that they had been receiving. 
The primary outcome measure was the percentage change in Positive and Negative 
Syndrome Scale total score between baseline and 12 weeks. Secondary efficacy measures 
were the changes in the Positive and Negative Syndrome Scale positive, negative, and 
general psychopathology subscale scores. Extrapyramidal symptoms were assessed by the 
changes in total Extrapyramidal Symptom Rating Scale scores and in the scale’s subscores 
for dyskinesia, dystonia, akathisia, and parkinsonism. A dietician reviewed the dietary intake 
of each subject at baseline and throughout the study. EPA intake was calculated according to 
standard food supplementation tables provided by the South African Medical Research 
Council. 
Comparisons were performed with Student’s t test. An intent-to-treat design was 
used, with the last observation carried forward for any subject who did not complete the 12-
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week study. An additional analysis was performed with analysis of covariance (ANCOVA) to 
control for the effects of dietary EPA, medication, duration of illness, and gender. A p value of 
0.05 was considered statistically significant. All tests were two-tailed. 
 
 
Results 
Baseline demographic and clinical variables were similar for the two groups. The 
age and illness duration were 46.2 years (SD=10.6) and 23.1 years (SD=8.5) for the E-EPA 
group, and 43.6 years (SD=13.9) and 22.2 years (SD=12.4) for the placebo group. 
Antipsychotic doses (chlorpromazine equivalents) were 1011 mg/day (SD=532) for the E-EPA 
group and 931 mg/day (SD=652) for the placebo group. No additional medication was 
prescribed throughout the trial, except for occasional analgesics for headache and lorazepam 
for insomnia. There were no differences between groups regarding dietary intake of omega-3 
polyunsaturated fatty acids. All subjects received a balanced diet before and throughout the 
trial. Dietary EPA intake was generally low, ranging from 0.56 g/week to 1.13 g/week. 
Antipsychotic medication remained unchanged for all subjects throughout the trial. Nine 
subjects in each group were receiving clozapine, and the rest were receiving conventional 
antipsychotics. One subject from the E-EPA group was withdrawn from the trial after taking an 
overdose of medication. No other serious adverse events were recorded. 
For the primary outcome measure the difference between the groups was 
statistically significant in favor of the E-EPA group (mean=12.6 [SD=14.0] versus 3.1 
[SD=13.3]) (t=2.2, df=38, p=0.03), and this difference remained significant after controlling for 
effects of dietary EPA, medication, duration of illness, and gender (Figure 1). The reduction 
tended to be greater in the E-EPA patients taking conventional antipsychotics than in those 
taking clozapine (mean=17.4, SD=12.1, versus mean=6.8, SD=14.6) (t=1,8, df=18, p=0.09). 
For the Positive and Negative Syndrome Scale subscales, the only significant difference was 
in favor of E-EPA in the percentage change in the general psychopathology subscale score at 
endpoint (t=2.08, df=38, p=0.04). There were no group differences for the changes in 
Extrapyramidal Symptom Rating Scale parkinsonism, dystonia, or akathisia scores. However, 
the E-EPA group showed a significantly greater reduction in Extrapyramidal Symptom Rating 
Scale dyskinesia scores at 12 weeks (t=2.82, df=38, p=0.008). A further analysis of 
covariance using change in Positive and Negative Syndrome Scale total score as the 
dependent variable and change in dyskinesia score as a covariate was performed. The 
difference between the E-EPA and placebo groups was no longer significant (F=3.08, df=1, 
39, p=0.09), suggesting that reduction in Positive and Negative Syndrome Scale scores is 
associated with reduction in dyskinesia scores. 
 
 
Discussion 
This study shows a significant advantage for E-EPA over placebo in the primary 
outcome measure. The between-group difference had reached significance after 3 weeks of 
treatment, signifying an early onset of action. We regard these results as remarkable, 
considering the refractory nature of schizophrenia in the subjects. The reduction in dyskinesia 
scores for the E-EPA group was unanticipated, although an inverse relationship between 
tardive dyskinesia scores and blood levels of EPA has been reported (12). Given the chronic 
nature of the disorder in the subjects, most of these dyskinetic symptoms are likely to have 
been due to neuroleptic-induced tardive dyskinesia. The following factors limit the 
generalization of our findings. First, the study was conducted in a small group of subjects. 
Second, whether E-EPA is an effective antipsychotic on its own is not known. And third, the 
results of the analysis of covariance suggest that reduction in Positive and Negative 
Syndrome Scale scores may at least in part be related to reduction in dyskinesia scores. 
E-EPA may be an effective, safe, and well-tolerated add-on treatment in chronic 
schizophrenia. The extent of its antipsychotic activity remains to be determined. The 
beneficial effect observed on dyskinesia also requires further exploration. If efficacy in 
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psychosis and tardive dyskinesia is confirmed, it is likely to lead to revision of our 
understanding of the pathophysiology and treatment of these disorders. 
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Figure 1. Mean Total Scores on the Positive and Negative Syndrome Scale of Patients Who 
Received Ethyl-Eicosapentaenoic Acid (E-EPA) or Placebo in a 12-Week Randomized, 
Parallel-Group, Double-Blind Study of Supplemental Treatment for Schizophreniaa 
 
 
aLast observation carried forward. 
bSignificant difference between groups (t=2,2, df=38, p0.05). 
cSignificant difference between groups (t=2,9, df=38, p0.05). 
dSignificant difference between groups (t=2,2, df=38, p0.05). 
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Abstract 
Objective: Recent studies suggest an early onset of antipsychotic action, and early prediction 
of non-responders.  We examined whether this was the case in first-episode schizophrenia by 
investigating the time to clinical response.  
Method:   The time to attaining a clinical response (≥20% improvement on PANSS total 
scores) was determined in 522 participants in a randomized, controlled trial comparing 
risperidone and haloperidol.  The median treatment length was 206 days.   
Results:  A clinical response was achieved in 76% of subjects.  Of these, 23.4%, 23.4%, 
18.6% and 12.6%, was attained at weeks 1, 2, 3 and 4, respectively.  However, 25% did not 
respond until after the fourth week, and 11% after the eighth week.  Forty-five percent of 
patients responded on 1-2 mg, 27% on 3 mg, 17% on 4 mg and the remaining 11% on higher 
dosages.  Response of at least 30%, 40% and 50% respectively were achieved by 62.5%, 
44.5% and 27.3% of patients.        
Conclusions: The time to response varied widely, suggesting that, in first-episode 
schizophrenia, longer treatment trials may be necessary.  
 
 
Introduction 
Early identification of non-responders to antipsychotic treatment could avoid 
unnecessary persistence with ineffectual agents, thereby diminishing the risk of adverse 
events. This in turn could reduce duration of hospitalization, level of care required, amounts of 
concomitant medication prescribed, and costs incurred.  While most studies to date have 
examined putative response predictors prior to the initiation of treatment, symptom changes 
shortly after commencement of treatment may be a more reliable way of predicting response.  
A recent meta analysis has challenged the belief that the onset of action of antipsychotics is 
delayed, by providing evidence for a robust early onset (13.8% reduction in symptom scores 
after 1 week)  (1).  This suggests that response during the first week of treatment might 
provide an indication as to how patients are likely to respond later in the course of treatment.  
In keeping with earlier findings that early symptom changes could be a useful predictor of 
outcome  (2), Correll et al. (3)  investigated the predictive value of early symptom changes 1 
week after initiation of treatment and found that early non-improvement (<20% reduction 
BPRS total score at 1 week) predicted non-response at 4 weeks in 100% of cases, 
suggesting that treatment refractoriness may already be identifiable after 1 week. 
Using data from a large multinational, randomized, double-blinded trial comparing 
risperidone and haloperidol, we determined the time to response in first-episode 
schizophrenia.  We also examined as possible predictors of response previous antipsychotic 
exposure, duration of untreated psychosis, highest level of pre-morbid functioning age and 
sex.   
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Method 
 The study methodology has been published elsewhere (4).  Patients with 
schizophrenia, schizophreniform disorder or schizoaffective disorder for ≤12 months were 
treated with either risperidone or haloperidol 1 mg/day, increased if necessary by 1 mg/day 
after 3 days, and weekly, to a maximum dose of 4 mg/day.  In exceptional cases, i.e., for 
subjects showing insufficient response in whom not more than mild EPS were observed at 4 
mg per day, the dose could then be increased further by 1 mg a week up to a maximum daily 
dose of 8 mg.  The mean modal dose for risperidone was 3.3 mg/day, and for haloperidol 2.9 
mg/day. The median treatment length was 206 days (maximum 1514).  Thirty-one percent 
(n=163) had no previous exposure to antipsychotic medication.   Clinical response was 
defined as ≥20% reduction on the Positive and Negative Syndrome Scale (PANSS) total 
score.   
 
 
Results 
Of the 522 patients, 400 (76.6%) achieved at least 20% reduction in PANSS total 
score.  However, time to response varied considerably (Figure 1), with 93 (23.4%) occurring 
during the first week of treatment, while at weeks 2, 3 and 4 the numbers were 93 (23.4%), 74 
(18.6%) and 50 (12.6%), respectively.  About one quarter (n=112) did not respond until after 
the fourth week and 53 (11.5%) after the eighth week.  Dose at time of response was as 
follows: 1 mg, 15.5% (n=62),  2 mg, 29.8% (n=119), 3 mg, 27.3% (n=109), 4 mg ,16.8% 
(n=67) and more than 4 mg 11% (n=43).   
Response of at least 30%, 40% and 50% respectively was achieved by 62.5%, 44.5% 
and 27.3% of patients.  Response occurred on the PANSS positive, negative and 
psychopathology scales with the most improvement on the positive subscale (Table 1).         
 Based on Cox regression analysis, which controlled for baseline PANSS and study 
centre,   patients with poor pre-morbid functioning (as measured using the Premorbid 
Adjustment Scale global assessment of highest functioning (5)) were less likely to respond 
(OR=.89; CI=.83 to .95; p<.001), as were those with previous antipsychotic exposure 
(OR=.77; CI=.61 to .97; p<.03).  Age, sex and study medication were not significantly 
associated with response.  For the neuroleptic naïve patients (n=163; 20 non-responders) a 
longer DUP (which was transformed with log transformation to make the distribution normal) 
was associated with decreased likelihood of response (OR=.86; CI=.76 to .96, p=.01), as was 
poorer pre-morbid functioning (OR=.85, CI=.74 to .97, p=.01).   
 
 
Discussion 
The majority of our subjects responded to antipsychotic treatment, in keeping with the 
previously reported favorable response in first-episode schizophrenia (6).  Also, our findings 
provide further evidence that, at least in some patients, the onset of antipsychotic action is 
early – i.e. in the first week of treatment (1).  However, the time course to response varied 
widely, with some responders only achieving 20% improvement after > 10 weeks of treatment 
with a median of almost 3 weeks.  
Our findings therefore differ from those of a multi-episode sample (3) insofar as we 
did not find early non-response to be a reliable predictor of later non-response.  Whereas 
Correll et al found that all patients who failed to achieve 20% improvement after 1 week of 
treatment failed to do so after 4 weeks of treatment, we found that 52% (n=184/353) of such  
patients did not respond by week 4.  Moreover we found that of the non-reponders at week 1 
(n=353), 78.5% (n=277) went on to have a clinical response.  Correll et al found that 35% of 
those who had responded by week 1 were also responders at week 4; we found that 77.4% 
(n=72/93) of such patients were responders at week 4.    
If, according to practice guidelines (7), treatment trial periods of one month or even 
six weeks were applied to our subjects, many would incorrectly have been regarded as non-
responders.  Additional research is indicated, and if similar results emerge then practice 
guidelines recommending shorter durations of treatment (7) may need to be revised for 
patients with first-episode psychosis.  A possible explanation for the discrepant findings is that 
in the Correll et al (3) study the treatment period was of short duration (4 weeks).  Also, in our 
study a low-dosing strategy was adopted which could explain the slow response in some 
patients.  We consider this unlikely however, as low doses of both risperidone (8) and 
haloperidol (9)  have been shown to be at least as effective as high doses in first-episode 
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psychosis.  Our finding that shorter DUP and better pre-morbid functioning was a predictor of 
response is in keeping with previous work (10, 11).  
Strengths of this study include the large sample, the fact that this was a first-episode 
sample, the use of standardized assessment and diagnostic criteria, the ability to test 
treatment response in a typical and atypical antipsychotic and the long treatment period.  The 
flexible dosing design was both an advantage in that it allowed mimicking clinical practice and 
also a limitation in that time to response for a specific dose could not be examined.  Future 
studies should examine the relationship between early symptom reduction and later overall 
outcome. 
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Table 1 Perecent improvement from baseline for PANSS total and subscales (n=526) 
 Positive 
 
Negative 
 
General 
Psychopathology 
Total 
60% or more 10.5% (n=149) 12.3% 
(N=65) 
11.4% 
(N=61) 
10.3% 
(n=54) 
50% or more 48.1% (n=253) 26.8% 
(N=141) 
28.7% 
(N=151) 
27.3% 
(n=144) 
40% or more 63.3% 
(n=333) 
43.0% 
(N=226) 
43.1% 
(N=233) 
44.5% 
(n=234) 
30% or more 73.8% (n=388) 59.1% 
(N=311) 
61.6% 
(N=324) 
62.5% 
(n=329), 
20% or more 82.2% 
N=432) 
72.5% 
(N=381) 
76.2% 
N=401 
76.2% 
(n=401) 
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Abstract  
Background: Previous attempts to identify clinically useful predictors of treatment outcome in 
schizophrenia have been hampered by methodological inconsistencies, including a lack of 
standardised outcome measures. Recently proposed operationally defined criteria for 
remission provide an opportunity to re-address this topic.  
Method: We applied the remission criteria to a sample of 57 subjects with first-episode 
psychosis, treated according to a fixed protocol over two years. Various demographic, 
baseline clinical and early response variables were subjected to discriminant analysis for their 
ability to predict remission or non-remission. We also assessed the symptom improvement 
patterns over time and compared endpoint psychopathology in the remitters and non-
remitters. 
Results: A model incorporating neurological soft signs, 6 week treatment response, duration 
of untreated psychosis, pre-morbid functioning and PANSS excited factor baseline score was 
able to correctly predict 89% of the remitters and 86%of the non-remitters.  Symptom 
reduction at 6-weeks, including core-psychotic symptoms, was similar in the two groups, 
where after the remitting group continued to improve while the non-remitting group failed to do 
so. Considerable overlap of endpoint symptoms was observed, and depressive symptom 
scores were similar in remitters and non-remitters 
Discussion: A combination of demographic, baseline clinical and acute treatment response 
variables may accurately predict treatment outcome. Persistent non-core psychotic symptoms 
in subjects meeting proposed remission criteria require further investigation. 
 
 
Introduction  
Since the introduction of antipsychotic medication some fifty years ago, considerable attempts 
have been made to identify predictors of treatment outcome.1  Reliable predictors of 
antipsychotic treatment outcome would be of great benefit, particularly by avoiding 
unnecessary persistence with ineffectual treatment before attempting alternative strategies. 
This in turn would reduce the risk of accruing morbidity, the development of side effects, the 
duration of hospitalization, the level of care required, the amounts of concomitant medication 
prescribed, and overall costs incurred.  
Factors determining the response to antipsychotic treatment in schizophrenia are poorly 
understood, and results of studies thus far have been inconclusive and sometimes 
conflicting.2   A poorer response has been associated, amongst other factors, with male 
gender, history of obstetric complications, more severe positive symptoms, the development 
of parkinsonism during antipsychotic treatment,3 extrapyramidal symptoms (EPS) prior to 
antipsychotic exposure,4 neurological soft signs,5 the development of tardive dyskinesia (TD), 
family history of schizophrenia6 and prolonged duration of untreated psychosis (DUP).7 
However, associations as such do not necessarily imply predictive value, and none of these 
factors can be regarded as clinically useful in forecasting treatment outcome.2  An alternative 
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approach has recently produced promising results: early treatment response appears to 
closely parallel later outcome,8;9 and recently evidence has emerged that a lack of early 
treatment symptom reduction may be an accurate predictor of later non-response.2 
 
Part of the difficulty in interpreting the findings of studies to date is related to the divergent 
methodologies that were employed.10 Sample populations (e.g. first-episode, multi-episode), 
treatment durations and assessment instruments differ across studies. Another significant 
problem has been that the endpoint measures of outcome have varied widely. For example, 
clinical treatment trials often report a reduction in symptom severity from baseline to endpoint 
as the primary outcome measure, while other studies have attempted to define criteria for 
treatment response (e.g. 20% improvement in psychopathology scores),11 relapse12 or 
remission.13 Recently, in the hope of improving the assessment of treatment outcome, 
operational criteria defining remission in schizophrenia were proposed by a ‘Remission in 
Schizophrenia Working Group’.14 These criteria define remission according to a threshold of 
severity of selected rating scale items rather than percentage improvements from a particular 
baseline. The items were selected on the basis of their representing 3 major symptom 
domains identified in factor analyses (negative, psychosis and disorganized factors) and the 
five criteria specified in DSM-IV for a diagnosis of schizophrenia. The proposed criteria define 
remission as absent, borderline or mild symptom intensity level where such symptoms do not 
influence an individual’s behavior. An additional requirement is that these criteria must have 
been met for a duration of at least 6 months, 
 
We applied these criteria in a post-hoc fashion to a sample of subjects with first-episode 
psychosis who were treated according to a fixed protocol over 24 months, and evaluated 
various potential predictors of outcome. The primary aim of our study was to identify any 
baseline and early treatment variables that could be useful to clinicians in predicting remission 
and non-remission. As a secondary aim, we explored the symptom improvement patterns 
over time and differences in endpoint psychopathology in remitters and non-remitters. 
 
 
Methods: 
 
Subjects 
The sample comprised 57 participants in a 2-year prospective study of first episode psychosis 
in the Stikland Hospital catchment area in Cape Town, South Africa. The patient sample and 
study procedure have been described in detail elsewhere.15 Briefly, inclusion criteria 
comprised in- or outpatients aged 16 to 55 years, meeting DSM-IV16 diagnostic criteria for 
schizophreniform disorder, schizophrenia or schizo-affective disorder, who had been exposed 
to less than 4 weeks of antipsychotic treatment. Exclusion criteria were another DSM-IV axis I 
diagnosis including substance abuse or dependence, significant general medical condition 
and mental retardation. The study was approved by the Ethics Committee of the University of 
Stellenbosch and subjects and/or their guardians provided written, informed consent to 
participate in the trial.  
 
Assessments 
Participants were assessed by means of the Structured Clinical Interview for DSM-IV 
(SCID).17  Psychopathology was measured by means of the Positive and Negative Syndrome 
Scale (PANSS)18 and the Calgary Depression Scale for Schizophrenia (CDSS);19 and 
extrapyramidal symptoms (EPS) by means of the Abnormal Involuntary Movement Scale 
(AIMS),20 the Barnes Akathisia Scale (BAS)21 and the Simpson-Angus Scale (SAS).22  For the 
purpose of this analysis we used baseline, 6 and 12 week, and then 3 monthly assessments.  
 
Treatment 
Subjects were treated according to a fixed protocol with low doses of haloperidol starting on 
1mg/day, gradually increasing the dose for non-responders (≤ 20% reduction in PANSS total 
score) to a maximum of 10mg/day. The treatment was generally effective and well tolerated.15 
 
Remission criteria 
The symptom severity threshold comprises a score of 3 (mild) or less on each of the following 
PANSS items: Delusions (P1), conceptual disorganization (P2), hallucinatory behaviour (P3), 
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blunted affect (N1), social withdrawal (N4), lack of spontaneity (N6), mannerisms/posturing 
(G5) and unusual thought content (G9). The minimum time threshold for maintaining these 
symptom severity levels is 6 months.14 
 
Symptom improvement patterns 
PANSS total scores over time were compared for remitters and non-remitters by repeated 
measures analysis of variance (RANOVA). To examine whether any initial symptom reduction 
in the non-remitting group could be accounted for by improvement in non-core psychotic 
symptoms, we compared baseline to 6 week reductions in the PANSS symptoms used to 
define remission.14 Endpoint scores for PANSS total and factor scores, as well as CDSS 
scores were compared between the two groups. 
 
Predictors of remission 
The following variables were investigated as potential predictors of remission: 
Sex, age, diagnosis (schizophrenia vs schizophreniform/schizo-affective disorder), 
educational status (rated on a scale from 0-8), employment status, marital status (ever 
married), family history of schizophrenia, DUP (greater or less than 1yr), baseline PANSS 
scores (PANSS total scores and previously described PANSS factor scores23), baseline 
CDSS scores, baseline neurological soft signs (total scores from the Neurological Evaluation 
Scale (NES)24), the development of EPS other than tardive dyskinesia (TD) (a score of ≥1 on 
the BAS scale and ≥14 on the SAS at any stage during the study),  and TD. Also, as a 
measure of acute symptom reduction we investigated the degree of clinical response at 6 
weeks.  (We chose 6 weeks as earier time points did not show significant correlations with 
outcome.) 
 
Statistical analyses 
Due to the relatively small sample and the uncertainty regarding the predictive power of the 
individual variables, we adopted the following procedure to determine the predictive power of 
the selected variables: First, we split the data into a ‘training’ (n=25) and ‘test’ (n=16) set, only 
including the cases with no missing data (n=41). For the training set, we drew a random 
sample (n= 25) with a replacement (bootstrap) sample. We then applied the best subsets 
method to the bootstrap sample using discriminant analysis and support vector machines 
(SVM), and noted which variables were included in the “best model”. Support Vector 
Machines are learning machines that can perform binary classification (pattern recognition) 
and real valued function approximation (regression estimation) tasks to solve classification 
and regression problems.25  These steps were repeated until we were satisfied that clear 
patterns had emerged. The number of times each variable was included as a predictor 
determined its predictive power. Based on these findings, a subset of variables was selected 
and a final model constructed for the 25 ‘training’ cases, and tested on the 16 ‘test’ cases.  
 
All statistical tests were two-tailed and a 5% (p<0.05) significance level was set throughout. 
Results are expressed as the mean ± standard deviation. Where appropriate, 95% confidence 
intervals are reported.  
 
 
Results 
 
The sample comprised 57 participants (51% women) aged 28±8.5 yrs at study entry. Seventy-
two percent were diagnosed with schizophrenia, 21% with schizophreniform disorder, and 7% 
with schizo-affective disorder. The mean DUP was 229±358 days. Subjects were acutely ill at 
study entry, with a mean PANSS total score of 93.4±16.6.  Twenty-eight (49%) completed the 
24 months of treatment, the majority as out-patients.  Of the 29 who discontinued, 23 were 
lost to follow-up, 3 were withdrawn due to poor response, 2 relocated and 1 committed 
suicide.  While 40 (70%) met cross-sectional symptom reduction for remission at some point 
in the study, only 23 (40%) managed to achieve the full remission criteria when the 6-month 
duration was applied. Of these 23 subjects, nineteen (83%) maintained their remission status 
throughout the trial. For those attaining it, the mean time to remission was 10±4.13 months. 
The remission and non-remission groups did not differ significantly regarding the endpoint 
dose of haloperidol (1.2±0.8 vs 1.8±1.3, p=0.08).  
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Symptom improvement patterns 
Figure 1 depicts the PANSS total scores at each assessment point for the remitted and non-
remitted groups separately. Group differences in PANSS total symptom reduction were highly 
significant (p<0.01). Both groups showed significant early (baseline to 6 week) reductions 
(remitters p<0.0001; non-remitters p<0.0001), although the remission group reductions were 
significantly greater than the non-remission group (p=0.004).  However, whereas the remitting 
group continued to improve thereafter to endpoint (p<0.01), the non-remitters failed to do so 
(p=0.55). To assess whether these early symptom changes included improvement in ‘core’ 
psychotic symptoms rather than just non-specific treatment effects, we compared composite 
scores for the eight PANSS items included in the remission criteria,14  at 6 weeks.  Significant 
reductions were observed in both the remitter (p<0.01) and non-remitter groups (p<0.01). 
 
The endpoint PANSS scores for remitters and non-remitters are given in Table 1. PANSS total 
scores for the remitted and non-remitted groups were 40.7±9.5 and 65.9±20.7 (p<0.01), 
respectively. However, there was considerable overlap between the groups, and several non-
remitting subjects had lower PANSS total scores than some of the remitters. (Some subjects 
with a low PANSS total score who did not meet remission criteria had a score of >3 on jus one 
of the PANSS remission items. On the other hand, one subject managed to meet the 
remission criteria with a PANSS total score of 72.) There were highly significant endpoint 
differences between the remitter and non-remitter groups for the negative, disorganized and 
psychosis factor scores. This was of course expected, as the remission criteria were 
specifically selected to represent these three symptom domains. However, while the excited 
factor scores also differed significantly between the groups, the depressive factor scores did 
not.  
 
Predictors of remission 
Differences between the remitters and non-remitters for the potential predictors that we 
evaluated are given in Table 2. After inspection of the data we excluded TD as a variable, 
because there were too few cases. Guarding against over-fitting, the initial best subsets 
discriminant analysis identified the following predictors: NES total score; DUP less than 1 yr; 
marital status; educational status; early treatment response; and PANSS excited factor 
baseline score. The model was able to correctly predict 92% of the remitters and 85%of the 
non-remitters in the train set, and 89% of the remitters and 86%of the non-remitters in the test 
set.  For the SVM verification model five predictors were identified (NES total score; early 
treatment response; DUP less than 1 yr; marital status; and PANSS excited factor baseline 
score), that were able to correctly predict 92% of the remitters and 85%of the non-remitters in 
the train set, and 89% of the remitters and 86%of the non-remitters in the test set.   
 
 
Discussion 
 
Application of the remission criteria14 to our sample of first-episode patients demonstrates 
once again that the overall outcome in schizophrenia is poor, despite a favourable initial 
treatment response.8;10  The fact that 70% of all of our subjects achieved the cross sectional 
symptom reduction criteria for remission at some time attests to the efficacy of antipsychotic 
treatment in first-episode schizophrenia in the acute setting.13 However considerably fewer 
than half managed to maintain these criteria for 6 months, and even fewer until the 
completion of the trial - highlighting the need for improved maintenance strategies in the early 
course of the illness.   
 
The fact that both groups showed early (6 week) symptom improvement, including that of 
core psychotic symptoms, suggests that remitters and non-remitters are difficult to 
differentiate in the early phase of treatment. More specifically, early clinical response does not 
necessarily imply ongoing improvement and sustained remission. Conversely however, a lack 
of early response is highly predictive of non-remission. This is in keeping with the findings in a 
multi-episode sample, where 100% of subjects not responding after 1 week of treatment failed 
to respond after 4 weeks of treatment.2  While early non-response may accurately predict 
later poorer outcome in both first-episode and multi-episode patients, there may be important 
differences between these patients insofar as some first-episode patients appear to take 
longer to respond to treatment.26  This has implications for practice guidelines recommending 
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the duration of treatment trials, and suggests that clinicians need to persist longer with a 
particular treatment in the case of first-episode psychosis. 
 
The differences in symptom profiles at endpoint between remitters and non-remitters are of 
interest. As expected, significant differences were found in PANSS total scores at endpoint. 
However, the considerable overlap between the remitters and non-remitters shows that 
patients who improve on core symptoms may still have other residual symptoms requiring 
attention. The significance of this finding needs to be investigated further. Particularly, the 
persistence of some depressive symptoms in remitted patients counts against the proposal 
that depression is one of the core symptoms of schizophrenia insofar as they do not respond 
to antipsychotic treatment.27 Also, these ‘post-psychotic’ depressive symptoms are likely to 
require clinical intervention, considering their association with poor social and vocational 
functioning28 and increased risk of relapse29  
 
Our discriminate analysis findings suggest that a combination of certain baseline and early 
clinical response variables may be useful to clinicians in predicting outcome at an early stage 
of treatment. The predictor variables identified in our study were generally not unanticipated, 
as they have previously been linked with treatment outcome. The association between DUP 
and remission is consistent with many, although not all other studies showing a longer DUP to 
be associated with poorer outcome;30-33 neurological soft signs have been associated with 
poor treatment outcome;5 higher educational and positive marital status, as measures of good 
premorbid adjustment have been associated with a more favourable outcome;34 and finally, 
early treatment response is well known to correlate strongly with later outcome.2;35 As was the 
case in a previous longitudinal study of patients with chronic schizophrenia, we failed to find 
significant associations between baseline psychopathology (other than the 
excitement/hostility factor) and outcome.8 
 
In terms of their clinical usefulness, the predictor variables identified in our study are all easy 
to assess. In future, other variables not identified in this study may further refine our ability to 
predict treatment outcome.  Strengths of this study are the uniform treatment protocol that 
was followed for all participants, the relatively long duration of follow-up and the fact that all 
subjects were assessed by the same investigator (PO). The study is limited by its post-hoc 
nature and the relatively small sample, compounded by the high attrition rate accompanying 
long-term studies such as this one.  Also, no attempt was made to assess the role of  
compliance in our subjects. Given the high levels of non- and partial adherence to medication 
in first-episode samples,36  persistent symptoms in the non-remitted subjects in our study 
could in part be explained on this basis. This is further supported by the finding that some 
previously “stable” non-remitted patients achieved symptom remission after receiving 
‘ensured’ medication delivery, in the form of long-acting risperidone injection.37  A further 
potential limitation is that this was a flexible dose study, and we did not investigate a possible 
role for dose of medication. However, the fact that both predictor models produced similar 
results, suggests that the accurate prediction of remission and non-remission based on the 
selected variables may be possible.  Also, future studies should investigate the relationships 
between these operationally defined remission criteria and other measures of outcome. 
 
In conclusion, this study provides further evidence that, in spite of a good initial response to 
antipsychotic medication, most patients do not maintain a state of sustained symptom 
improvement after a first episode of psychosis. Our findings also suggest that a combination 
of certain clinical and early treatment response variables may be useful in predicting later 
remission.  
 
  
Acknowledgement: This work was supported in part by the Medical Research Council of 
South Africa  
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Table 1. Mean±SD PANSS total and factor scores at 24 months for subjects who had 
achieved remission and those who had not. 
 
 
Score at 24 months remitters non-remitters p value 
PANSS total 40.7±9.5 65.9±20.7 <0.01 
Negative factor 9.1±3.4 15.4±6.0 <0.01 
Disorganised factor 6.5±2.2 10.4±3.0 <0.01 
Psychosis factor 5.1±1.9 10.0±4.6 <0.01 
Excited factor 4.4±1.0 6.4±3.5 =0.02 
Depression factor 4.5±2.3 4.5±2.2 =0.90 
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Table 2. Differences between remitters and non remitters for the selected potential predictor 
variables  
Potential predictor Remitters 
(n=19)a 
Non-remitters 
(n=22) a 
p value 
Gender (male:female) 10:9 12:10 0.90 
Race (black:white) 15:4 16:6 0.64 
Employed (yes:no) 12:7 18:4 0.18 
Ever married (yes:no) 8:11 5:17 0.18 
Family history (yes:no) 7:12 7:15 0.74 
DUP<1yr (yes:no) 18:1 14:8 0.01 
EPS(yes:no) 7:12 9:13 0.79 
TD(yes:no) 2:17 4:18 0.48 
PANSS total % reduction at 6 wks  38±17 20±18 0.004 
Age (yrs)b 27 (23-32) 32 (28-35) 0.14 
PANSS total baselineb  97(89-104) 91(84-98) 0.26 
PANSS positive factorb  17(16-18) 16(15-18) 0.32 
PANSS negative factorb  14(11-17) 14(11-16) 0.97 
PANSS disorganised factorb  13(12-16) 13(11-15) 0.47 
PANSS excited factorb  11(10-13) 10(9-11) 0.26 
CDSS baseline scoreb  3.5(1.9-5.1) 1.3(0-2.8) 0.05 
NES total scoreb  4.6(2.9-6.4) 8.1(6.5-9.8) <0.01 
Educational levelc  5.6(4.7-6.4) 5.6(4.8-6.4) 0.98 
Diagnosis (schizophrenia: 
schizophreniform/schizo-affective disorder) 
14:5 19:3 0.56 
 
a The sample size for the discriminant analysis model was 41 
b Values are given as mean (.95 confidence interval) 
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Abstract 
 
Background: Recently, the “Remission in Schizophrenia Working Group” proposed 
remission criteria consisting of a reduction to mild levels on key symptoms for at least 6 
months.   
Aims: This study applied these remission criteria to a large first-episode psychosis 
sample in order to (1) determine the rates of remission; (2) explore predictors of remission; 
and (3) test the external validity of these criteria.   
Methods:  We analyzed data from 462 subjects with a first-episode of psychosis who 
participated in a long-term, multinational, randomized, double-blinded trial of risperidone and 
haloperidol over 2 to 4 years.   
Results: At some time point in the study 323 (70%) of the 462 subjects had a 
reduction to mild levels on the key symptoms as measured by the PANSS although only 109 
(23.6%) maintained this level for at least 6 months thereby meeting remission criteria.  The 
two strongest predictors of remission were shorter duration of untreated psychosis (p=0.01) 
and treatment response at 6 weeks (p=0.001).  Compared to non-remitted patients, those in 
remission experienced greater improvement on all PANSS subscales (p<.0001), CGI-S 
(p<.0001), better quality of life (p=0.006), fewer relapses (p<.0001), displayed a more 
favorable attitude towards their medication (p=.002), had lower EPS levels according to the 
ESRS (p=<.0001) and received lower doses of antipsychotic medication (p=0.003).  The 
remission and non-remission groups did not differ significantly regarding composite cognitive 
scores, suicidality and body mass index.  
Conclusions:  The results suggest that the remission criteria, although based solely 
on core symptom improvement, can effectively identify patients who have a more favorable 
overall outcome.  
Keywords: remission, schizophrenia, outcomes  
 
 
Introduction 
 
Notwithstanding the fact that subjects with a first-episode of schizophrenia generally 
respond well to antipsychotic treatment in the short term (Lieberman et al., 1993; Robinson et 
al., 1999), the overall outcome for this illness remains unsatisfactory.  While some patients 
may experience a relatively circumscribed deterioration early in the illness, with stabilization 
thereafter, the majority of affected individuals do not.  Recurrent relapses, often precipitated 
by partial or complete non-adherence to treatment, result in persistence of symptoms, 
accruing morbidity and enduring deficits in cognition and psychosocial function (Andreasen et 
al., 2005; Harrow and Jobe, 2005; Robinson et al., 2004).  Estimates of outcome have varied 
considerably, ranging from very pessimistic in earlier studies to more optimistic in some 
recent studies (for a review see Jobe and Harrow (2005).  While these outcome differences 
may in part reflect the heterogeneity of the illness, they are also likely due to differences in 
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samples studied and methodologies employed.  Efforts to accurately assess treatment 
outcome have been hampered by a multitude of methodological pitfalls, one of which has 
been a lack of standardized outcome measures.  For example, many clinical trials report the 
degree of symptom reduction from baseline to endpoint as the primary efficacy measure.  
Others have defined criteria to assess rates of response (Schooler et al., 2005), relapse 
(Csernansky et al., 2002), remission (Lieberman, 1993) and recovery (Robinson et al., 2004).  
To further compound the problem, different cut-off scores and criteria have been employed 
across studies to assess these outcome measures.  
In an attempt to standardize the definition for outcome in schizophrenia, a ‘Remission 
in Schizophrenia Working Group’ recently proposed operationally defined criteria for 
remission in schizophrenia (Andreasen et al., 2005). They defined remission as a state in 
which patients have experienced improvement to the extent that any remaining symptoms are 
of low intensity and no longer interfere significantly with behavior. These criteria define 
remission according to a threshold of severity for selected rating scale items representing the 
‘core features’ of the illness. The items were selected to represent the 3 major symptom 
domains identified in factor analyses (negative, psychosis and disorganized factors) and the 
five criteria specified in DSM-IV for a diagnosis of schizophrenia.  The proposed criteria define 
remission as absent, borderline or of mild symptom intensity level where such symptoms do 
not influence an individual’s behavior.  An additional requirement is that these criteria must 
have been met for a minimum duration of 6 months. The hope has been expressed that these 
criteria enhance the conduct and reporting of clinical investigations, and also reset 
expectations of treatment outcome to a higher level (van Os et al., 2006).  
We applied the remission criteria to a sample of subjects with a early episode  
psychosis who participated in a long-term, multinational, randomized, double-blinded trial of 
risperidone and haloperidol. The sample was deemed very suitable for such an analysis 
because of its large size, the controlled nature of the study, utilization of standardized 
assessment tools, and the fact that subjects were followed over a long period from early in 
their illness.  The aims of this post-hoc analysis were firstly, to determine the rates of 
remission after a first-episode of psychosis; secondly, to explore predictors of remission; and 
thirdly, to test the external validity of these criteria by comparing patients achieving remission 
with those who remained symptomatic, in terms of selected clinical, functional and quality of 
life outcome measures.   
 
 
 
Methods 
The study was conducted in 11 countries between November 1996 and January 
2000.  Patients were followed for between two and four years. Details of the study 
methodology and efficacy and safety results have been published elsewhere (Schooler et al., 
2005). 
Participants 
The key inclusion criteria were age 16 to 45 years, having a DSM-IV diagnosis of 
schizophrenia, schizophreniform disorder or schizoaffective disorder for no more than 12 
months, during which period they had no more than two psychiatric hospitalizations for 
psychosis, having persistent current psychotic symptoms requiring long-term antipsychotic 
treatment, and having had 12 weeks or less of cumulative lifetime exposure to antipsychotic 
medications.  Exclusion criteria were meeting DSM-IV criteria for another Axis I diagnosis 
including substance dependence or abuse, requiring psychotropic medication other than an 
antipsychotic at enrolment, and having a serious or unstable medical illness.   Approval was 
obtained from local Institutional Review Boards, and participants provided informed, written 
consent to participate in the study. 
Five hundred and fifty nine patients from 11 countries were randomly assigned to 
receive either haloperidol or risperidone.  For the purpose of this analysis we excluded 41 
subjects, for the following reasons: Not receiving study medications (n=4); Good Clinical 
Practice violations (n=21); and missing baseline data (n=16).  Additionally, 56 patients who at 
baseline had mild symptom levels on the key PANSS items used to define relapse were 
excluded, leaving a total sample of 462.   
Two-hundred and sixteen (47%) subjects discontinued prematurely, for the following 
reasons: adverse events (n=30), insufficient response (n=41), ineligible to continue in the trial 
(n=4), lost to follow-up (n=36), non-compliant (n=13), withdrew consent (n=66), and other 
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reasons (n=26).  As previously reported, the major efficacy findings in the original study were 
as follows: In both the risperidone and haloperidol treatment groups, the PANSS total and 
subscale scores and CGI scores improved significantly from baseline, with no significant 
differences between the treatment groups. Three-quarters of the patients achieved initial 
clinical improvement defined by more than 20% reduction in total PANSS score.  Among 
those who achieved clinical improvement, 42% of the risperidone group and 55% of those in 
the haloperidol group experienced a relapse defined according to broad criteria (Csernansky 
et al., 2002) (Log rank=7.10, p=. 008) (Schooler et al., 2005).  
Treatment 
Subjects were randomly allocated to receive either risperidone or haloperidol after a 3 
to 7 day drug washout period that was waived in extremely ill patients. A low-dosing strategy 
was followed, using equivalent doses of risperidone and haloperidol.  Both treatment groups 
started with a once daily dose of 1 mg that was increased if necessary by 1 mg per day after 
3 days, and thereafter by 1 mg per day each week, up to a maximum daily dose of 4 mg.  In 
exceptional cases, the dose could be increased further by 1 mg a week up to a maximum 
daily dose of 8 mg.  Thirty-one percent (n=163) of the participants had no previous exposure 
to antipsychotic medication.  Participants were treated with trial medication for a mean of 
381±426 days. The mean modal dose of risperidone was 3.3 mg and of haloperidol 2.9 mg.  
The median treatment duration was 206 days (maximum 1514).    
Assessments 
The investigators (N=49) and other designated raters underwent training for the 
assessment scales at investigator meetings prior to, and during the study. Psychopathology 
was assessed by means of the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 
1987) and Clinical Global Impressions (CGI) (Guy, 1976), which were completed weekly 
during the first four weeks and subsequently every four weeks (rating symptoms manifest at 
the time of the interview and for the previous week for the PANSS and ESRS).  PANSS 
factors were derived according to a previous factor analysis conducted on this sample 
(Emsley et al, 2003). Quality of life (WQoL) was assessed using the Wisconsin QoL Index – 
Patient version (Becker et al., 1993). This self-administered questionnaire assesses nine 
separate domains that together encompass quality of life.   We used the global score to 
compare remission and non-remission groups.  Premorbid functioning was assessed with the 
Premorbid Adjustment Scale (PAS) (Cannon-Spoor et al., 1982) a 28 item rating scale that 
measures social isolation, peer relationships, functioning outside the family and school 
performance during four age periods (ages up to 11, 12-15, 16-18 and 19 and above), as well 
as social-sexual aspects of life starting at age 15 and a section of general items relating to 
various aspects of life.  The PAS was completed on the basis of all available information, 
including patient interviews and collateral information. Using the scoring method developed by 
Cannon-Spoor et al (1982), average scores for each life stage were calculated by summing 
the item scores for each item in a section and dividing them by the possible score.   
Patient attitudes towards treatment were evaluated by means of the self-report Drug 
Attitude Inventory (DAI) (Hogan and Awad, 2000).  This is a 30-item inventory focusing on the 
subjective effects of antipsychotic medications in patients with schizophrenia.  Neurocognitive 
performance was assessed by means of a composite score derived from a battery of 
neuropsychological tests (Wisconsin Card Sorting Test; Digit Symbol Test; California Verbal 
Learning Test or Ray Auditory Verbal Learning Test; Wechsler Memory Scale – Revised 
Visual Production and Verbal Fluency tests) (Harvey et al., 2005).  Neurocognitive tests were 
performed at baseline, 3 and 6 months, and then at 6-monthly intervals.  Extrapyramidal 
symptoms were evaluated by means of the Extrapyramidal Symptom Rating Scale (ESRS) 
(Chouinard and Margolese, 2005).  The PANSS, CGI and ESRS were all rated at the same 
intervals, thus the exact evaluation point was used.  The Wisconsin QoL and DAI were 
administered at week 1 (not the DAI), months 4, 8, 12  and then at 6-monthly intervals.  The 
cognitive testing was done at baseline, after 3, 6 and 12 months and thereafter every 
6 months following completion of the first year of the trial.  Since 86% of patients achieving 
remission had done so by one year, the longest time between assessment of remission status 
and the other outcome measures was 2 months on Wisconsin QoL and DAI and 3 months on 
cognitive functioning. 
Relapse was defined according to Csernansky et al )2002(  criteria, which defines 
relapse as any one of the following occurring after clinical  improvement, defined as 20% or 
greater decrease on PANSS total: (a) 25% or more increase in PANSS (or 10 points if the 
initial score is 40 or less); (b) CGI-C score of “much worse” or “very much worse”; (c) 
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deliberate self-injury; (d) emergence of clinically significant suicidal or homicidal ideation as a 
reported adverse effect; or (e) violent behavior resulting in significant injury to another person 
or significant property damage.  Suicidality was assessed according to Adverse Event 
reporting.  
Remission criteria 
Remission consists of maintaining for at least 6 months a mild or lower level on 8 key 
PANSS items which are: delusions (P1), conceptual disorganization (P2), hallucinatory 
behavior (P3), blunted affect (N1), social withdrawal (N4), lack of spontaneity (N6), 
mannerisms/posturing (G5) and unusual thought content (G9) (Andreasen et al., 2005).  Each 
PANSS item is rated on a scale of 1-7, with 1= absent, 2 = minimal or borderline and 3 = mild.  
For the remission group we included all participants who achieved remission at any stage in 
the trial, regardless of whether they were able to maintain this status for longer than 6 months 
until the study endpoint.  For the non-remission group we included all subjects who never 
achieved remission despite having received antipsychotic treatment for an adequate 
treatment period which we defined as 9 months as it was the mean and median time to 
remission in the remission group.   
Predictors of remission 
The following variables were investigated for their potential as predictors of remission: 
Sex, age, age at onset of first symptoms, body mass index (BMI), previous antipsychotic 
treatment, duration of untreated psychosis (DUP), “good” vs. “poor” premorbid adjustment 
using Haas and Sweeney criteria (1992), trial medication treatment group (risperidone vs. 
haloperidol), mean dose of antipsychotic medication, and baseline PANSS factor scores 
(Emsley et al., 2003).  DUP was defined as the time from the onset of overt hallucinations or 
delusions.  The baseline interview had a special section in the case reporting form devoted to 
taking a detailed treatment and symptom history.  Raters were trained in eliciting and 
recording this information.  This section included an item noting the date of initiation of 
treatment with antipsychotic medication and an item noting estimated date of onset of first 
psychotic symptoms.  These two items were used to compute DUP.  Information was obtained 
using all available sources including patients, close family members, carers and psychiatric 
and medical records.  
We also assessed the value of acute treatment response as a predictor of remission, 
as early lack of symptom reduction (after one week of treatment) has been shown to be highly 
predictive of later non-response (Correll et al., 2003).  However, we decided to use a later 
assessment point (6 weeks) as a predictor variable, as the time to response has been found 
to vary widely in first-episode psychosis, with a substantial proportion of subjects being slow 
responders (Emsley et al., 2006).   As defined in the study protocol and as reported in 
previous study publications (Schooler et al, 2005; Emsley et al, 2006), clinical response was 
defined as ≥20% reduction in PANSS total scores.  
Statistical analysis 
All analyses were performed on an intent-to-treat basis.  We created variables to 
indicate whether or not the 8 key PANSS remission items were rated as mild or lower at each 
measurement interval.  An additional two variables were created, one indicating whether or 
not remission was attained as indicated by sustained mild or lower levels on the key PANSS 
items for 6 months, and the other indicating the time to first reduction to mild level on the 8 
key PANSS items among patients who achieved remission.  To examine the role of key 
variables as predictors of remission, Cox regression (a type of regression for survival 
analysis) was used.  For those  patients who met remission criteria, survival time was the first 
time symptom severity criteria were met, and for those not meeting remission criteria it was 
the end of the trial.  The CHAID algorithm for recursive partitioning was used to examine the 
association of DUP and remission.  Recursive partitioning in general and CHAID specifically 
construct trees, where each (non-terminal) node identifies a split condition, to yield optimum 
prediction (of continuous dependent or response variables) or classification (for categorical 
dependent or response variables).  It has been has been previously used in schizophrenia 
research (Subotnik et al., 2005),  
To test the external validity of the remission criteria patients achieving remission were 
compared with those who did not, in terms of selected clinical, functional and quality of life 
outcome measures using analysis of covariance (ANCOVA) and cross tabulations with Chi-
square.  For the purpose of this analysis  we defined the remission group as those patients 
achieving remission, whether or not this was maintained until the end of the study.  The 
remission group was compared to non-remitted participants who were in the trial for at least 9 
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months and never achieved remission.  Nine months was chosen because it was the mean 
and median time to obtaining remission, in the remission group.  This was to exclude those 
patients who did not achieve remission because they were not in the trial for a sufficient 
period of time.  The measurement point used for the remission group was  the first evaluation 
point that they achieved remission status, and for the non-remission group we used the last 
evaluation that was performed.  Some of the scales were not assessed at all of the time 
points.  For these, we took the one closest to the evaluation point for the non-remission 
group.  For the remission group we did the  same, with an additional requirement that the 
assessment had to be while they were in remission.  All statistical tests were two-tailed.  A 
significance level of 0.05 was used throughout. 
 
 
Results 
Remission rates 
At some time during the study 323 (70%) of the 462 subjects had a reduction to mild 
or less on the key PANSS remission items.  However, only 23.6% (n=109/462) were able to 
maintain this status for at least 6 months in order to meet the remission criteria, whereas 353 
were not.  Among those patients who met remission criteria (n=109), the mean time to first 
reaching remission symptom levels was 153± SD 173 days.  Of the 353 non-remission 
patients, 214 had at least one visit in which they met remission criteria.  Of the 214, 38 were 
in remission for only 1 such visit and 58 for more than 1 visit, although not consecutively.  Of 
the 176 who were in remission for at least 2 consecutive visits, the median time in remission 
was 1.5 months (69 had 1.5 months or less, 39 had 2 to 4 months and 10 had between 4 and 
6 months).  
Baseline characteristics of the remission and non-remission groups are provided in 
Table 1.  There was a significant difference between the groups in terms of diagnostic 
distribution, with a higher proportion of schizophrenia in the remission group. Also, compared 
with the non-remission group, patients in remission had a shorter DUP; the PANSS negative 
factor score at baseline was 1.5 points lower; and they expressed greater medication 
satisfaction (DAI) at month 4.   
Predictors of remission 
Since there were differences in the length of stay in the trial between the diagnostic 
groups (with schizoaffective and schizophreniform patients spending less time in the trial), 
separate Cox regression survival analyses were conducted for patients with a diagnosis of 
schizophrenia on the one hand, and those with a diagnosis of 
schizoaffective/schizophreniform disorder on the other.  The predictor variables examined and 
the results at the bivariate level are presented in Table 2.  As can been seen the only variable 
to be associated with remission in both diagnostic groupings was DUP.  This was followed by 
a stepwise (forward) analysis which found significant effects for DUP in both the 
schizophrenia (OR=.83 [.72; .95], Chi-square=7.02, p=.008) and the 
schizophreniform/schizoaffective group (OR=.66 [.45; .97], Chi-square=4.50, p=.03).  The 
other significant predictors were, for the schizophrenia group, the negative symptom factor 
(OR=.95 [.92; .98], Chi-square=10.50, p=.001) and for the schizophreniform/schizoaffective 
group age at onset of first psychotic symptoms (OR=1.10 [1.03; 1.16], Chi-square=9.44, 
p=.002).  There were no differences between the treatment groups regarding remission rates 
or time to remission. 
To further explore the relationship between DUP and remission we performed 
recursive partitioning, a procedure designed to determine optimal cutting points.  The most 
suitable DUP cutting point for the schizophrenia group was 391 days (21% of the patients had 
a DUP of at least this duration).  Of the subjects with a DUP of ≤391 days, 33% achieved 
remission as compared to only 18% of those with a DUP > 391 days.  As premorbid 
adjustment and baseline symptom severity have both been proposed as possible 
confounders for the DUP effect (Marshall et al., 2005; Verdoux et al., 2001), we re-ran the 
Cox regression model adjusting for total PANSS scores at baseline and premorbid 
adjustment, age and sex.  The significant effect for DUP was found to be independent of 
these two variables in both the schizophrenia group (p=0.01) and schizo-
affective/schizophreniform group (p=0.02).   
Another round of analyses was performed to test whether early clinical response 
(defined as ≥20% reduction on PANSS at 6 weeks) could predict remission.  In a Cox 
regression equation controlling for baseline PANSS scores, response at 6 weeks was found 
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to be a significant predictor of remission in both the schizophrenia groups (OR=1.72 [1.06; 
2.77], Chi-Square=10.19, p=.001) and the schizo-affective/schizophreniform group (OR=5.25 
[1.90; 14.52], Chi-Square=10.19, p=.001).  Survival curves for the time to remission for the 
responders vs. non-responders at 6 weeks are depicted for the schizophrenia group (Figure 
1a) and the schizoaffective/schizophreniform group (Figure 1b) respectively.  Interestingly, a 
considerable number of non-responders at 6-weeks in the schizophrenia went on to achieve 
remission later, in contrast to the schizo-affective/schizophreniform group where almost all of 
the non-responders did not achieve remission. 
Clinical and functional outcome correlates of remission and non-remission 
Table 3 depicts the differences between subjects who achieved remission and those 
who did not, despite sufficiently long study drug exposure, for the selected clinical and 
functional outcome variables.  As expected, the remission group showed greater reductions in 
PANSS total scores, as well as in all of the 5 PANSS factor domains and CGI.  Patients in 
remission also reported much greater improvement in QoL, had fewer relapses (as per criteria 
used elsewhere (Csernansky et al., 2002)), displayed a more favorable attitude towards their 
medication, received lower doses of antipsychotic medication and had lower levels of 
extrapyramidal symptoms.  The only variables that did not show a significant difference 
between the groups were suicidality, the composite neurocognitive score, BMI and treatment 
group.  Figure 2 portrays the time to relapse for patients achieving remission compared with 
those who did not.  Differences were highly significant (Chi-sq 29; df=1; p<0.0001).  After 90, 
180, 270, 360, and 450 days respectively, the cumulative proportion of patients relapsing for 
the remission group was 16%, 18%, 21%, 26% and 30% and for the non-remission group 
37%, 50%, 60%, 67% and 72%.   
 
Discussion 
The fact that the majority (70%) of the participants in this study managed to achieve a 
rating of mild or less on the 8 key PANSS remission items representing the core symptoms of 
schizophrenia at some stage in the trial, confirms the efficacy of antipsychotic medication in 
first-episode psychosis in the short term (Lieberman et al., 1993; Robinson et al., 1999). The 
mean time to first reduction on these items of about 5 months is consistent with our previous 
finding that some first-episode patients take a considerable period of time to respond to 
treatment (Emsley et al., 2006), in contrast to the rapid onset of action that has been reported 
in multi-episode subjects (Agid et al., 2003; Kapur et al., 2005; Leucht et al., 2005).  But 
despite the favorable initial response, only one in three of our subjects who achieved 
symptom reduction were able to maintain a relatively asymptomatic state for at least 6 months 
to meet remission criteria.  While this, and other randomized controlled trials, may not 
accurately reflect a “real world” setting,(Wahlbeck et al., 2001), our results seem to once 
again highlight the shortcomings of oral antipsychotic medication, emphasizing the need for 
improved maintenance strategies after a first-episode of schizophrenia. One likely important 
variable is non- or inadequate adherence to medication, which has been reported in almost 
59% of patients 12 months after a first psychotic episode (Coldham et al, 2002).  In a similar 
vein the “CATIE” study, reported rates of treatment discontinuation over 18 months ranging 
from 64% to 82%, and the authors concluded that, although effective in symptom reduction, 
antipsychotic drugs have substantial limitations in their overall effectiveness in patients with 
chronic schizophrenia (Lieberman et al., 2005; Stroup et al., 2006) 
The low remission rate reported in our sample would at first glance appear to differ 
considerably from rates reported in other studies such as Malla et al (2006) (82.2%) and 
Lieberman et al (2003) (80%). However, in the Malla et al (2006) study remission was defined 
as the absence of psychotic symptoms lasting at least 1 month, and the Lieberman et al 
(2003) study remission was defined as a 50% reduction in total BPRS score and no score > 
mild on the 5 BPRS psychosis items, with no temporal requirement. These studies are 
therefore consistent with our own findings of high rates of acute symptom improvement. 
Another recent study reported a somewhat better outcome in their first-episode sample, with 
47.2% achieving remission within 5 years (Robinson et al, 2004).  Remission in this study 
required a symptom reduction level of mild or less on positive and disorganized symptoms, 
moderate or less on selected negative symptoms, and a duration of 2 years.   However, only 
a quarter of the subjects achieved sustained social/vocational recovery, and only 13.7% met 
criteria for full recovery. 
The most significant predictors of remission in this study were a shorter DUP and an 
early (6 wk) response to treatment. The finding of female sex being associated with better 
 125
outcome is in keeping with previous work (Angermeyer et al., 1990; Robinson et al., 1999; 
Seeman, 1986), as is an association between negative symptoms and poorer outcome (The-
Scottish-Schizophrenia-Research-Group, 1987). However, baseline levels of psychopathology 
were not associated with outcome in other studies (Breier et al., 1991; Robinson et al., 1999), 
although depressive symptoms have been (Emsley et al., 1999; Oosthuizen et al., 2002).  Our 
DUP results add to an already substantial literature supporting a relationship between DUP 
and treatment outcome (Marshall et al., 2005; Perkins et al., 2005). Our results also support 
the view that DUP is an independent predictor variable, not confounded by premorbid 
adjustment level or baseline symptom severity (Marshall et al., 2005).  This is of considerable 
importance, as DUP is one of few prognostic indicators that are potentially modifiable.  Finally, 
early treatment response is well known to correlate strongly with later outcome (Correll et al., 
2003; Stern et al., 1993) and symptom levels after acute treatment have been proposed as a 
critical predictor of outcome (Breier et al., 1991).  Our results suggest that this relationship is 
stronger in patients with a diagnosis of schizo-affective or schizophreniform disorder, while 
some patients with schizophrenia who achieve remission seem to respond more slowly.  It 
could be that combining these two variables (DUP and early treatment response) may 
increase their predictive power to a level where they could be useful clinical tools in the early 
identification of patients who are non-responsive to first-line antipsychotic treatment.  Future 
studies could explore such a possibility. 
Our findings contribute to the validation of the remission criteria proposed by the 
Remission in Schizophrenia Working Group (Andreasen et al, 2005).  Although based on core 
symptom reduction only, the criteria appear to effectively identify patients who do well on 
several other outcome measures. These patients report a better quality of life, display a more 
favorable attitude towards their medication, have lower levels of “non-core” symptoms 
(excitement/hostility and depression/anxiety), require a lower dose of antipsychotic 
medication, and experience fewer extrapyramidal symptoms and fewer relapses. 
Our failure to demonstrate significant differences in cognitive performances between 
the remission and non-remission groups was surprising, considering a previously reported 
association between cognitive function and treatment outcome (Addington and Addington, 
1993).  One possible explanation is that, due to the high discontinuation rate, the trial did not 
have sufficient power to detect differences between the groups.  However, an alternative 
explanation is that cognitive deficits are independent of the core symptoms of psychosis, and 
reflect a more enduring trait-like status (Lieh-Mak and Lee, 1997). This possibility was 
proposed by Auslander and Jeste (2004) when they similarly failed to demonstrate significant 
differences in cognitive performance between older patients with sustained remission 
compared with symptomatic controls, although Kopelowicz and co-workers reported 
differences between recovered schizophrenics and matched controls (Kopelowicz et al., 
2005).  
The lower mean daily dose of antipsychotic medication in patients in remission does 
not necessarily mean that lower antipsychotic doses are more effective than higher doses. 
More likely, it may reflect increases in doses in patients who failed to respond sufficiently.  
While the lower ESRS scores in patients in remission are consistent with the lower 
antipsychotic dose that they received, the similar increases in BMI between the remission and 
non-remission groups are not. The latter finding could be explained by the fact that the 
subjects in remission tended to stay in the trial longer, thereby being exposed to more 
antipsychotic treatment days.  Another probable contributory factor is that the non-remitting 
patients were likely to have been less adherent to antipsychotic medication, thereby having 
less exposure to the weight-gain effects of antipsychotics. This would not be surprising, 
considering that 59% of patients are either non-adherent adherent or inadequately adherent 
12 months after a first-episode of psychosis (Coldham et al., 2002), and psychotic symptoms 
are likely to emerge in the majority (Gitlin et al., 2001). 
There are several aspects of this study that limit the generalisability of our findings.  
One difficulty was in choosing the most suitable endpoints to compare the remission and non-
remission groups because those who achieved remission did so at different times during the 
study. This resulted in different treatment durations for the remission and non-remission 
groups, which could have influenced some of the group comparisons of outcomes.  Also, it 
could be expected that patients who remained in remission would continue to show 
improvement in outcome measures beyond the 6 months.  This may have biased against the 
remission group achieving an even better outcome, and more treatment side-effects.  Further, 
the involvement of many investigators posed challenges for standardizing the rating 
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instruments. To minimize these problems, training courses were conducted at the start of, and 
during the study. (While inter-rater reliability assessments were not conducted, investigators 
were required to attain a high level of agreement with a videotaped interview.)  Also, there 
may be difficulties in comparing patients across countries due to service provision and cultural 
differences.  Another limitation was the reduced sample sizes at later assessment points in 
the study due to the high dropout rate that occurs in long-term trials such as this one 
(Wahlbeck et al., 2001). It could also be argued that, by excluding patients who met cross-
sectional remission criteria at baseline, we omitted patients with the most favorable prognosis. 
This would not explain the poor outcome that we observed however, as the majority of 
patients were able to achieve cross sectional reduction – the problem was in the maintenance 
thereof.  
In conclusion, this study provides further evidence for a favorable acute effect for 
antipsychotics in treating early episode psychosis, but highlights the failure of the medication 
to maintain this improved status.  DUP and early treatment response are two promising 
predictors of outcome.  Finally, those patients who achieved remission according to the 
proposed operational criteria (Andreasen et al., 2005) also displayed a better overall outcome 
in terms of various functional and quality of life measures.  
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Figure 1a. One minus survival curve for time to remission for patients achieving a clinical 
response at 6 weeks vs. those who did not, for patients with a diagnosis of schizophrenia 
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Figure 1b. One minus survival curve for time to remission for patients achieving a clinical 
response at 6 weeks vs. those who did not, for patients with a diagnosis of schizoaffective or 
schizophreniform  disorder 
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 Table 2.  Results of the Cox regression bivariate analysis of potential predictor variables of 
remission, for the diagnostic groups of schizo-affective/schizophreniform disorder and 
schizophrenia.  
 
 
Schizoaffective-
Schizophreniform 
(n=162) 
Schizophrenia 
(n=300) 
  Chi-Square P Chi-Square P 
Age 6.06 0.01 1.34 0.25 
Age of onset 9.58 0.00 0.00 0.96 
Sex 0.20 0.66 5.81 0.02 
BMI 0.01 0.93 1.89 0.17 
Previous antipsychotic exposure 0.20 0.66 0.94 0.33 
Duration of untreated psychosis 3.90 0.05 6.24 0.01 
Characteristic   
 
Remission Group 
(n=109) 
Non-remission Group 
(n=353) 
 
Male sex (n, %) n=74, 67.9% n=259, 73.4% Χ2=1.24, df=1, p=.26 
Race or ethnic group (n, %)    
   White N=85, 78% n=253, 71.7% Χ2 =5.5, df=3, p=.14 
   Black  n=53, 15.0% n=7, 6.4%  
   Hispanic  N=4, 3.7% n=11, 3.1%  
   Other N=9, 8.3% n=30, 8.5%  
Mean age (yr) 25.5 sd 6.14  n=109 25.2 sd 6.88n=353 T=.34, df=460, p=.73 
DSM-IV diagnosis (n, %)   Χ2 =11.4, df=2, p=.003 
  Schizophrenia n=85, 78.0% n=215, 60.9%  
  Schizoaffective disorder N=3, 2.8% n=30, 8.5%  
  Schizophreniform disorder n=21, 19.3% n=108, 30.6%  
Antipsychotic naïve  (n, %)   n=34, 31.2% n=122, 34.7% Χ2 =.45, df=1, p=.50 
Duration of untreated psychosis Mean: 272.5 sd 576.0 Mean: 535.0 sd 1246 T=3.03, df=393.4,  
PANSS Total score (mean, SD) 82.6 sd 16.6 
n=109 
85.4 sd 16.9 
n=353 
T=1.53, df=460, p=.13 
PANSS positive factor (mean, SD)  26.6 sd 6.4 
n=109 
26.1 sd 6.32 
n=353 
T=.74, df=460, p=.46 
PANSS negative factor (mean, SD)  19.9 sd 6.5 
n=109 
21.5 sd 7.0 
n=353 
T=2.03, df=460, p=.04 
PANSS disorganization (mean, 
SD)  
18.0 sd 5.3 
n=109 
19.1 sd 5.7 
n=353 
T=1.73, df=460, p=.08 
PANSS excitement (mean, SD)  7.5 sd 3.3 
n=109 
7.8 sd 3.4 
n=353 
T=0.88, df=460, p=.38 
PANSS depression (mean, SD)  10.5 sd 3.5 
n=109 
10.9 sd 3.7 
n=353 
T=0.99, df=460, p=.32 
CGI-S score (mean, SD) 4.57 sd .89 
n=109 
4.59 sd .87 
n=353 
T=.18, df=460, p=.86 
Wisconsin QoL score (mean, SD) .48 sd .96 
n=64 
.41 sd .84 
n=202 
T=.56, df=264, p=.57 
Premorbid adjustment scale scores 
(mean, SD)  
.36 sd .14 
n=109 
.38 sd .15 
n=349 
T=1.17, df=456, p=.24 
DAI score (mean, SD)  (Month 4) 4.19 sd 4.47 
(n=94) 
2.92 sd 4.66 
(n=132) 
T=2.05, df=224, p=.04 
Composite neuro-cognitive z-score 
(mean, SD) 
-.08 sd .61 
n=106 
-.01 sd .77 
n=335 
T=0.18, df=460, p=.86 
ESRS total score (mean, SD) 3.20 sd 4.22 
n=109 
3.40 sd 4.63 
n=351 
T=.39, df=458, p=.70 
BMI (mean, SD) 23.6 sd 4.3 
n=108 
23.4 sd 5.2 
n=346 
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(logged) 
Mean dose 3.99 0.05 0.92 0.34 
Treatment group 0.17 0.68 0.18 0.67 
Premorbid functioning 1.74 0.19 3.03 0.08 
Positive symptom factor 0.46 0.50 0.07 0.79 
Negative symptom factor 1.98 0.16 9.92 0.00 
Disorganized thoughts factor 0.94 0.33 5.52 0.02 
Excitement/ hostility factor 0.11 0.74 0.06 0.80 
Depression/anxiety factor 0.85 0.36 0.48 0.49 
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Table 3. Comparison of clinical, functional and quality of life measures for the patients who 
achieved remission vs. those who did not and who had at least 9 months of treatment 
                                            
1 Mean (standard error) when covariates included adjusted mean presented. 
 
2 According to the criteria of Csernansky et al (8), only patients achieving clinical response 
(20% decrease on PANSS). 
 
3 Serious suicidal ideation or attempts, reported as adverse events. 
 Remission group 
(at time of first 
meeting 
remission 
criteria) 
Non-remission 
group  
(at study 
endpoint) 
P  value  
Wisconsin Quality of Life scale, 
change from baseline1 
0.72 (0.11)  
n=60 
0.30 (0.10) 
N=57 
P=0.006 
Drug attitude inventory, change 
from baseline1 
4.84 (.38) 
n=103 
3.51 (.45) 
N=90 
P=0.02 
Composite neuro-cognitive z-
score, change from baseline1 
.02 se .06 
n=103 
.04 se .06 
N=92 
P=0.81 
Antipsychotic dose after 12 
months of treatment (mg/d)1 
2.99 (.17) 
n=106 
3.81 (.21) 
N=93 
p=0.003 
PANSS total score, change from 
baseline1 
-41.0 (1.39) 
n=106 
-22.8 (1.49) 
n=93 
 
p<.0001 
PANSS positive factor score 
change from baseline 
-14.7 (.49) 
n=106 
-10.3 (.53) 
N=93 
p<.0001 
PANSS negative factor score 
change from baseline 
-9.46  
(ץ.56)n=106 
-3.56 (.56) 
N=93 
p<.0001 
PANSS disorganization factor 
score change from baseline 
-9.05 (.39) 
n=106 
-4.87 ( .41) 
n=93 
 
p<.0001 
PANSS excitement/hostility factor 
score change from baseline 
-3.02 ( .20) 
n=106 
 
-1.90 (.21) 
N=93 
p<.0001 
PANSS depression/anxiety factor 
score change from baseline 
-4.44 (.27) 
n=106 
-2.45 (.29) 
N=93 
p<.0001 
CGI-S score, change from 
baseline1 
-2.49 (.10)  
n=106 
-1.52 (.11) 
N=93 
<0.0001 
ESRS total score change from 
baseline1 
-.97 (.45) 
n=106 
1.62 (.48) 
N=93 
P<.0001 
Relapse rates (%)2 34.0% 
n=36/106 
63.2% 
n=55/87 
 
0.0001 
Body mass index change from 
baseline (Kg/M2) 1 
3.21 (.33) 
n=105 
 
3.00 (.35) 
n=91 
p=.66 
Suicidality (%) 3 6.6% 
n=7/106 
8.6% 
n=8/93 
0.59 
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Figure 2. Survival curve for time to relapse from time of clinical response for patients 
achieving remission vs. those who did not. 
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Abstract 
While atypical antipsychotics appear to be effective in reducing depressive symptoms in the 
acute phase of schizophrenia, little is known about their efficacy in patients with ongoing 
symptoms. The present study assessed whether quetiapine (Seroquel®) is more effective 
than haloperidol in treating depressive symptoms in patients with persistent positive 
symptoms, and investigated whether this effect is independent of, or secondary to, reductions 
in other symptoms such as positive, negative or extrapyramidal symptoms (EPS). Patients 
with schizophrenia and a history of partial refractoriness to conventional antipsychotics who 
had not responded to 4 weeks’ fluphenazine treatment (20 mg/day) were randomised to 
receive either quetiapine (600 mg/day) or haloperidol (20 mg/day) for a further 8 weeks. 
Change in the PANSS depression factor score from baseline to endpoint was calculated and 
path analyses were performed on data from 269 patients. Quetiapine produced a greater 
reduction in depressive scores than haloperidol (-1.60 vs -0.54; p=0.006). The path analyses 
indicated that this was a direct effect on depressive symptoms. These findings extend the 
evidence for an antidepressant effect for the novel antipsychotics in schizophrenia, and 
suggest that this is not limited to acutely psychotic patients. 
Key Words: Quetiapine, haloperidol, schizophrenia, depression, clinical efficacy 
 
 
Introduction 
Symptoms of depression are common in schizophrenia, the prevalence having been reported 
at between 7% and 70%, depending on the samples studied and criteria applied (Barnes et 
al., 1989; Siris, 1991). They are often not easy to recognise, as they may mimic negative 
symptoms (Tollefson et al., 1998a), neuroleptic-induced akinesia (van Putten and May, 1978) 
or akathisia (van Putten and May, 1975). There are numerous factors that could produce 
depressive symptoms in schizophrenia, such as a psychological response to the illness and 
its accompanying adverse life events (Birchwood et al., 1993), substance abuse (Tollefson et 
al., 1998a), co-morbid major depressive disorder or anxiety disorders, and neuroleptic-
induced dysphoria (Harrow et al., 1994). It is also possible that depressive symptoms 
represent a core feature of the schizophrenic illness itself (Johnson, 1981; Koreen et al., 
1993). The majority of depressive symptoms appear to occur concurrently with the acute 
psychotic symptoms, and resolve as the psychosis remits (Koreen et al., 1993). Although not 
clear-cut, the presence of depressive symptoms in the acute phase of the illness may be 
associated with a favourable outcome (Kay and Lindenmayer ,1987; Siris, 1991).  
However, there are patients with schizophrenia who experience persistent depressive 
symptoms that are not responsive to conventional antipsychotic treatment alone. A 
depressive syndrome was found in 12.9% of patients with chronic schizophrenia, and these 
symptoms persisted beyond 3 months in 60% of the subjects. (Barnes et al., 1989). Persistent 
depressive symptoms may be particularly important, considering their association with poor 
social and vocational functioning (Mandel et al., 1982; McGlashan and Carpenter, 1976), 
increased risk of relapse (Birchwood et al., 1993) and suicide (Roy et al., 1983). Therefore, 
when present in the chronic course of schizophrenia, depressive symptoms appear to be 
negative prognostic indicators (Mandel et al., 1982; McGlashan and Carpenter, 1976).  
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Recently, there has been renewed interest in depression in schizophrenia and it is now recognised 
that these symptoms may be an important target for treatment. Owing to their novel 
pharmacological profiles, and particularly their serotonergic effects, the atypical antipsychotics 
could be valuable in treating these symptoms. Indeed, considerable supportive evidence exists. 
Clozapine decreases suicidality in treatment-refractory schizophrenia (Meltzer and Okayli, 1995; 
Walker et al., 1997), and exerts mood-stabilising thymoleptic properties in treatment-refractory 
schizophrenia, schizo-affective disorder and psychotic mood disorder (McElroy et al., 1991; Suppes 
et al., 1992; Zarate et al., 1995; Calabrese et al., 1996). There is also evidence of an effect on 
depressive symptoms in schizophrenia for risperidone (Marder et al., 1997), olanzapine (Tollefson 
et al., 1998a; Tollefson et al., 1998b), and quetiapine (Arvanitis et al., 1997).  
While these results are encouraging, they were conducted in samples with acute 
exacerbations of schizophrenia, ie those patients in whom the depressive symptoms would be 
expected to respond to antipsychotic treatment (Koreen et al., 1993). It is also important from 
a clinical point of view to assess the efficacy of the atypical antipsychotics in treating 
depressive symptoms other than those associated with acute psychotic exacerbations. An 
important group of patients are the partial responders, in whom positive symptoms persist 
after conventional antipsychotic treatment (Breier et al., 1994). These patients represent the 
majority of schizophrenic patients that a practising psychiatrist is likely to treat (Weiden et al., 
1996) and a group at risk for persistent depressive symptoms (Barnes et al., 1989). We 
recently reported the results of a multinational controlled trial in which the efficacy and 
tolerability of quetiapine (Seroquel®) and haloperidol were compared in such a group of 
patients (Emsley et al., 2000). The present study examined the efficacy of quetiapine 
compared with haloperidol in reducing depressive symptoms in this sample, and assessed 
whether any beneficial effects observed were related to the improvement in positive 
symptoms, negative symptoms or extrapyramidal symptoms (EPS). 
 
 
  
Methods 
Patients and study design 
This was a multicentre, double-blind, randomised trial comparing the use of quetiapine and 
haloperidol in patients with no more than a partial response to conventional antipsychotic 
treatment. A detailed description of the study design, patient selection criteria, and efficacy 
and safety measures has been reported elsewhere (Emsley et al., 2000), and so will only be 
briefly described here. Patients meeting DSM-IV (American Psychiatric Association, 1994) 
diagnostic criteria for schizophrenia and who had a history of only partial response to 
conventional antipsychotics (defined as persistent positive symptoms while previously taking 
therapeutic doses of antipsychotics) were subjected to a 4-week active run-in treatment 
phase with fluphenazine (20 mg/day). Those patients showing either no response, or only a 
partial response to the fluphenazine treatment (defined as <30% reduction in the Positive and 
Negative Syndrome Scale (PANSS) total score), were randomised to receive either 
quetiapine (600 mg/day) or haloperidol (20 mg/day). Doses were titrated over a 7-day period, 
and then fixed for the next 7 weeks. Key exclusion criteria included severe resistance to 
conventional antipsychotics, known nonresponders to clozapine, and an acute psychotic 
exacerbation within the past 3 months. 
Clinical outcome 
Depressive symptoms were measured by means of the depressive factor identified by Kay 
(Kay, 1991) in his original factor analysis of the PANSS and used subsequently in other 
studies (Marder et al., 1997; Emsley et al., 1999). The PANSS depressive factor has been 
found to correlate strongly with other scales specifically designed to measure depressive 
symptoms (El Yazagi et al., 2002).  This factor comprises the composite score for the PANSS 
items of somatic concern (G1), anxiety (G2), guilt feelings (G3), and depression (G6). All 
analyses were performed on the intent-to-treat (ITT) population using the last value carried 
forward (LVCF). Scores were calculated for the patient’s baseline assessments (Week 4) and 
their final assessments either at withdrawal or Week 12 (endpoint). The change in the 
composite PANSS depression factor score from the patient’s baseline to their final or 
endpoint score was calculated. These changes from baseline were used in analyses of 
covariance (ANCOVA) of the difference between the two treatments, with the covariate being 
baseline factor score. Response rates, defined as the proportion of patients with a reduction 
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of ≥20%, ≥30%, ≥40% and ≥50% in the depression factor score, were considered by logistic 
regression, including pooled centre as covariate (LVCF on ITT population). 
In order to assess the treatment effect on depressive symptoms in those patients with more 
prominent symptoms, all of the analyses were repeated on patients with a baseline PANSS 
depression factor score of ≥8 (ie an average score of ≥2 for each of the four items, with a 
score of 2 indicating the definite presence of that symptom).  
Path analyses 
Path analysis (Retherford, 1993) as an analysis of psychiatric data was popularised by Moller 
and co-workers (1995) to estimate to what degree the effect of an antipsychotic on a specific 
symptom domain (in this case depressive symptoms) is mediated by its effects on other 
symptoms (positive symptoms, negative symptoms or extrapyramidal symptoms [EPS]).  In 
comparison with linear or multiple regression, path analysis allows the response variable to 
be affected both directly by the predictor variable and indirectly through one or more 
intervening variables, and allows the analysis of possible causal relationships.   In this case it 
can be estimated whether there is a ‘direct effect’ of treatment on depressive symptoms. Path 
analyses were performed on the depression factor in order to explore whether the differential 
effects of quetiapine and haloperidol on depressive symptoms could be attributed to 
differential effects on other symptoms. Change from baseline in the depression factor score 
was the response variable and change from baseline in the PANSS positive subscale score, 
negative subscale score and Simpson–Angus Scale score were the intervening variables. 
These variables were intended to represent positive symptoms, negative symptoms and EPS, 
respectively. 
Figure 1 provides a simple diagrammatic representation of the path analysis.  Baseline scores 
were also included in the ‘Path Model’, but are omitted from the diagram for clarity.  The path 
co-efficients were calculated by simultaneous linear regressions of the individual paths.   
Hence the total effect of treatment on depressive symptoms ([P1 x P5] + [P2 x P6] + [P3 x P7] 
+ P4) was calculated.  The direct effect (P4), and the contributions from the indirect paths, 
were compared by calculating the percentage of the total effect accounted for by each 
individual path.  Only those patients whose final PANSS and final Simpson–Angus scores 
were measured during the same week were analysed. The analyses were designed so that 
positive coefficients implied a better result for quetiapine, in terms of a larger difference from 
baseline compared with haloperidol.  
Path analysis is a statistical approach based on multiple regression analysis developed to 
differentiate between the direct and indirect effects of antipsychotic drugs on specific 
symptoms. It has often been used to assess the effect of antipsychotic medication on 
negative symptoms (eg. Kopelowicz et al., 2000), and depressive symptoms (Tollefson et al, 
1998a; Tollefson and Anderson, 1999)In brief, the analysis was based on the assumptions of 
weak causal order and causal closure. The first of these two assumptions tells us that, given 
any two variables such as x and y, it is known or assumed that x may affect y but that y 
cannot affect x. The second tells us that the covariance between the two variables x and y is 
solely the result of the direct causal relationship of one on the other or to other variables that 
are included in the model. If either a variable or a connection between variables is missing 
from the model, then the model itself is incorrect and inadequate and the required 
assumptions have been broken. It has been pointed out that the path analysis method is 
limited by how completely the model identifies relevant variables and relationships between 
them. The validity of this technique rests on the assumption that all relevant ‘causes’ have 
been included (Kopelowicz et al., 2000), 
 
 Results 
A total of 365 patients were recruited into the fluphenazine run-in phase. Of these, 288 
(78.9%) were randomised to treatment with either quetiapine (n=143) or haloperidol (n=145). 
Seventy-seven patients were not randomised for the following reasons: condition deterioration 
(n=9); lost to follow-up (n=4); adverse events (n=14); protocol noncompliance (n=10); 
informed consent withdrawn (n=16); and other reasons (n=24; predominantly due to a good 
efficacy response during the fluphenazine run-in). Seven of the 288 randomised patients who 
did not have post-baseline efficacy data were excluded, as were a further seven whose final 
PANSS and Simpson–Angus Scale scores were not carried out in the same week. A further 5 
patients who were randomised to receive quetiapine were excluded because they did not 
satisfy the USA label requirements of achieving a maintenance dose of at least 150 mg/day. 
Hence, the ITT population (n=269) comprised 132 patients on quetiapine and 137 on 
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haloperidol.  Eighty-four percent of the ITT population completed the trial. Demographic and 
baseline characteristics for all patients in the two treatment groups and those with a baseline 
Kay’s depressive factor score ≥8 are provided in Tables 1 and 2. 
The depression factor score, from baseline to endpoint, was reduced in both quetiapine (-
1.60) and haloperidol (-0.54) treated groups,  and the difference between the two treatments 
(1.05; confidence interval 0.31 to 1.79) attained statistical significance in favour of quetiapine 
(p=0.006).  
A summary of response rates, defined as the proportion of patients with a reduction of ≥20%, 
≥30%, ≥40% and ≥50% in the depression factor score (LVCF on ITT population), is provided 
in Table 3. There were significantly more responders in the quetiapine group when both 20% 
and 30% improvement were used to define response.  
Path analysis of the total patient group gave a total effect size of 1.1 and a direct effect size of 
0.8 and revealed that the direct ‘path’ from treatment to depressive symptoms was 
significantly in favour of quetiapine compared with haloperidol (p=0.016) and accounted for 
79% (0.8/1.1) of the total effect size (Table 4; Figure 2).  
Repeating the analysis in 94 quetiapine-treated patients and 86 patients receiving haloperidol 
who had more prominent symptoms (baseline PANSS depression factor score of ≥8) revealed 
a mean change from baseline to endpoint for the quetiapine group of -2.24 compared with 
-1.27 for the haloperidol group. Therefore, as expected, greater reductions were seen in the 
more symptomatic patients. The difference between the two treatments approached statistical 
significance (p=0.057). Path analysis of this group of patients gave a total effect size of 1.0 
and a direct effect size of 1.0 and revealed that the direct ‘path’ from treatment to effect on 
depression was significantly in favour of quetiapine compared with haloperidol (p=0.029) and 
accounted for 99.5% of the total effect size (Table 5; Figure 3).  
For both the analyses of the whole patient group, and the patients who had more prominent 
symptoms, the path co-efficients relating to the indirect paths exhibit a similar pattern.  Firstly, 
the path from treatment to EPS was statistically significant (P<0.001, in favour of quetiapine), 
whereas the path from EPS to depressive symptoms was NOT statistically significant.  Hence 
the indirect (or compound) path from treatment to depressive symptoms via EPS only 
accounted for approximately 10% of the total effect.   Secondly, neither of the paths from 
treatment to positive or negative symptoms were statistically significant, although both of the 
paths from either positive or negative to depressive symptoms were highly statistically 
significant.  Hence the compound paths from treatment to depressive symptoms via either 
negative or positive symptoms only accounted for less than 10% of the total effect.    
Thus, there is a differential treatment  effect on EPS, however EPS did not affect depressive 
symptoms;  positive and negative symptoms did affect depressive symptoms, but there was 
no differential effect of treatment on either positive or negative symptoms.Hence, the 
compound (indirect) paths had no effect on depressive symptoms and all the differential 
treatment effect on depressive symptoms is concluded to be direct. 
 
 
Discussion 
The results of this study suggest that quetiapine is more effective than haloperidol in reducing 
depressive symptoms in patients with refractory schizophrenia. Although the magnitude of the 
improvement in depressive symptoms is modest, we believe that it is of considerable 
significance bearing in mind the refractory nature of the sample and the fact that all patients 
had received antipsychotic treatment immediately prior to entry into the randomised phase of 
the trial. Consequently, it will be important to determine over the longer term whether by 
reducing depressive symptoms more effectively, quetiapine might ameliorate some of the 
sequelae of chronic depression in schizophrenia, namely impaired social and vocational 
functioning (Mandel et al., 1982; McGlashan and Carpenter., 1976), the risk of relapse 
(Birchwood et al., 1993) and suicide (Roy et al., 1983). Also, because of its beneficial effect 
on depressive symptoms, quetiapine may be more acceptable to patients than conventional 
antipsychotics. Indeed, alongside its favourable side-effect profile, this effect may play a role 
in the enhanced patient satisfaction that has previously been reported with this drug 
(Hellewell et al., 1999). 
The results of the path analyses indicate that the superior efficacy of quetiapine in treating the 
depressive symptoms is not secondary to differential treatment effects on positive or negative 
symptoms, or the development of EPS, and suggest a direct effect of the agent on depressive 
symptoms. While both agents were associated with improvement in depressive symptoms, 
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only quetiapine exhibited a significant direct effect distinct from positive or negative symptom 
change. It has been suggested that this difference may be related to the wider 
pharmacological binding profiles of  the atypical antipsychotics compared to haloperidol 
(Tollefson et al, 1988a). Changes in positive and negative symptoms were associated with 
changes in the depressive factor score, but as there were no statistically significant treatment 
differences in changes of positive or negative symptoms, this mechanism does not explain 
the differential antidepressant effect. These findings are supported by other studies. In a post-
hoc analysis of data from two acute treatment trials, quetiapine, but not haloperidol, was 
superior to placebo in improving Brief Psychiatric Rating Scale (BPRS) mood cluster scores. 
Depressive symptoms associated with schizophrenia were improved in significantly more of 
quetiapine-treated patients than either haloperidol or placebo groups (Arvanitis et al., 1997). 
In a 4-month comparative study of quetiapine and risperidone among patients with 
schizophrenia and related psychoses (30% had a diagnosis of depression/bipolar disorder), 
quetiapine proved superior to risperidone in reducing depressive symptoms in both 
schizophrenia and related mood disorder patients (Goldstein et al., 2000). 
Depressive symptoms were common in our sample, with 67% of patients having prominent 
symptoms, as indicated by a score of ≥8 on the PANSS depression factor. The mean ± SD 
baseline depressive factor scores (11.29 ± 2.96 and 11.86 ± 3.02 in the quetiapine and 
haloperidol groups, respectively) are higher than those previously reported in acutely 
psychotic multi-episodic schizophrenia (7.4 ± 2.84), even when compared with patients 
experiencing their first episode of schizophrenia (8.5 ± 3.32) (Emsley et al., 1999), a group in 
whom depressive symptoms have been found to be particularly common (Johnson, 1981; 
House et al., 1987; Koreen et al., 1993; Emsley et al., 1999; Lancon et al., 2001). There are 
several possible explanations for the prominence of depressive symptoms in our sample: they 
could have occurred concurrently with positive symptoms within the context of the acute 
psychotic episode (Koreen et al., 1993) and, because of the refractoriness of the sample, the 
depressive symptoms have persisted together with the positive symptoms. This would be in 
keeping with previous observations of a significant association between positive symptoms 
and depressive symptoms (Barnes et al., 1989; Norman and Malla., 1994; Lysaker et al., 
1995; Emsley et al., 1999). Alternatively, they could represent a psychological response 
(demoralisation) to an apparently uncontrollable life event, namely the illness and its 
attendant disabilities (Birchwood et al., 1993; Rooke and Birchwood, 1998). In fact, in the 
stress–diathesis context, depressive symptoms may themselves constitute a stressor that 
triggers a psychotic episode (Siris, 1993). Another possibility is that they could be a 
consequence of the antipsychotic treatment, although the existence of so-called neuroleptic-
induced dysphoria is controversial (Koreen et al., 1993; Siris, 2000). 
Finally, the depressive symptoms in our patients could also be explained on the basis of 
‘post-psychotic depression’ (which probably includes some of the above possibilities). The 
ICD-10 (World Health Organization, 1992) definition of post-psychotic depression requires 
that, along with general criteria for schizophrenia during the previous 12 months, the patient 
must still exhibit persistent hallucinations, thought disorder or negative symptoms not due to 
depression or antipsychotic medication. Clearly, the majority of patients in the present study 
would meet these criteria. However, recent work indicates that depressive symptoms may 
also emerge irrespective of positive symptoms. In a 12-month prospective study of 105 
patients with schizophrenia, two patterns of depressive symptoms were identified: those 
following the same course as positive symptoms during psychotic episodes; and those 
emerging de novo without a change in positive symptoms (Birchwood et al., 2000). The 
depressive symptoms in our sample of refractory schizophrenic patients most likely represent 
a combination of the above mentioned factors. 
 
Limitations of this study include the lack of a specific scale for the assessment of depressive 
symptoms, the high dose of haloperidol used, and the previously mentioned possible 
drawbacks of path analysis. 
In conclusion, this study indicates that depressive symptoms are common in patients with 
schizophrenia with persistent positive symptoms. Our findings extend the evidence for an 
antidepressant effect for the novel antipsychotics such as quetiapine in schizophrenia, and 
suggest that this effect is not limited to the reduction of depressive symptoms in acutely 
psychotic patients.  
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Table 1. Demographic and baseline characteristics (mean [SD]) for all patients receiving 
either quetiapine 600 mg/day or haloperidol 20 mg/day 
 
 Treatment 
 Quetiapine Haloperidol 
n 132 137 
Sex: Male 93 97 
 Female 39 40 
Age (years) 37.5 (10.4) 38.8 (11.4) 
PANSS total score 88.32 (18.01) 87.78 (21.16) 
PANSS positive score 21.69 (4.54) 21.96 (5.53) 
PANSS negative score 24.05 (6.32) 23.18 (6.44) 
PANSS depression factor 9.66 (3.64) 9.64 (3.81) 
Simpson–Angus Scale score 15.56 (5.32) 15.03 (4.81) 
 
 
Table 2. Demographic and baseline characteristics (mean [SD]) for all patients with a baseline 
Kay’s depressive factor score ≥8 receiving either quetiapine 600 mg/day or haloperidol 20 
mg/day 
 
 Treatment 
 Quetiapine Haloperidol 
n 94 86 
Sex: Male 67 58 
 Female 27 28 
Age (years) 37.1 (10.6) 38.3 (11.5) 
PANSS total score 90.71 (18.48) 94.16 (21.97) 
PANSS positive score 21.99 (4.86) 23.34 (5.95) 
PANSS negative score 23.91 (6.41) 23.97 (6.43) 
PANSS depression factor 11.29 (2.96) 11.86 (3.02) 
Simpson–Angus Scale score 15.84 (4.92) 15.32 (4.63) 
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Table 3. Response rates, defined as the proportion of patients with a reduction of ≥20%, 
≥30%, ≥40% and ≥50% in the depression factor score (last value carried forward [LVCF] on 
intent-to-treat [ITT] population) for all patients receiving either quetiapine 600 mg/day or 
haloperidol 20 mg/day 
 
 Quetiapine Haloperidol  
Responders Responders PANSS depression 
factor response 
rates 
Total number 
assessed 
n % 
Total number 
assessed 
n % 
p-value 
≥20% reduction 132 56 42.4 137 41 29.9 0.023 
≥30% reduction 132 45 34.1 137 27 19.7 0.004 
≥40% reduction 132 25 19.7 137 17 12.4 0.072 
≥50% reduction 132 17 12.9 137 9 6.6 0.051 
        
PANSS depressive 
factor ≥8 at baseline 
       
≥20% reduction 94 43 45.7 86 30 34.9 0.138 
≥30% reduction 94 36 38.3 86 22 25.6 0.067 
≥40% reduction 94 24 25.5 86 15 17.4 0.186 
≥50% reduction 94 17 18.1 86 9 10.5 0.143 
PANSS: Positive and Negative Syndrome Scale 
 
 
 
 
 
 
Table 4. Effect sizes for change from baseline to endpoint in Kay’s depressive factor, for 
quetiapine compared with haloperidol and the contribution of direct and indirect effects 
(n=269) 
 Effect 
 Total Direct Positive Negative EPS 
Effect sizes 1.106 0.803 0.057 0.090 0.066 
Percentage effect sizes 100.00 79.02 5.62 8.90 6.47 
p-value for direct effect 
(quetiapine vs haloperidol) 
  
p=0.016 
   
EPS: extrapyramidal symptoms 
 145
Table 5. Effect sizes for change from baseline to endpoint in Kay’s depressive factor for 
quetiapine compared with haloperidol and the contribution of direct and indirect effects in 
patients with baseline PANSS depression factor score of ≥8 (n=180) 
 
 Effect 
 Total Direct Positive Negative EPS 
Effect sizes 0.995 0.990 0.085 0.031 0.121 
Percentage effect sizes 100.00 99.61 -8.52 -3.10 12.12 
p-value for direct effect 
(quetiapine vs 
haloperidol) 
  
p=0.029 
   
EPS: extrapyramidal symptoms; PANSS: Positive and Negative Syndrome Scale. 
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Figure 1. Diagrammatic representation of the path analysis. 
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Figure 2. Diagrammatic representation of the path analysis containing path coefficients and p-
values (in parentheses) for the complete dataset (n=269). 
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Figure 3. Diagrammatic representation of the path analysis containing path coefficients and p-
values (in parentheses) for the symptomatic at baseline dataset (n=180). 
 
 
  POSITIVE SYMPTOMS    
 -0.585 (0.549)           0.145 (<0.001)  
                    
0.196  
(0.805) 
NEGATIVE SYMPTOMS   
0.157 
(<0.001) 
 
     
  EPS SYMPTOMS    
  
 
1.999 (<0.001) 
 0.060  
(0.230) 
 
 TREATMENT    
0.990 (0.029) 
DEPRESSIVE 
SYMPTOMS  
 
 
 
 
 
 
 
 
 148
3.a.vi  Clinical Potential of Omega-3-Fatty Acids in the Treatment of Schizophrenia. 
 
Robin Emsley,* Piet Oosthuizen,* Susan J van Rensburg** 
 
From the Departments of Psychiatry* and Chemical Pathology,** Faculty of Health Sciences, 
University of Stellenbosch, Cape Town, South Africa. 
 
Acknowledgements 
The authors have received funding for research on EPA from the South African Medical 
Research Council and the Stanley Research Foundation. 
 
 
Published in: CNS Drugs 2003;17(15):1081-91 
 
 
Abstract 
It has been hypothesised that abnormalities of phospholipid metabolism are present in 
schizophrenia, and that the omega-3 fatty acids, and eicosapentaenoic acid (EPA) in 
particular may have a role in treating this illness. Considerable pre-clinical and clinical 
evidence provides support for this proposal. An epidemiological study reported a better 
outcome for schizophrenia in countries whose diet was rich in unsaturated fatty acids. 
Evidence of abnormalities of essential fatty acids (EFAs) has been found in erythrocyte 
membranes and cultured skin fibroblasts, and abnormal retinal function and niacin skin flush 
tests have been reported in patients with schizophrenia. Case reports and an open-label 
clinical trial reported efficacy for EPA in schizophrenia. Four randomised controlled trials using 
EPA versus placebo as supplemental medication have now been reported. Two of these trials 
showed significant benefit for EPA, while the other two were negative on the primary efficacy 
measure. One study also reported a beneficial effect on dyskinesia. In the only published trail 
in which EPA versus placebo was used as monotherapy in schizophrenia, some evidence 
was found to suggest antipsychotic activity. Taken together, there is considerable evidence to 
suggest abnormalities of EFAs in cell membranes, and there is preliminary evidence that EPA 
is effective as supplemental treatment in schizophrenia.  
 
 
 
 
 
While the introduction of conventional antipsychotic agents almost 50 years ago heralded a 
major advance in the treatment of schizophrenia and other psychotic disorders, these 
compounds have serious limitations in terms of both efficacy and tolerability. Patients treated 
with these agents often have persistent psychotic symptoms, suffer frequent relapses, 
develop prominent functional impairment and experience distressing and disabling side-
effects.[1]  With regard to efficacy of conventional antipsychotics, approximately 70% of 
patients show substantial symptom reduction in the short-term. However, in the longer term 
the majority of patients experience persistent positive and/or negative symptoms. The most 
important side-effects are extrapyramidal symptoms (EPS), particularly tardive dyskinesia 
(TD). 
 
The development of the novel antipsychotic drugs has effectively addressed some of these 
problems. Accumulating evidence indicates significant advantages over their predecessors. In 
particular, it has been shown that the newer drugs are less likely to induce acute EPS.[2] Other 
reported advantages include improved efficacy in treatment-refractory patients,[3] negative 
symptoms,[4] depressive symptoms,[5] reduced levels of suicidality,[6] less neurocognitive 
impairment,[7] better subjective quality of life,[8] reduced incidence of TD[9] and improved 
overall outcome.[10] But even these newer agents have troublesome side effects such as 
leukopenia (with clozapine), weight gain [11], increase in serum triglycerides, and the 
development of insulin resistance  and diabetes mellitus. Clearly therefore, there is still a lot of 
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room for improvement in the treatment of schizophrenia. In addition, the high acquisition costs 
of these new compounds has put them beyond the reach of many patients worldwide.[12] The 
search for alternative treatments for psychosis therefore remains a high priority.  One such 
candidate is omega-3 polyunsaturated fatty acids (PUFA’s). There is now considerable 
evidence to suggest that the omega-3 polyunsaturated fatty acids may offer an affordable and 
effective alternative in the treatment of psychosis. 
  
  
1. The membrane phospholipid hypothesis 
A disorder of membrane phospholipid metabolism has been proposed as the biochemical 
basis for the neurodevelopmental hypothesis of schizophrenia,5 and provides a rationale for 
intervention studies using these compounds. In addition to their structural role in membranes 
(e.g. in the formation and remodelling of dendrites and synapses), phospholipids are involved 
in various biochemical reactions. One of these is the phospholipase A2 (PLA2) cycle which 
involves the release of arachidonic acid (AA) and other highly unsaturated fatty acids from 
phospholipids for cell signaling and prostaglandin synthesis. Specifically, it is postulated that 
in schizophrenia there is an accelerated rate of loss of unsaturated fatty acids. When present 
to a mild degree, this increased rate of loss will be compensated  for by increased 
incorporation, but there will be a change in membrane composition if there are deficiencies in 
the enzymes involved in phospholipid synthesis, the elongases, desaturases, and 
acyltransferases, in addition to a reduced dietary intake of EFA’s.[13] The phospholipase A2 
(PLA2) cycle is one of the intra-neuronal signal transduction systems that link the receptors of 
neurotransmitters such as dopamine, serotonin and glutamate. This cycle involves the 
release of arachidonic acid (AA) and other highly unsaturated fatty acids from neuronal 
membrane phospholipids. It has been proposed that there may be abnormalities in 
phospholipid-AA signalling in schizophrenia.[14]  Horrobin[15] summarised various research 
findings and noted the existence of clinical, biochemical and genetic evidence to suggest that 
schizophrenia is caused by a disorder of membrane phospholipid metabolism.  He proposed 
that this involves excessive loss of highly unsaturated fatty acids from membranes, owing to 
enhanced activity of PLA2. He postulated that this abnormality results in changes in the 
properties of membranes throughout the body, with such physical abnormalities as reduced 
vasodilator responses to niacin and histamine and altered immunological functions. The most  
serious consequences however,  are produced in the brain. Horrobin has further proposed his 
membrane phospholipid hypothesis as a biochemical substrate for the well-known 
neurodevelopmental hypothesis of schizophrenia.[16] In essence, the neurodeveopmental 
hypothesis states that genetic and environmental factors interact to influence the ways in 
which nerve cells are laid down, differentiated, selectively culled by apoptosis and remodelled 
by expansion and contraction of dendrites and synaptic connections. These changes begin in 
utero, are affected by events around birth, and become fully expressed in early adulthood.[17]  
 
Pregnancy and perinatal events which have been found to be related to later schizophrenia 
can be explained by their effects on the availability of normally-structured phospholipids.[13] 
Starvation during pregnancy increases the risk of schizophrenia: strong evidence for the 
impact of maternal food deprivation, especially EFA deficiency, on later schizophrenia comes 
from the study of Sinclair[18] of the Dutch famine of 1944-45. Low head circumference is also a 
risk factor for schizophrenia. The supply of AA to the developing foetus is a determinant of 
brain growth. The consistent increase in the risk of schizophrenia in association with obstetric 
complications, particularly pre-maturity and perinatal hypoxia,  causing mobilization of EFAs 
from brain phospholipids, which would exacerbate any tendency towards low AA and DHA 
levels in neuronal membranes. Stress during pregnancy is associated with a small, but 
significant, increased risk of schizophrenia in the offspring. Stress leads to elevation of cortisol 
and catecholamines, both of which are known to reduce the rate of formation of AA and DHA 
from dietary precursors. Stress could therefore lead to reduced availability lf brain-specific 
EFAs for the foetus.[13] 
 
Preterm infants receiving DHA supplementation or breast milk (which is high in n-3 FAs, 
especially DHA) have scored better on intelligence and development scales than infants fed 
on formula feeds, which are deficient in these PUFAs.[19] The effect of severe pre-eclampsia 
on maternal and cord erythrocyte membrane EFA profiles were investigated by Kirsten et 
al.[20] It was found that the cord blood DHA levels of infants of pre-eclamptic women are lower 
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than those of the infants of normotensive women, suggesting that infants born to pre-
eclamptic women need dietary DHA to replenish DHA stores. Generally, preterm formulas and 
parenteral lipid emulsions do not contain AA and DHA. 
 
 
Neuronal membranes are made up largely of phospholipids.[21] Brain phospholipids are 
uniquely rich in highly unsaturated fatty acids with three to six double bonds, falling into the 
general class of essential fatty acids (EFAs). These EFAs cannot be manufactured de novo in 
the mammalian body.[22] In schizophrenia, the basic abnormality in phospholipids creates a 
vulnerable state, which may be exacerbated by nutritional deficiencies. Horrobin has pointed 
out that the hypothesis could be tested in the form of relatively simple and safe treatment 
modalities.[15] Other workers have proposed that supplemental omega-3 fatty acids exert their 
action via their role in correcting oxidative stress that causes cellular injury through 
peroxidation of membrane phospholipids.[23] 
 
Interestingly, similar alterations in EFAs have also been postulated in depressive and 
neurodegenerative disorders. Lower n-3 EFA (particularly DHA) levels were found in 
erythrocyte membranes of depressed patients compared to control subjects. There were also 
significant negative correlations between the Beck Depression Inventory scores and n-3 red 
blood cell membrane fatty acid levels.[24]   
 
 
Lower levels of EPUFAs have also been reported in patients with neurodegenerative 
disorders such as multisystem neurodegeneration, multiple sclerosis and Huntington’s 
disease.[25] In a subsequent clinical trial of EPA in Huntington’s significant clinical 
improvement was shown.[26] 
 
 
2. Epidemiological evidence 
There is some evidence that diet may have a role in the pathogenesis and course of 
schizophrenia. In an analysis of data from an outcome study conducted in eight different 
countries, it was found that differences in dietary intake correlated significantly with the course 
and outcome of schizophrenia. Better outcome was reported in countries whose diet was rich 
in unsaturated fatty acids from vegetable and marine sources, compared to countries with 
high intake of saturated fatty acids from land animals and birds.[27] 
  
 
3. Evidence of abnormalities of essential fatty acids in patients with schizophrenia 
On the basis of a generalised disorder of membrane phospholipid metabolism, Horrobin 
postulated that changes in the properties of membranes throughout the body would be 
apparent.[15]  A number of studies have in fact reported such changes. 
 
3.1  Erythrocytes: 
One study measured the fatty acid composition of red blood cell membranes from 23 
medicated patients with schizophrenia and a healthy control group. Substantial depletions of 
fatty acids from the omega-6 and omega-3 series, particularly arachidonic and 
docosahexanoic acid, were found. An inverse relationship between depleted omega-6 fatty 
acids and plasma levels of thiobarbituric acid reactive substances suggested that the 
depletion was caused by increased breakdown of the fatty acids, rather than by impaired 
incorporation of fatty acids into membranes. Arachidonic and docosahexanoic acids appear to 
show a bimodal distribution. The authors postulated that their findings  might represent an 
abnormality in cell membrane fatty acid composition in schizophrenia, which is of aetiological 
importance.[28] Similar abnormalities in levels of EFAs in blood cells have also been noted in 
association with the presence of tardive dyskinesia (TD). The relationships between 
psychiatric symptoms, dyskinesia and relative levels of the omega-3 and omega-6 fatty acids 
were examined in red blood cell membranes and plasma in a sample of 72 subjects with 
schizophrenia or schizoaffective disorder. Subjects were followed up over a period of 4.5 
years to determine whether changes in symptoms were related to changes in EFA levels. It 
was hypothesised that subjects with schizophrenia would show lowered levels of omega-6 
and omega-3 series fatty acids, compared with healthy controls, and that this abnormality 
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would be greater in the patients with TD and  prominent negative rather than positive 
symptoms. However, the only consistent findings were that the patient sample had lower 
levels of linoleic acid and higher levels of dihomogamma-linolenic acid compared with the 
healthy controls. The authors noted that there was considerable variability in patients' EFA 
profile.[29] 
 
The long chain polyunsaturated EFA derivatives, particularly AA  and docosahexaenoic acid 
(DHA), are highly concentrated in the brain. However, red blood cell levels may be 
aperipheral marker of central EFA status. Red blood cell levels of fatty acids are influenced by 
diet, medications, and other factors. A study by Mahadik et al (1994) examined cell plasma 
membrane compositions of AA and DHA in cultured skin fibroblasts from 12 patients with 
schizophrenia, 8 of whom were drug-naive and in a first episode of psychosis, 6 bipolar 
patients, and 8 healthy control subjects. They found DHA as well as total omega-3 EFA 
contents to be significantly lower in cell lines from the patients with schizophrenia than in cell 
lines from the bipolar patients and healthy controls, with no difference between the latter two 
groups. AA levels did not differ across the groups. They concluded that their findings could be 
explained on the basis of deficient delta-4 desaturase activity in schizophrenia.[30] In another 
study, significantly reduced DHA and docosapentaenoic acid (DPA) concentrations were 
found in erythrocyte membranes from patients with schizophrenia compared with a carefully 
matched control group. Polyunsaturated fatty acid concentrations were measured in the 
erythrocyte membranes of 19 medicated young patients with schizophrenia and compared 
with matched healthy controls. Symptoms were rated by means of the Positive and Negative 
Symptom Scale (PANSS) and Montgomery-Asberg Depression Rating Scale.  Significant 
differences in erythrocyte fatty acid composition were found. The most prominent finding was 
that fatty acids of the omega-3 series were significantly decreased. The differences could not 
be explained on the basis of nutritional or hormonal status, medication or substance use. No 
consistent pattern emerged from the different fatty acid abnormalities and the clinical 
symptom scores.[31] 
 
In a recent study, Yao et al[32] investigated the correlations between the concentrations of 
EPUFAs in erythrocyte membranes and in vivo brain phospholipid metabolites, using 31P 
Magnetic Resonance Spectroscopy, in first episode, neuroleptic-naïve schizophrenic subjects. 
The results support the association between decreased EPUFAs in erythrocyte as well as 
neuronal membranes. 
 
 
 
3.2  The niacin flush test: 
 
The niacin skin flush test has been investigated as a possible marker for schizophrenia. This 
test, which involves prostaglandin-induced vasodilatation, has been proposed as a method of 
exploring essential fatty acid metabolism, and may serve to define a subgroup of patients  
with schizophrenia. This test is based on the effect of topically applied aqueous methyl 
nicotinate (AMN) on the production of prostaglandin D2 (PGD2) from skin macrophages and 
the resultant cutaneous capillary vasodilatation. Skin flushing after oral administration of 
nicotinic acid is due to the same reaction described above. It has been shown to be normal in 
subjects with mood disorders and neurosis. Furthermore, the ingestion of cyclo-oxygenase 
inhibitors such as aspirin, may result in false-positive findings, i.e. failure of vasodilatation. 
 
 The effect of topically applied niacin was investigated in patients with schizophrenia with 
prominent negative symptoms. The investigators examined the clinical accompaniments of 
the niacin response. Patients failing to flush with niacin had significantly lower levels of AA 
and DHA. Conversion from non-flushing to flushing during the 6-month supplementation 
period was predicted by an increase in AA levels in red blood cell membranes, irrespective of 
the nature of supplementation. While negative or positive symptoms did not predict flushing, 
more prominent affective symptoms were significantly associated with a positive flush 
response.[33] In another study the sample comprised 38 patients with schizophrenia and 22 
healthy controls. Four concentrations of AMN were applied topically to the  skin of the forearm 
in all subjects, and any resulting vasodilatation was rated as redness after 5 min.  At all 
concentrations of AMN, the patients with schizophrenia were significantly different from the 
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controls. The greatest degree of differentiation was when 83% of patients with schizophrenia, 
but only 23% of controls, had a zero or minimal response to AMN. The results of this study 
are consistent with the concept of reduced membrane AA levels in schizophrenia.  The 
authors suggested that this test might contribute to the reliable diagnosis of schizophrenia.[34] 
 
3.3  Cultured skin fibroblasts: 
Utilization of radiolabeled linoleic (omega-6) and alpha-linolenic (omega-3) acids was studied 
in cultured skin fibroblasts from patients with first-episode psychosis, chronic schizophrenia 
and healthy controls. Uptake and incorporation of both of the EFAs was similar in fibroblasts 
from all 3 groups. However, the utilization of EPA into DHA was significantly lower in first-
episode psychotic patients versus the healthy controls. These results suggest that the level of 
delta 6- as well as delta 5-desaturase is normal, while the levels of delta 4-desaturase may be 
lower in fibroblasts of patients with schizophrenia.[35] 
 
3.4  Retinal function: 
Retinal function has also been investigated as a possible marker for cell membrane omega-3 
fatty acid depletion in schizophrenia. The omega-3fatty acids, particularly DHA, are found in 
high concentrations in the photoreceptor cells of the retina and abnormalities of light 
sensitivity have been reported in patients with schizophrenia. Animal studies have 
demonstrated that reduced EFA levels are associated with changes in the electrophysiological  
response of the retina to light, as measured by the electroretinogram (ERG). The ERG of 9 
largely unmedicated patients with schizophrenia and 9 age and sex matched control subjects 
was measured. Subjects with schizophrenia had significantly reduced a-wave amplitudes on 
the ERG when compared with healthy controls. The a-wave amplitude was independent of 
the dose of antipsychotic agents being taken. The a-wave of the ERG is thought to reflect 
activity of the photoreceptor cells. These findings lend support to the hypothesis that patients 
with schizophrenia have abnormalities of photoreceptor function, as a consequence of 
reduced levels of omega-3 fatty acids in the cell membrane.[36] 
 
3.5 Post mortem studies 
In a study of post-mortem caudate cell membrane composition of schizophrenic patients vs 
controls, significantly lower amounts of phosphatidylcholine, phosphatidylethanolamine and 
total PUFAs were found in the schizophrenic brain samples, while the reduced PUFAs were 
largely attributable to decreases in AA, suggesting that deficits identified in peripheral tissues 
such as erythrocytes, may also be present in the brains of schizophrenic patients.[37]  
 
 
4. Case reports 
In a single case report a 30-year-old male with severe, refractory DSM-IV schizophrenia with 
prominent positive symptoms, was treated for 6 months with a fatty acid supplement.  For 2 
years prior to the study his clinical profile had remained unchanged, and he had not received 
antipsychotic medication during this period. Treatment with 30 ml/day of emulsion rich in EPA 
was initiated, and the patient was assessed at monthly intervals, by means of the  Schedules 
for the Assessment of Positive Symptoms and Negative Symptoms. A marked reduction in his 
symptoms was observed at 2 months, and further improvement followed.  At 6-months few 
symptoms remained. These findings suggest that treatment with certain fatty acids may have 
significant benefits in the management of schizophrenia.[38] 
 
Another case report involved a 30-year-old woman with chronic schizophrenia, who 
experienced an episode of acute exacerbation of psychotic symptoms during pregnancy. The 
subject was treated with omega-3 fatty acids as monotherapy.  Dramatic improvements in 
both positive and negative symptoms were reported, accompanied by  a significant increase 
of omega-3 fatty acids in erythrocyte membranes.[39]  
 
5. Clinical trials 
5.1  Open label: 
In an extension to a study reported above, in which substantial depletions of fatty acids were 
found in red cell membranes,[28] dietary analysis revealed no deficiency of fatty acid intake in 
the patients with schizophrenia, although greater intake of omega-3 fatty acids was 
associated with less severe symptomatology. Patients were then given dietary 
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supplementation with 10 g per day of concentrated fish oil for six weeks, which resulted in 
significant improvement in psychotic symptoms. This clinical improvement was associated 
with an increased level of omega-3 fatty acids in the red cell membranes.[40] 
 
 
5.2  Randomised controlled trials: 
Four randomised, placebo controlled EPA supplementary studies in schizophrenia have been 
reported in the literature. The first was designed to distinguish between the possible effects of 
two different omega-3 fatty acids: EPA and DHA. Forty-five outpatients with schizophrenia 
with persistent symptoms while on stable antipsychotic medication were randomised to 
treatment with EPA, DHA or placebo for 3 months in addition to their normal antipsychotic 
medication. Symptoms were assessed by means of the PANSS. Subjects receiving EPA 
showed significantly greater total PANSS score reduction than both the DHA and placebo 
groups. Furthermore, a greater response rate (>25% PANSS total reduction) was also found 
in the EPA group. Within the EPA group, there was a significant association between the 
change in positive PANSS scores and baseline omega-3 fatty acid levels. Baseline EPA 
emerged as a significant predictor of improvement in clinical scores.[41] 
 
A recent, multi-site, randomised, placebo-controlled trial of ethyl-EPA supplementation for 
residual symptoms and cognitive impairment in schizophrenia reported negative findings. The 
sample comprised 87 outpatients meeting DSM criteria for schizophrenia or schizoaffective 
disorder, with persistent symptoms despite antipsychotic treatment. Subjects had to have had 
no change in medication in the 30 days prior to the trial, and the presence of significant 
residual symptoms (defined as either one or more positive and/or negative symptom scores > 
4 or total PANSS scores > 45 with a score of 3 or more on at least 3 positive or negative items 
on the PANSS scale). Participants were randomly assigned to receive either ethyl-EPA 3 
g/day (N=43) or placebo (N=44) in a 16-week, double-blind design, in addition to their 
standard antipsychotic treatment. Subjects were assessed at baseline and at weeks 1, 2, 4, 8, 
12, and 16, and cognitive testing was performed at baseline and at week 16. No significant 
differences were found between the groups in positive or negative symptoms, mood, 
cognition, or global impression ratings. Results were similar for the intention-to-treat (N=87) 
and completer (N=75) analyses. The mean reduction in PANSS total scores from baseline to 
endpoint was 5 for the ethyl-EPA group and 6 for the placebo group. The AA/EPA ratio change 
(used to index pre- and post- treatment fatty acid composition in red blood cells) from 
baseline to endpoint was not significantly associated with any efficacy variable.[42] 
 
Another multi-centre, but this time dose-ranging study of the effects of ethyl-
eicosapentaenoate as supplemental medication in patients with persistent schizophrenic 
symptoms was recently conducted. The sample comprised 115 patients with DSM-IV-defined 
schizophrenia. Thirty-one were on clozapine, 48 on new atypical drugs and 36 on 
conventional antipsychotics. Patients were randomised to receive, in addition to their other 
antipsychotic medication, the following: ethyl-EPA 1mg/day, 2mg/day, 4mg/day or placebo.  
The study was conducted over 12 weeks. The primary efficacy measure was change from 
baseline to 12 weeks on the PANSS total score and its sub-scales. No treatment-related side 
effects or adverse biochemical or haematological effects were reported. Patients on 2 and 4 
g/day EPA showed significant reductions in triglyceride levels, which had been elevated by 
clozapine. All groups improved significantly from baseline but there were no significant 
differences between groups. Specifically, no difference was found between EPA and placebo 
in terms of the primary efficacy outcome measure. There was a large mean reduction in total 
PANSS scores in the placebo group (-16.6). In patients on EPA 2 g/day there were 
improvements on the PANSS and its sub-scales, but there was no difference between active 
treatment and placebo. However, patients on clozapine showed little placebo response, but a 
statistically significant reduction of symptoms if they received EPA. This effect was greatest at 
2 g/day. A positive relationship was reported between improvement on rating scales and rise 
in red blood cell AA concentration.[43]  In this study, EPA produced a dose-related increase in 
red cell EPA concentrations, but a plateau was reached at 2 g per day. DHA showed little 
change in the 1 g/day group, rose to a small extent in the 2 g/day group, but fell overall in the 
4 g/day group. AA levels rose in the 1 and 2g/day groups, but fell in the 4 g/day group.[44]   
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A further randomized, placebo-controlled study of ethyl-EPA as supplemental treatment was 
conducted in 40 patients with persistent symptoms of schizophrenia despite at least 6 months 
of stable conventional antipsychotic medication. The patients were randomised 1:1 to receive 
either EPA 3 g/day or placebo, as a supplement to their existing treatment.  This was a fixed-
dose, double-blinded study over 12 weeks. In this study the EPA group had a significantly 
greater reduction of the Positive and Negative Syndrome Scale (PANSS) total scores, as well 
as PANSS negative subscale scores at 12 weeks. An early onset of action was suggested by 
significant differences being evident at 3 weeks. A significantly greater reduction in 
Extrapyramidal Symptom Rating Scale (ESRS) dyskinesia scores for the EPA group was also 
observed at 12 weeks.  The authors concluded that these results suggest that EPA may be an 
effective, safe and well tolerated supplemental treatment in schizophrenia, with an additional 
benefit of improving tardive dyskinesia. They further point out that EPA offers the prospect of 
an effective, well-tolerated and affordable treatment for schizophrenia – a matter of great 
relevance particularly to lower income countries, where the high acquisition costs of the novel 
antipsychotics put them beyond the reach of most patients.[45]  
 
Thus, of the four published randomised controlled trials comparing EPA to placebo as 
supplemental treatment, two were positive and two were negative on the primary efficacy 
measure. It is not clear why these studies reported such different results, given the fact that 
the designs were similar in many ways. Samples comprised chronic patients with persistent 
symptoms, and EPA doses were similar. Possible explanations for the differences are: 
 (1) Background fatty acid intake may be substantially different between the populations 
studied. Fatty acids compete with one another for uptake, so that a diet rich in fatty acids may 
result in less uptake of EPA. Erythrocyte levels of EFAs in the samples suggest that this could 
explain the different outcome in the Fenton et al[42] and the Emsley et al studies[45]  
(2) The study by Fenton et al[42] had a moderate placebo response rate, and the dose ranging 
study[43] had a high placebo response rate. This could have affected the assay sensitivity of 
these studies. 
 (3) It needs to be kept in mind that negative studies are frequently reported in schizophrenia. 
A recent article reported that 25% of studies comparing novel antipsychotics with placebo 
failed to differentiate between the active compound and placebo.[46] 
 
In the only published trial in which EPA was used as monotherapy, antipsychotic drugs were 
allowed if this was thought to be clinically imperative. By the end of the study, all 12 patients 
on placebo, but only eight of 14 patients on EPA, were taking antipsychotic drugs. The EPA 
subjects also had significantly lower scores on the PANSS. The authors concluded that EPA 
may represent a new treatment approach to schizophrenia.[41] 
 
6. Reviews 
A review article evaluated all potentially relevant English-language articles that were identified 
from the medical and psychiatric literature with the aid of computer searches, using key words 
such as lipids, phospholipids, prostaglandins and schizophrenia. All studies that included 
human subjects were reviewed.  The authors reported that the most consistent clinical 
findings included red blood cell fatty acid membrane abnormalities, NMR spectroscopy 
evidence of increased phospholipid turnover and a therapeutic effect of omega-3 fatty acid 
supplementation of neuroleptic treatment in some schizophrenia patients. They pointed out 
that greater attention  to factors that influence tissue EFA levels, such as diet, tobacco and 
alcohol, are required to reconcile inconsistent findings. They concluded that treatment 
studies, although promising, required independent replication.[47] 
 
Another review based on a Medline search was conducted in September 1999. At that stage 
the authors could find only four studies that used fatty acids as an adjunctive therapy in 
schizophrenia.  They felt that the data on schizophrenia were conflicting, but that omega-3 
and omega-6 fatty acids had been proved effective. Most of the evidence suggested that the 
main effect is an improvement in negative symptoms.[48]  The author of another review article 
felt that substantial evidence existed supporting a potential role of omega-3 fatty acids in 
schizophrenia, although treatment data are needed. He furthermore suggested that omega-3 
fatty acids may prove to be a safe and efficacious treatment for psychiatric disorders in 
pregnancy and in breastfeeding.[49] 
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A Cochrane Database Systematic Revue was published in 2000, evaluating the evidence for 
the use of polyunsaturated fatty acids for schizophrenia. The meta-analysis was conducted to 
specifically review the effects of  supplementing standard antipsychotic treatment in 
schizophrenia with polyunsaturated fatty acids, EFA’s and non-EFAs, and to also evaluate the 
effects of EFA's as a sole, antipsychotic treatment. Relevant randomised trials were identified 
and the authors selected all randomised clinical trials of polyunsaturated fatty acid 
supplementation to standard treatment or as primary intervention for schizophrenia (however 
defined) versus standard care. They found that four relatively small trials (total n=204) 
showed low levels of loss to follow up and adverse effects for subjects taking EFAs. The 
results suggest a positive effect of EPA over placebo. However, the authors caution that the 
data is limited so that the results are difficult to interpret with confidence. There were no clear 
effects of primrose oil (omega-6) EFA supplementation. They concluded that the data are all 
preliminary, but that results look encouraging. EPA does not seem harmful, may be 
acceptable to people with schizophrenia and have moderately positive effect.  They also 
pointed out that, considering that EPA may be an acceptable intervention, large, long simple 
studies reporting clinically meaningful data should be undertaken.[50] 
7. Conclusions 
A lot of the research conducted in this field to date could be criticised for its methodological 
limitations. Samples were generally small, and some studies were unblinded. However, it 
needs to be kept in mind that funding available for studies like these is not comparable to 
studies conducted by large pharmaceutical companies. Taken together, there is now 
considerable evidence indicating abnormalities of EFAs in cell membranes of subjects with  
schizophrenia. There is also preliminary evidence for EPA specifically, as  an effective 
supplementary treatment in schizophrenia (although there are some negative findings), with 
potentially  additional benefits in TD.  Further studies currently underway will hopefully shed 
more light on the subject.  In particular, EPA still has to be tested properly as a stand-alone 
antipsychotic agent in schizophrenia. Most clinical studies are short term and nothing is 
known about the possible consequences of longer term supplementation like the induction of 
unwanted effects in the different PUFA series and their derivatives (eicosanoids.) Future 
studies should pay more attention to aspects such as body mass index, detailed and 
validated dietary questionnaires and substance abuse. Laboratory analyses should include 
cholesterol and triglyceride profiles, vitamins B12, B6 and folic acid, homocystine and the 
hormones cortisol, dehydroepiandrosterone-sulphate, testosterone and prolactin. “Fish 
flavour” should also be added to the capsules for a real double-blind placebo-controlled study. 
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Table. Randomised controlled trials of EPA vs. placebo as supplementation in 
schizophrenia. 
Authors Sample size Dose of EPA Duration Outcome 
Peet et al, 2001 45 (including 
DHA arm) 
2 g/day 12 weeks EPA significantly 
better than 
placebo and 
DHA 
Fenton et al, 
2001 
87 3g/day 116 weeks No difference 
Peet & Horrobin, 
2002 
115 1, 2 and 4g/day 12 weeks No difference 
Emsley et al, 
2002 
40 3g/day 12 weeks EPA significantly 
better 
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ABSTRACT 
Background: While the atypical antipsychotics should ultimately reduce its prevalence, 
tardive dyskinesia (TD) is likely to remain a significant clinical problem for a long time to 
come. No strategy has clearly emerged as the treatment of choice for TD. Atypical 
antipsychotics have reduced propensities for producing acute extrapyramidal symptoms and 
possibly TD, and may be effective in treating patients with established TD.  
Method: This 12-month, randomised, investigator-blinded study compared the efficacy 
of quetiapine (‘Seroquel’; n=22) with haloperidol (n=23) in treating patients with schizophrenia 
or schizoaffective disorder and established TD.  Dyskinesia was assessed using the 
Extrapyramidal Symptom Rating Scale (ESRS) dyskinesia subscale scores and the Clinical 
Global Impression (CGI) dyskinesia scores.  Other EPS, weight, serum prolactin and 
glycosylated haemoglobin were also assessed. 
Results:Mean endpoint doses were 400 mg/day quetiapine and 8.5 mg/day haloperidol.  
Compared with haloperidol, the quetiapine group showed significantly greater improvements 
in ESRS dyskinesia (6 and 9 months [p<0.01]) and CGI dyskinesia (from 6 months onwards), 
and with repeated measures analysis (p=0.002).  Response rate (≥50% symptom reduction) 
was greater with quetiapine than haloperidol (64% and 37% at 6 months; 55% and 28% at 12 
months).  Other EPS decreased significantly with quetiapine.  Endpoint serum prolactin levels 
reduced with quetiapine but increased with haloperidol (p=0.005).  No significant changes in 
weight or glucose metabolism were recorded in either group. 
Conclusion: Quetiapine effectively reduces the severity of TD and is well tolerated in 
patients with established TD. 
 
 
 
INTRODUCTION 
 
While the new generation of atypical antipsychotics may ultimately reduce its prevalence, 
tardive dyskinesia (TD) is likely to remain a significant clinical problem for a long time to 
come. TD is a common complication of conventional antipsychotic treatment, and worldwide 
clinicians continue to use these agents extensively for the treatment of psychosis.  Five 
percent of patients on conventional antipsychotics develop TD each year for the first eight 
years, with an average reported prevalence rate of approximately 20% depending upon the 
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patient populations studied.1 Even the use of very low-doses of conventional antipsychotics 
does not protect against the development of TD.2  The condition is under-recognised in 
clinical settings.3 Although in many cases the disorder is mild and non-distressing, TD 
symptoms contribute to social and vocational impairment, as well as to the further 
stigmatisation of psychotic illness.  Some patients develop more severe symptoms, which are 
extremely distressing and disabling, and may even be life-threatening.4  
 
Treatment of TD is problematic, and no strategy has emerged that is clearly the treatment of 
choice.5  Although antipsychotic drug withdrawal is a course of action that needs to be 
considered, this may result in an exacerbation of the TD symptoms in the short term,6,7 as 
well as an increased risk of psychotic relapse.5  Also, there are no controlled trials assessing 
the effect of dose reduction and intermittent dosing strategies, such as drug holidays.8 
Paradoxically, ongoing treatment with a conventional antipsychotic may suppress, and even 
improve symptoms,9 particularly in the short-term.10 With the exception of clozapine,11,12,13 and 
possibly branched-chain amino acids,14 little evidence exists to indicate efficacy for any 
treatment modality for TD.  There is no good evidence to support the use of 
benzodiazepines,15 cholinergic agents,16 vitamin E,17 melatonin,18 gamma-aminobutyric 
acid,17 calcium channel blockers,19 or various miscellaneous treatments such as endorphins, 
essential fatty acids, ganglioside, insulin, lithium, naloxone, oestrogen, periactin, 
phenylalanine, piracetam, stepholidine, tryptophan, and electro-convulsive therapy.20 
 
While earlier clozapine studies suggested modest efficacy after extended periods of 
treatment,11,12 a more recent study13 indicated efficacy after a relatively brief period of 
treatment (5 to 6 weeks), and at a relatively low dose.  However, the moderate improvements 
in TD need to be weighed against the higher reported morbidity and poorer tolerability of 
clozapine.12 There are indications that the newer atypical antipsychotic agents, with a reduced 
propensity to produce acute extrapyramidal symptoms (EPS) are also less likely to cause TD. 
This raises the possibility that they may also have an antidyskinetic effect in patients with 
established TD. However, while a reduction in dyskinesia scores has been reported in 
patients with chronic schizophrenia treated with risperidone compared to placebo,21 efficacy 
has yet to be demonstrated in samples of patients with TD.5  Quetiapine is a novel 
antipsychotic that, like clozapine, has a reported incidence of acute EPS across the dose 
range that is no different to that of placebo.22  Quetiapine appears to be associated with a low 
risk of tardive dyskinesia in adult23 and elderly24 patients. Its low striatal D2 receptor binding 
profile,25 rapid release from D2 receptors,26 possible neuroprotective action27  and its lack of 
antimuscarinic activity (reported to exacerbate TD),28 theoretically make it a particularly good 
candidate for the treatment of TD. 
 
This study aimed to evaluate the efficacy of quetiapine compared with haloperidol in treating 
schizophrenic patients with established TD in a controlled design over a 12-month period. 
Previous TD treatment trials have often been limited by very small samples, brief durations 
and lack of blinding procedure. The present study was designed with these potential pitfalls in 
mind. 
 
 
 
METHOD 
 
Patients: 
In- and out-patients from Stikland and Tygerberg Academic Hospitals, as well as surrounding 
community clinics in Greater Cape Town were screened for the presence of TD. Males and 
females aged 18 - 65 years were considered for inclusion if they met DSM IV criteria and 
Schooler and Kane criteria29 for the diagnosis of TD. The latter criteria comprise: a) a history 
of at least three months cumulative antipsychotic exposure, b) the presence of at least 
moderate abnormal, involuntary movements in one or more body areas or at least mild 
movements in two or more body areas and c) an absence of other conditions that might 
produce abnormal involuntary movements.  Additionally, patients were required to have a 
diagnosis of schizophrenia or schizo-affective disorder. Exclusion criteria were: neurological 
disease, any general medical condition that may cause movement disorders; psychiatric 
disorder not stabilised; and patients currently receiving clozapine. The study protocol and 
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patient information and consent procedures were approved by the University of Stellenbosch 
Ethics Committee, and all subjects provided written, informed consent to participate. The 
study complied with International Conference on Harmonization Guidelines for Good Clinical 
Practice.30 
 
Study design: 
This was an investigator-blinded, parallel-group comparison of flexible doses of quetiapine 
and haloperidol in patients with TD. After an initial screening visit, subjects were tapered from 
all psychotropic medication over a 2 week period (although a shorter period was allowed if 
there was concern regarding the clinical status of the patient during this period). Subjects 
were then randomised to receive either quetiapine or haloperidol for a 50-week treatment 
period. The dose of medication was titrated over seven days to the starting dose (haloperidol: 
5mg/day for 4 days, 10mg/day for 3 days; quetiapine, 100mg/day for 2 days, 200mg/day for 2 
days, 300mg/day for 2 days and 400mg/day for 1 day).  At the end of the titration period all 
patients were receiving either quetiapine 400mg/day or haloperidol 10mg/day.  Thereafter, 
flexible dose adjustment was allowed at the discretion of the investigator, according to the 
status of psychiatric and motor symptoms, up to a maximum dose of haloperidol 20mg/day 
and quetiapine 800mg/day.  Haloperidol was adjusted in 2.5mg increments and quetiapine in 
100mg increments. Medication compliance was assessed by ‘pill counts’ at each visit. 
 
The following concomitant medication was allowed: benzodiazepines for agitation or 
insomnia; and anticholinergic agents in the event of treatment emergent or worsening EPS. 
Medications that were not allowed were other antipsychotics, or other medication known to 
improve or exacerbate movement disorders. 
 
Assessments were conducted at two-weekly intervals for the first 6 weeks, and thereafter 4 
weekly, until the completion of the trial (50 weeks of treatment). Patients were assessed by 
means of the following scales: Extrapyramidal Symptom Rating Scale (ESRS);31 Clinical 
Global Impression (CGI) for dyskinesia; and Positive and Negative Syndrome Rating Scale 
(PANSS).32 The investigators were experienced psychiatrists who participated in training 
sessions.  The inter-rater-reliability testing concordance coefficients were above 0.8 for the 
ESRS and PANSS.  Blood samples for serum prolactin and glycosylated haemoglobin 
(HbA1c) were collected at screening and every three months. Subjects were weighed at 
screening and 3 monthly.  
 
Primary analysis: 
The primary outcome of interest was the change in dyskinesia scores over time. Severity of 
dyskinesia was assessed by the ESRS dyskinesia subscale scores (items 49-55) and the CGI 
dyskinesia scores. Treatment groups were compared at 3, 6, 9 and 12 months. The 
percentage change in scores from baseline to endpoints at 6 and 12 months was calculated. 
The percentage of responders was also calculated at 6 and 12 months (response being 
defined as ≥50% reduction in ESRS dyskinesia subscale and CGI dyskinesia scores). 
 
Secondary analysis: 
The effect of the treatments on psychotic symptoms was assessed by means of the PANSS. 
Other EPS (parkinsonism, including an item for akathisia, and dystonia) were assessed by 
means of the ESRS total score minus the ESRS dyskinesia subscale score.  Mean group 
values for weight, body mass index (BMI), serum prolactin and glycosylated haemoglobin 
were compared at three monthly intervals. 
 
Statistical analyses: 
The sample size was not based on formal statistical criteria. We initially conducted an 
observed cases (OC) analysis for between-group comparisons. For assessing the treatment 
effects over time and dealing with the problem of missing values due to subject withdrawals 
we performed two analyses on the intent to treat population. We employed a repeated 
measures mixed effects modeling approach for the primary efficacy measures (change in 
dyskinesia scores) and a last observation carried forward (LOCF) approach for the secondary 
measures.33 For the repeated measures mixed effects model, plots of dyskinesia scores 
versus time indicated some dependence between the two variables, and that this could 
adequately be represented by a straight line. So the model we fitted assigned a slope and an 
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intercept to every subject; they are, therefore the random effects. The variation between times 
within subjects was modeled via an "unstructured" option. Student’s t-test was used to 
compare the treatment groups with respect to continuous variables. Significance tests were 
performed at a two-sided alpha level of 0.05. Results are expressed as mean±SD.  
 
 
 
RESULTS 
 
Forty-seven subjects were entered into the study between 5 April 2000 and 13 March 2002. 
Two were excluded (one withdrew before reaching the target treatment dose, and one had 
unrelated medical illness). Thus, the analysis was conducted on 22 subjects in the quetiapine 
group and 23 in the haloperidol group. Baseline demographic and clinical details were similar 
for the two treatment groups (Table 1). Ten quetiapine-treated subjects failed to complete the 
trial, for the following reasons: worsening of psychosis (n=7); non-compliance (n=1); 
withdrawal of consent (n=1); and pregnancy (n=1). In the haloperidol group eight subjects did 
not complete the trial, due to worsening of psychosis (n=4); non-compliance (n=1); withdrawal 
of consent (n=1); severe, persistent dystonia (n=1); and disallowed concomitant treatment 
(n=1). For the OC analysis the sample sizes for quetiapine and haloperidol were, respectively, 
19 and 21 at 3 months; 15 and 16 at 6 months; 13 and 16 at 9 months and 12 and 15 at 12 
months.  The mean±SD endpoint doses were 400±147.7mg/day for quetiapine and 
8.5±5.6mg/day for haloperidol. 
 
Effect of treatment on TD: 
For both treatment groups there was a significant reduction in ESRS dyskinesia subscale 
scores from baseline to endpoint (p>0.0001). For the OC analysis, quetiapine-treated patients 
showed significantly greater improvement than haloperidol-treated subjects at 6 (p=0.01) and 
9 (p=0.004) months, but not at 12 months (p=0.1). For the CGI-dyskinesia scores the 
quetiapine patients did significantly better than those treated with haloperidol at 6 (p=0.03), 9 
(p=0.001) and 12 months (p=0.03). In the repeated measures, mixed effects model analysis, 
both treatments produced significant dyskinesia reductions as reflected by the baseline to 
endpoint total change scores. There were statistically significant differences between 
treatments in the rates of change in the CGI dyskinesia score (but not the ESRS dyskinesia 
subscale scores). The model demonstrated that CGI dyskinesia scores declined significantly 
more in subjects taking quetiapine than in those taking haloperidol (F=10.52, df=1:43, 
P=0.002) (Figure 1).  The response rates (≥50% CGI dyskinesia reduction) for quetiapine and 
haloperidol respectively, were 64% and 37% at 6 months and 55% and 28% at 12 months.  
 
Effect of treatment on psychosis: 
Baseline PANSS scores were low in each treatment group, as patients were required to be 
clinically stable to be eligible for the study. There were no differences at any stage between 
the two treatment groups for the PANSS total scores, as well as for the PANSS positive, 
negative and general psychopathology subscale scores (Table 2). 
 
Tolerability: 
EPS: 
The quetiapine-treated subjects showed a significantly greater reduction of EPS other than 
dyskinesia at 3, 6 and 9 months (p=0.01; p=0.01 and p=0.002, respectively), but not at 12 
months (p=0.3). Fourteen (60%) subjects in the haloperidol group required ongoing or newly 
prescribed anticholinergic medication compared to 6 (27%) subjects in the quetiapine group. 
 
Weight and glucose metabolism: 
The mean body weights did not change significantly throughout the study, and did not differ 
significantly between groups (Table 3). Glycaemic control as evaluated by glycosylated 
hemoglobin (HbA1c) also did not change throughout the study for the quetiapine 
(baseline=6.4±1.1%; endpoint=6.1±2.4%) and haloperidol-treated patients 
(baseline=7.0±2.4%; endpoint=5.5±1.2%), and there were no between-group differences. 
 
Serum prolactin: 
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For the haloperidol-treated patients the mean±SD serum prolactin levels increased from 
15.2±9.2 ng/ml at baseline to 25.5±14.9 ng/ml at endpoint, while for the quetiapine group they 
decreased from 25.4±23.3 ng/ml at baseline to 9.1±10.2 ng/ml at endpoint. Endpoint values 
differed significantly between the groups (p=0.005). 
 
 
DISCUSSION 
 
The results of this study confirm previous case-reports34,35;36 suggesting that quetiapine is an 
effective treatment for TD.  While both treatments were associated with improvement in 
dyskinesia, the quetiapine-treated patients did significantly better. The beneficial effect for 
quetiapine was substantial, and sustained, as exemplified by the finding that 55% of the 
subjects achieved ≥50% reduction in dyskinesia at the end of the trial, with their mean CGI 
dyskinesia scores declining from 4 (moderate) at baseline, to 2 (borderline) at endpoint.  
 
Our findings confirm that paradoxically, antipsychotics (including conventional antipsychotics) 
are effective in reducing the severity of TD.37 While previous work indicated an antidyskinetic 
effect in short-term studies, the long-term outcome of continuous antipsychotic treatment in 
patients with TD was unknown.5 The present study indicates that this effect is enduring. 
Furthermore, we found no indication of worsening of TD, even in the haloperidol-treated 
subjects, thus supporting the observation that TD does not seem to progress with ongoing 
antipsychotic treatment.5  
 
The underlying mechanism of the beneficial effect on dyskinesia is not clear. The fact that 
substantial improvement was apparent even after 12 weeks of treatment suggests either an 
early masking or suppressant effect on TD. However, the sustained improvement in the 
quetiapine-treated subjects supports a direct antidyskinetic effect with this agent. Although not 
directly confirmed in our trial, the results of another study suggest that this may well be the 
case for atypical antipsychotics. Withdrawal of clozapine after 12 months of treatment was not 
associated with an exacerbation of TD symptoms, whereas withdrawal of haloperidol was.38 
 
These results are also of interest in that they provide data on the long-term use of quetiapine 
under blinded conditions. Psychotic symptoms were comparable in both groups at baseline 
and throughout the treatment period. This was not unexpected despite a previously reported 
superior response rate for quetiapine over haloperidol,39 as a requirement for selection was a 
stable psychiatric condition, and the baseline PANSS scores were low. Quetiapine-treated 
patients had fewer other EPS (parkinsonism, akathisia and dystonia), and were prescribed 
less anticholinergic medication. Whereas serum prolactin levels increased in the haloperidol 
group, they decreased in the quetiapine group. Differences between the groups were highly 
significant, in keeping with findings in previous short-term studies.22 Neither treatment group 
showed any tendency toward persistent weight gain, and glycaemic control was also 
maintained in both groups. 
 
It deserves to be noted that 10 (45%) of the quetiapine-treated subjects were withdrawn from 
the trial, and 8 (34%) from the haloperidol group. While the dropout rates did not differ 
significantly between the groups, and were in line with what could be expected from a 
controlled study over 12 months,40 the relatively low doses of quetiapine used may also be 
partially responsible for this. The most common reason for withdrawal in the quetiapine group 
was worsening of psychosis (31%). The low doses prescribed probably reflect the fact that 
investigators were primarily concerned with motor symptoms, and were reluctant to use 
higher doses of antipsychotics in subjects with TD.  Future studies should further address this 
issue. 
 
The following factors limit the generalization of our findings. First, the sample size was 
relatively small, thereby increasing the chances of type II errors. (A substantially larger 
sample in a TD study would be difficult to obtain from a single site however, as recruiting 
these subjects proved to be difficult - it having taken us 2 years to complete  enrollment for 
this study.) This problem was compounded by the high withdrawal rate associated with trials 
of long duration such as this. Second, the dose of quetiapine was lower than that generally 
recommended in clinical practice. While the use of higher doses may possibly have reduced 
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the number of dropouts due to worsening of psychosis, it is not clear what the effect would 
have been on dyskinesia symptoms. Finally, our study did not investigate whether the 
improvement in dyskinesia was maintained after discontinuation of quetiapine. 
 
 
 
CONCLUSION 
The best treatment for TD is prevention. In this regard, the use of atypical antipsychotics as 
first-line medications is likely to reduce the incidence of TD. Patients with established TD who 
are taking conventional antipsychotics are candidates to be switched to an atypical 
antipsychotic.41 While clozapine has been reported to be moderately effective, its use in the 
treatment of TD is limited by the risk of agranulocytosis41 and poor tolerability.12 To date, no 
other controlled studies exist evaluating the efficacy of other atypical antipsyschotics in the 
treatment of TD.  Quetiapine appears to be effective and well tolerated in TD, and seems to 
be a good treatment option for these patients. 
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Table 1. Baseline demographic and clinical details of the two treatment groups (mean±SD). 
 Quetiapine (n=22) Haloperidol (n=23) 
Male : female 14:8 15:8 
Age  49.2±14.5 yrs 50.1±8.6 yrs 
ESRS Dyskinesia scores  10.8±5.0 13.8±5.7 
CGI Dyskinesia scores 4.0±0.9 4.0±0.9 
ESRS total scores 35.0±12.8 37.2±15.8 
Duration of psychosis 15.9±11.7 yrs 17.4±10.6 yrs 
Antipsychotic dose prior to 
randomization (Chlorpromazine 
equivalents) 
393.6±420 mg/day 234.5±142 mg/day 
 
 
 
 
Table 2. Baseline and 12 month PANSS scores (mean±SD) for the two treatment groups. 
 Quetiapine Haloperidol 
 Baseline Endpoint Baseline Endpoint 
PANSS total 55.5±12.9 49.2±11.5 57.0±14.1 51.5±15.4 
PANSS positive 10.8±4.4 8.0±2.1 10.7±5.4 9.3±3.9 
PANSS negative  19.4±5.5 20.0±6.1 20.6±5.9 18.8±5.1 
PANSS general 
psychopathology 
25.5±5.9 21.1±5.2 25.6±6.1 23.3±7.7 
 
 
 
 
 
 
 
Table 3. Mean±SD body weight (Kg) for the two treatment groups. 
 
 Quetiapine Haloperidol 
Baseline  71.9±21.3 66.6±11.7 
3 months 77±22.5 66.5±11.2 
6 months 71.0±25.8 66.8±11.0 
9 months 71.7±22.3 66.0±10.6 
12 months 71.2±2 66.9±11.1 
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Figure 1. Mean CGI-dystonia scores over 12 months for the two treatment groups. 
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Objective:  Worldwide, conventional antipsychotic medication continues to be used 
extensively, and tardive dyskinesia (TD) remains a serious complication. The primary 
objective of the present study was to compare the efficacy of EPA versus placebo in reducing 
symptoms of TD. 
Method:  This was a 12-week, double-blinded, randomised, study of ethyl-EPA 2g/d versus 
placebo as supplemental medication, in patients with schizophrenia or schizoaffective 
disorder, with established TD. 
Results:  Eighty-four subjects were randomised, of whom 77 were included in the analysis. 
Both the EPA and placebo groups displayed significant baseline to endpoint improvements in 
Extrapyramidal Symptom Rating Scale dyskinesia scores, but there were no significant 
between-group differences (p=0.4). Response rates (≥30% improvement in TD symptoms) 
also did not differ significantly between EPA treated subjects (45%) and placebo treated 
subjects (32%) (p=0.6).   However, a post-hoc linear mixed model repeated measures 
analysis of variance indicated an effect for treatment group and duration of TD. The EPA 
treated patients had significantly greater mean reductions in dyskinesia scores initially, 
although this was not sustained beyond 6 weeks.  
Conclusions:  This trial failed to demonstrate an antidyskinetic effect for ethyl-EPA 2 g/d on 
the primary efficacy measure. However, a modest and transient benefit is suggested in 
patients with more recent onset of TD. The lack of clear-cut efficacy could be explained on the 
basis of the dose of EPA being too low, the study being underpowered, TD being too chronic 
in the majority of cases, differences in dietary fatty acid intake, or that EPA lacks an 
antidyskinetic action. 
 
 
 
1. Introduction  
 
Results from available long-term studies indicate that new-generation antipsychotics 
have a reduced risk for inducing tardive dyskinesia (TD), compared to conventional 
antipsychotics (Correll et al., 2004; Margolese et al., 2005). While the increasing use of new 
generation antipsychotics should therefore ultimately reduce its prevalence, TD remains a 
significant clinical problem. TD is a frequent complication of conventional antipsychotic 
treatment (Kane et al., 1988), and worldwide these agents continue to be used extensively to 
treat psychotic disorders. This occurs largely in lower income countries due to the high 
acquisition costs of the newer agents (Emsley et al., 1999).  
 
TD is usually persistent, and refractory to treatment.  With the exception of clozapine 
(Lieberman et al., 1991; Tamminga et al., 1994; Spivak et al., 1997), quetiapine (Emsley et al., 
2004) and possibly branched-chain amino acids (Richardson et al., 2003) and a presynaptic 
monoamine depleting agent tetrabenazine (Ondo et al., 1999), little evidence exists to 
indicate efficacy for any other treatment modality for TD.  No adequate studies exist to 
support the use of benzodiazepines (Umbrich and Soares, 2003), cholinergic agents 
(Tammenmaa et al., 2002), vitamin E (Soares and McGrath., 2001a), melatonin (Nelson et al., 
2003), gamma-aminobutyric acid (Soares et al., 2001), calcium channel blockers (Soares and 
McGrath, 2001b), non-neuroleptic catecholaminergic agents (El-Sayeh et al., 2006) or various 
miscellaneous treatments such as endorphins, essential fatty acids, ganglioside, insulin, 
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lithium, naloxone, oestrogen, cyproheptadine, phenylalanine, piracetam, stepholidine, 
tryptophan, electro-convulsive therapy (McGrath and Soares, 2000a) and 
acupuncture(Rathbone and Xia, 2005). Withdrawal of the offending antipsychotic drug is 
usually not feasible, as this may result in an exacerbation of the TD symptoms (Gardos et al., 
1984; Dixon et al., 1993), and dramatically increases the risk of precipitating a psychotic 
relapse (Egan et al., 1997).  The effect of dose reduction and intermittent dosing strategies, 
such as drug holidays has not been adequately assessed in controlled trials (McGrath and 
Soares, 2000b). Paradoxically, ongoing treatment with a conventional antipsychotic may 
suppress, and even improve symptoms (Jeste et al., 1979; Emsley et al., 2004), particularly in 
the short-term (American Psychiatric Association Task force on Tardive Dyskinesia, 1992). 
 
Clearly, there remains an unmet need for an effective and affordable treatment for TD. 
One possible candidate is eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty 
acid obtained from marine and plant sources (Stensby, 1969). It has been hypothesised that a 
disorder of neuronal membrane phospholipid metabolism is present in schizophrenia 
(Horrobin, 1998), and that the omega-3 fatty acids, and EPA in particular, may have a role in 
treating this illness. Reports of abnormalities of essential fatty acids in erythrocyte 
membranes and cultured skin fibroblasts in patients with schizophrenia, as well as case 
reports, open-label clinical trials and some but not all, of randomised controlled trials using 
EPA as supplemental medication lend support to this hypothesis (for review see (Emsley et 
al., 2003)). 
 
In addition to its possible antipsychotic effect, there is reason to believe that EPA may 
have a role in the treatment of TD. In a study of 20 hospitalised subjects with chronic 
schizophrenia, a significant inverse correlation between dietary EPA and severity of TD has 
been reported. Subsequent open-label treatment of these subjects with a standard EPA-rich 
marine oil for 6 weeks resulted in significant improvement in TD (Peet et al., 1996). In a 
controlled study of essential fatty acid (EFA) supplementation in psychiatric patients with TD, 
evidence of EFA deficiency was found, and a marginally significant antidyskinetic effect of 
EFA supplementation was reported (Vaddadi et al., 1989). In a study assessing the 
relationships between psychiatric status, TD and levels of essential fatty acids in red blood 
cell membranes and plasma, 72 patients with schizophrenia or schizoaffective disorder were 
followed up over 4 to 5 years. It was found that patients with TD had lower levels of linoleic 
acid and higher levels of dihomogamma-linolenic acid (but not reduced levels of omega-3 
fatty acids) (Vaddadi et al., 1996).   
 
We previously reported a 12-week randomised, double-blind study with ethyl-EPA 
3g/day versus placebo as add-on to standard antipsychotic treatment, in forty subjects with 
chronic, refractory schizophrenia. While there were no differences between the groups 
regarding changes in the Extrapyramidal Symptom Rating Scale (ESRS) parkinsonism, 
dystonia or akathisia scores, the ethyl-EPA group showed a significantly greater reduction in 
dyskinesia scores (p=0.008). This study also reported a significant advantage for the ethyl-
EPA group in terms of overall psychosis symptom reduction (PANSS total). An analysis of co-
variance indicated an interaction between PANSS total score reduction and ESRS dyskinesia 
score reduction, suggesting a common mechanism for antidyskinetic and antipsychotic 
actions (Emsley et al., 2002).  
 
The present study was undertaken to assess the antidyskinetic effect of EPA in patients 
with established TD.  
 
 
 
2.  Methods: 
2.1   Objectives: 
The primary objective was to compare the efficacy of EPA versus placebo as 
supplementary medication in reducing symptoms of TD. Secondary objectives were to 
compare the efficacy of EPA versus placebo as supplementary medication in reducing 
symptoms of psychosis in these subjects. Safety and tolerability assessments were also 
performed, but will be reported in a separate publication. 
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2.2   Study setting and design: 
This was a double-blinded, randomised, parallel-group comparison of EPA and placebo 
in the treatment of established TD in patients with schizophrenia or schizoaffective disorder. It 
was a single-site study, and patients were recruited from Stikland Academic Hospital and its 
surrounding community psychiatric services in the greater Cape Town area of South Africa.  
Participants were recruited between 4 April 2003 and 31 December 2004. There was a pre-
trial screen, following which subjects were entered into the randomised treatment phase for 
12 weeks.  
 
2.3  Participants: 
Eligible patients were male or female; aged 18 to 60 yrs; meeting Diagnostic and 
Statistical Manual of Mental Diseases, Fourth Edition (DSM-IV) (American Psychiatric 
Association, 1994) criteria for TD, as well as for schizophrenia or schizoaffective disorder; 
with a CGI severity of TD score ≥ 3; and who had received a fixed dose of antipsychotic 
medication for at least 6 weeks prior to trial entry. Patients were excluded if their psychiatric 
disorder was not stable; they had significant neurological disorder other than TD; significant 
other medical illness; substance abuse; were pregnant or breast-feeding; or were currently 
receiving clozapine. 
 
The study complied with ICH Guidelines for Good Clinical Practice (International 
Conference on Harmonization, 1996). The trial was approved by the Institutional Review 
Board of the University of Stellenbosch, and the Medicines Control Council of South Africa 
(national regulatory authority).  Written informed consent was obtained from the participants at 
the screening visit. 
 
2.4  Assessments: 
All patients were screened to assess their eligibility for the trial.  The screening visit 
included the following: Demographic details, psychiatric history, medical history, physical 
examination, vital signs and laboratory tests. The duration of TD was assessed by 
interrogation of the participants and family members where possible, as well as by scrutinizing 
the clinical files.  Patients were assessed at baseline and at 3-weekly intervals by means of 
the Extrapyramidal Symptom Rating Scale (ESRS) (Chouinard and Margolese, 2005), Clinical 
Global Impressions for TD, and the Positive and Negative Syndrome Scale (PANSS) (Kay et 
al., 1987). 
 
2.5  Trial treatment: 
Subjects were randomly assigned to receive either an encapsulated ethyl-EPA 
supplement 2 g/day (2X500 mg capsules twice daily) (Amarin Neuroscicence Ltd.), or an 
identical capsule containing placebo (medicinal liquid paraffin BP 2 g/day), in addition to the 
medication that they had been receiving, for the duration of the study. Ethyl-EPA is a highly 
purified derivative of fish-oil. The Food and Drug Administration of the United States of 
America has affirmed the status of fish-oil as generally recognised as safe with EPA doses up 
to 3 g/day (Department of Health and Human Services, 1997). Trial supplies were packed by 
an independent contract clinical trials supplies company (DHP), who prepared the placebo 
and active packs for the entire trial and assigned the randomisation numbers to the packs. 
The randomisation code was broken after completion of the trial.  
 
2.6  Concomitant treatment: 
In addition to the trial medication and the ongoing, fixed antipsychotic medication, the 
following concomitant medication was allowed: Anticholinergic medication for treatment-
emergent extrapyramidal symptoms (EPS); anxiolytic or hypnotic medication for treatment-
emergent insomnia or anxiety; any medication for physical conditions that were present prior 
to the commencement of the trial, or that arose during the course of the trial. 
 
2.7  Outcome measures: 
The primary outcome measure was the change in ESRS dyskinesia subscale scores 
from baseline to week 12.  Secondary outcome measures for an antidyskinetic effect were: 
The proportion of TD responders (defined as an improvement in ESRS dyskinesia subscale 
score ≥ 30%); and change in TD CGI scores from baseline to 12 weeks. Additional secondary 
outcome measures were change from baseline to week 12 for ESRS parkinsonism, akathisia 
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and dystonia subscale scores. Finally, for an effect of EPA on psychosis we examined change 
from baseline to week 12 in PANSS total scores, positive, negative and general 
psychopathology subscale scores; and the proportion of responders (defined as an 
improvement in PANSS total scores ≥ 20%). 
 
2.8  Statistical analysis: 
The primary intent of this study was to evaluate the ability of ethyl-EPA versus placebo 
to reduce TD symptoms after 12 weeks of treatment. The principal null hypothesis was 
therefore that ethyl-EPA would not differ from placebo on the primary efficacy measure. For 
sample size determination we obtained an estimate of the variability of the change in ESRS 
dyskinesia scores after 12 weeks of treatment with ethyl-EPA and placebo as add-on to their 
previous antipsychotic medication from the previous trial conducted at our centre (Emsley et 
al., 2002), which gave 2.13 as the standard deviation (unpublished). We calculated that, with 
a significance level of 5% and 90% power, 32 patients per randomised group would be 
sufficient to detect a 1.75 point difference in change in ESRS dyskinesia scores (the 
difference obtained in our previous study) from baseline to endpoint.  Allowing for an 
estimated withdrawal rate of 30%, we decided to recruit 42 patients per treatment group. 
 
Comparisons between the treatment groups were performed by intention-to-treat (all 
subjects who were treated and with at least one post-baseline assessment), with last 
observation carried forward. Analysis of variance and the Chi-square test were used for 
comparing univariate differences between numeric and categorical variables respectively. We 
used analysis of covariance for the assessment of changes from baseline to endpoint for 
ESRS dyskinesia, parkinsonism, dystonia and akathisia subscale scores and TD CGI scores, 
including the baseline ESRS subscale score, treatment received, age and duration of TD as 
factors. For PANSS changes from baseline to endpoint, we included baseline PANSS total 
score, treatment received, age and duration of schizophrenia as factors. Comparison of the 
time to response for the two groups was calculated by means of Kaplan-Meier survival 
curves. Controlling for covariates was done by Cox proportional hazard regression. 
 
For assessing the treatment effects over time we adopted the linear mixed model 
approach, modelling the time trends in dyskinesia scores by straight lines. Treatment group 
was a class variable, while age and duration of TD were numerical variables. All of the tests 
were interpreted at 5%, 2-tailed significance level.  
3  
4  
5  
6 Results: 
3.1  Characteristics of the two treatment groups: 
Out of a total of 125 patients who were pre-screened, 84 were recruited and 
randomised to double blind supplemental treatment with either ethyl-EPA or placebo.  The 
data on 7 patients (3 on ethyl-EPA and 4 on placebo) were excluded from analysis because 
they failed to complete at least one post-randomisation visit. Data from the remaining 77 
patients were included in the final analysis.  The demographic characteristics and baseline 
PANSS scores in the two treatment groups were similar, but baseline ESRS dystonia 
subscale and TD CGI scores differed significantly (Table 1).  Most patients had been ill for 
more than a decade and had TD for more than 5 years. All had were being treated with 
conventional antipsychotics at study entry. None had received new generation antipsychotics 
in the preceding 6 weeks.  The number of subjects who discontinued medication prematurely 
in the ethyl-EPA group was 8 (19%) (consent withdrawal n=4; non-compliance n=3; protocol 
violation n=1), and in the placebo group 14 (33%) (consent withdrawal n=9; non-compliance 
n=3; adverse events n=2 [congestive cardiac failure; nose-bleed]) (Chi-square=2.2, df=1, 
p=0.1). 
 
3.2  Effect of treatment on dyskinesia: 
There was a significant reduction from baseline to endpoint in ESRS dyskinesia scores 
for the ethyl-EPA treatment group (p=0.0001), as well as for the placebo group (p=0.004). 
However, there were no between-group treatment differences for the primary efficacy 
measure. Analysis of covariance found that changes in dyskinesia scores were not 
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significantly influenced by age, duration of TD, baseline dyskinesia scores or treatment group 
(F[1, 60]=0.003, p=0.95). Dyskinesia response rates did not differ significantly between the 
treatment groups (ethyl-EPA group n=17 [45%]; placebo group n=12 [32%], p=0.3), and the 
time to TD response was similar (ethyl-EPA group 7.7±3.5 wks; placebo group 8.1±3.4 wks, 
p=0.6).  
 
Details of the fitting of a linear mixed model allowing for random between-subject 
effects are provided in Table 2. Several of the coefficients were significantly different from 
zero, and an effect for duration of TD as well as treatment group is suggested. In the linear 
mixed model repeated measures ANOVA, both EPA (Figure 1 (a)) and placebo (Figure 1 (b)) 
produced significant dyskinesia score reductions. In view of the fact that there were several 
significant interactions between coefficients (Table 2), we compared the expected means of 
the two treatment groups at the same values of duration of TD. Figure 2 shows a plot of the 
estimated mean differences with two-sided 90% and 95% confidence bands. The EPA treated 
patients had significantly greater mean reductions in dyskinesia scores up to approximately 6 
weeks, but this was not sustained.  
 
Table 2 about here 
Figures 1a and 1b about here 
Figure 2 about here 
 
3.3 Effect of treatment on other EPS 
There were no differences between the EPA and placebo groups respectively, for baseline to 
endpoint change in the ESRS parkinsonism subscale (-0.8±3.2 vs. -1.1±3.3 [F91, 67)=0.1, 
p=0.7], dystonia subscale (0.05±0.5 vs. 0.4±0.5 [F91, 67)=0.1, p=0.7], and akathisia score (-
0.1±0.4 vs. -0.06±0.7 [F(1, 67)=0.1, p=0.7).  
3.4  Effect of treatment on psychosis: 
There were no significant differences in the change in PANSS total scores from 
baseline to endpoint between the ethyl-EPA and placebo treatment groups. The analysis of 
covariance found that changes in PANSS total scores were not significantly influenced by 
age, duration of schizophrenia, baseline PANSS total scores or treatment group (F[1, 
62]=0.005, p=0.9). The response rates (≥20% PANSS total score) were 1 (2.5%) for the EPA 
group and 2 (5%) for the placebo group (Chi-square 0.5, df=1, p=0.5). In a post-hoc analysis 
to assess the effect on psychosis symptoms in the more symptomatic subjects (PANSS total 
score ≥ 60), again changes in PANSS total scores were not significantly influenced by age, 
duration of schizophrenia, baseline PANSS total scores or treatment group (F[1, 25]=0.008, 
p=0.9). 
7  
8  
9  
10 Discussion  
This study failed to demonstrate a beneficial effect for ethyl-EPA 2 g/day on TD on the 
primary efficacy measure. However, the linear mixed model analysis provides some evidence 
to suggest a beneficial effect for EPA treatment, although this was modest and not sustained.  
These findings therefore differ from those of our previous study that was conducted in a 
smaller sample of chronic schizophrenic patients, not specifically selected for the presence of 
TD (Emsley et al., 2002). 
 
There are several possible explanations for the failure of this study to demonstrate a 
clear-cut antidyskinetic effect.  First, it is possible that the dose of 2g/day was too low - in our 
previous study (Emsley et al., 2002) a dose of 3g/day was used. Second, the study may not 
have been sufficiently powered to detect a small treatment effect. The trend difference in TD 
response rates in favour of the EPA group suggest that this may be the case.   Third, most of 
our subjects had TD for a number of years – it is possible that ethyl-EPA may only be 
effective in cases of shorter duration. This is supported by the significant effect of duration of 
TD in the linear mixed-model analysis.  In this regard it is of interest that, in a double-blind, 
controlled trial of ethyl-EPA in Huntington disease, it was reported that, although EPA had no 
overall effect, some benefit was recorded in patients with later onset of disease (Puri et al., 
2005). Fourth, it is possible that dietary differences in fatty acid intake could account for the 
different findings between the studies. Fatty acids compete with one another for uptake, so 
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that the therapeutic effect of EPA may be most substantial in patients with low dietary intake 
of fatty acids (Emsley et al., 2003). We consider this unlikely to explain the different outcomes 
of the two trials however, as the subjects for both studies were from the same catchment 
area, and from similar ethnic and socio-economic backgrounds.  Although blood samples for 
erythrocyte EPA levels were obtained from subjects at baseline and during the trial, these 
have not yet been analysed. Finally, it may be that EPA is devoid of an anti-dyskinetic effect, 
and the previous positive result was spurious, possibly as a consequence of the small 
sample.  
 
The study also failed to demonstrate an antipsychotic effect for EPA. The lack of an 
effect on psychotic symptoms was not unanticipated, as our sample comprised largely 
symptom-free, stable patients. However, even the subset of more symptomatic patients 
showed no indication of improvement in PANSS scores with EPA treatment. Again, this could 
be due to the dose being too low, the study being underpowered, the chronicity of the sample, 
dietary differences in fatty acid intake, or a lack of antipsychotic activity for EPA. The absence 
of any clear-cut therapeutic effect for EPA in this study precluded us from investigating a 
relationship between antidyskinetic and antipsychotic effects.  
 
In conclusion, the results of this study do not support the efficacy of ethyl-EPA 2 g/d in 
the treatment of TD in patients with schizophrenia, although some effect on patients with a 
more recent onset of TD cannot be ruled out.  Further randomized, controlled trials with 
higher doses of EPA, and in subjects with recent onset of TD are warranted. Based on 
currently available evidence, patients with established TD should be treated with a new 
generation antipsychotic where possible. Although no differences in dyskinesia rates were 
observed between the new generation antipsychotics in a recently published comparative trial 
of these agents (Lieberman et al., 2005), the best evidence in terms of randomized, controlled 
trials for an antidyskinetic effect amongst these agents exists for clozapine (Lieberman et al., 
1991; Tamminga et al., 1994; Spivak et al., 1997) and quetiapine (Emsley et al., 2004). 
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Table 1.  Baseline characteristics of the 77 participants with tardive dyskinesia. 
Characteristic Ethyl-EPA Placebo P-values 
Age  42.4±10.3 yrs 43.4±10.9 yrs 0.7 
Gender (M:F) 27:12 24:14 0.6 
Duration of 
schizophrenia 16.0±10.5 yrs 16.8±10.4 yrs 0.7 
Duration of TD 5.6±4.4 yrs 6.7±7.4 yrs 0.4 
PANSS total score 59.2±13.0 57.5±11.8 0.6 
ESRS parkinsonism 
subscale 8.8±6.6 9.1±6.1 0.9 
ESRS dystonia subscale 0.1±0.4 0.7±1.7 <0.0001 
ESRS dyskinesia 
subscale 12.0±4.9 12.5±5.7 0.4 
ESRS total score 32.7±12.9 35.3±15.4 0.3 
CGI TD 3.5±1.0 4.1±1.1 0.01 
 
 
 
 
Table 2.  Details of the fitting of a linear mixed model allowing for random between-
subject effects 
Coefficient  Value  Std Error Degrees of 
Freedom 
t-value P-value 
(intercept) -3.903 1.467 173 -2.660 0.0085 
Age 0.045 0.026 62 1.700 0.0942 
Duration of TD 0.407 0.148 62 2.742 0.008 
Treatment group 5.006 1/245 62 4.020 0.0002 
Time point 0.026 0.332 173 0.078 0.9376 
Duration of TD: 
Treatment group 
-0.557 0.169 62 -3.299 0.0016 
Duration of TD: Time 
point 
-0.114 0.054 173 -2.117 0.0357 
Treatment group: 
Time point 
-1.221 0.421 173 -2.897 0.0043 
Duration of TD: 
Treatment group: 
Time point 
0.160 0.060 173 2.672 0.0083 
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This article reviews the English literature over the past 10 years with regard to treatment 
outcome in first-episode schizophrenia.  Particular attention is paid to factors associated with 
poor outcome and predictors of relapse, and the use of the new antipsychotic agents. 
 
Since the mid-1950s, conventional antipsychotic agents have consistently proved to be the 
most effective compounds in the treatment of schizophrenia.1  Considerable variation in 
individual patient outcome is observed, with approximately 70% of patients showing 
substantial reduction of symptoms in the short term.  Although a multitude of clinical trials has 
been conducted, no convincing data indicate that any one of these drugs, or a particular class 
of drugs, is more effective than any other.1  While the short-term efficacy of antipsychotics is 
well established, earlier trials generally failed to appreciate that measurement of symptom 
reduction alone – often after only 6 or 8 weeks of treatment – did not provide an accurate 
indication of actual treatment outcome.  A more comprehensive assessment of outcome is 
necessary, incorporating multiple outcome criteria such as level of occupational and social 
functioning, cognitive function, feeling of well-being, severity of side-effects, compliance, 
frequency of relapses and duration of hospitalisation.2,3 
 
When outcome is considered in these terms, an entirely different picture emerges.  In fact, the 
overall outcome for schizophrenia is anything but satisfactory.4,5  Most patients require 
numerous hospitalisations for recurrence of psychotic symptoms, have impairment of 
functioning due to persistent negative symptoms and side-effects, are alienated from society, 
have impairment of cognitive functions (particularly attention, memory and executive 
functions),6,7 and display frequent and protracted periods of depression.8  About 10% of 
patients with schizophrenia eventually commit suicide.9 
 
Major limitations of the conventional antipsychotic agents include the following: 
 
1. Negative symptoms respond poorly.10  Persistence of negative features such as 
akinesia and poverty of speech results in impairment of social and occupational 
functioning.  The degree of impairment is often severe, so that the majority of 
patients with schizophrenia are unemployed and socially isolated. 
2. Lack of responsiveness to treatment, even with high dosages.11  Treatment 
refractoriness, if severe, usually results in chronic institutionalisation and severe 
impairment of function. 
3. High incidences of extrapyramidal symptoms (EPS).  These side-effects are seen 
in approximately 75% of patients treated with conventional antipsychotic agents.  
EPS, particularly akathisia, cause great distress and discomfort, and are the 
single most important factor contributing to poor compliance.12  Poor compliance 
in turn leads to recurrence of psychotic episodes, readmissions to hospital, and 
increased morbidity.13 
 
A new and important development in schizophrenia research has been to focus studies on 
first-episode schizophrenia (FES).14  In this way, possible confounding variables such as the 
effects of medication and the development of chronic or secondary symptoms are eliminated.  
New information regarding the pathophysiology, psychopathology, course of illness and 
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response to treatment has emerged.  Several methodologically sound longitudinal studies 
have been conducted, and important findings reported. 
 
With regard to treatment, it has been shown that the clinical response is better in FES than in 
patients with recurrent episodes, and fewer FES patients are refractory to treatment.4,5,15,16  
Also, medication is effective at a lower dosage, and FES patients appear more sensitive to 
EPS.5,17  Very importantly, it has been found that the time between the first appearance of 
psychotic symptoms and initiation of treatment is the best predictor of long-term outcome.  
Patients with a recent onset of psychotic symptoms fare better in follow-up studies than do 
these with symptoms of longer duration.  Crow et al.18 reported that among 120 FES patients 
followed up for 2 years, relapse subsequent to initial hospital discharge was substantially 
more frequent in those whose pretreatment illness lasted more than 12 months.  Loebel et 
al.19 followed up 70 FES patients for 3 years.  Patients received standardised treatment and 
uniform assessments.  Outcome was measured in terms of time to remission as well as 
degree of symptom remission.  Duration of illness before treatment was found to be 
associated to a significant extent with time to remission as well as level of remission. 
 
Earlier studies also provide evidence for a relationship between early treatment and 
favourable outcome.  Angrist and Schulz20 reported poorer response to antipsychotics in 
chronic patients, Lo and Lo21 found that a shorter duration of psychosis before treatment was 
significantly associated with a favourable outcome, and Rabiner et al.22 found in a group of 64 
FES patients that the longer the duration of illness, the poorer the outcome.  Also, after each 
subsequent relapse there is a drop-off in response to treatment.23  It has been suggested that 
the acute psychotic symptoms could reflect an active morbid process which, if not ameliorated 
by antipsychotic drug treatment, may result in lasting morbidity.24  Otherwise put, it is possible 
that an extended period of dopaminergic neural dysfunction may result in a more severe, or 
less readily reversible, pathophysiological condition.  Whatever the mechanism, it is apparent 
that there is an evolution of resistance to treatment in the progression of the illness. 
 
For this reason, prompt and effective intervention in the early stage of schizophrenia is critical 
to the outcome.  Particular attention should be given to the initial diagnosis and treatment 
plan.  Care needs to be taken in choosing a drug at a dosage that is going to be effective and 
at the same time well tolerated.  According to Lieberman,25 if we can reduce the duration of 
the acute psychotic phase of the illness, we can reduce the lasting impairment that 
schizophrenic individuals may sustain.   
 
Another strategy to limit the accrued morbidity in schizophrenia concerns early identification 
of that important subgroup (10 - 20%) of FES patients who are refractory to treatment.  If 
these patients could be detected as close to the onset of their illness as possible, alternative 
treatments could be initiated before further deterioration occurs.  While factors such as male 
gender, early onset of illness, low educational level, affective blunting, premorbid personality 
disorder and high levels of expressed emotions in family members have been associated with 
poor outcome,25 these findings have not been replicated consistently.  The FES studies 
mentioned earlier in this article provide strong evidence that a longer duration of illness before 
treatment and frequent previous admissions significantly predict poor outcome.  There are a 
number of biological indicators that may predict which patients are at risk for relapse with 
reduction or discontinuation of maintenance medication.24  The most promising appears to be 
dopamine psychostimulant provocative tests – patients displaying transient activation of their 
symptoms after receiving methylphenidate are likely to relapse.26  Another risk factor identified 
by the same investigators is the presence of tardive dyskinesia. 
 
A further matter requiring careful attention in FES is the prevention of side-effects, particularly 
EPS.  Very often, with the initiation of treatment, the development of EPS such as severe 
dystonia or akathisia can have a profound negative impact on the patient’s compliance for 
years to come.12  It is important to initiate treatment in FES with low-dosage medication, and 
carefully titrate up until a clinical improvement is observed, or until side-effects emerge.  
Because FES patients are particularly likely to develop EPS, a strong case can be made out 
for the prophylactic use of antiparkinsonian medication in an FES.  An alternative would be to 
consider using a new antipsychotic, with a lower risk of inducing EPS. 
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The new antipsychotics 
 
Several new antipsychotics such as olanzapine, seroquel, ziprasidone and sertindole are at 
various stages of development, and should be available for clinical use within the next few 
years.  Only two are currently available, namely clozapine and risperidone.  Clozapine, of 
course, is not new, but its re-introduction to clinical practice after being severely restricted 
when found in rare cases to cause fatal agranulocytosis has been supported by an enormous 
amount of new safety and efficacy data.  The new antipsychotics can be classified according 
to their receptor-binding profiles – clozapine, olanzapine and seroquel being multireceptor 
antagonists and risperidone, ziprasidone and sertindole being dopamine (D2) – serotonin 
(5HT2) – norepinephrine (α1) antagonists.27 
 
There is compelling evidence to suggest that the new antipsychotics have distinct advantages 
over conventional agents.  Clozapine is associated with significantly fewer EPS, has a 
favourable effect across a broad spectrum of symptoms, and is effective in treatment-resistant 
schizophrenia.28  Clozapine is also reported to improve cognitive impairment in 
schizophrenia29 and to reduce suicidality.30  Risperidone, in recommended doses, is reported 
to be more effective than haloperidol in reducing both positive and negative symptoms of 
schizophrenia and causes fewer EPS than conventional antipsychotics.31-33  There are also 
indications that risperidone may be superior to the conventional antipsychotics in refractory 
schizophrenia.34 
 
Experience with these drugs in FES is limited.  Szymanski et al.35 have reported a modest 
outcome in a small cohort of FES patients treated with clozapine relatively early in the course 
of the illness.  Subjects were refractory to conventional antipsychotics in multiple clinical trials.  
Although none of the patients attained a complete remission, 2 of 10 patients showed a 
favourable response at 6 weeks and 1 other after 12 weeks.  In a large multicentre study,15 
183 subjects with first-episode schizophreniform disorder were treated with flexible doses of 
either risperidone or haloperidol for 6 weeks.  Efficacy was assessed at weeks 1, 2, 4 and 6 
by means of the positive and negative symptoms scale (PANSS), clinical global impressions 
and brief psychiatric rating scale (BPRS).  Clinical improvement was defined as a 50% or 
more reduction in total PANSS scores at endpoint.  EPS were rated according to the EPS 
rating scale.  At endpoint both treatment groups showed significant improvement on the 
PANSS and BPRS.  Sixty-three per cent of the patients on risperidone and 56% of those on 
haloperidol experienced clinical improvement.  Risperidone caused significantly fewer and 
less severe EPS, and significantly fewer patients on risperidone discontinued treatment. 
 
Cost is often given as the major reason for relegating the new antipsychotics to the second, 
third, or even last line of treatment for schizophrenia.  However, the cost of medication is only 
a very small part of the total costs involved in treating patients with schizophrenia, so the 
cheapest drug may not provide the most cost-effective treatment.  A re-thinking of this 
approach is likely.  Considering that most schizophrenics do poorly with traditional 
antipsychotics in the long term, and particularly because recent evidence indicates that early 
and effective treatment and prevention of relapses has enduring favourable effects on 
outcome, the use of the new antipsychotics at an earlier stage of the illness needs to be 
considered seriously.  Risperidone has proved to be a safe and effective antipsychotic that 
can be used as first-line treatment.  Whether its reported efficacy for negative symptoms is 
due to a reduced incidence of EPS or whether it actually has a direct effect on primary 
negative symptoms, is not clear.  Further experience will show whether it is also associated 
with a reduced rate of tardive dyskinesia and neuroleptic malignant syndrome, and whether it 
shares some of the other reported benefits of clozapine.  Although there is abundant evidence 
that clozapine has a number of advantages over the conventional antipsychotics, the risk of 
agranulocytosis will probably prevent it from being used as a first-line drug.  However, 
because its efficacy in refractory schizophrenia is well established, and because favourable 
long-term outcome depends on early response to treatment, it would be unwise to delay 
unnecessarily before switching non-responsive patients to clozapine.  It has been suggested 
that if there has been no significant response after 3 months of treatment it would be an 
appropriate time to consider using clozapine.2 
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The antipsychotics currently available will soon be augmented by the introduction of other 
new compounds.  Undoubtedly major revisions in our approach to the treatment of 
schizophrenia are under way, much the same as was the case with the treatment of 
depression after the introduction of the selective serotonin re-uptake inhibitors. 
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Abstract 
The introduction of the novel antipsychotics has had a major impact upon the treatment of 
schizophrenia. However, the greater acquisition costs of these drugs puts them beyond the 
reach of large sectors of the world’s population. Consequently, the gap between the levels of 
care in high-income and low-income countries is likely to widen even further. Co-ordinated 
global action is necessary to ensure greater accessibility of these drugs. Cost-effectiveness 
studies in low-income countries need to be undertaken. The considerable evidence for 
improved safety and efficacy of low-dose compared to high dose classical antipsychotics 
offers an alternative that could be implemented immediately in low-income countries.   
 
 
 
Introduction 
 
The development of the novel antipsychotic drugs has had a major impact upon our approach 
to the treatment of patients with schizophrenia. Evidence is accumulating that these drugs 
hold significant advantages over their predecessors in terms of both efficacy and tolerability. 
In particular, it has been shown that the newer drugs are less likely to induce acute 
extrapyramidal symptoms (Thomas and Lewis, 1998), previously a major obstacle to the 
effective treatment of schizophrenia. Other reported advantages of these drugs include 
improved efficacy in treatment-refractory patients (Marder, 1996) and patients with negative 
symptoms (Carman et al, 1995) and depressive symptoms (Tollefson et al, 1998), reduced 
levels of suicidality (Meltzer and Okayli, 1995), less neurocognitive impairment (Rossi et al, 
1997), better subjective quality of life (Franz et al., 1997), reduced incidence of tardive 
dyskinesia (Beasley et al, 1999) and improved overall outcome (Weiden et al, 1996).  While 
some of these advantages may be modest, they are likely to make a substantial difference to 
patients in terms of improved social and vocational functioning and general quality of life. The 
clinical advantages of these drugs appear to be greatest close to the onset of the illness, and 
they are increasingly being advocated as first-line agents (Lieberman, 1996). The acquisition 
costs of the novel antipsychotics are, however, much greater than those of the older drugs, 
and their availability in lower-income countries, particularly in Africa, Latin America, Asia and 
the Pacific, is extremely limited.  In contrast, the generic classical psychotropic drugs used 
extensively in state health services in developing countries are very cheap. These countries 
tend to rely on a handful of psychotropic drugs. For example, the South African Essential 
Drugs List for primary health care has 8 psychotropic drugs, of which 4 are classical 
antipsychotics (chlorpromazine tablets, fluphenazine decanoate injection, haloperidol 
injection, and zuclopenthixol acetate injection). There are no novel antipsychotics on the list 
(Gous et al, 1996). While some low-income countries are apparently making use of generic 
novel antipsychotics such as clozapine the efficacy and safety of these compounds is 
undocumented in the literature, and availability limited. 
 
Until recently, psychiatry operated relatively cheaply, with most of its budget being allocated to 
salaries of mental health workers and a few inexpensive psychotropic drugs. As awareness of 
newer methods of treatment permeates both the medical profession and the public, we are 
facing the challenge of having to compete with other specialities for a larger portion of the 
health budget. In low-income countries, the situation is made more difficult by the limited 
resources for which disciplines must compete and a lag in official attitudes. Policy makers 
usually regard mental illness as low priority, with other health issues being perceived as more 
important (Desjarlais et al, 1995). Thus, while there have often been dramatic improvements 
in general health care and living standards in developing countries, the same cannot be said 
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for mental health care. The socio-economic impact of psychiatric disorders has been grossly 
underrepresented by conventional public health statistics, where the focus has tended to be 
on mortality rather than morbidity (Desjarlais et al, 1995). Mental health problems are an 
increasing part of the global health burden, and now rate as one of the largest causes of lost 
years of quality of life (Sadik, 1992). 
 
Costs of schizophrenia 
 
Schizophrenia obviously forms a significant part of this burden, being the most costly illness 
that psychiatrists treat (Andreasen, 1991). It imposes a disproportionately large economic 
burden on patients and their families, health care systems and society, because of its early 
onset, devastating effects, and usually lifelong course (Glazer and Johnstone, 1997). Cost 
estimates vary from country to country, but invariably confirm that schizophrenia is an 
exceptionally expensive illness. In 1993 the disease consumed an estimated $30 billion in the 
United States of America, $18 billion of which were direct costs and $15 billion indirect costs. 
This constitutes 2.5% of the annual total health care allocations (National Advisory Mental 
Health Council, 1993). In England, the identifiable direct and indirect costs of schizophrenia 
suggest an annual total cost of £2.6 billion, and some indirect costs are omitted from this 
estimate (Knapp, 1997). In Belgium the mean direct treatment cost was $12,050 per patient 
per year, or $304 million for all schizophrenia patients per year. This constitutes 1.9 percent of 
the Belgian Government’s total health expenditure (De Hert et al, 1998). In the Netherlands 
about 2% of the total health care budget is spent on the treatment of schizophrenia patients 
(Evers & Ament, 1995) and in Spain the direct cost per patient per year was $2,243 (Haro et 
al, 1998). Direct costs include hospitalisation, day care, residential accommodation, 
medication, special investigations and disability grant payments. High among the indirect 
costs are those associated with lost employment or reduced productivity and family costs 
(e.g. household expenditure, travel costs, lost earnings) (Knapp, 1997). Medications comprise 
a very small portion of the costs of schizophrenia, estimated at 4% of the direct costs in the 
United Kingdom (National Health Service Executive, 1996), 5.6% in France (Rouillon et al, 
1994) and 1.1% in the Netherlands (Evers & Ament, 1995). 
 
The previous under-recognition of the importance of psychiatric disorders such as 
schizophrenia was due in part to a lack of available information, resulting in policy makers 
having to make ill-informed decisions. In the past these policy makers frequently refused to 
look beyond the acquisition costs of the drugs. However, recent research findings focussing 
on pharmaco-economics and quality of life issues indicate that, in fact, psychiatric disorders 
are amongst the most important causes of disability in both developing and developed nations 
(Murray and Lopez, 1997). These and other similar findings are likely to alter perceptions of 
the relative importance of mental health.  As governments begin to insist on the submission of 
high-quality economic evaluations before deciding on how to allocate their limited resources, 
cost-effectiveness analyses will increasingly be introduced into clinical trial protocols 
(Maynard and Bloor, 1998). A crucial issue in many health-care systems is that the high 
acquisition costs of the new drugs fall into one part of the system, whereas the cost savings 
are enjoyed elsewhere in the system. This means that budget allocations need to be adjusted 
accordingly. While cost-effectiveness studies report advantages for novel antipsychotics over 
their predecessors in terms of overall cost of treating schizophrenia, these studies have been 
based in developed countries. Some multinational studies have included developing 
countries, but there is no specific indication that the overall findings apply in these countries. 
The findings may not, in fact, be applicable to low-income countries, as schizophrenia has 
been reported to run a different course in the latter (Sartorius et al, 1986), and the relative 
contribution of factors to direct and indirect costs probably differs substantially from that in 
developed countries. Indeed, a cost-effectiveness study carried out in Nigeria indicated that 
the cost of the antipsychotic drugs accounted for 52.8% of the cost of treating schizophrenia. 
Factors such as currency devaluation and the lack of both disability benefits and residential 
facilities were identified as altering the proportional costs of treating the illness (Suleiman et 
al, 1997). Most patients in such countries are cared for by families at no direct cost to the 
state, other than outpatient medication. Residential care, when available, tends to be 
custodial, with relatively low staff and infrastructure expenditure. It would be important to 
undertake cost-effectiveness studies with the novel antipsychotic agents in developing 
 191
countries before it could be effectively argued that these drugs should be made more widely 
available. 
 
The inaccessibility of new drugs because of economic considerations raises important human 
rights issues. With the advent of these apparently more expensive new treatment options, 
there is a very real danger that the gap between levels of psychiatric care in developed and 
developing countries will widen further. The international psychiatric community needs to take 
cognizance of the deteriorating situation and the further marginalisation of much of the world’s 
population. Co-ordinated global action is necessary to ensure that effective psychiatric care 
also reaches people in low-income societies. Concern has been voiced that the increasing 
globalisation of the pharmaceutical industry may result in the setting of uniform world-wide 
prices rather than allowing for lower prices to less developed countries (Pécoul et al, 1999). In 
some parts of the world, pharmaceutical and other private companies have recently involved 
themselves in psycho-educational programmes, patient support programmes, and other 
community responsibilities. This seldom results in direct profit, but appears to be motivated by 
goodwill. It would be encouraging to see them extend this social conscience to poorer 
countries, possibly in closer collaboration with organisations like the World Health 
Organisation, UNICEF and the World Bank (Pécoul et al, 1999). Access to an acceptable 
standard of psychiatric care should be a fundamental right of all people.  
 
It may be argued that in developing countries, access to drugs for treating diseases such as 
malaria, tuberculosis and bacterial meningitis will always be more important than having a 
wider range of psychotropic drugs available. However, this “either/or” approach would 
preclude psychiatrists from campaigning for the global availability of effective mental health-
care when in fact the opposite should hold – if psychiatry is to regard itself as a champion of 
humane medical practice, it should be playing a leading role in this respect.   
 
Another initiative that could fruitfully be pursued is the establishment of consumer advocacy 
groups in developing countries. Such groups have been very successful in lobbying policy 
makers and private companies in North America and Europe, and may also prove effective in 
low-income countries.  
 
Low-dose classical antipsychotics 
 
An interim option for improved treatment of schizophrenia in low-income countries is perhaps 
more easily attainable – that of low-dose classical antipsychotic medication. There is now 
substantial evidence that low-dose antipsychotic treatment holds definite advantages over 
high-dose treatment. Indeed, in a comprehensive survey of dose-effect relationships, no 
support was found for the use of antipsychotics in daily doses above 500 – 600 mg 
chlorpromazine equivalents (Baldassarini et al, 1988).  In fact, patients receiving 20mg 
haloperidol per day did significantly worse than those receiving 10mg per day (Van Putten et 
al, 1990). Other studies have borne out this finding, indicating that doses of haloperidol above 
10mg per day, in addition to causing increased side-effects, have no additional benefits, and 
may in fact be less effective than lower doses (Zimbroff et al, 1997; Donlon et al, 1980; Rifkin 
et al, 1991). McEvoy et al (1991), by determining the neuroleptic threshold in individual 
patients, found that 72% recovered clinically within 5 weeks on an average dose of 3.7mg 
haloperidol per day. Higher dosages given to non-responders did not lead to greater 
improvement. Further support for low-dose efficacy is forthcoming from positron emission 
tomographic studies of striatal D2 receptor occupancy. With conventional antipsychotics 
clinical efficacy has been reported even with relatively low occupancy.  For example, doses of 
2 mg haloperidol per day recorded occupancies between 53% and 74% and were associated 
with clinical efficacy (Kapur et al., 1996). Finally, patients with plasma haloperidol levels above 
25ng/ml did significantly worse than those with levels less than 18ng/ml.  The high-dose 
patients who failed to respond showed significant improvement once the dose was reduced. 
Interestingly, in this study, patients with lower plasma levels of haloperidol also had greater 
improvement in negative symptom ratings than those with higher plasma levels (Coryell et al, 
1998). In spite of the evidence supporting low-dose haloperidol usage, many patients 
continue to receive dosages far in excess of what they require. This may be particularly the 
case in low-income countries, where mental health resources are stretched and reliance is 
placed on sedative side effects for behavioural control of the mentally ill.  
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Clearly, considerable evidence exists for the advantages of low-dose versus high-dose 
classical antipsychotic treatment in terms of tolerability and probably efficacy. Whether these 
advantages are comparable to the advantages offered by the novel antipsychotics is not clear, 
as studies comparing low-dose traditional antipsychotics to the novel antipsychotics are very 
scarce. Most of the clinical trials comparing the novel antipsychotics to haloperidol have used 
haloperidol in dosages of 10mg or greater and this may represent a biased comparison in 
terms of optimal dosage. However, one study suggests that there are advantages for the 
novel antipsychotics over low-dose haloperidol.  Sertindole was compared to haloperidol 4, 8 
or 16 mg daily and placebo, and found to have advantages in ameliorating negative 
symptoms and in avoiding extrapyramidal effects (Zimbroff et al, 1997). This study, 
representing the first multicentre, placebo-controlled assessment of the dose-response effects 
of haloperidol, unexpectedly found relatively high rates of EPS, and significant symptom 
reduction in only some measures of efficacy at the 4mg haloperidol dose level. It would be 
interesting to see the results of further studies in this vein, to establish whether any of the 
other advantages of the novel antipsychotics – such as efficacy in refractory schizophrenia, 
negative symptoms, reduced induction of tardive dyskinesia and increased productivity – can 
be demonstrated against low-dose classical antipsychotic therapy. 
 
As an interim measure, low-income countries would do well to implement low-dose classical 
antipsychotic treatment strategies for patients with schizophrenia, while efforts are made to 
extend the availability of the novel antipsychotics globally. 
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Summary  
This article reviews the evidence for the atypical antipsychotics other than clozapine in 
patients with schizophrenia who are resistant to treatment with conventional agents. 
Clozapine remains the one drug with proven efficacy in severely refractory patients. However, 
while modestly effective in 30 to 70% of these patients, there are many who are either 
intolerant of, or non-responsive to clozapine. The initial hope that the new atypical 
antipsychotics would play a major role here has not really materialised. Nevertheless, it is 
increasingly recognised that perhaps the majority of patients with schizophrenia have milder 
degrees of refractoriness  –  so-called partial responders – and considerable evidence is 
emerging for an important role for risperidone, olanzapine and quetiapine in these patients. 
These drugs appear to have advantages over the conventional antipsychotics in terms of both 
efficacy and tolerability in these patients. More studies are required to establish optimal 
dosages of the atypical antipsychotics in refractory patients, as well as whether some 
individuals respond differentially to a particular drug.  
 
 
 
1.  Introduction 
The advent of the atypical antipsychotics has had a major impact upon the way we treat 
patients with schizophrenia. Evidence is accumulating that these drugs hold significant 
advantages over their predecessors in terms of both efficacy and tolerability. In particular, it 
has been shown that the newer drugs are less likely to induce acute extrapyramidal 
symptoms (EPS),[1] previously a major obstacle to the effective treatment of schizophrenia. 
Other reported advantages of these drugs include improved efficacy in treating negative 
symptoms[2] and depressive symptoms,[3] reduced levels of suicidality,[4] less neurocognitive 
impairment,[5] better subjective quality of life,[6] reduced incidence of tardive dyskinesia[7] and 
improved overall outcome.[8] These advantages are not necessarily shared to the same extent 
by the currently available atypical antipsychotics, clozapine, risperidone, olanzapine and 
quetiapine.  
 
Another area where the atypical antipsychotics have raised expectations is in the treatment of  
patients who are refractory to conventional agents. For years conventional antipsychotics 
were the only effective drugs in treating schizophrenia and other psychotic disorders, with 
approximately 70% of patients showing clear-cut symptom reduction in short-term clinical 
trials.[9] However, in the longer term, and in real-world clinical practice, a different picture 
emerges. It has been estimated that two thirds of first-episode schizophrenia patients 
continue to experience positive symptoms after one year, and about one-third will continue to 
have them after six years.[8] The persistence of positive symptoms may have important clinical 
ramifications, for a number of reasons. First, ongoing positive symptoms, particularly if 
accompanied by bizarre behaviour, are likely to further stigmatise and marginalise these 
patients. Further, the risk of relapse is likely to be greater due to reduced insight and 
compliance. Finally, a longer duration of positive symptoms before effective treatment is 
associated with a poorer outcome.[10,11] Indeed, it has been suggested that positive symptoms 
are clinical manifestations of a progressive encephalopathy, which, if not arrested may result 
in lasting morbidity.[12]  
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Treatment options for refractory schizophrenia were previously extremely limited - a patient 
who is unresponsive to one conventional antipsychotic, is unlikely to respond to another. Also, 
increasing the dose of a conventional agent above the usually prescribed range, or adding 
supplementary drugs, is unlikely to be helpful.[13] 
 
2.  Defining resistant schizophrenia 
Schizophrenia by definition requires an extended period of illness with significant social and 
occupational dysfunction.[14] Long-term outcome studies indicate that 80 – 90% of patients 
develop varying degrees of social and occupational impairment.[15] Historically, treatment 
resistance has been defined in terms of a lack of response among positive symptoms. 
However, this is an inadequate definition that needs to be expanded to include other domains 
such as negative, cognitive and mood symptoms. Marder[16] proposes that patients should be 
regarded as refractory to a particular treatment after they have failed an adequate trial with 
that agent. Most patients should have at least a 6 week trial, and if they demonstrate even a 
mild degree of improvement it may be reasonable to continue, as further improvement may 
occur for 3 to 6 months. In most studies, patients are defined as treatment-resistant according 
to their response to conventional antipsychotics. Perhaps the best definition and the one most 
frequently referred to in the literature is that of Kane et al:[17] A failure to respond to at least 
three periods of treatment in the preceding 5 years with antipsychotic agents from at least two 
different chemical classes at dosages equivalent to at least 1000 mg of chlorpromazine per 
day for a period of at least 6 weeks each, and had no period of good functioning within the 
previous 5 years. In addition, patients in that particular study failed to respond to an open 
prospective 6-week trial of haloperidol (up to 60mg/day or higher). 
 
3.  Clozapine 
Clozapine was the first agent to show superior efficacy over conventional antipsychotic drugs 
in treatment-refractory patients with schizophrenia. The first controlled trial was published in 
1988.[17] The methodolgy of this study set the standard for future studies, and the so-called 
Kane criteria described above were subsequently widely adopted to identify a subset of 
severely refractory patients. 
 
A comprehensive meta-analysis of all available clinical trials published in all languages 
investigating the efficacy of clozapine versus conventional antipsychotics in schizophrenia 
was recently published.[18]  This review included 2530 randomly assigned subjects in 30 
clinical trials. Clozapine–treated patients showed more clinical improvement and experienced 
fewer relapses. The evidence for clozapine superiority was clear-cut. However, the effect size, 
at best, was modest. The improvement corresponded to approximately a 6-point difference in 
Brief Psychiatric Rating Scale (BPRS) total score after up to 3 months of treatment compared 
to conventional antipsychotics. Fewer than one third of adult treatment-resistant patients 
showed clinical improvement, defined as at least a 20% decrease in BPRS or Positive and 
Negative Syndrome Scale (PANSS) score from baseline. Treatment-resistant children and 
adolescents seemed to respond more favourably. The evidence for superior efficacy was 
accompanied by fewer EPS. Clinical improvement was most pronounced in patients with 
treatment-resistant schizophrenia, but was also significant in non-resistant schizophrenia.  
 
This review does not attempt to cover the considerable literature on clozapine in resistant 
schizophrenia, but rather aims to focus on the role of the newer atypical antipsychotics. The 
reader is referred to the various studies published on clozapine in resistant 
schizophrenia,[17,20-22] in which the response to clozapine is reported as being between 30% 
and 70%. There remain however a substantial number of patients with schizophrenia who 
either do not improve substantially on clozapine treatment, or who are unable to take the drug 
because of the risk of side-effects or unwillingness to undergo regular hematological 
monitoring. 
 
4. Risperidone 
A recent meta-analysis of risperidone in the treatment of schizophrenia[23]concluded that, 
compared with conventional antipsychotics, slightly more patients showed clinical 
improvement (57% vs 52%), the dropout rate was lower (29.1% vs 33.9%) and the use of 
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concomitant medications for extrapyramidal symptoms was lower (22.8% vs 38.4%). On the 
other hand, weight gain and tachycardia were significantly more common in the risperidone 
patients. Indirect evidence points towards efficacy for risperidone in refractory schizophrenia - 
in a large multicentre study conducted over 8 weeks,[24] risperidone 6mg/day had its greatest 
advantage over haloperidol for patients who had been hospitalised for more than 6 months. 
These patients were likely to have been treatment resistant. 
 
A number of studies have directly investigated the efficacy and safety of risperidone in 
treatment-resistant schizophrenia. A randomised, double blind, multicentre study conducted 
over 8-weeks comparing risperidone to clozapine[25] The sample comprised 86 inpatients with 
chronic schizophrenia who were either resistant to, or intolerant of, conventional treatment. 
Patients had previously failed to respond to or were intolerant of at least two different classes 
of conventional antipsychotic drugs given in appropriate doses for at least 4 weeks each. This 
was determined retrospectively from the patients’ files. No subject had previously received 
clozapine. After a one-week titration phase, doses were fixed at 6mg/day of risperidone and 
300mg/day of clozapine for one week, and then adjusted according to individual responses. 
The mean doses prescribed were 6.4mg/day of risperidone and 291.2mg/day of clozapine. At 
endpoint 67% of the risperidone group and 65% of the clozapine group were clinically 
improved by 20% or more on the PANSS. Clinical Global Improvement (CGI) change scores 
were also similar for the two drugs at endpoint. Risperidone appeared to have a faster onset 
of action (median time to response 14 days for risperidone vs. 21 days for clozapine). Dropout 
rates were similar in both groups (9 subjects each). Extrapyramidal symptoms and other 
adverse events were scarce and mild in both groups. This trial provides good evidence for the 
efficacy of risperidone in refractory patients. Certain concerns have been raised regarding this 
study:[26-28] First, the study population was not well defined, and included both neuroleptic 
intolerant and neuroleptic resistant patients. Also, the sample size was relatively small, so that 
actual differences between the treatment groups may have been concealed. Further, 
clozapine dosing was relatively low, and the titration period fairly rapid. Finally, the treatment 
period was possibly too short, as clozapine has been shown to require up to 6 months to 
achieve its full benefits.[20,29] In response, the authors[25] point out that their sample 
corresponds with the criteria normally applied when considering patients for clozapine 
treatment, and suggest that a less restrictive definition of treatment resistance may be more 
helpful in clinical settings. A further important point to emerge from this study is that relatively 
low doses of risperidone were found to be effective in this partially refractory sample. This is 
important in terms of fewer side-effects as well as reduced acquisition costs. 
 
In an open comparison of clozapine and risperidone in severely treatment-resistant 
schizophrenia[30]clozapine showed superior efficacy although risperidone appeared to yield 
better response rates than those reported with classical antipsychotics. The sample 
comprised 57 subjects treated with clozapine and 29 with risperidone. Patients met DSM IV 
criteria[14] for schizophrenia and had a Global Assessment of Function scale (GAF) score of 
less than 41 in the preceding year, a score on the Degree of Resistance to Treatment 
scale[31]of four or five, a total PANSS score of at least 60, and previous adequate trials of at 
least three different antipsychotic medications from at least two different classes. The mean 
treatment duration of the trial was 12.1 weeks. The mean dose of clozapine was 420mg, and 
risperidone 7.75mg. The clozapine group showed greater improvement in PANSS total scores 
and positive subscale scores. The PANSS-derived factors of excitement, psychosocial 
withdrawal and psychomotor retardation showed greater improvement in the clozapine group, 
as did the GAF scores. The CGI scores indicated that 33% of the clozapine group and 14% of 
the risperidone group were  “much improved” or “very much improved”. Forty-four percent of 
the clozapine group and 28% of the risperidone group achieved a 20% reduction in total 
PANSS scores. Within the obvious limitations of an open trial and the relatively small sample 
size, this study suggests superiority for clozapine over risperidone in severely refractory 
patients. However, it also suggests that some severely resistant patients may obtain benefit 
from risperidone. On the other hand, six patients in the risperidone group were “minimally 
worse” and three “much worse”, compared to only one subject in the clozapine group being 
regarded as “minimally worse” and none as “much worse”. 
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Four studies undertaken by a research group investigated the effects of risperidone versus 
haloperidol on certain cognitive functions, as well as on the perception of emotion in treatment 
resistant patients with schizophrenia. All four of the studies employed a similar design (and 
possibly included overlapping subjects). Treatment-resistance was defined according to the 
criteria of Kane et al.[17] In addition, patients met symptom severity criteria comprising a score 
of at least 45 on the BPRS, a minimum score of 4 on two of the BPRS psychosis items and a 
CGI score of at least 4. Patients were randomly assigned to an initial 4 week fixed dose 
phase of either risperidone 6mg/day or haloperidol 15 mg/day followed by a further 4 week 
flexible dose phase.  In the first study [32]the effects of risperidone vs. haloperidol on verbal 
working memory were compared in 59 subjects. Risperidone treatment had a greater 
beneficial effect on verbal working memory than haloperidol in both the fixed and flexible dose 
phases. The treatment effect remained significant after controlling for the effects of 
benztropine co-treatment, change in psychotic symptoms and change in negative symptoms. 
In the second study investigating a sample of 56 patients[33] the effects of risperidone and 
haloperidol on reaction time, manual dexterity and motor learning were compared. The 
patients receiving risperidone showed greater improvement in reaction time and manual 
dexterity than those receiving haloperidol. Again, differences were not related to 
extrapyramidal symptoms or changes in symptoms. In the third study[34] the effects of 
risperidone and haloperidol on secondary memory were compared in 64 subjects. It was 
found that risperidone-treated patients showed greater improvement than haloperidol-treated 
patients in general verbal learning ability, suggesting that risperidone may exert a facilitating 
effect on the acquisition of new verbal information. No significant treatment effects were noted 
on retention or learning strategy. These three studies provide evidence for superior efficacy of 
risperidone over haloperidol in treatment resistant patients in terms of specific cognitive 
functions. The fourth study[35] compared 20 patients on their ability to perceive emotion. The 
risperidone patients were better able to identify emotion than the haloperidol patients. These 
improvements are important in terms of the current broader concept of treatment outcome. 
The overall outcome in the four above studies has yet to be reported. A possible criticism of 
these three trials is that the haloperidol dose was too high and may have biased the results in 
favour of risperidone.  
 
A prospective, open-label study investigated the effects of switching patients with treatment-
resistant schizophrenia from clozapine to risperidone in a small sample of 10 patients.[36] 
Subjects were inpatients who had been continuously treated with clozapine for at least 13 
months. Criteria for treatment resistance were similar to those of Kane et al.[17] Patients were 
included if it was felt that a switch was indicated, either due to sub-optimal clozapine 
response or intolerance to clozapine-induced adverse events. Clozapine was tapered and 
discontinued over 10 days, and risperidone was then titrated up to 6mg/day over nine days 
and then continued for 12 weeks. The mean clozapine dose at baseline was 565mg/day. Five 
subjects failed to complete the 12 weeks of risperidone treatment due to exacerbation of 
psychotic symptoms or intolerable side-effects. No subjects improved on risperidone. These 
findings need to be interpreted with caution for a number of reasons. The sample was very 
small; the study was unblinded; the patients were highly refractory (being poor responders to 
clozapine); and clozapine withdrawal phenomena[37] could have accounted for the 
exacerbation of psychotic symptoms in at least some of these patients. On the other hand, 
these findings do highlight the fact that great caution is required when switching patients from 
clozapine to risperidone (and possibly to other antipsychotics as well).  
 
In another study comparing risperidone to clozapine, risperidone was found to be at least as 
effective as clozapine and significantly better tolerated.[38] This was a randomised, double-
blind study of 4 weeks duration comparing risperidone 4mg (20 patients) and 8mg (19 
patients) and clozapine 400mg (20 patients).  However, this was a non-treatment refractory 
sample, and a number of patients were in fact drug-naive. Two studies comparing risperidone 
and clozapine in treatment-resistant schizophrenia that have been presented as posters have 
reported equal efficacy for the two drugs.[39,40] Details of these studies have yet to be 
published. 
 
 198
Taken together, there is considerable evidence for efficacy of risperidone in treatment-
resistant schizophrenia. Less severely refractory patients are more likely to benefit from 
risperidone. Non-responders to clozapine may do less well, and particular care needs to be 
taken when switching patients from clozapine to risperidone. 
 
 
 
5. Olanzapine 
Because of its pharmacological similarities to clozapine, the efficacy of olanzapine in 
treatment resistant schizophrenia is of great interest.  An open-label study in a small sample 
(N=25) of patients with treatment-refractory schizophrenia reported significant improvement at 
6 weeks[41]In this study refractoriness was defined as an absence of significant improvement 
with at least two antipsychotics for at least 4 weeks at doses equivalent to at least 750mg/day 
chlorpromazine. Nine subjects (36%) obtained a 35% or greater reduction in BPRS total score 
and only one patient discontinued treatment because of an adverse event. Olanzapine doses 
ranged between 15 and 25mg/day. The drug was well tolerated - no patients reported 
extrapyramidal symptoms, and none required anticholinergic medication. 
 
In a retrospective analysis of a sub-population of treatment-resistant patients selected from a 
large, multicentre, double-blind, 6-week study,[42] the efficacy of olanzapine and haloperidol 
were compared.[43] Subjects who met the following criteria were included: 1) failure to respond 
to at least one antipsychotic over a period of at least 8 weeks during the previous 2 years; 2) 
BPRS total score of at least 24; and 3) BPRS positive score of at least 8, or scores of at least 
4 on any of the BPRS psychosis items. Patients were randomised (2:1) to olanzapine or 
haloperidol, with starting doses at 5mg/day and increased if necessary to a maximum dose of 
20mg. Both last observation carried forward (LOCF) and completers analyses were 
conducted. Olanzapine was superior to haloperidol for key symptom domains and side-
effects. Olanzapine demonstrated significantly greater improvement in PANSS negative 
symptoms, depressive symptoms, akathisia and EPS with both LOCF and completers 
analyses. Also, in the completers, olanzapine was significantly superior for BPRS total and 
PANSS positive symptoms. The olanzapine-treated patients showed significantly greater 
response rates (47%) than the haloperidol treated patients (35%) in the LOCF analysis. 
 
A prospective randomised double-blind study compared the efficacy of olanzapine versus 
chlorpromazine in treatment-resistant schizophrenia.[44]Criteria for resistance were similar to 
those of Kane et al,[17] except that only two periods of failed antipsychotic treatment were 
required. However, the patients were then subjected to a prospective trial of haloperidol 10-
40mg/day, and benztropine 4mg/day, for 6 weeks. Previous resistance to clozapine was an 
exclusion criterion. Of 103 initial subjects, 84 failed to respond to haloperidol (defined as 20% 
or less decrease in total BPRS score; endpoint BPRS score of 35 or more; and a CGI severity 
score of greater than 4) and were entered into the double-blind trial. This was an 8-week 
fixed-dose trial of either olanzapine 25mg/day or chlorpromazine 1200mg/day plus 
benztropine 4mg/day (both drugs were given at half-dose for the first week). Response was 
defined as at least a 20% reduction in total BPRS score and a post-treatment CGI score of 3 
or less or BPRS score of 35 or less. No differences in efficacy were demonstrated between 
the two drugs. Seven percent of the olanzapine-treated patients and none of the 
chlorpromazine patients responded.  There were also no differences in dropout rates.  
Olanzapine was significantly better tolerated than chlorpromazine. The olanzapine-treated 
patients had fewer motor and cardiovascular side-effects. No antiparkinsonian drugs were 
necessary in the olanzapine group. This study had essentially the same criteria as other 
studies assessing clozapine efficacy[17,19-22] in which clozapine response was reported as 
between 30% and 70%. Although it is possible that higher doses of olanzapine may be 
effective, this study indicates that the drug is not as effective as clozapine in severely 
refractory patients. 
 
In another study the same group of investigators report on switching treatment-resistant 
patients from olanzapine to clozapine.[45] The subjects who received clozapine (N=27) were 
treatment-resistant according to the Kane criteria.[17] They had failed to experience a greater 
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than 20% total BPRS score improvement after a prospective 2 to 6 week trial of haloperidol at 
10 to 40mg/day, and had failed to respond to olanzapine either in the previously mentioned 
trial or in open therapy at doses between 12.5 to 25 mg/day.  This was an 8-week open label 
trial. Forty-one percent of the patients responded to clozapine treatment (greater than 20% 
total BPRS score improvement) at a mean dose of 693mg/day. The authors conclude that, 
despite extensive pharmacologic similarities, olanzapine and clozapine do not have the same 
clinical actions in treatment-resistant patients. 
 
In an open-label extension to the trial of Conley et al,[44]the response to olanzapine in 
treatment-refractory patients with and without a history of substance abuse was compared.[46] 
Subjects received up to 25mg olanzapine per day for 7 weeks. Of the entire group, 63% 
responded according to a priori criteria (a 20% BPRS fall plus a one-point fall in CGI). 
Treatment outcomes were comparable in both the substance abusing and non-substance 
abusing group, and the authors concluded that a history of substance should be considered 
as a possible indication for olanzapine therapy. The high response rate in this study is very 
surprising considering that these patients had not responded in the initial double blind study to 
olanzapine. Possible explanations here include the unblinded nature of the study, slightly less 
stringent response criteria that were applied and the longer duration of treatment.  
 
In a prospective, 12 -week, open label trial in sixteen hospitalised patients with severely 
refractory schizophrenia or schizoaffective psychosis, fairly low-dose olanzapine was found 
not to be effective.[47] The patients had not responded to at least two antipsychotic drugs for at 
least 6 weeks each within the past 5 years. Three patients had previously received clozapine, 
and 10 had received risperidone – none had responded to either atypical agent. The 
olanzapine dose was 10mg/day for at least the first 6 weeks  and never exceeded 
20mg/day.Only three patients received more than 10mg/day olanzapine at week eight. 
Overall, significant clinical improvement was noted only for motor side-effects. Patients 
frequently became more agitated within the first several weeks of the study, requiring 
increased use of benzodiazepines and often leading to the discontinuation of olanzapine. 
 
Higher doses of olanzapine in treatment-resistant patients have not yet been properly 
evaluated. Given the drug’s favourable side-effect profile in this and other studies, it would be 
important to evaluate the effects of higher doses in refractory patients. In a naturalistic case 
series outcome study, 16 treatment-resistant patients were treated with olanzapine up to 
40mg/day for 16 weeks.[48] Treatment-resistance was defined according to the criteria of Kane 
et al.[17] Significant improvement from baseline in BPRS total scores and GAS scores was 
observed at weeks 4, 8, 12 and 16, and 50% patients responded to olanzapine, as defined by 
a 20% decrease in BPRS score by week 16. The results of this study are encouraging, and 
suggest that higher dose olanzapine may be effective in severely refractory patients. 
However, these findings need to be validated in randomised controlled trials. 
 
The efficacy of olanzapine for treatment-refractory childhood-onset schizophrenia was 
examined in eight subjects who underwent an 8-week open-label trial.[49] At least two different 
conventional antipsychotics had been ineffective. Most patients had undergone trials of high 
doses of these drugs, as well as risperidone. Some of the patients were intolerant of 
clozapine, although the drug had been effective. Dosages were titrated to a maximum of 
20mg/day. At week 8 there was a mean BPRS improvement of 17%. The mean improvements 
for the SANS and SAPS scores were, respectively, 27% and 1%. These effect sizes were 
smaller than that observed in a similarly designed study with clozapine conducted by the 
same investigators.[50] 
 
The results of these studies together suggest that olanzapine is an effective and safe drug in 
refractory patients defined according to less stringent criteria. However, olanzapine appears 
not to share the efficacy of clozapine in severely refractory patients in doses up to 25mg. It is 
possible that higher doses given over a longer period may prove beneficial. Switching of 
refractory patients to olanzapine may sometimes be associated with increased agitation and 
worsening of psychotic symptoms. 
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6.  Quetiapine 
Some anecdotal evidence suggests that quetiapine, the most recently introduced atypical 
antipsychotic, may be effective in refractory schizophrenia. A case was recently reported of a 
14 year old male with childhood onset schizophrenia who failed therapeutic trials with both 
risperidone and olanzapine, who had a marked remission with quetiapine monotherapy.[51]  
Another case was reported where quetiapine 400 mg/day was effective in a patient with 
schizophrenia who was partially resistant to treatment with conventional antipsychotic 
agents.[52] 
 
A recently completed international, multicentre, double-blind, randomised trial[53] provides 
evidence that quetiapine has advantages over haloperidol in terms of both efficacy and 
tolerability in patients with schizophrenia showing partial resistance to conventional 
antipsychotics. Inclusion criteria were persistent positive symptoms while previously taking 
therapeutic doses of antipsychotic treatment; a PANSS positive scale score of 15 or more; a 
score of at least 4 for one or more of the positive scale items; and a CGI score of 3 or more.  
Eligible patients then entered a 4-week active run-in phase of open treatment with 
fluphenazine, titrated to 20mg/day. At the end of the 4 weeks, those patients not responding 
or only partially responding (PANSS score reduction of less than 30% and PANSS positive 
score of 15 or more) entered the randomisation phase of the trial. This phase compared 
quetiapine 600mg/day to haloperidol 20mg/day (both agents were titrated over a 7 day 
period). Of 365 patients initially recruited, 288 continued to meet criteria for partial response 
and were entered into the randomised phase of the trial. Significantly more patients receiving 
quetiapine (52%) than haloperidol (38%) showed a clinical response (defined as > 20% 
reduction in PANSS total scores) at endpoint. There was a non-significant trend towards 
superiority for quetiapine in the primary efficacy measure of PANSS total score reduction from 
baseline (LOCF on intention to treat population). Quetiapine patients had a reduced risk of 
developing EPS (p < 0.001 at 12 weeks) and fewer required anticholinergic medication (5% 
vs. 20% after week 4). This is the largest prospective study to date of an atypical 
antipsychotic other than clozapine in treatment resistant schizophrenia. The trial was 
specifically designed to study “partial responders”, who may represent the majority of patients 
seen in “real-world” clinical practice. While the efficacy of quetiapine in severely refractory 
patients is not yet known, this study indicates superiority over conventional antipsychotics in 
this particular group of patients. 
 
7.  Other atypical antipsychotics in resistant schizophrenia 
Other antipsychotics sometimes regarded as atypical - zotepine, loxapine, amisulpiride and 
sulpiride – together with atypical drugs that are not currently available in clinical practice such 
as sertindole and ziprasadone, have proven efficacy in schizophrenia. However, they are not 
included in this review as no controlled studies in treatment resistant subjects were found in 
the literature.  
 
 
8. Conclusions 
Within the large group of patients with schizophrenia displaying varying degrees of treatment 
resistance a strategy for their management is emerging. Clozapine is the most effective 
treatment in patients with severe refractoriness and remains the treatment of choice for 
patients meeting the Kane criteria[17] for treatment resistance. Clozapine is also effective in 
patients with lesser degrees of refractoriness. However, because of difficulties associated with 
the administration of this drug, other options should first be considered. Risperidone, 
olanzapine and quetiapine have been shown to be more effective than conventional 
antipsychotics. This, together with their generally favourable side-effect profile, make them 
good options for refractory patients. Unfortunately, it is not possible to make comparisons 
between the new agents. There are only three double blinded studies measuring general 
outcome with these new agents,[25,44,53] all with different comparators and in differently defined 
refractory schizophrenia populations. Much remains to be established regarding the use of 
these agents in refractory schizophrenia. For example, the optimal dose for resistant patients 
is not known. Also, studies need to be conducted to investigate the role of augmentatory 
agents such as valproate and electroconvulsive therapy together with the atypical 
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antipsychotics. Hopefully, more and more patients will benefit from an improved knowledge 
and optimal application of these new agents. 
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INTRODUCTION 
Following the introduction of the first antipsychotic agents more than 40 years ago, 
the pharmacotherapy of schizophrenia essentially stagnated for a long time. However, a 
number of new compounds have been introduced over the past few years, that have 
considerably changed the way we treat our patients. These additional therapeutic options 
have provided grounds for heightened optimism for improved clinical outcomes among 
persons suffering from schizophrenia. Important differences between these compounds are 
emerging, so that drug choice needs to be tailored for individual patients. 
 
Much literature has already appeared on these new, atypical antipsychotics, and 
additional findings are being reported at a rapid pace. However, in spite of the burgeoning 
literature, much remains to be learnt in order to utilise them optimally. 
  
A good deal of this literature needs to be interpreted with caution, owing to a 
plethora of methodological shortcomings in many of the published studies. This chapter 
attempts to critically evaluate the evidence for efficacy of the new atypical antipsychotics by 
selecting only published randomised clinical trials (RCTs) and meta-analytical reviews. The 
drugs included are risperidone, olanzapine, quetiapine, ziprasidone, sertindole and 
amisulpride. The role of each drug during key stages in the course of the illness (acute 
treatment, maintenance, first-episode and refractory) is assessed, as well as differential 
effects on specific symptom domains. While this chapter focuses purely on efficacy, the 
adverse effects of these agents being dealt with in a separate chapter, it is obviously 
necessary, in selecting a drug, to consider many other aspects. 
 
TREATMENT OF ACUTE SYMPTOMS 
Atypical antipsychotics versus placebo 
In spite of ethical and scientific concerns associated with these trials, it is still 
generally accepted that efficacy of a new compound needs to be established against 
placebo.(1)  
Risperidone 
Two RCTs compared risperidone 2, 6, 10 or 16 mg /day, haloperidol 20 mg/day, or 
placebo over 8 weeks in the treatment of schizophrenia. The first investigated 135 inpatients 
with chronic schizophrenia. Doses of 6 to 16mg/day were superior to placebo in overall and 
positive symptom improvement, while only risperidone 6mg/day was significantly better than 
placebo on negative symptom improvement.(2) The second study comprised 388 subjects 
with schizophrenia. Compared with placebo, significant improvements were found for 
risperidone 6 and 16 mg/day for overall clinical improvement and negative symptoms, and 
for risperidone 6, 10 and 16 mg/day for positive symptoms.(3)  
Olanzapine 
Two studies comparing olanzapine to placebo for 6-weeks in acute schizophrenia 
reported significant advantages for olanzapine in overall symptom improvement, as well as 
improvement in positive and negative symptoms.(4;5) The first study involved 152 subjects 
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who received fixed doses of either olanzapine 1mg/day or 10mg/day, or placebo. The 
significant differences were all between the olanzapine 10mg/day group versus placebo, 
with the olanzapine 1mg/day subjects showing no differences from the placebo group.(4) 
The second study involved 335 subjects who received olanzapine in dose ranges of 5 ± 
2.5mg/day, 10 ± 2.5mg/day or 15 ± 2.5mg/day, or placebo. Advantages were for the medium 
and high dose ranges of olanzapine for overall and positive symptomatology, and for the low 
and high dose ranges for negative symptomatology.(5) 
Quetiapine 
In a multicentre RCT 286 hospitalised subjects with chronic or subchronic 
schizophrenia received 6 weeks of treatment with high-dose quetiapine (750mg/day), low-
dose quetiapine (250mg/day) or placebo. High withdrawal rates were recorded in all three 
treatment groups (42%, 57% and 59%), primarily because of treatment failure. High-dose 
quetiapine was significantly better than placebo in reducing Brief Psychiatric Rating Scale 
(BPRS) total, BPRS positive and Clinical Global Impression (CGI) scores. Reduction of 
negative symptoms was less consistent; quetiapine was significantly better than placebo for 
Scale for the Assessment of Negative Symptoms (SANS), but not on the PANSS negative 
subscale.(6) A multiple fixed dose study of quetiapine (75, 150, 300, 600 and 750mg/day), 
haloperidol (12mg/day) and placebo conducted in 361 subjects over 6 weeks reported 
significant differences between the four highest doses of quetiapine and placebo for BPRS 
total, BPRS positive symptoms and CGI Severity of Illness scores and between quetiapine 
300mg/day and placebo for SANS summary score.(7) 
Ziprasidone 
A RCT was conducted in 139 subjects with acute exacerbation of schizophrenia, 
comparing ziprasidone 40 or120mg/day and placebo for 28 days. Ziprasidone 120mg/day 
was significantly more effective than placebo in improving the BPRS total, CGI-S, BPRS 
depression cluster and BPRS anergia cluster scores, and had significantly more responders 
(>30% BPRS reduction) than placebo.(8) In another study 302 subjects were randomised to 
either ziprasidone 80 or 160mg/day or placebo for 6 weeks. Both doses of ziprasidone were 
significantly more effective than placebo in reducing PANSS total, BPRS total, BPRS core 
items, CGI-S, and PANSS negative subscale scores. Ziprasidone 160mg/day significantly 
improved depressive symptoms in subjects with higher baseline depression compared with 
placebo.(9) 
Sertindole 
A 40-day RCT in 205 previously treatment responsive, hospitalised patients with 
schizophrenia compared sertindole 4, 8, 12 and 20mg/day with placebo. A dose-related 
improvement was observed for PANSS total, BPRS and CGI scores, with significant 
differences being recorded between sertindole 20mg/day and placebo.(10) A further study 
compared sertindole 12, 20 and 24mg/day with haloperidol 4, 8 and 16mg/day, and placebo 
in 497 hospitalised patients with schizophrenia over 8 weeks. All doses were significantly 
more effective than placebo. For treating negative symptoms, only sertindole 20mg/day was 
superior to placebo.(11) 
Amisulpride 
Low-dose: 
Three RCTs were conducted to assess efficacy of low-dose amisupride (50-
300mg/day) versus placebo in treating negative symptoms in subjects with predominantly 
negative symptoms over 6 to 12 weeks.(12-14) Amisulpride was consistently better than 
placebo in these studies, and the effect on negative symptoms was apparently unrelated to 
any changes in positive symptoms.(14)     
High-dose: 
No controlled studies were found comparing high-dose amisulpride with placebo. 
However, fixed doses of amisulpride (400, 800 and 1200mg/day) and haloperidol16 mg/day 
were compared with a sub-therapeutic dose of amisulpride (100mg/day) for 4 weeks in 319 
subjects with acute exacerbation of schizophrenia. The greatest improvement, in terms of 
BPRS total reductions, occurred in the two groups taking 400mg or 800mg 
amisulpride/day.(15) 
 
Atypical antipsychotics versus haloperidol 
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Risperidone 
A dose-finding study comparing risperidone 2, 6, 10 or 16 mg /day, haloperidol 20 
mg/day, or placebo over 8 weeks in 135 inpatients with chronic schizophrenia found that 
risperidone 6mg/day was significantly superior to haloperidol on the total PANSS, General 
Psychopathology, and BPRS scales.(2) A similar study in 388 subjects found risperidone 
6mg/day and 16mg/day groups to have significantly more responders (defined as > 20% 
reduction in total PANSS scores), although no other efficacy differences were found between 
risperidone and haloperidol.(3) A small (n=35) RCT compared risperidone to haloperidol over 
8 weeks and reported no differences in outcome.(16) A large multinational study compared 
risperidone 1, 4, 8, 12 and 16 mg/day with haloperidol 10mg/day over 8 weeks in 1362 
patients. The optimum risperidone doses were 4mg and 8mg/day, but no significant efficacy 
advantages over haloperidol were reported.(17) However, a later sub-analysis of patients 
from Germany, Austria and Switzerland reported significant advantages for risperidone over 
haloperidol  according to PANSS total and subscale scores.(18) Further post-hoc sub-
analyses reported that patients receiving risperidone 4mg/day improved more rapidly than 
those receiving haloperidol,(19) and those hospitalised for >60 days (median 351 days) who 
received risperidone 4mg/day improved significantly more than those treated with 
haloperidol.(20) 
Olanzapine 
Three large RCTs have compared olanzapine with haloperidol.(5;21;22). In these 
studies olanzapine demonstrated several efficacy advantages over haloperidol. In the first 
study (n=335) olanzapine 15 ± 2.5mg/day was significantly better than haloperidol15 ± 
5mg/day in reducing negative symptoms after 6 weeks, (5) while in the second study 
(n=431) olanzapine 15 ± 2.5mg/day over 6 weeks was equal to haloperidol 15 ± 5mg/day on 
all efficacy measures.(21) In a study with a very large sample (n=1,996) olanzapine 5-
20mg/day (mean 13.2mg/day) was significantly better than haloperidol 5-20mg/day (mean 
11.8mg/day) over 6 weeks in reducing overall psychopathology,(21) positive symptoms, (21) 
negative symptoms(5;22) and depressive symptoms.(22) A recent RCT compared 
olanzapine with haloperidol over a period of 8 weeks in a sample of 182 Asian patients with 
chronic schizophrenia. Olanzapine was found to be as effective as haloperidol in treating 
overall symptomatology, and significantly superior in treating negative symptoms.(23) 
Quetiapine 
In the multiple fixed dose study of quetiapine (75, 150, 300, 600 and 750mg/day) 
versus haloperidol (12mg/day) and placebo conducted in 361 subjects over 6 weeks,(7) 
differences between quetiapine and haloperidol were not significant for any of the efficacy 
measures.  Another RCT compared flexible doses of quetiapine (mean 455mg/day) and 
haloperidol (mean 8mg/day) over 6 weeks in 448 hospitalised patients with acute 
exacerbation of schizophrenia. Both quetiapine and haloperidol produced clear reduction in 
symptoms, with equal efficacy.(24) 
Ziprasidone 
Ninety patients with schizophrenia or schizo-affective disorder participated in this 
dose-finding study comparing ziprasidone 4, 10, 40  and 160 mg/day and haloperidol 
15mg/day for 4 weeks. Ziprasidone 160mg/day was found to be comparable with haloperidol 
in reducing overall psychopathology and positive symptoms, as well as overall response 
rate.(25) 
Sertindole 
In the study comparing sertindole 12, 20 and 24mg/day with haloperidol 4, 8 and 
16mg/day, and placebo in 497 hospitalised patients with schizophrenia over 8 weeks, 
sertindole and haloperidol were comparably effective.(11) 
Amisulpride 
In a RCT of 41 subjects with schizophrenia, flexible doses of amisulpride or 
haloperidol were given over 42 days. Both groups showed similar overall improvement, with 
amisulpride patients doing significantly better regarding depressive symptoms.(26) in a 
further study, fixed doses of amisulpride (100, 400, 800 and 1200mg/day) and haloperidol16 
mg/day were compared for 4 weeks in 319 subjects with acute exacerbations of 
schizophrenia. The greatest improvement, in terms of BPRS total reductions, occurred in the 
two groups taking 400mg or 800mg amisulpride/day.(15) Amisulpride 800mg/day was also 
compared to haloperidol 20mg/day over 6 weeks in 191 patients with acute exacerbations of 
schizophrenia. Amisulpride was as effective as haloperidol for positive symptoms, and 
significantly more effective against negative symptoms (PANSS negative subscale).(27) In a 
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flexible dose study, 199 subjects with schizophrenia or schizophreniform disorder received 
amisulpride 400-1200mg/day or haloperidol 10-30mg/day for 4 months. The drugs were 
equally effective in reducing BPRS total scores and PANSS positive scores, while PANSS 
negative score reduction was significantly greater with amisulpride, as was the percentage 
of CGI responders.(28) 
 
Atypical antipsychotics versus other conventional antipsychotics 
Risperidone 
Flexible doses of risperidone (mean dose 8mg/day) and flupenthixol (mean dose 
38mg/day) were compared over 6 weeks in 98 subjects with acute exacerbation of 
schizophrenia or schizophreniform disorder. Both groups displayed comparable efficacy, with 
the onset of action being significantly faster in the risperidone group.(29) 
Quetiapine  
A 6-week RCT compared flexible doses of quetiapine (mean endpoint dose 
407mg/day) and chlorpromazine (mean endpoint dose 384mg/day) in 201 hospitalised 
patients with acute exacerbation of schizophrenia. Both treatments were equally effective in 
treatment of positive and negative symptoms.(30) 
Amisulpride 
Amisulpride 1000mg/day was compared with flupenthixol 25mg/day in 132 patients 
with acute exacerbation of schizophrenia over 6 weeks. Results were similar for both drugs, 
except that amisulpride was significantly better in reducing positive symptoms.(31) 
 
Head-to-head comparisons of atypical antipsychotics 
 
Risperidone versus olanzapine 
Two multi-site RCTs have compared olanzapine with risperidone. The first, 
sponsored by Eli-Lilly, evaluated 339 subjects over a 28-week period. Both olanzapine (10-
20mg/day) and risperidone (4-12mg/day) were found to be effective, with olanzapine 
demonstrating superiority over risperidone in reducing negative symptoms, overall response 
rate and maintenance of response at 28 weeks.(32) The second study, sponsored by 
Janssen-Cilag, investigated a sample of 377 subjects over 8 weeks. Once again, both 
olanzapine (5-20mg/day, mean 12.4 mg/day) and risperidone (2-6mg/day, mean 4.8mg/day) 
were found to be effective. There were no differences in efficacy between the groups 
according to the last-observation carried forward analysis, although the completers analysis 
reported significant advantages for risperidone in treating both positive and 
anxiety/depression symptoms.(33) 
 
Risperidone versus clozapine (non-refractory sample) 
Risperidone 4mg/day (n=20), 8mg/day(n=19) and clozapine 400mg/day (n=20) were 
compared over 28 days in a non-refractory sample. No differences in efficacy were 
reported.(34) Other studies comparing risperidone and clozapine were in samples with 
various degrees of refractoriness, and are dealt with below. 
Risperidone versus amisulpride 
Amisulpride (800mg/day) was compared with risperidone (8mg/day) over 8 weeks in 
a RCT of 228 patients with acute exacerbation of schizophrenia. The drugs showed equal 
efficacy.(35) 
 
In a meta-analysis 9 RCTs (5 with clozapine; three with olanzapine and one with 
amisulpride), olanzapine and risperidone appeared to be broadly similar in terms of 
response rates, while olanzapine caused fewer people to leave the study early. Amisulpride 
seemed broadly similar to risperidone. High attrition rates, short-term follow-up and doses of 
risperidone higher than those recommended in practice were some of the limitations 
highlighted by the authors.(36) 
 
Acute intramuscular administration 
Olanzapine 
The efficacy of intramuscular olanzapine has been compared to intramuscular 
haloperidol and intramuscular placebo in treating acute agitation in hospitalised patients with 
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schizophrenia. Subjects received one to three injections of olanzapine 10mg, haloperidol 
7.5mg or placebo over a 24-hour period. Intramuscular olanzapine provided rapid, effective 
and safe treatment for acute agitation, showing superiority over haloperidol at 15, 30 and 45 
minutes following the first injection. Both olanzapine and haloperidol reduced agitation 
significantly more than placebo at 2 and 24 hours following the first injection.(37) 
Ziprasidone 
A RCT conducted in acutely agitated psychotic patients compared 2mg with 10mg 
intramuscular ziprasidone injections (up to 4 injections in 24 hrs) in 119 subjects. The 10mg 
dose was significantly more effective up to 4 hrs after the first injection.(38) In an identical 
trial design, ziprasidone 2mg and 20mg injections were compared in a sample of 79. The 
20mg dose substantially and significantly reduced symptoms of acute agitation.(39) 
 
MAINTENANCE TREATMENT  
Some empirical evidence is emerging to suggest that atypical antipsychotics may 
differ from conventional agents in altering the long-term course of schizophrenia. 
Risperidone 
A RCT compared relapse rates in 397 clinically stable adult outpatients with 
schizophrenia or schizoaffective disorder receiving flexible doses of risperidone or 
haloperidol for a minimum of one year. Risk of relapse at the end of the study was 
significantly lower for the risperidone group (34%) than  for the haloperidol group (60%).(40) 
By using the National Psychiatric Hospital Case Registry of Israel, rehospitalisation status 
over two years was monitored for subjects discharged while taking risperidone (n=268) and 
olanzapine (n=313). Rehospitalisation rates of risperidone and olanzapine subjects were 
similar, both being more effective than conventional antipsychotics.(41) 
Olanzapine 
The efficacy of standard-dose oral olanzapine (5-15mg/day) was compared with 
placebo and with ineffective-dose olanzapine (1mg/day) in maintenance therapy of 120 
subjects with schizophrenia. The standard-dose olanzapine treated patients experienced 
significantly lower relapse risk over one year compared to patients treated with placebo or 
ineffective-dose olanzapine.(42) Three RCTs compared olanzapine and haloperidol in 
maintenance treatment for schizophrenia and related psychoses.(5;21;22) All were double-
blind extensions of acute studies. Data from these three studies were pooled and results 
reported separately.(43) Fewer subjects experienced relapse at one year with 
olanzapine(19.7%) than with haloperidol (28%). Olanzapine has also been compared with 
risperidone for prevention of relapse in a RCT conducted over 28 weeks. Survival analysis 
revealed that significantly more olanzapine patients maintained their response at 
endpoint.(44) 
Sertindole 
Long-term efficacy was assessed in 282 clinically stable treatment-responsive 
outpatients with schizophrenia treated up to one year with sertindole or haloperidol. Time to 
treatment failure was not significantly different between the groups, but sertindole patients 
remained free of hospitalisation for exacerbation of schizophrenia and remained compliant 
significantly longer than did the haloperidol treated patients.(45) 
Amisulpride 
A study again involving schizophrenics with predominantly negative symptoms 
compared low-dose amisulpride (100mg/day) and placebo over 6 months in 141 subjects. 
Significantly more amisulpride patients completed the study - dropout rates were 27% with 
amisulpride and 47% with placebo.(46) 
 
No blinded maintenance studies were found for quetiapine and ziprasadone. 
 
META-ANALYTICAL REVIEWS 
Risperidone 
A meta-analysis of 11 RCTs comparing risperidone to conventional antipsychotics 
concluded that short-term efficacy of risperidone is comparable to that of other 
antipsychotics. The risperidone patients showed slightly greater clinical improvement and 
lower overall dropout rate.(47) Another meta-analysis of 6 trials comparing risperidone with 
haloperidol in subjects with chronic schizophrenia treated for at least 4 weeks in RCTs 
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reported significantly higher response rates with risperidone and lower dropout rates.(48) A 
Cochrane review reported on 12 short-term studies and 2 long-term studies comparing 
risperidone with conventional antipsychotics, providing data on 3401 subjects. Risperidone 
increased the odds of moderate clinical improvement, but appeared to have little or no 
additional effect on the positive and negative symptoms of schizophrenia. When data from 
subjects on higher doses of haloperidol (>10mg/day) was excluded the advantage for 
risperidone was lost. (49) 
Olanzapine  
In a Cochrane review of 20 RCTs comparing olanzapine to placebo or any 
antipsychotic treatment in subjects with schizophrenia or schizophreniform psychosis, 
olanzapine appeared superior to placebo (but results were equivocal regarding negative 
symptoms), and equally as effective as typical antipsychotics. These authors point out that 
high attrition rates in both the olanzapine and typical antipsychotic groups make it difficult to 
draw firm conclusions from these studies.(50) 
Quetiapine 
A Cochrane review including 11 RCTs comparing quetiapine to placebo and other 
antipsychotic agents reported as follows: In comparison to placebo, data suggest that people 
allocated to quetiapine were less likely to leave the study early, particularly for treatment 
failure. Psychotic symptoms showed significant improvement in the quetiapine group. 
Compared to conventional antipsychotics, the proportion of people leaving the studies early 
was marginally, but significantly, less for the quetiapine group.  Symptom reduction was 
significantly greater in the high dose range of quetiapine. High dropout rates and short 
duration of studies were cited as factors limiting interpretation of these studies.(51) 
Ziprasidone 
A Cochrane review of available RCT’s reported that in studies ranging from one 
week (intramuscular preparation) to over 6 months, ziprasidone seemed more effective than 
placebo and as effective as haloperidol. The authors noted that data are currently limited, 
and that well-planned, conducted and reported long-term RCT’s are needed.(52) 
Sertindole 
A Cochrane review included only two RCT’s, as data on two others were incomplete. 
The evidence suggested that sertindole was more effective than placebo. The authors 
expressed reservations about its use in clinical practice because of cardiac problems that 
were evident in the trials.(53) 
 
TREATMENT OF SPECIFIC SYMPTOM DOMAINS  
It has been suggested that the atypical antipsychotics may have a broader spectrum 
of efficacy than conventional agents. In addition to positive symptoms, their effects on 
negative, cognitive, depressive and excited symptoms have been investigated. It has been 
suggested that they may differ from one another in their effects on these domains, as well as 
aspects such as overall quality of life, and hospitalisation status.(54)  
Negative symptoms 
 
Contrary to popular belief, conventional antipsychotics are effective in treating 
negative symptoms,(55) although the effect is modest at best. Atypical antipsychotics have 
been reported to ameliorate negative symptoms to various degrees when compared to high 
doses of conventional antipsychotics. However, few trials have specifically examined primary 
negative symptomatology and it has been suggested that improvements may be related to 
decreases in positive symptoms, reduced sedation or fewer extrapyramidal side-effects.(56) 
 
Risperidone 
A meta-analysis of the pooled results from 6 RCTs comparing risperidone to 
conventional antipsychotics (haloperidol, perphenazine and zuclopenthixol) reported that 
risperidone at doses between 4 and 8mg/day had a significantly higher negative symptom 
response rate (>20% reduction in PANSS negative subscale).(57) 
Olanzapine 
Three of four RCTs comparing olanzapine with conventional antipsychotics reported 
superior efficacy for olanzapine (see Table 2). A post-hoc analysis of a RCT comparing low, 
medium and high dose ranges of olanzapine with 10-20mg of haloperidol and placebo for up 
to 52 weeks focussed on negative symptom outcome. Significantly greater improvement was 
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observed in negative symptoms for the high dose olanzapine group compared to both 
placebo and haloperidol. Path analysis suggested that this was a direct medication 
effect.(58) 
Amisulpride 
Low-dose amisulpride improved negative symptoms compared to placebo in 
subjects with predominantly deficit symptomatology (Table 1). Also, two of 4 RCTs 
comparing higher dosage of amisulpride with conventional antipsychotics reported 
superiority for amisulpride in improving negative symptoms (Table 2).   
 
Cognitive symptoms 
Risperidone 
Three studies, employing a similar design, investigated the effects of risperidone 
versus haloperidol on cognitive functions in treatment resistant schizophrenia. Risperidone 
treatment had a greater beneficial effect on verbal working memory,(59) reaction time and 
manual dexterity(60) and greater improvement in general verbal learning ability.(61)  
Olanzapine  
In a neuropsychological study 65 patients were randomly assigned in a double-blind 
design to olanzapine (5-20mg/day), risperidone (4-10mg/day) or haloperidol (5-20mg/day) 
over 6, 30 and 54 weeks. Olanzapine patients showed significantly greater improvement in 
general cognitive function at 6, 30 and 54 weeks, compared to both haloperidol and 
risperidone.(62) 
Quetiapine 
A RCT compared neuropsychological changes in 25 patients treated with either 
quetiapine or haloperidol. Quetiapine subjects showed improvement on cognitive skills, 
particularly verbal reasoning and fluency skills and immediate recall, with additional 
improvements on executive skills and visuomotor tracking.(63) 
 
Depressive symptoms 
Risperidone 
In a retrospective analysis of pooled data from 6 RCTs, change scores on the 
PANSS anxious/depressive cluster were significantly greater for risperidone than for 
haloperidol or placebo.(64) 
Olanzapine 
In a separate analysis of a previously discussed RCT(5) in which 335 subjects were 
treated for 6 weeks with 3 fixed dose ranges of olanzapine, haloperidol 10-20mg or placebo, 
BPRS depression/anxiety depression cluster was significantly improved for two dose ranges 
of olanzapine (10 ± 2.5 mg/day and 15 ± 2.5mg/day), whereas haloperidol was not.(65) 
Another post-hoc analysis of the largest olanzapine pivotal study (22) reported that 
olanzapine therapy was associated with greater baseline to endpoint improvement in BPRS 
anxiety/depression symptom cluster compared to haloperidol.(65) A post-hoc evaluation of 
the respective effects of olanzapine and risperidone on the PANSS depression cluster in a 
28-week prospective, double-blind, randomised study reported that olanzapine was 
associated with a significantly greater improvement in depressive symptoms. In the 
risperidone group the patients with a greater degree of improvement in depressive 
symptoms had a significantly greater chance of psychotic relapse.(66) In the other head-to 
head study comparing olanzapine and risperidone no significant differences were found with 
a last-observation carried forward analysis, although a completers analysis revealed an 
advantage for risperidone in reducing depressive/anxiety symptoms.(33) 
Quetiapine 
A post-hoc analysis of quetiapine versus haloperidol subjects with schizophrenia 
who displayed a partial response to treatment(67) found that quetiapine produced a greater 
reduction in depressive scores than haloperidol. Path analyses indicated that this was a 
direct effect on depressive symptoms (manuscript submitted). 
 
 211
Excitement/hostility 
Risperidone 
The effect on PANSS hostility item scores was compared in 139 subjects who 
participated in a multicentre study comparing  risperidone, haloperidol and placebo. 
Risperidone had a greater selective effect on hostility than did haloperidol or placebo.(68) 
 
PANSS five factor domains 
In a post-hoc analysis combining two RCTs, 513 patients with chronic schizophrenia 
who received either risperidone (2, 6, 10 and 1mg/day), haloperidol (20mg/day) or placebo 
over 8 weeks were compared in terms of the 5 symptom domains identified by a factor 
analysis of the PANSS items (positive, negative, cognitive, excited and depression/anxiety). 
Factor score reduction was significantly greater for patients receiving risperidone 6-
16mg/day than in patients receiving haloperidol or placebo. Differences were greatest for 
negative symptoms, uncontrolled hostility/excitement, and anxiety/depression, but were also 
significant for positive symptoms and disorganised thought.(69) 
 
OTHER MEASURES OF OUTCOME 
Pharmacoeconomic studies 
Olanzapine 
Clinical, quality-of-life and resource utilization data were prospectively collected from 
patients with schizophrenia who were participating in a multicentre, randomised, double-
blind clinical trial comparing olanzapine 5-20mg/day (n=551) with haloperidol 5-20mg/day 
(n=266) for 6-weeks. Responders entered a 46-week maintenance phase. Olanzapine was 
more effective than haloperidol in producing a clinical response in the acute phase, but no 
significant differences in clinical improvement were observed in the maintenance phase. 
However, olanzapine led to reductions in inpatient and outpatient costs that more than offset 
olanzapine’s higher acquisition costs.(70) 
Olanzapine versus risperidone 
A RCT compared clinical and economic outcomes in 150 subjects receiving either 
olanzapine (10-20mg/day) or risperidone (4-12mg/day) for up to 28 weeks. Olanzapine 
patients were reported to be more likely to maintain response, translating into savings in 
costs of care for both inpatient and outpatient services.(71) 
A review of the evidence from pharmacoeconomic studies reported that clozapine is 
a cost-effective treatment for refractory schizophrenia. Compared to conventional 
antipsychotics, risperidone and olanzapine appear to be cost-neutral to slightly cost-saving 
while there is too little available data for quetiapine, ziprasidone and sertindole.(72) 
Quality of life 
In a separate analysis of the study reported above,(70) quality of life (QOL) was 
assessed as an outcome measure by means of the Quality of Life Scale (QLS) and SF-36 
Health Survey. Compared to haloperidol, olanzapine treatment resulted in modestly better 
improvement in overall QOL, as well as on various subscale scores, both during the 6-week 
acute phase and during the extension phase.(73) 
Another separate analysis of a previously reported RCT comparing 3 dose-ranges of 
olanzapine with haloperidol 10-20mg/day and placebo examined quality of life outcome in 
responders who were entered into a 46-week extension. Advantages were reported for 
olanzapine-treated subjects.(74)  
 
 
FIRST-EPISODE SCHIZOPHRENIA 
Risperidone 
An international RCT was conducted in 183 patients with a first episode of 
schizophrenia or schizophreniform disorder. Flexible doses of risperidone (mean endpoint 
dose 6.1mg/day) and haloperidol (mean endpoint dose 5.6mg/day) were given over 8 
weeks. The two compounds showed similar efficacy, with response rates for risperidone and 
haloperidol being 63% and 56% respectively.(75) 
Olanzapine 
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A post-hoc analysis of a subpopulation of first-episode patients from a larger 
RCT(22) reported a significantly greater reduction in the BPRS total and negative scores 
and the PANSS total and positive scores, as well as a significantly higher response rate for 
the olanzapine subjects compared to the haloperidol subjects.(76) 
 
REFRACTORY SCHIZOPHRENIA 
Risperidone 
Risperidone (mean dose 6.4 mg/day) was compared to clozapine (mean dose 
291.2mg/day) over 8 weeks in 86 patients with chronic schizophrenia who were either 
resistant or intolerant to conventional antipsychotics. Treatments were found to be 
essentially similar, with a more rapid onset of action reported for risperidone.(77) While this 
trial provides good evidence for the efficacy of risperidone in moderately refractory patients, 
certain concerns have been voiced: The study population was not well defined, the sample 
size was relatively small, clozapine dosing was relatively low, and the treatment period was 
possibly too brief.(78) (79) (80) The authors responded by pointing out that their sample 
corresponds with the criteria normally applied when considering patients for clozapine 
treatment, and suggested that a less restrictive definition of treatment resistance may be 
more appropriate in clinical settings. In a RCT of 29 patients with partial response to 
conventional antipsychotics, risperidone  was compared to clozapine over 6 weeks. 
Endpoint dose was 5.9mg/day for risperidone and 403.6mg/day for clozapine. Clozapine 
was superior to risperidone for positive symptoms, while total symptoms, negative symptoms 
and depression did not differ between groups.(81) A recent RCT compared increasing 
increments of risperidone and clozapine over 8 weeks in 273 subjects with severe chronic 
schizophrenia. The magnitude of improvement in mean BPRS and CGI scores was 
significantly greater in the clozapine group, as were most of the secondary efficacy 
measures.(82) 
A RCT investigated the effects of risperidone versus haloperidol in a severely 
refractory sample of subjects with schizophrenia. Patients were randomly assigned to an 
initial 4 week fixed dose phase of either risperidone 6mg/day or haloperidol 15 mg/day 
followed by a further 4 week flexible dose phase.  Risperidone was significantly better than 
haloperidol in reducing overall symptomatology at 4 weeks, but not at endpoint.(83) 
Olanzapine 
A prospective randomised double-blind study compared the efficacy of olanzapine 
versus chlorpromazine in treatment-resistant schizophrenia.(84) Criteria for resistance were 
similar to those of Kane et al,(85). This was an 8-week fixed-dose trial of either olanzapine 
25mg/day or chlorpromazine 1200mg/day plus benztropine 4mg/day (both drugs were given 
at half-dose for the first week). No differences in efficacy were demonstrated between the 
two drugs. Seven percent of the olanzapine-treated patients and none of the chlorpromazine 
patients met a priori criteria for clinical response.  There were also no differences in dropout 
rates.  
Quetiapine 
A RCT was conducted to assess the efficacy of quetiapine in 288 patients with 
schizophrenia who had been partially responsive to treatment. Subjects who experienced 
persistent symptoms on conventional antipsychotics were subjected to 4 weeks open 
treatment with fluphenazine, and those showing partial or no response were randomised to 
quetiapine 600mg/day and haloperidol 20mg/day for 8 weeks. Treatments were equally 
effective in total PANSS symptom reduction, while quetiapine patients had a significantly 
greater response rate(67) and significantly greater reduction of depressive symptoms 
(submitted). 
 
In a recently reported RCT, clozapine, olanzapine, risperidone and haloperidol were 
compared in a sample of 157 inpatients with chronic schizophrenia who had not responded 
adequately to other antipsychotic medications.  Trial duration was 14 weeks (8 weeks fixed-
dose, followed by 6-week flexible dose). Respective mean endpoint doses for clozapine, 
olanzapine, risperidone and haloperidol were 526.6, 30.4, 11.6 and 25.7 mg/day. Compared 
to haloperidol, there were significant advantages for clozapine and olanzapine regarding 
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overall improvement (PANSS total), and general psychopathology, and for clozapine, 
risperidone and olanzapine regarding negative symptoms.(86) 
 
A review and meta-analysis of 12 studies comparing typical and atypical 
antipsychotics in subjects with refractory schizophrenia reported that clozapine exhibits 
superiority over typical antipsychotics in terms of both efficacy and safety. However, the 
magnitude of the advantage for clozapine was not consistently robust. Efficacy data for other 
atypical antipsychotics in the treatment of refractory schizophrenia were inconclusive.(87) 
CONCLUSIONS 
Based on the evidence presented here, the following tentative conclusions can be 
drawn. Atypical antipsychotics (except amisulpride) have demonstrated superiority over 
placebo in acute schizophrenia. Compared to conventional antipsychotics, they are at least as 
effective. Generally, analyses employing conservative criteria (eg Cochrane reviews) report 
few efficacy differences between atypical and conventional agents. However, there are now a 
considerable number of well-controlled studies indicating modest advantages for the atypical 
antipsychotics, particularly in specific symptom domains. For the treatment of negative 
symptoms, olanzapine and to a lesser extent amisulpride appear most promising. 
Risperidone, olanzapine and quetiapine display advantages in improving cognitive and 
depressive symptoms. There are indications that the atypical antipsychotics are associated 
with decreased likelihood of re-hospitalisation and improved quality of life. In head-to head 
comparisons of atypical antipsychotics, none have shown consistent efficacy advantages. In 
severely refractory samples, no atypical antipsychotics have consistently been shown to be 
as effective as clozapine, or superior to conventional agents. However, there are indications 
that risperidone, olanzapine and quetiapine have advantages over conventional agents in less 
severely refractory patients. Surprisingly few maintenance RCTs have been published, and 
efficacy advantages for atypical antipsychotics in prospective RCTs in first-episode 
schizophrenia have yet to be reported.  
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 Table 1. Acute randomised controlled trials of atypical antipsychotics versus placebo 
Outcome vs.placebo Ref.no N Duration Dose (mg/day) 
Overall Positive 
symptoms 
Negative symptoms 
Risperidone  
2 135 8 weeks 2, 6, 10, 16 6-16mg 
superior 
6-16mg 
superior 
6mg superior 
3 388 8 weeks 2, 6, 10, 16 6-16mg 
superior 
6-16mg 
superior 
6 & 16mg superior 
Olanzapine  
4 152 6 weeks 1 and 10 10mg 
superior 
10mg 
superior 
10mg superior 
5 335 6 weeks 5±2.5; 10±2.5 
and 15±2.5 
Medium & 
high dose 
superior 
Medium & 
high dose 
superior 
Low & high dose 
superior 
Quetiapine  
6 286 6 weeks 250 and 750 750mg 
superior 
750mg 
superior 
750mg superior on 
SANS, not PANSS 
neg. 
7 361 6 weeks 75, 150, 300, 
600 and 750 
150-750mg 
superior 
150-750mg 
superior 
300mg superior 
Ziprasidone  
8 139 4 weeks 40 and 120 120mg 
superior 
No 
differences 
No differences 
9 302 6 weeks 80 and 120 Both doses 
superior 
Both doses 
superior 
Both doses superior 
Sertindole  
10 205 40 days 4, 8, 12, 20 20mg 
superior 
No 
differences 
No differences 
11 497 8 weeks 12, 20, 24 All doses 
superior 
20 and 
24mg 
superior 
20mg superior 
Amisulpride  
12 27 6 weeks 50 to 100 No 
differences 
No 
differences 
Superior  
13 104 6 weeks 100 and 300 Not 
assessed 
Not 
assessed 
Both doses superior 
14 243 12 weeks 50 and 100 Not 
assessed 
Not 
assessed 
Both doses superior 
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Table 2.   Acute randomised controlled trials of atypical antipsychotics versus 
conventional antipsychotics 
 
Outcome vs. conventional agent Ref.no N Duration Dose 
(mg/day) Overall Positive 
symptoms 
Negative 
symptoms 
Risperidone  
2 135 8 weeks 2, 6, 10, 16 6mg superior Equal Equal 
3 388 8 weeks 2, 6, 10, 16 Equal Equal Equal  
17 1362 8 weeks 1, 4, 8, 12, 16 Equal  Equal Equal 
29 98 6 weeks Mean 8 Equal  Equal  Equal 
Olanzapine  
5 335 6 weeks 5±2.5; 10±2.5 
and 15±2.5 
Equal Equal  15±2.5mg 
superior 
21 431 6 weeks 5±2.5; 10±2.5 
and 15±2.5 
Equal  Equal  Equal  
22 1996 6 weeks 5-20 Superior  Superior Superior 
23 182 8 weeks 5-15 Equal  Equal  Superior 
Quetiapine  
7 361 6 weeks 75, 150, 300, 
600 and 750 
Equal  Equal Equal 
24 448 6 weeks Mean 455 Equal Equal Equal  
30 201 6 weeks Mean 407 Equal  Equal Equal  
Ziprasidone  
25 90 4 weeks 4, 10, 40 and 
160 
160mg equal 160mg equal 160mg equal 
Sertindole  
11 497 8 weeks 12, 20, 24 Equal  Equal Equal 
Amisulpride  
26 41 6 weeks  Equal Equal Equal 
15 319 4 weeks 100, 400, 800, 
1200 
400 & 
800mg equal 
400 & 
800mg equal 
400 & 800mg 
equal 
27 191 6 weeks 800 Equal Equal Superior  
28 199 4 months 400-1200 Equal Equal Superior  
31 132 6 weeks 1000 Equal Superior Equal  
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Table 3. Head-to-head randomised controlled trials of atypical antipsychotics in non-
refractory samples 
 
Outcome vs. conventional agent Ref.no N Duration Dose 
(mg/day) Overall Positive 
symptoms 
Negative 
symptoms 
Risperidone vs olanzapine 
32 339 28 weeks Ol 10-20 
Ris 4-12 
Equal Equal Olanzapine 
superior 
33 377 8 weeks Ol 5-20 
Ris 2-6 
Equal Equal Equal 
Risperidone vs clozapine 
34 59 4 weeks Ris 4 and 8 
Clo 400 
Equal  Equal Equal 
Risperidone vs amisulpride 
35 228 8 weeks Ris 8 
Ami 800 
Equal Equal Equal 
 
 
 
 
 
Table 4.  Randomised controlled trials of atypical antipsychotics in refractory 
schizophrenia. 
 
Outcome vs. conventional agent Ref.no N Sample 
description 
Duration Dose 
(mg/day) Overall Positive 
symptoms 
Negative 
symptoms 
Risperidone vs clozapine  
72 86 Resistant or 
intolerant 
8 weeks Ri mean 
6.4 
Cl mean 
291 
Equal Equal Equal 
76 29 Partial response 6 weeks Ri mean 
5.9 
Cl mean 
403.6  
Equal Clozapine 
superior 
Equal  
77 273 Severe chronic 
schizophrenia 
8 weeks Ri 9 
Cl 642 
Clozapine 
superior 
Clozapine 
superior 
Clozapine 
superior 
Risperidone vs haloperidol 
82 67 Severe 
resistance 
8 weeks Ri  mean 
7.5 
Equal Equal Equal 
Olanzapine vs chlorpromazine 
83 84 Severe 
resistance 
8 weeks Ol 25 Equal Equal Equal  
Clozapine, olanzapine and  risperidone vs haloperidol 
Ref 157 Chronic 
schizophrenia 
with inadequate 
response 
14 weeks Mean 
doses: Cl 
526.6 
Ol 30.4 
Ri 11.6 
Clozapine 
and 
olanzapine 
superior 
Equal Clozapine, 
olanzapine 
and 
risperidone 
superior 
Quetiapine vs haloperidol 
64 288 Partial 
responders 
8 weeks Qu 600 Equal Equal Equal 
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BRIEF SYNOPSIS 
This chapter reviews the published randomised controlled trials and meta-analyses in which 
the new atypical antipsychotics are compared with placebo, conventional antipsychotics or 
head-to-head comparisons. Agents included are risperidone, olanzapine, quetiapine, 
ziprasidone, sertindole and amisulpride. Efficacy has been demonstrated against placebo, 
and studies show at least equal efficacy compared with conventional antipsychotics. Although 
not always consistent, there are indications of superior efficacy for the domains of negative, 
depressive and cognitive symptoms, as well as reduced re-hospitalisation rates and improved 
quality of life. 
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Abstract 
The introduction of the new generation antipsychotics has changed the way we treat patients 
with schizophrenia. This article reviews these agents, focussing mainly on the published 
randomised controlled trials and meta-analyses in which the new generation antipsychotics 
are compared with placebo, conventional antipsychotics or with one another. Agents included 
are risperidone, olanzapine, quetiapine, ziprasidone, sertindole, amisulpride and aripiprazole. 
Acute-phase and maintenance studies are reviewed, as well as randomised trials for pre-
psychotic, first-episode schizophrenia and refractory schizophrenia. Finally, specific areas of 
current clinical interest are dealt with. These are: conventional versus new generation 
antipsychotics, head-to-head comparisons of new generation antipsychotics, and side-effect 
profiles. 
  
 
 
Introduction 
The introduction of the new generation antipsychotics has changed the way we treat patients 
with schizophrenia. A number of agents are now available, providing new treatment options 
and producing heightened optimism for improved clinical outcomes. While commonly lumped 
together as a class, important differences are emerging among these compounds, particularly 
regarding their side-effect profiles. A great deal has been published on these agents and new 
important studies regularly appear in the literature. However, unanswered questions remain 
regarding their safety and efficacy, and a much remains to be learnt in order to place them in 
their correct perspective. 
 
For antipsychotic trials, demonstration of superiority over placebo is still a requirement of 
most regulatory authorities (Laughren 2001). Most of the earlier randomised controlled trials 
(RCTs) for the new generation antipsychotics used haloperidol as a comparator. However, a 
recent Cochrane meta-analysis of haloperidol versus placebo in clinical trials highlighted the 
neurotoxicity of the compound. The authors recommend that, for countries where haloperidol 
is not widely used, it should not be a control drug of choice for randomised trials of new 
antipsychotics (Joy et al. 2001). Most studies undertaken these days compare one new 
generation antipsychotic with another. 
 
This paper evaluates the evidence for efficacy, tolerability and safety of the new generation 
antipsychotics  risperidone, olanzapine, quetiapine, ziprasidone, sertindole, amisulpride and 
aripiprazole. It attempts to address the following: 1) the best first-line treatment of 
schizophrenia, 2) the best approach to treatment-resistant patients, and 3) recommendations 
for maintenance treatment. In order to avoid the potential pitfalls of uncontrolled studies, we 
have focused mainly on published RCTs and meta analytical reviews. A PubMed (National 
Library of Medicine) search of the English language literature was undertaken, using each of 
the individual compounds names as a search term. The drugs are discussed separately, 
under the following headings: acute treatment; maintenance treatment; side-effect profiles; 
prodromal; first-episode; and refractory schizophrenia. Finally the following focuses of current 
clinical interest are addressed: conventional versus new generation antipsychotics, head-to-
head comparisons of new generation antipsychotics, and side-effect profiles. 
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RISPERIDONE 
Acute phase trials 
Versus placebo 
The efficacy of oral risperidone has been demonstrated in two placebo-controlled trials. A 
dose-ranging study found risperidone 6 to 16mg/day to be superior to placebo in overall and 
positive symptom improvement, while only 6mg/day was better than placebo on negative 
symptom improvement (Chouinard et al. 1993b). A similar study reported significant 
improvements for 6 and 16 mg/day for overall clinical improvement, positive and negative 
symptoms, and 10 mg/day for positive symptoms only. The incidence of extrapyramidal 
symptoms (EPS) was significantly higher in patients treated with 16mg of risperidone and 
20mg of haloperidol (Marder and Meibach 1994). 
 
Versus conventional antipsychotics 
In one dose-ranging study, risperidone 6mg/day was significantly better than haloperidol in 
reducing the Positive and Negative Symptom Scale (PANSS) total and General 
Psychopathology scores. Haloperidol produced significantly more EPS than risperidone or 
placebo (Chouinard et al. 1993a). In another dose-ranging study, risperidone 6 and 16 
mg/day were significantly better than haloperidol 20mg/day in reducing overall symptoms. 
Significantly more subjects responded to risperidone 6 mg/day. The incidence of EPS was 
significantly higher in patients treated with 16mg of risperidone and 20mg of haloperidol 
(Marder and Meibach 1994).  A large multinational study compared risperidone 1, 4, 8, 12 and 
16 mg/day with haloperidol 10mg/day. The optimum risperidone doses were 4mg and 
8mg/day, but no significant efficacy advantages over haloperidol were reported. Total EPS 
were greater in the haloperidol-treated patients than in the risperidone 1, 4, 8 and 12mg 
groups (Peuskens 1995). However, a later sub-analysis of patients from Germany, Austria and 
Switzerland reported significant advantages for risperidone over haloperidol  according to 
PANSS total and subscale scores (Moller et al. 1997a). Further post-hoc sub-analyses 
reported that patients receiving risperidone 4mg/day improved more rapidly than those 
receiving haloperidol (Rabinowitz et al. 2001), and those hospitalised for >60 days (i.e. 
probably the more refractory patients) who received risperidone 4mg/day improved 
significantly more than those treated with haloperidol (Rabinowitz and Davidson 2001). 
 
Flexible doses of risperidone (mean dose 8mg/day) and flupenthixol (mean dose 38mg/day) 
displayed comparable efficacy, and fewer patients experienced EPS with risperidone 
(Huttunen et al. 1995). A small RCT (n=35) compared risperidone to haloperidol and reported 
no differences in outcome, with risperidone causing fewer side-effects (Min et al. 1993). 
 
Long acting risperidone injection 
The first long-acting new generation antipsychotic has recently been introduced. A RCT 
comparing long-acting injectable risperidone (25mg, 50mg, or 75mg 2-weekly) to placebo in 
400 patients over 12 weeks reported it to be effective and well tolerated. No efficacy 
advantages were reported for 75mg compared to 25 or 50mg 2-weekly (Kane et al. 2003). 
  
 
Versus other new generation antipsychotics 
Risperidone has been compared to other new generation antipsychotics in several studies. 
Two RCTs have been reported comparing risperidone with olanzapine. In the first, 339 
subjects were evaluated over 28-weeks. Both olanzapine (10-20mg/day) and risperidone (4-
12mg/day) were found to be effective, with olanzapine demonstrating superiority over 
risperidone in reducing negative symptoms, overall response rate and maintenance of 
response at 28 weeks. A greater proportion of olanzapine subjects maintained their response 
at 28 weeks. The incidence of EPS, hyperprolactinaemia and sexual dysfunction was greater 
in the risperidone treated patients (Tran et al. 1997b). The second study, this time with a lower 
dose of risperidone, investigated 377 subjects with schizophrenia over 8 weeks. Once again, 
both olanzapine (5-20mg/day, mean 12.4 mg/day) and risperidone (2-6mg/day, mean 
4.8mg/day) were found to be effective. There were no differences in efficacy between the 
groups according to the last-observation carried forward analysis, although the completers 
analysis reported significant advantages for risperidone in treating both positive and 
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anxiety/depression symptoms. EPS were similar in the two groups. Greater weight gain was 
associated with olanzapine treatment (Conley and Mahmoud 2001). 
 
In a small RCT, risperidone 4mg/day (n=20), 8mg/day (n=19) and clozapine 400mg/day 
(n=20) were compared over 28 days in a non-refractory sample of patients with 
schizophrenia. No differences in efficacy were reported and risperidone appeared to be better 
tolerated  (Klieser et al. 1995).  Three studies have compared risperidone and amisulpride.  
Risperidone (8mg/day) was compared with amisulpride (800mg/day) over 8 weeks in a 228 
patients with acute exacerbation of schizophrenia. The drugs showed equal efficacy, with both 
demonstrating good safety profiles. EPS did not differ between the two groups (Peuskens et 
al. 1999). A 6-month trial in 309 subjects comparing amisulpride (400-1000mg/day) and 
risperidone (4-10mg/day) reported a superior response rate for amisulpride, similar incidence 
of EPS and less weight-gain and endocrine/sexual symptoms with amisulpride (Sechter et al. 
2002). A small (n=48) trial reported similar efficacy and EPS for amisulpride (400-800mg/day) 
and risperidone (4-8mg/day), with greater weight gain for risperidone (Hwang et al. 2003). 
 
The efficacy and safety of clozapine, olanzapine. risperidone and haloperidol were compared 
over 14 weeks in 150 patients with a suboptimal treatment response. Clozapine, risperidone 
and olanzapine (but not haloperidol) treatment resulted in significant PANSS total score 
improvements. Negative symptoms improved significantly more for clozapine and olanzapine  
than haloperidol treated patients. Olanzapine and clozapine were associated with weight gain 
(Volavka et al. 2002). In a separate report of the neurocognitive effects of treatment in the 
same sample, global cognitive function improved significantly more with olanzapine and 
risperidone than with haloperidol (Bilder et al. 2002). 
 
Maintenance treatment 
Until recently, very few RCTs had evaluated the efficacy and safety of the new generation 
antipsychotics in the maintenance treatment of schizophrenia. However, there are now a few 
studies suggesting advantages for new generation antipsychotics over their predecessors. 
 
A RCT compared relapse rates in 365 clinically stable adult outpatients with schizophrenia or 
schizoaffective disorder receiving flexible doses of risperidone or haloperidol for a minimum of 
one year. Risk of relapse at the end of the study was significantly lower for the risperidone 
group (34%) than  for the haloperidol group (60%). Early discontinuation of treatment was 
more frequent among the haloperidol patients. Risperidone patients had greater reductions in 
EPS scores (Csernansky et al. 2002). In a 2-year maintenance trial comparing risperidone 
6mg/day with haloperidol 6mg/day in 63 stable patients, both groups experienced similar 
improvements in symptoms and similar risks of psychotic exacerbations. However, 
risperidone-treated patients appeared to feel subjectively better, as indicated by less anxiety 
and depression and fewer extrapyramidal side effects (Marder et al. 2003a)  
 
Meta-analyses 
A meta-analysis of 11 RCTs comparing risperidone to conventional antipsychotics concluded 
that short-term efficacy of risperidone is comparable to that of other antipsychotics. 
Risperidone patients showed slightly greater clinical improvement and lower overall dropout 
rate. Weight gain and tachycardia were more common in risperidone. There were significantly 
fewer EPS with risperidone (Song 1997). Another meta-analysis of 6 trials comparing 
risperidone with haloperidol in subjects with chronic schizophrenia treated for at least 4 weeks 
in RCTs reported significantly higher response rates with risperidone and lower dropout rates. 
There was also significantly less prescribing of anticholinergic medication with risperidone 
patients (Davies et al. 1998). A Cochrane review reported that in both the short and long term 
risperidone was more likely to produce improvement in symptoms, and to reduce the relapse 
rate at 12 months. Risperidone was less likely to cause motor disorders, but more likely to 
cause weight gain (Hunter et al. 2003). 
 
OLANZAPINE 
Acute phase trials 
Versus placebo 
Two pivotal dose-ranging studies found olanzapine to be significantly better than placebo in 
overall symptom improvement, as well as improvement in positive and negative symptoms 
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(Beasley et al. 1996a; Beasley et al. 1997). The most common treatment-emergent adverse 
events were somnolence, agitation, asthenia and nervousness (Beasley et al. 1996a). Plasma 
prolactin elevation did not differ from placebo (Beasley et al. 1996a). 
 
Versus conventional antipsychotics 
Three RCTs have compared olanzapine with haloperidol (Beasley et al. 1996b; Danion et al. 
1999; Tollefson et al. 1997). Olanzapine demonstrated some efficacy advantages over 
haloperidol in these studies. In the first, (n=335) olanzapine 15 ± 2.5mg/day was significantly 
better than haloperidol 15 ± 5mg/day in reducing negative symptoms after 6 weeks, (Beasley 
et al. 1996b) while in the second study (n=431) olanzapine 15 ± 2.5mg/day over 6 weeks was 
equal to haloperidol 15 ± 5mg/day on all efficacy measures (Beasley et al. 1997). In a very 
large study (n=1,996) olanzapine 5-20mg/day (mean 13.2mg/day) was significantly better 
than haloperidol 5-20mg/day (mean 11.8mg/day) over 6 weeks in reducing overall 
psychopathology (Beasley, Jr. et al. 1997), positive symptoms (Beasley et al. 1997), negative 
symptoms (Beasley et al. 1996b; Wyatt et al. 1998) and depressive symptoms (Tollefson et al. 
1997).  Significant advantages for olanzapine over haloperidol treatment were found for EPS 
(Beasley et al. 1996b; Beasley et al. 1997; Tollefson et al. 1997).  A RCT compared 
olanzapine with haloperidol in a sample of 182 Asian patients with schizophrenia. Olanzapine 
was as effective as haloperidol in treating overall symptomatology, and significantly superior 
in treating negative symptoms and EPS (Ishigooka et al. 2001). In a recently reported non-
industry sponsored multi-site RCT the long-term (12 month) effectiveness of olanzapine 5-
20mg/day versus haloperidol 5-20mg/day (with prophylactic benztropine) was evaluated in 
309 subjects with serious symptoms, and serious dysfunction for the previous 2 years. There 
were no significant differences between groups in study retention; positive, negative, or total 
symptoms; quality of life; or overall EPS. Olanzapine was associated with reduced akathisia, 
possibly less TD and slight cognitive advantages, but more frequent reports of weight gain 
(Rosenheck et al. 2003). 
 
Intramuscular (IM) olanzapine 
IM olanzapine was compared to IM haloperidol and IM placebo in treating acute agitation over 
a 24-hour period in hospitalised patients with schizophrenia. Olanzapine showed superiority 
over haloperidol at 15, 30 and 45 minutes following the first injection. Both olanzapine and 
haloperidol reduced agitation significantly more than placebo at 2 and 24 hours following the 
first injection. No patients treated with olanzapine experienced acute dystonia, compared with 
7% of those treated with haloperidol (Wright et al. 2001). In a similar study in 270 acutely 
agitated patients with schizophrenia olanzapine (2.5mg; 5mg; 7.5mg or 10mg) showed a 
dose-response relationship in reduction of agitation. All doses of olanzapine, except 2.5mg, 
were more effective than placebo at 30 minutes after injection, although not more effective 
than haloperidol. The lower doses of olanzapine (2.5mg; 5mg and 7.5mg), produced less 
treatment-emergent parkinsonism than haloperidol (Breier et al. 2002). 
 
Versus other new generation antipsychotics 
Two studies comparing olanzapine and risperidone are reported above. A RCT comparing 
amisulpride (200-800mg/day) and olanzapine (5-20mg/day) in 377 subjects reported similar 
efficacy and low EPS in both groups. Weight gain was significantly greater in the olanzapine 
treated patients (Martin et al. 2002) .  
 
Maintenance treatment 
The efficacy of a standard-dose of oral olanzapine (5-15mg/day) was compared with placebo 
and with an ineffective-dose olanzapine (1mg/day) in maintenance therapy of 120 subjects 
with schizophrenia. The standard-dose olanzapine treated patients experienced significantly 
lower relapse risk over one year compared to patients treated with placebo or ineffective-dose 
olanzapine (Dellva et al. 1997). Data from three double-blind extensions of acute studies 
(Beasley et al. 1996b;Beasley et al. 1997;Meltzer 1999) comparing olanzapine and 
haloperidol in maintenance treatment were pooled and reported together. Fewer subjects 
experienced relapse at one year with olanzapine (19.7%) than with haloperidol (28%) (Tran et 
al. 1998). Olanzapine has also been compared with risperidone for prevention of relapse in a 
RCT conducted over 28 weeks. Survival analysis revealed that significantly more olanzapine 
patients maintained their response at endpoint. The incidence of EPS, hyperprolactinaemia 
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and sexual dysfunction was significantly lower in the olanzapine treated patients (Tran et al. 
1997a). 
 
Meta-analyses 
A Cochrane review included 21 RCTs comparing olanzapine to placebo or any antipsychotic 
treatment in subjects with schizophrenia or schizophreniform psychosis. Olanzapine was 
found to be superior to placebo (although results were equivocal for negative symptoms), and 
equally as effective as conventional antipsychotics. There were fewer EPS with olanzapine 
than with haloperidol. Weight change data were not conclusive. (Duggan et al. 2003). 
 
QUETIAPINE 
Acute phase trials 
Versus placebo  
High-dose (750mg/day) and low-dose (250mg/day) quetiapine were compared to placebo 
over 6 weeks in 286 hospitalised subjects. High withdrawal rates were recorded in all three 
treatment groups (42%, 57% and 59%), primarily because of treatment failure. High-dose 
quetiapine was significantly better than placebo in reducing overall and positive scores. 
Reduction of negative symptoms was less consistent. Quetiapine was well tolerated, and did 
not induce EPS, sustained elevations of prolactin, or clinically significant haematological 
changes (Small et al. 1997). A multiple fixed dose study of quetiapine (75, 150, 300, 600 and 
750mg/day), haloperidol (12mg/day) and placebo reported significant differences between the 
four highest doses of quetiapine and placebo for overall and positive symptoms, and between 
quetiapine 300mg/day and placebo for negative scores. Across the dose range, quetiapine 
was no different from placebo regarding the incidence of EPS or change in prolactin 
concentrations (Arvanitis and Miller 1997). 
 
Versus conventional antipsychotics 
In the above dose-ranging study, there were no differences between quetiapine and 
haloperidol regarding the efficacy measures (Arvanitis and Miller 1997).  In a study comparing 
flexible doses of quetiapine (mean 455 mg/day) and haloperidol (mean 8 mg/day) both 
compounds produced clear reductions in symptoms. At endpoint, the mean PANSS total 
score was reduced by -18.7 in the quetiapine group, and -22.1 in the haloperidol group (P = 
0.13, between-treatment). Significantly fewer EPS and reduced prolactin levels were reported 
at endpoint for the quetiapine treated patients (Copolov et al. 2000).  Flexible doses of 
quetiapine (mean endpoint dose 407 mg/day) and chlorpromazine (mean dose 384 mg/day) 
were equally effective in the treatment of positive and negative symptoms. The quetiapine 
group had a lower incidence of adverse events and EPS than the chlorpromazine group 
(Peuskens and Link 1997). 
 
Versus other new generation antipsychotics 
No RCTs were found comparing quetiapine to other new generation antipsychotics. 
 
Maintenance studies 
No blinded maintenance studies were found for quetiapine. 
 
Meta-analyses 
A Cochrane systems review included 11 RCTs comparing quetiapine to placebo and other 
antipsychotic agents, and found that, compared to placebo, people treated with quetiapine 
showed greater symptom reduction and were less likely to leave the study early, particularly 
for treatment failure. Compared to conventional antipsychotics, the proportion of people 
leaving the studies early was marginally, but significantly, less for the quetiapine group.  
Symptom reduction was significantly greater in the high dose range of quetiapine. Less 
anticholinergic medication was required in the quetiapine-treated patients. It was noted that 
most data are very short term (Srisurapanont et al. 2000). 
 
ZIPRASIDONE 
Acute phase trials 
Versus placebo  
A study comparing ziprasidone 40 or 120mg/day and placebo found 120mg/day to be 
significantly more effective than placebo in improving the overall, depressive and anergia 
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scores, and had significantly more responders than placebo. The most frequently reported 
adverse events were dyspepsia, constipation, nausea and abdominal pain. There were no 
differences between ziprasidone and placebo regarding EPS (Keck, Jr. et al. 1998). In 
another placebo-controlled trial comparing ziprasidone 80 or 160mg/day, both doses of 
ziprasidone were significantly more effective than placebo in reducing overall, core-item and 
negative symptom scores. Ziprasidone had a very low liability for inducing movement 
disorders and weight-gain (Daniel et al. 1999). 
 
Versus conventional antipsychotics 
A dose-finding RCT comparing ziprasidone 4, 10, 40 and 160 mg/day and haloperidol 
15mg/day found ziprasidone 160mg/day to be comparable with haloperidol in reducing overall 
psychopathology and positive symptoms, as well as overall response rate. In ziprasidone 
patients, only transient elevations in prolactin were recorded, and fewer required benztropine 
to treat EPS (Goff et al. 1998). 
 
IM ziprasidone 
A RCT evaluated IM ziprasidone (2mg and 10mg) injections in acutely agitated psychotic 
patients. The 10mg dose was significantly more effective in reducing agitation up to 4 hrs after 
the first injection. No acute dystonia was reported (Lesem et al. 2001). In another similar 
study, ziprasidone 2mg and 20mg injections were compared. The 20mg dose substantially 
and significantly reduced symptoms of acute agitation. Both doses were well tolerated, and 
were not associated with EPS (Daniel et al. 2001). 
 
Maintenance studies 
Patients with stable, chronic schizophrenia were treated with ziprasidone 40mg/day; 
80mg/day or 160mg/day or placebo for one year. All the ziprasidone groups showed a lower 
probability of relapse than placebo. Discontinuation due to adverse events was similar for 
ziprasidone and placebo. Ziprasidone treatment was not associated with increased risk of 
movement disorders, weight gain or cardiovascular abnormalities (Arato et al. 2002). Another 
study compared ziprasidone (modal dose 80 mg/day) with haloperidol (modal dose 5 mg/day) 
in stable patients over 28 weeks. Similar reductions in all mean efficacy variables were 
observed. More ziprasidone treated patients were negative symptom responders. Despite the 
low dose of haloperidol, ziprasidone had clear advantages in all evaluations of movement 
disorders. Changes in body weight were negligible with both treatments. No significant 
laboratory or cardiovascular changes were observed (Hirsch et al. 2002). 
 
Meta-analyses 
A Cochrane review of available RCT’s reported that in studies ranging from one week (IM 
preparation) to over 6 months, ziprasidone seemed more effective than placebo and as 
effective as haloperidol. There were fewer EPS in the ziprasidone-treated patients. The 
authors noted that data for ziprasidone were limited at that stage (Bagnall et al. 2000). 
 
 
SERTINDOLE 
Acute phase trials 
Versus placebo 
A RCT compared sertindole 4, 8, 12 and 20mg/day and placebo. A dose-related improvement 
was observed for total scores, with significant differences being recorded between sertindole 
20mg/day and placebo. EPS-related events were comparable in the placebo and sertindole 
groups (van Kammen et al. 1996). Another RCT compared sertindole 12, 20 and 24mg/day 
with haloperidol 4, 8 and 16mg/day, and placebo. All doses were more effective than placebo. 
For treating negative symptoms, only sertindole 20mg/day was superior to placebo (Zimbroff 
et al. 1997). 
 
Versus conventional antipsychotics 
In two dose-ranging studies, sertindole and haloperidol were comparably effective. For EPS 
measures, sertindole was indistinguishable from placebo, and rates of EPS were not dose 
related. All dose levels of haloperidol produced significantly more EPS than placebo or 
sertindole. Adverse events associated with sertindole treatment were mild in severity (van 
Kammen et al. 1996;Zimbroff et al. 1997). 
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Maintenance studies 
Long-term efficacy and time to treatment failure was assessed in 282 clinically stable 
treatment-responsive outpatients with schizophrenia treated up to one year with sertindole or 
haloperidol. Time to treatment failure was not significantly different between the groups, but 
sertindole patients remained free of hospitalisation for exacerbation of schizophrenia and 
remained compliant significantly longer than did the haloperidol treated patients. There were 
also significantly fewer reports of EPS in the sertindole patients (Daniel et al. 1998). 
 
Meta-analyses 
A Cochrane review of sertindole versus placebo and other antipsychotics in schizophrenia 
included only two RCT’s, as data on two others were incomplete. The evidence suggested 
that sertindole was more effective than placebo. Sertindole was associated with fewer EPS 
than haloperidol, but caused more weight gain. The authors expressed reservations about its 
use in clinical practice because of cardiac problems that arose in the trials (Lewis et al. 2000). 
 
AMISULPRIDE 
Acute phase trials 
Versus placebo 
The efficacy of low-doses (50-300mg/day) of amisulpride versus placebo for negative 
symptoms has been assessed in three RCTs (Boyer et al. 1995;Danion et al. 1999;Paillere-
Martinot et al. 1995).(Boyer et al. 1995;Danion et al. 1999) Amisulpride was consistently 
better than placebo in these studies, and the effect on negative symptoms was apparently 
unrelated to any changes in positive symptoms (Danion et al. 1999).  No controlled studies 
were found comparing high-dose amisulpride with placebo. 
 
Versus conventional antipsychotics 
Fixed doses of amisulpride (400, 800 and 1200mg/day) and haloperidol16 mg/day were 
compared with a sub-therapeutic dose of amisulpride (100mg/day). Total score reductions 
were greatest in the groups taking 400mg or 800mg amisulpride/day. Symptoms of 
parkinsonism did not increase for the amisulpride groups, whereas with haloperidol they did 
(Puech et al. 1998).  In a small flexible-dose study (n=41) both amisulpride or haloperidol 
groups showed similar symptom reduction, with amisulpride doing significantly better 
regarding reduction of depressive symptoms. Significantly fewer EPS were recorded in the 
amisulpride group (Delcker et al. 1990).  In another study, amisulpride 800mg/day was as 
effective as haloperidol 20mg/day for positive symptoms, and significantly more effective for 
negative symptoms. The amisulpride patients exhibited significantly fewer EPS (Moller et al. 
1997b). In a flexible dose study comparing amisulpride 400-1200mg/day to haloperidol 10-
30mg/day, overall and positive scores were equally reduced, while negative score reduction 
and percentage of responders was significantly greater with amisulpride. Haloperidol was 
associated with a greater incidence of EPS (Carriere et al. 2000).  Amisulpride (1000mg/day) 
was compared with flupenthixol (25mg/day) in a fixed-dose RCT. Efficacy results were similar 
for both drugs, except that amisulpride was significantly better in reducing positive symptoms. 
There were fewer EPS in the amisulpride group (Wetzel et al. 1998). 
 
Versus other new generation antipsychotics 
Three studies comparing amisulpride with risperidone, and one with olanzapine, are reported 
above. 
 
Maintenance studies 
Low-dose amisulpride (100mg/day) and placebo were compared in patients with 
predominantly negative symptoms over 6 months. Significantly more amisulpride patients 
completed the study. Dropout rates were 27% with amisulpride and 47% with placebo. The 
incidence of EPS was similar in both groups (Loo et al. 1997). 
 
Meta-analyses 
A meta-analysis of 11 RCTs, comparing amisulpiride to conventional antipsychotics, 
concluded that amisulpiride was more effective than conventional antipsychotics for both 
global schizophrenic symptoms and negative symptoms. Amisulpiride was associated with 
significantly lower use of antiparkinsonian medication and fewer dropouts due to adverse 
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events (Leucht et al. 2002). Another meta-analysis specifically assessed the evidence for 
negative symptom efficacy. The overall analysis reported improvement of negative symptoms 
that could probably not be accounted for by improvement of positive symptoms, depressive 
symptoms or EPS (Storosum et al. 2002). A Cochrane review of 19 randomised studies with a 
total of 2443 participants found that, compared to typical antipsychotics, amisulpride was 
more effective in improving global state, and the negative symptoms of schizophrenia. 
Regarding positive symptoms, amisulpride was as effective as typical antipsychotics. 
Amisulpride was less prone to cause  EPS or to require the use of antiparkinson medication, 
and also seemed to be more acceptable to patients than conventional drugs (Mota et al. 
2002). 
 
 
ARIPIPRAZOLE 
Acute phase trials 
Versus placebo and conventional agents 
A RCT comparing aripiprazole 15 and 30 mg/day to placebo and haloperidol 10 mg/day found 
both doses of aripiprazole and haloperidol produced significant improvements in total and 
positive scores. Aripiprazole 15 mg, and haloperidol 10 mg significantly improved negative 
scores. Unlike haloperidol, aripiprazole was not associated with significant EPS or prolactin 
elevation. There were no significant changes in body weight, and no clinically significant 
increases in QTc interval (Kane et al. 2002). In another study, aripiprazole 20 or 30 mg/day 
and risperidone 6 mg/day were significantly better than placebo on all efficacy measures. 
There were no significant differences between aripiprazole and placebo in EPS. Mean 
prolactin levels decreased with aripiprazole but significantly increased 5-fold with risperidone. 
Mean change in QTc interval did not differ significantly from placebo with any active treatment 
group. Both aripiprazole and risperidone groups showed similar low incidence of weight gain 
(Potkin et al. 2003). A pooled analysis reported data from five acute-phase RCTs involving 
patients treated with aripiprazole (n=932), placebo (n=416), or haloperidol (n=201). 
Aripiprazole was well tolerated, with similar adverse event incidence rates to placebo, and 
lower rates than haloperidol for EPS and somnolence. There was minimal mean weight 
change with aripiprazole and haloperidol, and no QTc prolongation. Serum prolactin increased 
with haloperidol, but not with aripiprazole  
(Marder et al. 2003b). 
 
Maintenance treatment 
In a 26-week RCT stable patients received fixed doses of aripiprazole 15 mg, or placebo. 
Time to relapse was significantly longer for aripiprazole compared with placebo. More patients 
relapsed with placebo (57%) than aripiprazole (34%). Aripiprazole was significantly superior to 
placebo from baseline to endpoint in PANSS total and positive scores. Aripiprazole was well 
tolerated, with no evidence of marked sedation and no evidence of hyperprolactinemia or 
prolonged QTc. EPS were comparable with placebo. There was a slight mean weight loss at 
endpoint in both groups (Pigott et al. 2003).  The prospectively pooled results of two 52-week 
RCTs evaluating aripiprazole 30 mg/day versus haloperidol 10 mg/day in 1294 patients were 
recently reported. Aripiprazole demonstrated efficacy comparable to haloperidol across most 
symptom measures, and greater improvements for negative and depressive scores. The time 
to discontinuation was significantly greater with aripiprazole than with haloperidol. Aripiprazole 
was associated with significantly lower scores than haloperidol on all EPS assessments 
(Kasper et al. 2003). 
 
SPECIAL POPULATIONS OF SCHIZOPHRENIA 
Prepsychotic period 
A RCT compared low-dose risperidone (mean dose 1.3mg/day) and cognitive behavioural 
therapy (CBT) with need-based intervention in 59 subjects at incipient risk of progression to 
first-episode psychosis. Both risperidone and CBT reduced the risk of early transition to 
psychosis (McGorry et al. 2002). Another RCT evaluated the short-term efficacy (8 weeks) of 
olanzapine 5-15 mg/day versus placebo in 60 patients with prodromal schizophrenia. Results 
suggest that olanzapine is associated with significantly greater symptom improvement, but 
also significantly greater weight gain than placebo (Woods et al. 2003). 
 
First-episode schizophrenia 
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In spite of increasing attention focussing on early intervention, few RCTs have evaluated the 
efficacy and safety of new generation antipsychotic medications directly in patients with a first 
episode of psychosis. An international RCT compared flexible doses of risperidone (mean 
6.1mg/day) and haloperidol (mean 5.6mg/day) over 8 weeks. The two compounds showed 
similar efficacy, with response rates for risperidone and haloperidol being 63% and 56% 
respectively. Both groups experienced considerable EPS, although this was significantly lower 
in the risperidone group. A post-hoc analysis showed that lower doses (<6mg/day) were 
efficacious, and associated with far fewer EPS (Emsley 1999). 
 
A post-hoc analysis was conducted in a subpopulation of patients experiencing their first-
epsiode of psychosis from a larger RCT (Tollefson et al. 1997).  A greater reduction in total, 
positive and negative scores, as well as a significantly higher response rate was found for the 
olanzapine subjects compared to the haloperidol subjects. Olanzapine treated patients 
showed a significant reduction in EPS, while haloperidol treated patients showed an increase 
in EPS (Sanger et al. 1999).  A large (n=263) prospective RCT compared olanzapine with 
haloperidol in first-episode psychosis. Twelve-week results reported similar symptom 
reduction for the two treatments with last-observation-carried-forward analyses, but greater 
decreases in PANSS total, negative and general psychopathology scales for olanzapine with 
a mixed-model analysis. Significantly more olanzapine-treated subjects than haloperidol-
treated subjects completed the acute phase of the study. Olanzapine-treated patients 
experienced a lower rate of treatment-emergent parkinsonism and akathisia but had 
significantly more weight gain. (Lieberman et al. 2003). 
 
Refractory schizophrenia 
Clozapine is the most effective treatment in patients with severe, refractory schizophrenia and 
remains the treatment of choice (Kane et al. 1988). However, the benefits of clozapine are 
limited, and many patients tolerate the drug poorly (Kane et al. 1988). The new generation 
antipsychotics have raised expectations in the treatment of patients who are refractory to 
conventional agents, although studies to date have not been entirely convincing.  
 
Risperidone 
A RCT compared risperidone (mean dose 6.4 mg/day) to clozapine (mean dose 
291.2mg/day) over 8 weeks in 86 subjects with chronic schizophrenia who were either 
resistant or intolerant to conventional antipsychotics. Both drugs were found to be essentially 
similar, with a more rapid onset of action reported for risperidone. EPS and other adverse 
events were scarce and mild in both groups (Bondolfi et al. 1998). This study does not 
represent a purely refractory sample, and has been criticised because the sample was not 
well defined, the sample size was relatively small, clozapine dosing was relatively low, and 
the treatment period was possibly too brief (Dunayevich and Chatterjee 1999;Meltzer 
1999;Rubin 1999). In a small RCT (n=29) of subjects showing only a partial response to 
conventional antipsychotics, risperidone (mean 5.9mg/day)  was compared to clozapine 
(mean 403.6mg/day) over 6 weeks. Clozapine was superior to risperidone for positive 
symptoms, while total symptoms, negative symptoms and depression did not differ between 
the groups (Breier et al. 1999). Another RCT compared flexible doses of risperidone and 
clozapine over 8 weeks in 273 subjects with severe chronic schizophrenia. Improvement in 
mean BPRS, CGI scores and most of the secondary efficacy measures was significantly 
greater in the clozapine group (Azorin et al. 2001).  A RCT investigated the effects of 
risperidone versus haloperidol in a severely refractory sample of subjects with schizophrenia. 
Risperidone was significantly better than haloperidol in reducing overall symptomatology at 4 
weeks, but not at endpoint (Wirshing et al. 1999). 
 
Olanzapine 
A RCT compared the efficacy of olanzapine (25mg/day) versus chlorpromazine (1200mg/day) 
in treatment-resistant schizophrenia (Conley et al. 1998). No differences in efficacy were 
demonstrated between the two drugs. Seven percent of the olanzapine-treated patients and 
none of the chlorpromazine patients met a priori criteria for clinical response.  There were also 
no differences in dropout rates. Olanzapine was significantly better tolerated than 
chlorpromazine. The olanzapine-treated patients had fewer motor and cardiovascular side-
effects. No antiparkinsonian drugs were necessary in the olanzapine group. 
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Quetiapine 
A RCT was conducted to assess the efficacy of quetiapine in patients who were partially 
responsive to conventional antipsychotic treatment. Subjects were randomised to quetiapine 
600mg/day and haloperidol 20mg/day for 8 weeks. Treatments were equally effective in 
symptom reduction, while quetiapine patients had a significantly greater response rate 
(Emsley et al. 2000) and significantly greater reduction of depressive symptoms (Emsley et al. 
2003b). The quetiapine treated patients experienced fewer EPS and had lower serum 
prolactin levels. 
 
In a recently reported RCT, clozapine, olanzapine, risperidone and haloperidol were 
compared in inpatients with chronic schizophrenia who had not responded adequately to 
other antipsychotic medications.  Respective mean endpoint doses for clozapine, olanzapine, 
risperidone and haloperidol were 526.6, 30.4, 11.6 and 25.7 mg/day. Compared to 
haloperidol, there were significant advantages for clozapine and olanzapine regarding overall 
improvement, and general psychopathology, and for clozapine, risperidone and olanzapine 
regarding negative symptoms (Volavka et al. 2002).  A review and meta-analysis of 12 studies 
comparing typical and new generation antipsychotics in subjects with refractory schizophrenia 
reported that clozapine exhibits superiority over conventional antipsychotics in terms of both 
efficacy and tolerability. However, the magnitude of the advantage for clozapine was not 
consistently robust. Efficacy data for other new generation antipsychotics in the treatment of 
refractory schizophrenia were inconclusive (Chakos et al. 2001). 
 
CONVENTIONAL VERSUS NEW GENERATION ANTIPSYCHOTICS: THE ONGOING 
DEBATE 
The most robust difference between the conventional and new generation antipsychotics has 
been the reduced propensity of the latter to produce EPS. However, it could be argued that 
this difference is spurious, and may be explained on the basis that the dose of the 
conventional comparators (usually haloperidol) was too high. In fact, by employing strategies 
to reduce the EPS risk with conventional antipsychotics, differences between the conventional 
and new generation agents are less obvious. Three strategies have been adopted to reduce 
EPS with conventional antipsychotics, namely the use of low doses, the addition of 
prophylactic anticholinergic agents and the use of low-potency conventional antipsychotics. 
First, the use of low-doses of haloperidol has been shown to be effective and well tolerated 
(Oosthuizen et al. 2001), and haloperidol 2mg/day was at least as effective, with significantly 
fewer EPS than 8mg/day in the acute treatment of first-episode schizophrenia (Oosthuizen et 
al. 2003b). Second, the addition of prophylactic benztropine to reduce the risk of EPS with 
haloperidol in a RCT comparing it with olanzapine reported no significant differences between 
groups in study retention; positive, negative, or total symptoms of schizophrenia; quality of 
life; or EPS. While olanzapine showed benefits in reducing akathisia and improving cognition, 
the authors pointed out that this has to be balanced with the problems of weight gain and 
higher cost (Rosenheck et al. 2003). Third, a recent meta-analysis of studies comparing new 
generation antipsychotics to low-potency conventional agents reported that mean doses less 
than 600 mg/day of chlorpromazine or its equivalent had no higher risk of EPS than new 
generation antipsychotics (Leucht et al. 2003). However, even when utilizing these strategies, 
important differences exist between conventional and new generation agents. Thus, even at 
very low-doses conventional agents are associated with some acute EPS (Oosthuizen et al. 
2003b), and importantly, no reduction in the incidence of TD (Oosthuizen et al. 2003a). Also, 
studies of conventional versus new generation agents in which more appropriately low doses 
of haloperidol were used showed significant differences in EPS in favour of the new 
generation antipsychotics (Emsley 1999;Hirsch et al. 2002;Lieberman et al. 2003;Marder et 
al. 2003a;Zimbroff et al. 1997). Finally, although low-potency antipsychotics did not cause 
more EPS, they were found to be moderately less effective than new generation 
antipsychotics (Leucht et al. 2003). 
 
A meta-regression analysis of 52 RCTs comparing new generation antipsychotics (clozapine, 
risperidone, olanzapine, quetiapine, amisulpride, and sertindole) with conventional 
antipsychotics or alternative new generation antipsychotics found that the dose of 
conventional antipsychotics was a confounding factor. When compared to ≤6mg/day 
haloperidol, new generation antipsychotics had no benefits in terms of efficacy or overall 
tolerability, although they still caused fewer EPS (Geddes et al. 2000). A recent meta-analysis 
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of RCTs comparing new generation antipsychotics with conventional agents or other new 
generations reported that, compared to conventional agents clozapine, amisulpride, 
risperidone and olanzapine had significantly greater effect sizes (0.49, 0.29, 0.25 and 0.21, 
respectively). Unlike Geddes et al (Geddes et al. 2000), these authors found no evidence that 
haloperidol dose affected the results (Davis et al. 2003).  
 
HEAD-TO-HEAD COMPARISONS OF NEW GENERATION ANTIPSYCHOTICS 
A number of direct comparisons of new generation antipsychotics have now been published, 
allowing some comparison between these agents. It can be seen that few, if any efficacy 
differences have been demonstrated between these agents. However, side-effect profiles 
differ considerably. 
 
FOCUSSING ON SIDE-EFFECT PROFILES 
As can be seen from the above, to date no conclusive evidence exists for efficacy superiority 
of any of the new generation antipsychotics other than clozapine. However, the clear-cut 
differences in side-effect profiles have become a critical focus area for clinicians when 
choosing an antipsychotic. The most important side-effects to consider are EPS, weight-gain, 
cardiotoxicity, and hyperprolactinaemia. 
 
Extrapyramidal symptoms 
By definition, new generation antipsychotics are effective at doses below those that would 
normally cause EPS. However, there are significant intra-class differences in the EPS risk 
between the new generation antipsychotics.  Risperidone and amisulpride, while not differing 
from placebo at the lower end of their therapeutic range, cause EPS in a dose-dependent 
manner.  On the other hand, clozapine and quetiapine have a very low risk of inducing EPS 
(Seeman 2002). 
 
Weight gain 
Whereas the treatment of schizophrenia previously focussed mainly on the control of acute 
psychotic symptoms and strategies to minimise EPS, the substantially increased risk of 
medical morbidity and mortality in these patients has more recently become an area of 
attention.  It has become apparent that new generation antipsychotics may contribute to this 
risk. Weight gain has been consistently associated with some of these agents, particularly 
clozapine and olanzapine. Risperidone appears to be associated with a modest risk, with 
ziprasidone, amisulpride and aripiprazole having a low risk of weight gain (Bobes et al. 
2003;Nasrallah 2003).  A meta-analysis and random effects meta-regression that estimated 
the weight change after 10 weeks of treatment with a standard dose of each of the new 
generation  antipsychotics showed the following mean increases in weight: clozapine, 4.45kg; 
olanzapine, 4.15kg; sertindole, 2.19kg; risperidone, 2.10kg and ziprasidone, 0.04kg (Allison et 
al. 1999). 
 
The possible metabolic concomitants of obesity, namely diabetes and hypertriglyceridemia 
have raised concern, and psychiatrists are now having to develop a better understanding of 
these conditions.  Clozapine, olanzapine and possibly risperidone have been significantly 
associated with glucose intolerance (Hedenmalm et al. 2002;Wirshing et al. 2002) and there 
appears to be an increased risk of diabetes mellitus in patients receiving new generation 
antipsychiotics (Citrome and Jaffe 2003). In a RCT conducted over 14 weeks, the effects of 
clozapine, olanzapine, risperidone and haloperidol on glucose and cholesterol levels were 
assessed. Clozapine, olanzapine and haloperidol were associated with an increase of plasma 
glucose, and clozapine and olanzapine were associated with an increase in cholesterol levels 
(Lindenmayer et al. 2003).  The combined risk factors of weight gain and elevated blood 
glucose and triglyceride levels increases the risk for coronary artery disease. For this reason, 
it has been recommended that routine monitoring of glucose and lipid levels should be 
undertaken during treatment with new generation antipsychotics (Wirshing et al. 2002). 
 
 
Hyperprolactinaemia  
Prolactin secretion is controlled by complex mechanisms, of which dopamine is the principal 
inhibitory component (Petty 1999). Hyperprolactinemia may be a concern in the treatment of 
patients with schizophrenia, although correlations between prolactin elevations and clinical 
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symptoms have not been well-established. Elevated levels of prolactin in females cause 
menstrual disturbances and galactorrhoea,  are associated with reduced bone density (Sauer 
and Howard 2002), have been linked with disturbed sexual function in terms of desire, 
erection and orgasm in the male and may even cause hypogonadism (Wilson 1993).  
 
Treatment with conventional antipsychotics has a profound effect on prolactin levels, 
producing increases of around two to three times above normal in most patients (Green and 
Brown 1988). The majority of the new generation antipsychotics have much less of an effect 
on prolactin, although there are considerable differences between compounds. At the one end 
of the spectrum, clozapine and quetiapine produce minimal sustained increases in prolactin 
levels that are no different from placebo, while olanzapine produces a transient increase in 
prolactin levels (Hamner 2002). With risperidone and amisulpiride, the effect is largely dose-
dependent, with higher doses causing a marked increase in prolactin levels (Peuskens 
1995;Peuskens et al. 1999).(Peuskens et al. 1999) There is evidence that with risperidone, 
the risk of hyperprolactinaemia is even greater than that with conventional antipsychotics 
(Kinon et al. 2003;Yasui-Furukori et al. 2002). Risperidone has been associated with 
decreases in bone mineral density in premenopausal females (Becker et al. 2003), as well as 
high levels of sexual dysfunction (Knegtering et al. 2003).  
 
QT interval prolongation 
QTc prolongation by antipsychotic drugs has become a major concern, as it appears to be 
linked to an increased risk of sudden death (Zareba and Lin 2003). Among antipsychotics 
available in the UK, droperidol was withdrawn, sertindole was voluntarily suspended, and 
restricted labelling was introduced for thioridazine and pimozide. The degree of QTc 
prolongation is dose-dependent, and varies amongst agents (Haddad and Anderson 2002). 
Ziprasidone prolongs QTc to a moderate degree, though to a greater extent than quetiapine, 
risperidone, olanzapine and haloperidol (Taylor 2003). 
 
Arrhythmias are more likely to occur if associated with other risk-factors, such as another drug 
prolonging the QTc interval, electrolyte imbalance, congenital long QT syndromes, heart 
failure, bradycardia, female sex, restraint, old-age, hepatic or renal impairment, and slow 
metaboliser status (Haddad and Anderson 2002). 
 
CONCLUSIONS 
The new generation antipsychotics discussed here are at least as effective as the 
conventional antipsychotics in the treatment of positive symptoms. Furthermore, there is 
some evidence of superiority in treatment of specific symptom domains, particularly negative 
symptoms  (Carman et al. 1995;Moller et al. 1997b), mood symptoms (Emsley et al. 
2003a;Peuskens et al. 2000;Tollefson et al. 1998;Tollefson et al. 1999)   and cognitive 
symptoms (Green et al. 1997;Kern et al. 1998;Kern et al. 1999;Purdon et al. 2000;Purdon et 
al. 2001) as well as advantages in maintaining/enhancing quality of life (Hamilton et al. 
1998;Revicki et al. 1999;Hamilton et al. 1998). There is also a small, but growing literature on 
the pharmaco-economic advantages of the new generation antipsychotics (Edgell et al. 
2000;Revicki 2000).  But the most marked advantage of the new generation antipsychotics is 
their superiority over traditional antipsychotics in terms of EPS. This is of great importance, 
since EPS have been shown to be the principal cause of non-adherence to medication (Hoge 
et al. 1990;Van Putten 1974). 
 
Taken together, there is extensive evidence to support the use of the new generation 
antipsychotics (excluding clozapine) as first-line treatment agents for schizophrenia. However, 
it needs to be borne in mind that these agents are not free of side-effects and appropriate 
caution should be exercised when prescribing them. In an acute setting, IM olanzapine or 
ziprasidone offer ensured drug delivery. In patients with partial refractoriness, quetiapine, 
risperidone and olanzapine may have some efficacy advantages over conventional 
antipsychotics. For subjects with persistent negative symptoms, addition of low-doses of 
amisulpride might be of benefit. In patients who do not respond adequately to the new 
generation antipsychotics, as well as severely refractory subjects, clozapine is the treatment 
of choice. For maintenance treatment, risperidone and olanzapine have demonstrated 
reduced relapse rates compared to haloperidol. Conventional depot antipsychotics were 
extensively used in the past. They simplified administration and improved patient compliance 
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considerably, and were better than their oral counterparts in reducing relapse rates in 
schizophrenia. They fell out of favour when the better tolerated new generation antipsychotics 
were introduced. The introduction of long-acting risperidone injection is likely to herald a 
return to the large scale use of this method of administration of antipsychotics.  
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Table 1. Acute phase randomised controlled trials for risperidone. 
 
Comparator Authors N Duration 
of trial 
Dose of 
risperidone 
(mg/day) 
Efficacy (overall, positive 
and negative symptoms)  
Placebo Chouinard 
et al, 1993 
135 8 weeks 2, 6, 10, 16 6-16 mg superior overall 
and positive, 6mg superior 
negative symptoms 
Placebo  Marder & 
Meibach, 
1994 
388 8 weeks 2, 6, 10, 16 6-16 mg superior overall 
and positive, 6 & 16 mg 
superior negative 
symptoms 
Placebo Kane et al, 
2003 
400 12 weeks 25, 50, 75 
mg IM 2 
weekly 
Superior overall, positive 
and negative symptoms 
Haloperidol  Chouinard 
et al, 1993 
135 8 weeks 2, 6, 10, 16 6 mg superior overall 
Haloperidol Marder & 
Meibach, 
1994 
388 8 weeks 2, 6, 10, 16 6 & 16 mg superior overall 
Haloperidol Peuskens et 
al, 1995 
1362 8 weeks 1, 4, 8, 12, 
16 
Equal  
Haloperidol Huttunen et 
al, 1995 
98 6 weeks Mean 8 Equal 
Haloperidol Emsley et 
al, 1999 
183 6 weeks 6 Equal 
Olanzapine  Tran et al, 
1997 
339 28 weeks 4-12 Olanzapine superior for 
negative symptoms 
Olanzapine  Conley & 
Mahmoud, 
2001 
377 8 weeks 2-6 Equal 
Clozapine  Klieser et al, 
2002 
59 4 weeks 4 and 8 Equal 
Amisulpride  Peuskens et 
al, 1999 
228 8 weeks 8 Equal 
Amisulpride Sechter et 
al, 2002 
309 6 months 4-10 Equal 
Amisulpride  Hwang et al, 
2003 
48 6 weeks 4-8 Equal 
 
Table 2. Acute phase randomised controlled trials for olanzapine. 
 
Comparator Authors  N Duration 
of trial 
Dose of 
olanzapine 
(mg/day) 
Efficacy (overall, positive 
and negative symptoms)   
Placebo Beasley et 
al, 1996a 
152 6 weeks 1 and 10 10mg superior overall, 
positive and negative 
Placebo Beasley et 
al, 1996b 
335 6 weeks 5±2.5; 
10±2.5 and 
15±2.5 
Medium & high dose 
superior overall and 
positive, low & high dose 
superior negative 
Haloperidol  Beasley et 
al, 1996b 
335 6 weeks 5±2.5; 
10±2.5 and 
15±2.5 
All doses equal overall and 
positive, 15±2.5mg 
superior for negative 
Haloperidol Beasley et 
al, 1997 
431 6 weeks 5±2.5; 
10±2.5 & 
Equal 
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15±2.5 
Haloperidol Tollefson et 
al, 1997 
1996 6 weeks 5-20 Superior overall, positive 
and negative 
Haloperidol Ishigooka et 
al, 2001 
182 8 weeks 5-15 Equal 
Haloperidol Lieberman 
et al, 2003 
263 12 weeks Mean 9.1 Superior overall and 
negative, equal positive 
Risperidone Tran et al, 
1997 
339 28 weeks 10-20 Olanzapine superior 
negative 
Risperidone  Conley & 
Mahmoud, 
2001 
377 8 weeks 5-20 Equal  
Amisulpride  Martin et al, 
2002 
377 8 weeks 5-20 Equal  
 
 
 
Table 3. Acute phase randomised controlled trials for quetiapine 
 
Comparator Authors N Duration 
of trial 
Dose of 
quetiapine 
(mg/day) 
Efficacy (overall, positive 
and negative symptoms)  
Placebo Small et al, 
1997 
286 6 weeks 250 and 
750 
750 mg superior overall, 
positive and negative 
Placebo  Arvanitis et 
al, 1997 
361 6 weeks 75, 150, 
300, 600 
and 750 
150-750mg superior 
overall and positive, 
300mg superior negative 
Haloperidol Arvanitis et 
al, 1997 
361 6 weeks 75, 150, 
300, 600 
and 750 
Equal  
Haloperidol Copolov et 
al, 2000 
448 6 weeks Mean 455 Equal 
Chlorpromazine Peuskens 
& Link, 
1997 
201 6 weeks Mean 407 Equal  
 
 
 
Table 4. Acute phase randomised controlled trials for ziprasidone 
 
Comparator Authors  N Duration 
of trial 
Dose of 
ziprasidone 
(mg/day) 
Efficacy (overall, 
positive and 
negative symptoms)   
Placebo  Keck et 
al, 1998 
139 4 weeks 40 and 120 120mg superior 
overall 
Placebo Daniel et 
al, 1999 
302 6 weeks 80 and 120 Both doses superior 
overall, positive and 
negative 
Haloperidol Goff et 
al, 1998 
90 4 weeks 4, 10, 40 and 
160 
160mg equal 
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Table 5. Acute phase randomised controlled trials for sertindole 
 
Comparator Authors  N Duration 
of trial 
Dose of 
sertindole 
(mg/day) 
Efficacy (overall, 
positive and negative 
symptoms) 
Placebo Van 
Kamen et 
al, 1996 
205 40 days 4, 8, 12, 20 20mg superior overall 
Placebo Zimbroff 
et al, 
1997 
497 8 weeks 12, 20, 24 All doses superior 
overall, 20 and 24 mg 
superior positive, 20mg 
superior negative 
Haloperidol  Zimbroff 
et al, 
1997 
497 8 weeks 12, 20, 24 Equal 
 
 
 
Table 6. Acute phase randomised controlled trials for amisulpride 
 
Comparator Authors  N Duration 
of trial 
Dose of 
amisulpride 
(mg/day) 
Efficacy (overall, positive and 
negative symptoms) 
Placebo  Paillere-
Martinot et 
al, 1995 
27 6 weeks 50 to 100 Superior for negative 
symptoms 
Placebo Boyer et al, 
1995 
104 6 weeks 100 and 300 Both doses superior for 
negative symptoms 
Placebo Danion et 
al, 1999 
243 12 weeks 50 and 100 Both doses superior for 
negative symptoms 
Haloperidol  Delcker et 
al, 1990 
41 6 weeks  Equal 
Haloperidol Peuch et 
al, 1998 
319 4 weeks 100, 400, 
800, 1200 
400 & 800mg equal 
Haloperidol Moller et al, 
1997 
191 6 weeks 800 Superior for negative 
symptoms 
Haloperidol Carriere et 
al, 2000 
199 4 months 400-1200 Superior for negative 
symptoms 
Haloperidol Wetzel et 
al, 1998 
132 6 weeks 1000 Superior for positive 
symptoms 
Risperidone  Peuskens 
et al, 1999 
228 8 weeks 800 Equal 
Risperidone Sechter et 
al, 2002 
309 6 months  Equal 
Risperidone Hwang et 
al, 2003 
48 6 weeks 400-800 Equal 
Olanzapine Martin et al, 
2002 
377 8 weeks 200-800 Equal 
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Table 7. Acute phase randomised controlled trials for aripiprazole 
 
Comparator Authors N Duration 
of trial 
Dose of aripiprazole 
(mg/day) 
Efficacy (overall, 
positive and negative 
symptoms) 
Placebo Kane et 
al, 2002 
414 4 weeks 15 and 30 Both doses superior 
overall and positive, 
30mg superior negative 
Placebo Potkin et 
al, 2003 
404 4 weeks 20 and 30 Superior 
Haloperidol  Kane et 
al, 2002 
414 4 weeks 15 and 30 Equal 
Risperidone  Potkin et 
al, 2003 
404 4 weeks 20 and 30 Equal 
 
 
 
 
Table 8. Head-to-head randomised controlled trials of atypical antipsychotics. 
 
 Authors N Duration 
of trial 
Efficacy  Tolerability  
Risperidone vs. 
Olanzapine  
Tran et al, 
1997 
339 28 weeks Olanzapine 
superior for 
negative 
symptoms 
Risperidone > EPS, 
hyperprolactinaemia, 
sexual dysfunction  
Risperidone vs. 
Olanzapine  
Conley & 
Mahmoud, 
2001 
377 8 weeks Similar Olanzapine > weight 
gain 
Risperidone vs. 
Clozapine  
Klieser et al, 
2002 
59 4 weeks Similar Risperidone better 
tolerated 
Risperidone vs. 
Amisulpride  
Peuskens et 
al, 1999 
228 8 weeks Similar Equal EPS  
Risperidone vs. 
Amisulpride 
Sechter et 
al, 2002 
309 6 months Similar Equal EPS. Risperidone 
> weight gain, sexual 
dysfunction 
Risperidone vs. 
Amisulpride 
Hwang et al, 
2003 
48 6 weeks Similar Equal EPS. Risperidone 
> weight gain 
Olanzapine vs. 
Amisulpride  
Martin et al, 
2002 
377 8 weeks Similar Equal EPS. Olanzapine 
> weight gain 
Risperidone vs. 
aripiprazole 
Potkin et al, 
2003 
404 4 weeks Similar Equal EPS. Risperidone 
> prolactin 
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Abstract 
 
An international, multicenter, double-blind study was conducted in 183 patients with a first 
psychotic episode (provisional schizophreniform disorder or schizophrenia; DSM-III-R) treated 
with flexible doses of risperidone or haloperidol for 6 weeks.  At endpoint, 63 percent of 
risperidone-treated patients and 56 percent of haloperidol-treated patients were clinically 
improved (> 50% reduction in Positive and Negative Syndrome Scale total scores).  
Risperidone was better tolerated than haloperidol: the severity of extrapyramidal symptoms 
was significantly lower in the risperidone-treated patients; significantly fewer risperidone-
treated patients required antiparkinsonian medication; and significantly fewer discontinued 
treatment because of adverse events.  A post hoc analysis revealed that low doses of these 
antipsychotics were efficacious in some patients.  Furthermore, the severity of extrapyramidal 
symptoms and the use of antiparkinsonian medications were significantly lower in patients 
receiving low doses (maximum, < 6 mg/day) than high doses (maximum, > 6 mg/day) of 
risperidone or haloperidol.  These findings are consistent with the suggestion that patients 
with a first psychotic episode may require low doses of antipsychotic medications.  Studies 
designed specifically to compare low and high doses of antipsychotics are warranted to help 
optimize treatment for these patients. 
 
 
 
 
Risperidone is both effective and well tolerated in patients with chronic schizophrenia 
(Chouinard et al. 1993; Marder and Meibach 1994; Peuskens 1995).  In the present 
randomized, controlled study we assessed the efficacy and safety of risperidone in first-
episode psychotic patients. 
 
Few prospective studies have been conducted on the effects of antipsychotic agents in first-
episode patients during the initial weeks after hospital admission (Scottish Schizophrenia 
Research Group 1987; Lieberman et al. 1989; Chakos et al. 1992; Syzmanski et al. 1996).  In 
general, these studies indicate that neuroleptic treatment reduces the severity of positive 
symptoms of schizophrenia but results in a high incidence of extrapyramidal symptoms 
(Scottish Schizophrenia Research Group 1987; Lieberman et al. 1989; Chakos et al. 1992).  
Thus it was postulated that an atypical antipsychotic agent such as risperidone, with its low 
propensity to induce extrapyramidal symptoms at therapeutically effective doses, would be 
preferable to conventional neuroleptics in the management of these patients.  Clinical 
experience with risperidone has shown that a regimen consisting of low doses (< 6 mg/day) 
and slow titration is essential to optimize patient outcome.  The results of the present study 
support the use of risperidone in patients with a first psychotic episode and are consistent 
with the recommendation for low doses to optimize outcome for many patients. 
 
Methods  
 
This double-blind, comparative study of risperidone and haloperidol was conducted at 61 
psychiatric centers in 10 countries: Australia, Belgium, Canada, France, Germany, Great 
Britain, Korea, The Netherlands, South Africa, and Sweden. 
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Patients.  Patients were included in the study if they were ages 15 to 45 years; had a 
diagnosis of provisional schizophreniform disorder (295.40) or schizophrenia without prior 
treatment according to DSM-III-R (American Psychiatric Association 1987); had psychotic 
symptoms requiring treatment with an oral antipsychotic agent; had received a maximum of 3 
days of emergency treatment for this disorder; had no clinically relevant neurological, 
electrocardiographic, or laboratory test abnormalities; and had given their informed consent 
(or that of relatives or guardians) to participate in the study. 
 
Excluded from the study were pregnant or lactating women; women of reproductive age not 
using adequate contraception; patients with mental illness other than schizophreniform 
disorder or schizophrenia (according to Axis I of DSM-III-R); patients with psychoactive 
substance abuse (DSM-III-R criteria); patients who had received emergency antipsychotic 
treatment for more than 3 days before study entry or previous depot antipsychotic treatment; 
patients with clinically significant organic disease; and patients who had participated in clinical 
trials of investigational drugs within 4 weeks of entry. 
 
Study Procedure.  Patients were randomly assigned to receive risperidone or haloperidol for 
6 weeks at a starting dose of 2 mg twice daily.  The investigator could increase the dose in 
increments of 2 mg/day according to patients’ needs to a maximum of 8 mg twice daily.  
Initially, patients could receive up to 10 mg twice daily, but this was later reduced to 8 mg 
twice daily.  The dose could be reduced at any time because of clinical response or adverse 
events; the minimum dose was 2 mg once daily.  Whenever possible, patients were kept in 
the hospital for the first 2 weeks of the study.  All antiparkinsonian drugs and psychotropic 
agents other than the study drugs were discontinued at selection.  Antiparkinsonian drugs or 
benzodiazepines were administered only if essential. 
 
Treatment Efficacy.  Treatment efficacy was assessed at weeks 1, 2, 4, and 6 by the Positive 
and Negative Syndrome Scale (PANSS; Kay et al. 1987) and the Clinical Global Impression 
scale (CGI; Guy 1976).  The PANSS is a validated 30-item scale consisting of three 
subscales: the positive and negative symptom subscales of 7 items each and the general 
psychopathology subscale of 16 items.  Each item is scored from 1, absent, to 7, extreme.  
The 18 items that constitute the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham 
1962) are included in the PANSS.  Clinical improvement, the primary measure of treatment 
efficacy, was defined a priori as a 50 percent or more reduction in total PANSS scores at 
endpoint.  The percentage of patients who had a 50 percent reduction in total PANSS-derived 
BPRS scores is also reported.  This stringent criterion for clinical improvement was chosen 
because of the nature of the patient population.  Patients with an acute first psychotic episode 
are likely to have high baseline PANSS scores and to be drug naïve; both factors could 
increase the likelihood of observing a clinical effect from antipsychotic drug treatment. 
 
The CGI is a global rating of the severity of illness (rated from 1, not ill, to 7, extremely ill) and 
of the overall change from baseline to endpoint (rated from 1, very much improved, to 7, very 
much worse). 
 
Treatment Safety.  Extrapyramidal symptoms were rated according to the Extrapyramidal 
Symptom Rating Scale (ESRS; Chouinard et al. 1980).  All adverse events that occurred 
during the trial (including intercurrent disease) and that were mentioned or reported by the 
patient either spontaneously or in response to questioning were noted and rated by the 
investigator.  At the first and last visit, an electrocardiogram was obtained from each patient 
and blood samples were drawn for standard laboratory tests.  Vital signs were measured 
weekly. 
 
Statistical Analyses.  All enrolled patients were included in the intent-to-treat (endpoint) 
analysis.  A minimum of 77 patients per treatment group as required to detect a 25 percent 
difference in the primary efficacy endpoint at the 5 percent significance level (two-tailed) with 
90 percent power.  Analyses were performed to control for country effects.  Between-group 
differences in PANSS total and subscale scores and PANSS-derived BPRS scores were 
analyzed by the Mann-Whitney U test.  A two-way analysis of variance (ANOVA) with factors 
for treatment and country and their interaction was used.  If the treatment by country 
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interaction was nonsignificant, the interaction term was omitted from the ANOVA.  
Nonparametric tests were applied to data not normally distributed (Mann-Whitney U test). 
 
The numbers of patients showing a clinical response at endpoint were analyzed using a 
Cochran-Mantel-Haenszel test for general association, which controlled for differences 
between countries.  CGI severity scores were analyzed by the Cochran-Mantel-Haenszel 
mean score test and CGI change scores by the Mann-Whitney U test.  Between-treatment 
differences in the changes in ESRS scores from baseline to the highest scores recorded 
during treatment were compared using the Mann-Whitney U test, supplemented by the 
ANOVA model described above.  Numbers of patients using antiparkinsonian medications 
were analyzed by Fisher’s exact test.  The frequency of other adverse events in each 
treatment group was compared using Fisher’s exact test.  A post hoc analysis was used to 
determine the effects of risperidone and haloperidol treatment at low (maximum, < 6 mg/day) 
and high (maximum, > 6 mg/day) doses. 
 
Results 
 
One hundred eighty-three patients were recruited for the study, 1 to 43 per country with an 
average of 18.3 per country (table 1).  Most were young white men, with a median age of 26 
years (risperidone group) and 24 years (haloperidol group).  Primary diagnoses at study entry 
were provisional schizopreniform disorder in 93 percent and schizophrenia in 7 percent.  The 
Global Assessment of Functioning indicated severe mental illness in most patients. 
 
The 6-week study was completed by 137 patients (79 in the risperidone group and 58 in the 
haloperidol group).  Six patients (8%) treated with risperidone withdrew because of adverse 
events (sometimes in combination with other reasons) compared with 15 patients (26%) 
treated with haloperidol (p = 0.02, Fisher’s exact test).  More patients withdrew from the study 
because of adverse events or insufficient efficacy, or both, in the haloperidol group (17 
patients) than in the risperidone group (9 patients; p = 0.03, Fisher’s exact test).  Other 
reasons for noncompletion (e.g., ineligibility, intercurrent event, lost to follow-up, good 
response, and treatment deviation) were reported in 11 percent of patients in each treatment 
group.  Fifty-five patients (55%) in the risperidone group and 43 (51%) in the haloperidol 
group were receiving medication when they entered the study.  Benzodiazepines were most 
common (42 in the risperidone group and 31 in the haloperidol group).  Duration of trial 
treatment was 1 to 42 days in both groups.  The mean daily dose at endpoint was 6.1 mg of 
risperidone (range, 2 to 16 mg) and 5.6 mg of haloperidol (range, 2 to 16 mg). 
 
Treatment Outcome in Risperidone- and Haloperidol-Treated Patients.  Patients in the 
risperidone and haloperidol groups had comparable PANSS and ESRS baseline scores 
(tables 2 and 3).  At endpoint, 63 percent of the risperidone patients and 56 percent of the 
haloperidol patients were clinically improved according to total PANSS scores (p = 0.19), and 
65 percent and 55 percent were improved according to total BPRS scores (p = 0.08) (figure 
1).  PANSS and BPRS total scores and PANSS subscale scores were significantly improved 
compared with baseline at all time points in both treatment groups (p < 0.001); between-
treatment differences were not statistically significant (table 2). 
 
At the start of the study most of the patients (69% of each group) had marked to severe 
illness.  At endpoint, most patients (67% of the risperidone group; 63% of the haloperidol 
group; p = 0.59, Cochran-Mantel-Haenszel mean score test, controlling for country) were not 
ill or had mild symptoms.  According to the CGI change scale, at endpoint 71 percent of the 
risperidone group and 70 percent of the haloperidol group were much or very much improved; 
21 percent and 25 percent, respectively, were minimally improved or unchanged; and 8 
percent and 5 percent were worse.  The between-group differences were not significant (p = 
0.817, Cochran-Mantel-Haenszel mean score test, controlling for country). 
 
Extrapyramidal symptoms were more severe in the haloperidol group than in the risperidone 
group on each of the ESRS items (table 3).  Significantly greater shifts from baseline to worst 
score with haloperidol than risperidone were seen on the hyperkinesia factor (p < 0.01) and 
total ESRS (parkinsonism + dystonia + dyskinesia) (p < 0.05), as well as on the parkinsonism 
symptoms of rigidity (p < 0.05), gait and posture (p < 0.05), tremor (p < 0.05), and akathisia (p 
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< 0.01).  In addition, antiparkinsonian medications were required by significantly more 
haloperidol- than risperidone-treated patients (75% vs. 50%; p < 0.001, Cochran-Mantel-
Haenszel test, controlling for country). 
 
Other adverse advents.  Total adverse events were reported by significantly more 
haloperidol patients than risperidone patients (90% vs. 78%; p < 0.05, Fisher’s exact test).  
Nonextrapyramidal side effects were reported by 59 percent of the risperidone-treated 
patients and 62 percent of the haloperidol-treated patients.  Adverse events other than 
extrapyramidal symptoms included insomnia (10% of the risperidone group and 16% of the 
haloperidol group), headache (10% of each group), agitation (8% and 11%), and anxiety (8% 
of each group). 
 
Safety measures.  No clinically relevant abnormalities were observed in electrocardiograms, 
heart rate, blood pressure, or laboratory test results. 
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Table 1.  Characteristics of patients treated with risperidone or haloperidol 
        Risperidone Haloperidol 
        (n = 99)  (n = 84) 
 
Men/women       68/31  54/30 
 
Age (yr) 
 Median       26  24 
 Range       15-50  16-45 
 
Age at onset of first symptoms of psychosis (yr) 
 Median       24  23 
 Range       15-44  2-45 
 
Race (%) 
 White       62  62 
 Oriental       16  17 
 Black       12  18 
 Other       10  4 
 
Primary diagnosis (%)1 
 Provisional schizophreniform disorder   93  94 
 Paranoid schizophrenia     4  5 
 Undifferentiated schizophrenia    2  1 
 Disorganized schizophrenia    1  0 
 
Level of functioning (%)2 
 1-20       11  12 
 21-50       76  73 
 51-80       13  15 
________________________________________________________________  
1DSM-III-R, Axis 1. 
2Global Assessment of Functioning (DSM-III-R, Axis V). 
 
 
 
 
Table 2. Mean (+SEM) baseline PANSS and BPRS scores and change 
from baseline to endpoint in patients receiving risperidone (R) or haloperidol (H)  
    Baseline  Endpoint 
   n1  Mean  Change2 95% Cl  p3 
PANSS 
Total  R 98  89.1 + 1.9 -30.9 + 2.5 -35.8 - -26.0
 0.412 
  H 84  89.6 + 2.2 -29.3 + 2.7 -34.7 - -23.9
 0.683 
 
Positive  R 98  23.7 + 0.5 -10.6 + 0.7 -12.0 - -9.2  
  H 84  23.8 + 0.6 -10.5 + 0.8 -12.1 - -8.9
 0.553 
 
Negative R 98  21.2 + 0.7 -5.8 + 0.7 -7.3 - -4.3 
  H 84  21.2 + 0.9 -5.3 + 0.8 -7.0 - -3.7
 0.336 
 
GPS  R 98  44.2 + 1.1 -14.5 + 1.3 -17.2 - -11.9 
  H 84  44.7 + 1.3 -13.4 + 1.5 -16.4 - -10.5
 0.410 
 
BPRS  
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Total  R 98  51.1 + 1.1 -17.9 + 1.4 -20.7 - -15.0 
  H 84  51.5 + 1.2 -16.8 + 1.6 -20.0 - -13.6 
__________________________________________________________________________ 
Note. – SEM = standard error of the mean; PANSS = Positive and Negative Syndrome Scale; 
BPRS = Brief Psychiatric Rating Scale; CI = confidence interval; GPS = General 
Psychopathology Scale. 
 
1Number of patients assessed; excludes patients with missing data. 
2Within-group changes in each variable were significant in both patient groups at  
  all time points (p < 0.001, Wilcoxon signed-rank test). 
3Analysis of variance, F test for treatment effects. 
 
 
 
Table 3. Mean baseline ESRS scores and shifts from baseline to worst score in 
patients receiving risperidone (R) or haloperidol (H)1  
        Baseline               Shift from Baseline 
    Mean 95% Cl  Mean 95% Cl        p2 
 
Questionnaire  R 1.4 0.9-1.9  3.9 3.0-4.9  0.101  
    H 1.5 1.0-2.0  5.1 4.0-6.1 
 
Hypokinesia factor3 R 1.4 0.8-2.1  4.5 3.5-5.6  
 0.273  
   H 1.3 0.8-1.8  5.4 4.2-6.5   
 
Hyperkinesia factor4 R 0.3 0.1-0.4  1.4 1.0-1.8  
 0.007 
   H 0.3 0.2-0.5  2.4 1.8-2.9    
 
Parkinsonism total R 1.8 1.1-2.5  6.1 4.7-7.5  
 0.060 
   H 1.8 1.1-2.4  8.1 6.4-9.8  
Parkinsonism + 
dystonia  R 1.8 1.1-2.5  6.3 4.9-7.8  
 0.060 
  H 1.8 1.2-2.5  8.6 6.8-10.4  
Parkinsonism + 
dystonia + dyskinesia R 1.9 1.2-2.6  6.5 5.0-7.9  0.046 H
 1.9 1.2-2.5  9.0 7.1-10.9 
 
CGI Parkinsonism  
severity    R 0.3 0.1-0.4  1.9 1.5-2.2  0.150 
   H 0.4 0.2-0.5  2.2 1.8-2.6 
__________________________________________________________________________
___ 
 
Note. – ESRS = Extrapyramidal Symptom Rating Scale; CI = confidence interval; CGI = 
Clinical Global Impression. 
 
1ESRS clusters are included if the change from baseline to worst score > 1.  Worst 
scores available for 94 patients in the risperidone group and 80 in the haloperidol 
group. 
2Mann-Whitney U test. 
3Expressive autonomic movements, bradykinesia, rigidity, gait and posture, and sialorrhea.  
4Tremor and akathisia. 
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Figure 1.  Percentages of patients receiving risperidone or haloperidol who were 
clinically improved at endpoint according to a > 50% reduction in total Positive and 
Negative Syndrome Scale (PANSS) or PANSS-derived Brief Psychiatric Rating Scale 
(BPRS) scores 
 
 
 
 
 
 
Post-Hoc Analysis – Low- and High-Dose Treatment 
 
Treatment Outcome in Patients Receiving Low and High Doses of Risperidone.  
Maximim dose data were available for 96 risperidone-treated patients (n = 34, < 6 mg/day; n = 
62, > 6 mg/day).  A post hoc analysis showed that low-dose risperidone (maximum, < 6 
mg/day) was efficacious in many patients and better tolerated than treatment with high-dose 
risperidone (maximum, > 6 mg/day).  Patients receiving low and high doses of risperidone 
had comparable baseline PANSS and ESRS scores.  Patients in both the low- and high-dose 
groups were clinically improved at endpoint according to total PANSS scores (74% and 59%, 
respectively).  PANSS scores were improved in both groups at most postbaseline time points. 
 
Shifts to worst ESRS scores were significantly greater in the high-dose than the low-dose 
group on the hypokinesia factor, hyperkinesia factor, total parkinsonism, total ESRS 
(parkinsonism + dystonia + dyskinesia), and CGI severity of parkinsonism scores (p < 0.05, 
Mann-Whitney U test) (table 4).  In addition, antiparkinsonian medications were used by more 
patients in the high-dose risperidone group than in the low-dose group (40% and 25%, 
respectively; p = 0.19, Cochran-Mantel-Haenszel test, controlling for country).  The numbers 
of patients requiring antiparkinsonian medication increased significantly with the dose (p = 
0.03; Cochran-Armitage trend test). 
 
Treatment Outcome in Patients Receiving Low and High Doses of Haloperidol.  
Maximum dose data were available for 81 haloperidol-treated patients (n = 34, < 6 mg/day; n 
= 47, > 6 mg/day).  Again, patients in both the low- and high-dose groups were clinically 
improved at endpoint according to total PANSS scores (62% and 55%, respectively).  Low 
doses of haloperidol were better tolerated than higher doses:  ESRS shifts to worst scores 
were greater in the high-dose group on several ESRS clusters (table 4); and antiparkinsonian 
medications were used by more patients in the high-dose group than in the low-dose group 
(53% and 46%, respectively; p = 0.66, Cochran-Mantel-Haenszel test, controlling for country).  
The numbers of patients requiring antiparkinsonian medication also increased significantly 
with the dose of haloperidol (p = 0.004; Cochran-Armitage trend test). 
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Table 4.  Mean baseline ESRS scores and shifts from baseline to worst score in 
patients receiving low-dose (< 6 mg) or high-dose (> 6 mg) risperidone (R) and 
haloperidol (H)1 
     Risperidone     
  Haloperidol 
             Baseline        Shift from Baseline     
Baseline        Shift from Baseline 
   Dose Mean 95% Cl Mean 95% Cl p2 Dose Mean
 95% Cl Mean 95% Cl` p2 
 
Questionnaire <6mg 1.6 0.5-2.6 2.9 1.4-4.4 0.143 <6mg 2.1 1.1-3.1 3.0
 1.4-4.5 0.0006 
   >6mg 1.2 0.6-1.8 4.5 3.3-5.6  >6mg 1.1 0.6-
1.6 6.6 5.2-8.0 
 
Hypokinesia factor3 <6mg 1.8 0.4-3.2 2.8 1.1-4.5 0.009 <6mg 1.2 0.4-
2.0 3.1 1.4-4.8 0.0002 
   >6mg 1.2 0.5-1.8 5.4 4.1-6.7  >6mg 1.2 0.5-
1.9 7.0 5.6-8.5 
 
Hyperkinesia factor4 <6mg 0.2 -0.1-0.5 0.8 0.4-1.3 0.041 <6mg 0.3 -
0.01-0.7 1.7 0.9-2.5 0.02 
   >6mg 0.3 0.1-0.4 1.7 1.2-2.2  >6mg 0.4 0.1-
0.6 2.9 2.1-3.6 
 
Parkinsonism total <6mg 2.1 0.6-3.6 3.8 1.8-5.9 0.004 <6mg 1.6 0.6-
2.6 5.0 2.6-7.4 0.0004 
   >6mg 1.5 0.8-2.3 7.3 5.6-9.1  >6mg 1.8 0.8-
2.7 10.4 8.3-12.6 
 
Parkinsonism + <6mg 2.1 0.6-3.6 3.9 1.9-5.9 0.223 <6mg 1.6 0.6-2.6 5.4
 2.9-7.8 0.0005 
dystonia  >6mg 1.5 0.8-2.3 7.7 5.8-9.5  >6mg 1.9 0.9-
2.8 11.0 8.6-13.3 
 
Parkinsonism +  <6mg 2.1 0.6-3.6 3.9 1.9-6.0 0.005 <6mg 1.7 0.7-2.7 5.5
 3.0-8.0 0.0003 
dystonia+dyskinesia>6mg 1.7 0.9-2.4 7.8 5.9-9.8  >6mg 1.9 1.0-
2.8 11.6 9.0-14.1 
 
CGI Parkinsonism  <6mg 0.4 0.01-0.8 1.1 0.6-1.7 0.002 <6mg 0.3
 0.1-0.6 1.7 1.1-2.3 0.009 
severity  >6mg 0.2 0.03-0.4 2.3 1.8-2.7  >6mg 0.4 0.1-
0.6 2.7 2.2-3.2 
Note.  - ESRS = Extrapyramidal Symptom Rating Scale;  CI = confidence interval;  CGI = 
Clinical Global Impression. 
 
1ESRS clusters and ESRS parkinsonism items are included if the change from baseline to 
worst score > 1.  Worst scores available for 33 patients in the low-dose risperidone group; 61 
in the high-dose risperidone group; 32 in the low-dose haloperidol group; and 47 in the high-
dose haloperidol group. 
2Mann-Whitney U test. 
3Expressive autonomic movements, bradykinesia, rigidity, gait and posture, and sialorrhea. 
4Tremor and akathisia. 
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Discussion 
 
It is well established that risperidone is a safe and effective antipsychotic agent in patients 
with chronic schizophrenia.  The results of the present study show that it is also efficacious 
and well tolerated in patients with a first psychotic episode.  The severity of psychotic 
symptoms (PANSS scores) was significantly reduced with risperidone treatment, and the 
severity of extrapyramidal symptoms (ESRS scores) was significantly lower in patients 
receiving risperidone than haloperidol.  An important issue in the management of these 
patients was raised in the post hoc analysis.  This analysis of patients receiving low and high 
doses was carried out because the trial was performed before the need for gradual titration 
and the optimal risperidone dose (< 6 mg/day) were well established.  Results showed that 
low-dose risperidone (maximum, < 6 mg/day) was efficacious in some patients and 
associated with significantly fewer severe extrapyramidal symptoms than high-dose 
risperidone (maximum, > 6 mg/day).  Similar findings were observed in patients receiving 
haloperidol, a conventional antipsychotic that differs from risperidone in chemical structure, 
receptor binding profile, and clinical effects.  Although illness heterogeneity likely contributed 
to the breakdown of patients who received low and high doses, the results show that low 
doses of these agents are efficacious as well as better tolerated in many patients.  These data 
are consistent with the idea that low doses of risperidone, haloperidol, and possibly other 
antipsychotic agents, may be best for many first-episode patients; these patients appear to be 
more sensitive to the therapeutic and extrapyramidal effects of antipsychotic medications.  A 
controlled study showed that neuroleptic threshold doses of haloperidol were as efficacious 
and more tolerable than higher doses in patients with schizophrenia or schizoaffective 
disorder (McEvoy et al. 1991).  A recent open-label study of 22 patients with first-episode 
schizophrenia showed that low-dose (2-4 mg/day) compared with high-dose (5-8 mg/day) 
risperidone was associated with a superior outcome (Kopala et al. 1997).  Further studies 
specifically designed to test this hypothesis are clearly warranted. 
 
This dosing issue is particularly important because several studies have shown that patients 
experiencing a first psychotic episode are at a greater risk of extrapyramidal  symptoms than 
patients with chronic disease.  In the 5-week Scottish trial (Scottish Schizophrenia Research 
Group 1987) of 46 first-episode schizophrenia patients treated with conventional antipsychotic 
agents (pimozide or flupenthixol), 38 patients (83%) required antiparkinsonian medications; 
78 percent and 85 percent of patients received pimozide and flupenthixol, respectively.  In the 
current study, antiparkinsonian medications were used by 75 percent of haloperidol-treated 
patients and 50 percent of risperidone-treated patients.  Lieberman et al. (1989) reported that 
79 percent of 53 patients experiencing a first psychotic episode exhibited acute 
extrapyramidal symptoms during treatment with fluphenazine (20 mg/day).  In a further study 
(Chakos et al. 1992) of first-episode schizophrenia, 41 (62%) of 66 patients treated with 
fluphenazine experienced acute extrapyramidal symptoms (parkinsonism, akathisia, and 
dystonia); 85 percent of these patients experienced the extrapyramidal symptoms before the 
end of the sixth week of treatment.  In a study of 29 first-episode schizophrenia patients 
treated with conventional neuroleptics, Chakos et al. (1994) found that increases in caudate 
volume were associated with higher doses of neuroleptic and younger age at onset of illness.  
Keshavan et al. (1994) reported that the caudate nucleus increased in size bilaterally and 
substantially in treatment-naïve first-episode patients during treatment with conventional 
neuroleptics.  These findings suggest that patients experiencing a first psychotic episode may 
be at high risk of extrapyramidal symptoms caused by dopamine D2 antagonism.  The results 
of these trials indicate that first-episode patients may be particularly sensitive to neuroleptic-
induced extrapyramidal disorders. 
 
For risperidone, the manufacturer now recommends that treatment should be initiated at 1 mg 
twice daily for most patients with schizophrenia (Risperdal 1996).  An even lower starting dose 
(< 1 mg/day) combined with slow increases (< 1mg/day at intervals of at least 1 week) may be 
appropriate in neuroleptic-naïve patients experiencing a first psychotic episode.  The current 
data suggest doses of 3 mg daily or less are appropriate for most of these patients.  As 
always, the target dose should be the lowest efficacious dose. 
 
Nonetheless, even with the dosing regimen used in the present study, the severity of 
extrapyramidal symptoms was significantly lower with risperidone than with haloperidol.  
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Moreover, significantly fewer risperidone patients required antiparkinsonian medication, and 
significantly fewer discontinued treatment because of adverse events.  These findings in first-
episode patients are consistent with results of studies in patients with chronic schizophrenia 
(Chouinard et al. 1993; Marder and Meibach 1994; Peuskens 1995). 
 
The severity of psychotic symptoms was reduced in both risperidone- and haloperidol-treated 
patients, and clinical improvement was observed in 63 percent and 56 percent of patients, 
respectively; between-group differences were not statistically significant.  In the Scottish first-
episode schizophrenia study (Scottish Schizophrenia Research Group 1987), the patients’ 
mental state improved significantly (reduction in Krawiecka et al. [1977] total scores from 
baseline) during each week of the 5 weeks of treatment, with no significant between-group 
differences (23 patients received pimozide and 23 received flupenthixol).  Positive symptoms 
also improved significantly, but no change was seen in negative symptoms.  In the 53 first-
episode patients studied by Lieberman et al. (1989), positive symptom ratings (Endicott and 
Spitzer 1978) were reduced 50 percent within the first 10 weeks of treatment with 
fluphenazine, but only a 10 percent reduction was seen in negative symptom scores 
(Andreasen 1983).  In contrast, risperidone and haloperidol effectively reduced both positive 
and negative symptoms in our patients.  The absence of between-group differences in 
changes in negative symptoms in the present study may have resulted from the low baseline 
negative symptom scores in both patient groups (table 2).  Risperidone was shown to be 
significantly more effective than haloperidol against negative symptoms in patients with 
chronic schizophrenia in the North American trial (Marder and Meibach 1994) and in the 
meta-analysis of these data by Carman et al. (1995) and the path analysis of Möller et al. 
(1995). 
 
The efficacy of risperidone in ameliorating positive and negative symptoms in patients with a 
first psychotic episode supports the results of Kopala et al. (1996).  This study reported 
significant positive and negative symptom improvement with risperidone in first-episode 
psychotic patients:  Mean changes in PANSS positive and negative subscale scores and in 
the positive and negative factors of the five-factor analysis were statistically significant. 
 
Prompt and effective amelioration of psychotic symptoms is important because many acutely 
ill patients are in great distress from frightening and confusing ideas and perceptions.  The 
effective control of symptoms without substantial adverse events, particularly extrapyramidal 
symptoms, can contribute to long-term compliance and optimal long-term outcome with these 
patients. 
 
Conclusions 
 
This is the largest study to date of first-episode psychotic patients in whom an atypical 
antipsychotic was assessed, and it points to some important facts relevant to the treatment of 
these patients.  The study supports the idea that first-episode psychotic patients should 
receive low doses of risperidone, haloperidol, and possibly other antipsychotic agents.  Both 
risperidone and haloperidol at maximum daily doses of 6 mg or less were efficacious in some 
patients and better tolerated than maximum daily doses greater than 6 mg.  Also, risperidone 
was at least as effective as haloperidol in ameliorating psychotic symptoms in these acutely ill 
patients and was better tolerated.  Because a patient’s first experiences with a drug are 
crucial in determining compliance, this good tolerance for risperidone may improve the long-
term outcome in patients with schizophrenia and other psychoses. 
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Quetiapine (‘Seroquel’) is a well-tolerated, novel, atypical antipsychotic with consistent 
efficacy in the treatment of schizophrenia.  To date, no clinical studies have evaluated the 
effect of quetiapine in patients who only partially respond to conventional antipsychotics, yet 
this type of patient is most frequently seen by psychiatrists.  Therefore, this international, 
multicentre, double-blind study was conducted to compare the efficacy and tolerability of 8 
weeks’ treatment of quetiapine 600 mg/day with haloperidol 20 mg/day in 288 patients who 
had a history of partial response to conventional antipsychotics and displayed a partial or no 
response to 1 month of fluphenazine (20 mg/day) treatment.  Patients on quetiapine tended to 
have greater improvement than those on haloperidol in the primary efficacy measure, mean 
Positive and Negative Symptom Scale (PANSS) score, after 4 weeks’ treatment (-9.05, -5.82, 
respectively, P = 0.061) and at study end (-11.50, -8.87, respectively, P = 0.234).  Similarly, 
there was a trend towards patients on quetiapine demonstrating greater improvements in the 
secondary efficacy measures (Clinical Global Impression, PANSS subscale and Brief 
Psychiatric Rating Scale scores) [week 4 (baseline) to week 12 (end)], but the difference 
between treatments did not reach significance.  Significantly more patients on quetiapine than 
on haloperidol showed a clinical response – patient response rates, defined as > 20% 
reduction in PANSS total score between weeks 4 and 12, were 52.2% for quetiapine and 
38.0% for haloperidol (P = 0.043).  Patients receiving quetiapine required less anticholinergic 
medication (P < 0.011), had greater reduction in extrapyramidal symptoms (EPS) (P = 0.005) 
and fewer treatment-emergent EPS-related adverse events compared to those on haloperidol 
(P < 0.001).  Serum prolactin concentrations were elevated at the end of fluphenazine 
treatment in 73% of patients.  Between weeks 4 and 12, elevated serum prolactin 
concentrations significantly decreased in quetiapine-treated patients compared to those 
receiving haloperidol (P < 0.001).  At the end of quetiapine treatment, 83% of patients had 
normal prolactin levels while only 21% of patients receiving haloperidol were within the normal 
range.  These results suggest that quetiapine may make a valuable contribution to the 
management of patients with a history of partial response to conventional antipsychotics. 
 
 
INTRODUCTION 
 
The majority of patients with schizophrenia are treated as outpatients.  For many, treatment 
with conventional antipsychotics is not fully effective and they continue to display clinically 
significant symptoms (Goldman and Manderscheid, 1987; Katz, 1987; Rosenstein et al., 
1989).  This population may be referred to as partial responders (Breier et al., 1994) and 
represents the majority of schizophrenic patients that a practising psychiatrist is most likely to 
treat.  Their treatment may be problematic since they may receive many different 
antipsychotic agents until a suitable therapy is found.  Such patients have not been studied 
extensively in conventional clinical trials and the concept of partial responders is not formally 
well established.  Results from clinical trials that have excluded such patients may not be 
strictly transferable to the heterogenous population seen in clinical practice. 
 
Quetiapine (‘Seroquel’) is a novel, atypical antipsychotic with consistent efficacy in treating the 
positive and negative symptoms of schizophrenia (Borison et al., 1996; Arvanitis et al., 1997; 
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Small et al., 1997) and is at least as effective as haloperidol (Arvanitis et al., 1997; Copolov et 
al., 2000) and chlorpromazine (Peuskens and Link. 1997).  A recent case report has shown 
quetiapine (maintenance dose 400 mg/day) to be effective in a male schizophrenic patient 
aged > 40 years who was diagnosed as being partially responsive to neuroleptic treatment, 
despite good compliance (Chincilla et al., 1997).  The incidence of extrapyramidal symptoms 
(EPS) observed with quetiapine across the full dosage range is not significantly different from 
placebo (Arvanitis et al., 1997), and the drug does not cause sustained elevation of plasma 
prolactin levels (Arvanitis et al., 1997), unlike many conventional antipsychotics and some 
newer agents. 
 
To date, no clinical trials have evaluated the effects of quetiapine in a specific population of 
schizophrenic patients who are partial responders to conventional antipsychotics.  The aim of 
this international, multicentre, double-blind study was to compare the efficacy and tolerability 
of 8 weeks’ treatment with quetiapine 600 mg/day or haloperidol 20 mg/day in patients who 
had a history of partial response to conventional antipsychotics. 
 
 
 
METHODS 
 
Patients 
 
Before entry into the randomization phase of the study, all patients received fluphenazine for 4 
weeks.  Key criteria for inclusion into the fluphenazine run-in phase of the trial were:  male or 
female aged 18 years or over; schizophrenia according to the DSM-IV diagnostic criteria 
(American Psychiatric Association, 1994) for either catatonic, disorganized, paranoid or 
undifferentiated type:  persistent positive symptoms while previously taking therapeutic doses 
of antipsychotic treatment; a total score of at least 15 on the positive scale of the Positive and 
Negative Symptom Scale (PANSS) (Kay et al., 1987), with a score of at least 4 (moderate) for 
one or more of the following items:  delusions, conceptual disorganization, hallucinatory 
behaviour and suspiciousness / persecution; and a score of at least 3 (mildly ill) on the 
Clinical Global Impression (CGI) (Guy and Bonato, 1970) Severity of Illness item.  All patients 
gave their written informed consent and were required to withdraw from psychotropic 
medication before entry to the fluphenazine run-in phase, with the exception of long-term use 
of benzodiazepine treatment. 
 
Key exclusion criteria were patients known to be resistant to standard antipsychotic 
medication; those known to be clozapine non-responders; those who had experienced acute 
exacerbation of schizophrenia within the previous 3 months, and those who had known 
sensitivity to drugs evaluated in this trial or a history of idiopathic or drug-induced 
agranulocytosis. 
 
Patients were eligible for randomization to either quetiapine or haloperidol treatment if they 
had a history of unsuccessful therapy for schizophrenia and had shown either a partial 
response or no response to 1 month of treatment with the conventional antipsychotic, 
fluphenazine.  Because these patients were considered to be difficult to treat, the quetiapine 
and haloperidol dosages were towards the upper end of their recommended dosage ranges, 
namely 600 mg/day and 20 mg/day, respectively. 
 
Study design and treatments 
 
The study was an international, multicentre, double-blind, randomized trial where medications 
were administered according to a twice-daily regimen (Fig. 1).  After undergoing a pre-trial 
screen, eligible patients entered a 4-week active run-in phase of open treatment with 
fluphenazine, the dosage of which was escalated from 5-15 mg/day during the first week and 
maintained at 20 mg/day for the next 3 weeks.  At the end of the fluphenazine run-in phase 
(week 4), patients were evaluated for their response to the drug.  Those patients not 
responding (defined as no change from week 1 to week 4 in PANSS total score or an increase 
at week 4) or considered to have a partial response to fluphenazine (defined as a reduction 
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from week 1 to week 4 in PANSS total score of < 30% and a PANSS positive score of > 15) 
were eligible to enter the randomization phase of the trial.  These patients were randomized to 
receive either quetiapine or haloperidol twice daily, dosages of which were titrated over a 7-
day period during week 5 up to 600 mg/day and 20 mg/day, respectively.  During the next 7 
weeks (weeks 6-12), dosages of quetiapine and haloperidol were fixed at 600 mg/day and 20 
mg/day, respectively.  Use of benzodiazepines or anticholinergics was permitted to treat any 
cases of acute agitation, severe insomnia, EPS or akathisia that emerged during the trial, and 
the continuation of long-term treatment with benzodiazepines was allowed.  Other 
concomitant medication was allowed at the discretion of the investigator. 
 
Evaluation of efficacy 
 
The severity of schizophrenic symptomatology during the trial was measured using the 
PANSS (1-7 scoring scale) and the CGI Severity of Illness score at weeks 1, 4, 8 and 12.  The 
primary efficacy endpoint was the change in PANSS total score from week 4 (baseline) to 
week 8 and week 12.  Secondary efficacy endpoints were change in score or response to 
treatment between week 4 (baseline) and week 12 measured by the PANSS subscale 
(positive, negative and general psychopathology);  derived Brief Psychiatric Rating Scale 
(BPRS; total, positive subscale and mood cluster) (Overall and Gorham, 1962); and CGI 
Severity of Illness.  The CGI Global Improvement score was analysed at week 12.  Response 
to treatment was measured according to three criteria:  (A) those patients who had a 
decrease in PANSS total score of > 20% from week 4 to week 12;  (B) those who had CGI 
Severity of Illness score < 3 at week 12;  and (C) those who fulfilled both of these criteria.  
The criterion for a response to treatment being defined as a decrease in PANSS total score of 
> 20% was based on current literature of trials involving refractory patients (Bondolfi et al., 
1998; Conley et al., 1998., Flynn et al., 1998; Kane et al., 1988; Conley et al., 1999). 
 
Evaluation of safety and tolerability 
 
Drug safety and tolerability were secondary endpoints in this trial.  These were evaluated by 
monitoring: the proportion of patients receiving anticholinergic medication between weeks 4 
and 12;  the proportion of patients experiencing adverse events related to EPS between 
weeks 4 and 12;  the proportion of patients experiencing worsening EPS between weeks 4 
and 12;  indicated by an increase in the Simpson Scale score (Simpson and Angus, 1970) 
which included an item for akathisia;  the proportion of patients developing clinically significant 
EPS between weeks 4 and 12 (defined by an increase in Simpson Scale score, which also 
included an item for akathisia to > 14 at some point between weeks 4 and 12;  and absolute 
change in serum prolactin from week 4 to week 12.  Adverse events were recorded 
throughout the trial.  Adverse events related to EPS were defined as:  hypertonia, neck 
rigidity, cogwheel rigidity, tremor, hypokinesia, akinesia, extrapyramidal syndrome, akathisia, 
dystonia, oculogyric crisis and torticollis.  Haematological tests and clinical chemistry were 
monitored pre-trial and at weeks 4, 8 and 12.  Vital signs were recorded at the pre-trial screen 
and at weeks 4 and 12. 
 
Statistical analysis 
 
The size of the trial population was calculated based on that required to show a clinically 
meaningful difference in efficacy between quetiapine and haloperidol at the 5% significance 
level and with 90% power.  All statistical tests were two-sided. 
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Efficacy 
 
The main analysis was a last-value-carried forward (LVCF) analysis conducted on the intent-
to-treat population (ITT), which consisted of all randomized patients who received quetiapine 
or haloperidol treatment and provided efficacy data for at least one visit after randomization.  
Two additional analyses were conducted to examine the statistical robustness of the main 
analysis.  These analyses were conducted on the ITT population without LVCF, i.e. observed-
cases analysis, and LVCF analysis on a per-protocol (PP) population, where data were 
excluded from patients who violated / deviated from the protocol in such a way as to affect the 
analysis.  The changes in PANSS total score (primary endpoint) from week 4 (baseline) to 
weeks 8 and 12 were analysed using analysis of covariance; this model included baseline 
score, treatment, centre and centre-by-treatment interaction as factors.  Differences between 
treatments were measured and presented with associated P-values and confidence intervals.  
Statistical analysis of the changes in secondary endpoint measures (PANSS subscale scores, 
derived BPRS scores and CGI scores) from week 4 to week 12 was performed as for the 
primary endpoint.  The response to treatment at week 12 was analysed using logistic 
regression;  this model included treatment, centre and centre-by-treatment interaction as 
factors. 
 
Safety and tolerability  
 
Assessment of the secondary safety and tolerability endpoints was conducted on the ITT 
population using logistic regression analysis;  this model included treatment, centre and 
centre-by-treatment as factors.  As for the efficacy endpoints, LVCF analysis was conducted 
on the endpoints which measured the proportion of patients receiving anticholinergic 
medication during weeks 4–12;  the proportion of patients experiencing adverse events 
related to EPS during weeks 4-12;  the proportion of patients experiencing a worsening of 
EPS during weeks 4-12;  the proportion of patients developing clinically significant EPS during 
weeks 4-12;  and change in serum prolactin levels.  The model included treatment, centre and 
centre-by-treatment interaction as factors.  Estimates of time to taking anticholinergic 
medication were evaluated using Kaplan-Meier survival curves.  No formal statistical analyses 
were performed on non-EPS adverse events, haematology, clinical chemistry or vital signs 
test results. 
 
 
Table 1. Patient demographics 
_____________________________________________________________Demographic 
characteristic  Quetiapine  Haloperidol 
 
Number of patients exposed   143   145 
Age (years) 
 Mean (SD)    37.7 (10.8)  38.8 (11.3) 
 Range     18-75   18-70 
Sex: number (%) of patients 
 Male     102 (71.3)  101 (69.7) 
 Female    41 (28.7)  44 (30.3) 
Race: number (%) of patients 
 Caucasian    113 (79.0)  117 (80.7) 
 Afro-Caribbean   10 (7.0)  4 (2.6) 
 Hispanic    9 (6.3)   9 (6.2) 
 Asian     3 (2.1)   6 (4.1) 
 Oriental    2 (1.4)   2 (1.4) 
 Mixed     2 (1.4)   3 (2.1) 
 Other     4 (2.8)   4 (2.8) 
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RESULTS 
 
Patient population 
 
A total of 365 patients with a history of partial response to conventional antipsychotic 
treatment were recruited into the fluphenazine run-in phase of the trial.  The mean (+ SD) 
rating scale scores at trial entry for those subsequently randomized to quetiapine and 
haloperidol were PANSS total 91.1 (+7.9), 93.2 (+21.4);  PANSS Positive Subscale 23.0 (+ 
4.5), 24.1 (+ 5.7); and CGI Severity of Illness 3.7 (+1.3), 3.9 (+1.2), respectively.  Two 
hundred and eighty-eight patients were randomized to treatment with either quetiapine (n = 
143) or haloperidol (n = 145).  Seventy-seven patients were not randomized due to:  condition 
deterioration (n = 9); lost to follow-up (n = 4); adverse events (n = 14); protocol non-
compliance (n = 10); informed consent withdrawn (n = 16); other reasons (n = 24).  Ninety-five 
(quetiapine n = 54; haloperidol n = 41) of the 288 patients randomized did not respond to 
fluphenazine.  Of these 288 patients, seven were excluded from the randomized population 
as they did not have post-baseline efficacy assessments and hence the ITT population (n = 
281) comprised 140 patients on quetiapine and 141 patients on haloperidol.  A per protocol 
population (n = 262) defined as those patients who had not violated / deviated from the 
protocol in such a way as to affect the analysis comprised 127 patients on quetiapine and 135 
patients on haloperidol.  All randomized patients were included in the safety population. 
 
The quetiapine and haloperidol groups were well-matched demographically (Table 1).  The 
majority of patients in the quetiapine and haloperidol groups had paranoid schizophrenia 
(73% versus 76%, respectively) and were moderately to markedly ill (mean baseline CGI 
Severity of Illness score of 4.4 and 4.5, respectively; Table 2). 
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Table 2. Baseline scores (week 4) and changes in rating scale scores from baseline to week 
12 in patients receiving either quetiapine 600 mg/day or haloperidol 20 mg/day for 8 weeks 
who were partially responsive to conventional antipsychotic treatment 
    Quetiapine    Haloperidol
   Difference between treatments 
    Baseline Change  Baseline Change 
 Difference 95% Cl P-value 
      from baselinea   from 
baselineb         (SE)     
__________________________________________________________________________
__________________________ 
PANSS total score  88.2  -11.50   88.1  -
8.87   -2.64 (2.21) -6.99, 1.72 0.234 
      (n = 140)    (n = 
141) 
PANSS subscale score 
 Positive Scale 21.7  -3.43   22.1  -2.85 
  -0.58 (0.74) -2.05, 0.88 0.433 
      (n = 140)    (n = 
140) 
 Negative Scale 24.0  -3.00   23.3  -2.39 
  -0.61 (0.60) -1.80, 0.57 0.309 
      (n = 139)    (n = 
140) 
 GP Scale  42.5  -4.93   42.8  -
3.72   -1.21 (1.09) -3.36, 0.94 0.267 
      (n = 139)    (n = 
141) 
Derived BPRS scores  
 Total   49.4  -6.95   49.2  -
4.78   -2.16 (1.33) -4.79, 0.46 0.105 
      (n = 140)    (n = 
141) 
Positive Subscale 12.0  -2.19   12.2  -
1.61   -0.58 (0.38) -1.33, 0.18 0.136 
      (n = 140)    (n = 
141) 
 Mood cluster  9.9  -1.21   10.0  -
0.68   -0.53 (0.39) -1.29, 0.23 0.173 
      (n = 140)    (n = 
141) 
CGI item scores  
 Severity of illness 4.4  -0.53   4.5  -
0.38    -0.15 (0.12) -0.39, 0.09 0.221 
      (n = 140)    (n = 
141) 
 Global Improvementb  -  2.86   -  2.97 
  -0.11 (0.16) -0.42, 0.20 0.471  
   (n = 115)    (n = 
121) 
__________________________________________________________________________
______________________________ 
aLeast squares mean, a negative mean change indicates an improvement from baseline  
bThe values at week 12 are presented: a low Clinical Global Improvement value indicates a 
greater improvement. 
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Efficacy 
 
Primary endpoint 
 
The results of the main analysis (LVCF on ITT population) showed that quetiapine and 
haloperidol were associated with marked mean reductions in PANSS total scores over time 
(Fig. 2).  The difference in the reduction in PANSS total score after 4 weeks’ treatment was 
greater with quetiapine (week 8) compared to haloperidol and approached statistical 
significance (P = 0.061).  Similarly, the magnitude of reduction in PANSS total score at week 
12 was greater for quetiapine than haloperidol but the difference between the two treatments 
was not statistically significant (P = 0.234).  The results of the additional analyses (observed 
cases on ITT and LVCF on PP populations) were consistent with the results of the main 
analysis. 
 
Secondary endpoints 
 
In the main analysis (LVCF on ITT population), response rates to treatment, defined as the 
proportion of patients experiencing a decrease in PANSS total score of > 20% from weeks 4-
12 (A), were higher in the quetiapine group than in the haloperidol group and reached 
statistical significance in favour of quetiapine at endpoint (P = 0.043) (Fig. 3).  The two other 
definitions of response to treatment were the proportion of patients demonstrating a CGI 
Severity of Illness score < 3 at week 12 (B) and the proportion of patients who fulfilled both 
these definitions (i.e. A and B) of treatment response (C).  A higher proportion of patients on 
quetiapine demonstrated a CGI Severity of Illness score < 3 at week 12 (B) compared to 
those on haloperidol (46% and 35%, respectively), but this difference was not significant (P = 
0.09).  The proportion of patients who fulfilled both these definitions of treatment response (C) 
was greater in the quetiapine group than the haloperidol group (36% and 24%, respectively), 
but the difference between treatments only approached significance (P = 0.08).  The results 
of the additional analysis (LVCF on PP population) were significant, in favour of quetiapine for 
all three definitions of response to treatment (A, P = 0.02; B, P = 0.03; C, P = 0.02). 
 
The results of the main analysis (LVCF on ITT population) showed that both treatments were 
associated with improvements in score from week 4 to week 12 for the PANSS subscale 
scores, derived BPRS scores and CGI item scores (Table 2).  Quetiapine was associated with 
a greater improvement than haloperidol for the majority of these rating scale scores, but none 
of the differences reached statistical significance (Table 2).  The results of the additional 
analyses (observed cases on ITT and LVCF on PP populations) were consistent with the 
results of the main analysis of these endpoints. 
 
Safety and tolerability 
 
The mean (range) durations of exposure to quetiapine and haloperidol were 49 (2-97) days 
and 50 (4-68) days, respectively.  The result of the main analysis (ITT) showed that, despite 
no washout period being allowed between the fluphenazine run-in and randomization, the 
proportion of patients who received anticholinergic medication between weeks 4 and 12 was 
significantly lower in the quetiapine group than the haloperidol group (44% and 60%, 
respectively; P = 0.011).  Of the 62 patients receiving quetiapine who required anticholinergic 
medication, only 5% (3 / 62) were given anticholinergics after week 4 (i.e. after the 
fluphenazine run-in phase), compared to 20% (17 / 84) of the 84 haloperidol patients during 
the same period of time.  The Kaplan-Meier survival estimate (ITT population) for time to 
treatment with anticholinergic medication was higher for the quetiapine group (0.555) 
compared to that for the haloperidol group (0.394), showing that patients on quetiapine had 
less risk of using anticholinergic medication than those patients on haloperidol (Fig. 4).  
Similarly, the proportion of patients on quetiapine who required the use of anticholinergic 
medication decreased from week 4 to week 12 (41% versus 32%, respectively) whereas, 
during the same period, the proportion of patients in the haloperidol group using 
anticholinergic medication increased (47% versus 53%, respectively). 
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Evaluation of the ITT population showed that treatment with quetiapine between weeks 4 and 
12 was associated with a reduced risk of developing EPS-related adverse events (P < 0.001) 
compared to haloperidol (14% versus 31%, respectively) (Fig. 5).  Similarly, the proportion of 
patients with an increase in the Simpson Scale score from week 4 to any time up to week 12 
was significantly greater in the haloperidol-treated group compared to the quetiapine group 
(39% versus 24%, respectively, P = 0.005) (Fig. 5).    Furthermore, the proportion of patients 
whose Simpson Scale score increased to > 14 from week 4 onwards was significantly greater 
in the haloperidol group than in the quetiapine group (28% versus 14%, P = 0.002) (Fig. 5). 
 
Serum prolactin concentrations were elevated at the end of fluphenazine treatment in 73% of 
patients.  Elevated baseline serum prolactin concentrations were significantly decreased in 
patients receiving quetiapine treatment compared to those receiving haloperidol (least 
squares mean change  –601.39 mU/l and –20.54 mU/l, respectively; P < 0.001).  At the end 
of quetiapine treatment, 83% (88 / 106) of patients had normal prolactin levels while only 21% 
(24 / 113) of patients receiving haloperidol were within the normal range (Fig. 6). 
 
The number of patients withdrawing during the randomized phase of the trial was similar in 
the quetiapine (n = 32, 22.4%) and haloperidol (n = 28, 19.3%) treatment arms (Table 3).  The 
study design allowed patients to ‘withdraw their consent’ at any time during the study;  the 
proportion of patients ‘withdrawing their consent’ was higher in the haloperidol group (7.6%) 
than the quetiapine group (1.4%).  The proportion of patients who withdrew because of 
adverse events was 8.4% in the quetiapine group compared to 3.4% in the haloperidol group.  
This was unexpected as quetiapine was statistically  significantly superior to haloperidol for all 
EPS and prolactin measures. 
 
Overall, treatment-emergent adverse events were reported in approximately half of the 
patients in both the quetiapine and haloperidol groups (53% and 56%, respectively).  The 
most frequently reported adverse events in the quetiapine group were somnolence (9.8% of 
patients), postural hypotension / dizziness (7.7%), dry mouth (5.6%), hypertonia (5.6%) and 
akathisia (5.6%), the majority of which are related to the known pharmacology of the drug.  In 
contrast, the most common adverse events experienced with haloperidol were, in general, 
related to EPS:  tremor (11.7% of patients), akathisia (9.0%), hypertonia (6.9%), EPS 
syndrome (6.2%) and insomnia (6.2%). 
 
There were no clinically important changes in clinical laboratory data, and neither treatment 
was associated with any clinically relevant changes in vital signs.  Small increases in body 
weight from weeks 4-12 (or withdrawal from the trial) occurred in both treatment groups;  the 
mean increase was 1.4 kg in the quetiapine group and 0.7 kg in the haloperidol group. 
 
 
Table 3. Reasons for withdrawal from the study 
      Number (%) of patients 
Reason for withdrawal Quetiapine (n = 143) Haloperidol (n = 145) 
______________________________________________________________ 
 
Death    0    0 
Adverse event  12 (8.4)   5a (3.4) 
Non-compliance with 
protocol  2 (1.4)    3 (2.1) 
Deterioration of condition 11 (7.7)   8 (5.5) 
Informed consent       
withdrawn   2 (1.4)    11b (7.6) 
Patient lost to follow-up 3 (2.1)    0 
Other    2 (1.4)    1 (0.7) 
Total    32 (22.4)   28 (19.3) 
______________________________________________________________ 
aIncludes two patients with adverse events (onset during the fluphenazine run-in phase) 
which led to withdrawal after randomization.   
bSee text for discussion of withdrawal of consent due to possibility of adverse events. 
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DISCUSSION 
 
The results indicate that quetiapine is at least as effective as haloperidol in the treatment of 
schizophrenia patients with a history of, and also demonstrating as part of the clinical trial, a 
partial response to conventional antipsychotic treatment.  For almost all of the primary and 
secondary efficacy endpoints, the effectiveness of quetiapine was greater than that of 
haloperidol, although the differences for most endpoints were not statistically significant.  The 
decreases in PANSS total score reported here for both treatments were less than those seen 
elsewhere (e.g. Copolov et al., 2000).  These relatively small reductions in PANSS total score 
are not unexpected as this cohort showed previous partial responsiveness and had received 
4 weeks fluphenazine treatment immediately prior to randomization.  However, the proportion 
of patients responding to treatment was always greater in the quetiapine group than in the 
haloperidol group for all three definitions of response to treatment.  The results of the main 
analysis, LVCF analysis on the ITT population, showed that the proportion of patients having 
a decrease of > 20% in PANSS total score between weeks 4 and 12 was significantly greater 
in the quetiapine group than the haloperidol group.  For the secondary analysis, LVCF on the 
PP population, quetiapine was statistically superior and was associated with a higher 
proportion of patients responding than haloperidol for all three definitions of response. 
 
As this patient population is likely to reflect the patients that practising psychiatrists are most 
likely to treat, it is possible that quetiapine may be clinically beneficial to more patients than 
haloperidol, especially in view of the EPS and prolactin tolerability advantages.  The results 
from previous clinical trial populations for antipsychotic drugs may not be relevant to clinical 
practice and the population used in this study probably more accurately reflects real-life 
practice.  Indeed, poor clinical improvement is observed in between 15% and 25% of patients 
with schizophrenia treated with antipsychotic agents (Conley and Buchanan, 1997).  In clinical 
practice, a spectrum of patients exists, ranging from those who respond completely to 
treatment to those who show a partial response, and extending to those who could be 
classified as resistant to treatment.  There are studies which show other atypical antipsychotic 
agents to be efficacious in the treatment of patients who are resistant or intolerant to 
conventional agents (Tollefson et al., 1997; Bondolfi et al., 1998; Flynn et al., 1998; Breier and 
Hamilton, 1999); however, to date there have been no studies including patients who had a 
partial response to treatment. 
 
When reviewing the safety results of this trial, the lack of a fluphenazine washout period in the 
design of this study is important to consider, as this may have artificially inflated the incidence 
and worsening of EPS-related adverse effects and also would have caused baseline serum 
prolactin levels to be elevated.  Despite this limitation, these data are consistent with other 
reports (Arvanitis et al., 1997; Copolov et al., 2000) and show that quetiapine has a superior 
safety and tolerability profile in these respects compared to that of haloperidol, and this was 
particularly evident regarding motor system disturbance.  The difference between treatments 
in a number of key measures assessing this were all statistically significant in favour of 
quetiapine:  fewer patients receiving quetiapine required anticholinergic medication, patients 
receiving quetiapine had fewer EPS-related adverse events, fewer had development or 
worsening of EPS (increase in Simpson Scale score), and fewer had development of clinically 
significant EPS (increase in Simpson Scale score from week 4 and > 14 at any time up to 
week 12). 
 
Compared to previous controlled studies evaluating anticholinergic use during treatment with 
quetiapine < 12% versus 14% placebo, (Arvanitis et al., 1997) and < 12-13% versus 48-49% 
haloperidol; (Arvanitis et al., 1997; Copolov et al., 2000), the use of anticholinergic medication 
in quetiapine patients in this study was relatively high (44%).  This is very likely to be 
artificially high as the study did not permit a fluphenazine washout between the run-in and 
randomization phases.  As a result, approximately 45% of patients were receiving 
anticholinergic medication at randomization.  However, despite no washout of fluphenazine, 
significantly fewer patients on quetiapine required use of anticholinergic medication than 
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those on haloperidol (P = 0.011) and, of the 62 patients receiving quetiapine who required 
anticholinergic medication, only three (5%) were given anticholinergic therapy after week 4.  
Furthermore, it is also important to consider that the use of anticholinergic medication from 
week 4-12 reduced in patients on quetiapine (from 41% to 32%) whereas, in contrast, it 
increased in patients on haloperidol (from 47% to 53%).  The observations from this study 
that quetiapine is associated with reduced onset and worsening of treatment-related EPS, 
compared to haloperidol, reinforces the conclusions of other reports, which have shown that 
the incidence of EPS with quetiapine across the full clinical dosage range of 150-750 mg/day 
is not significantly different from placebo (Arvanitis et al., 1997; Meats, 1997) and is 
significantly less than haloperidol (Arvanitis et al., 1997; Copolov et al., 2000). 
 
It is recognized that conventional antipsychotic-induced hyperprolactinaemia may lead to 
unwelcome side-effects, such as sexual dysfunction (Sullivan and Lukoff, 1990; Ghadirian et 
al., 1992), amenorrhoea and galactorrhoea.  Quetiapine does not cause a sustained elevation 
in plasma prolactin concentration (Saller and Salama, 1993; Hamner et al., 1998).  Over the 
8-week treatment period of this study, the elevated serum prolactin levels observed at 
baseline after fluphenazine treatment were dramatically reduced in patients treated with 
quetiapine, whereas no change was evident in the haloperidol group.  The difference between 
treatments was highly significant.   
 
During the course of the study, minimal increases in weight were observed in patients in both 
treatment groups.  It is difficult to assess the nature of such small changes in weight over a 
short-term study.  However, long-term treatment with quetiapine has been shown to have only 
minimal effects on weight (Rak et al., 2000), confirming that little further weight increase was 
observed after the first 5-6 weeks of treatment. 
 
In summary, both quetiapine and haloperidol were associated with marked improvements in 
patients demonstrating partial responsiveness to standard antipsychotic treatment.  However, 
the magnitude of improvement was always greater in the quetiapine group than in the 
haloperidol group and a greater proportion of patients on quetiapine responded to treatment 
compared to those on haloperidol.  Furthermore, in contrast to haloperidol, quetiapine 
lessened the EPS burden and facilitated normalization of previously elevated prolactin levels.  
These encouraging results indicate that quetiapine may make a valuable contribution to the 
management of patients who have a history of partial response to conventional 
antipsychotics. 
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1.  Abstract 
The topic of antipsychotic-induced weight-gain and its relationship to glucose metabolism is 
understudied.  We evaluated the long-term effects of a new generation antipsychotic, 
quetiapine and a conventional antipsychotic, haloperidol on body mass index (BMI) and 
glycaemic control in patients with schizophrenia previously treated with conventional 
antipsychotics.  Forty-five clinically stable patients with schizophrenia participated in this 
randomised, investigator-blinded, parallel-group comparison of flexible doses of quetiapine 
and haloperidol treatment over 52 weeks. Primary outcome measures were change from 
baseline in BMI and glycosylated haemoglobin (HBA1c) levels. There were no between-group 
differences at any of the time points for BMI (F=1.90, p=0.1) and HBA1c (F=1.17, p=0.3) 
values, and there were no significant changes in BMI from baseline for either group. HBA1c 
levels decreased significantly at endpoint for the haloperidol group (-1.5%; p=0.04), but not 
for the quetiapine group (-0.3%; p=0.5).   
Although the sample was not generally obese (mean baseline BMI 25.5±6.3 Kg/m2), a large 
proportion exhibited evidence of abnormal glycaemic control prior to randomisation (mean 
HBA1c 6.7±1.9%), with 48% having values that were at least mildly elevated (HBA1c>6.1%) 
and 19% markedly elevated (HBA1c>7%). The number of subjects with elevated HBA1c 
values decreased from baseline in both the haloperidol and quetiapine treatment groups.  
These findings suggest that switching treatment from a conventional antipsychotic to 
quetiapine is not associated with weight-gain or worsening of glycaemic control, even in the 
long-term. The study also highlights the high incidence of unrecognised glucose dysregulation 
in patients with schizophrenia receiving conventional antipsychotic treatment. 
 
 
Introduction 
 
Excessive body weight gain is a common side effect of some typical and atypical 
antipsychotic drugs. The relative risk of weight gain varies amongst antipsychotics, but 
particularly the low-potency phenothiazines and some of the new generation antipsychotics 
are associated with greater risk (Allison et al. 1999;Baptista et al. 2002). Weight gain is highly 
distressing to patients, and may reduce treatment adherence (Allison and Casey 
2001;McIntyre et al. 2001;Weiden et al. 2004). It is also related to poorer quality of life and 
decreased well-being and vitality (Allison et al. 2003).  Of greatest concern however, is the 
risk of progression to obesity-related medical conditions such as type 2 diabetes and 
cardiovascular disease (Tardieu et al. 2003).   
 
The so-called metabolic syndrome, characterized by excessive visceral fat, impaired glucose 
tolerance, dyslipidaemia, and hypertension occurs with increased frequency in patients with 
schizophrenia. This is the case even before antipsychotic treatment is administered.  The 
reasons for this are not clear, although factors such as life style, poor diet and lack of exercise 
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may play a role (Ryan and Thakore 2002). A recent study clearly demonstrated that first-
episode, drug-naive patients with schizophrenia have impaired fasting glucose tolerance, are 
more insulin resistant and have higher levels of plasma glucose, insulin, and cortisol than 
healthy comparison subjects (Ryan et al. 2003b),  
 
The use of antipsychotic medication further increases the likelihood of developing weight gain 
and disorders of glucose metabolism. The risk is greatest with some of the new generation 
antipsychotics, particularly clozapine and olanzapine (Lindenmayer et al. 2003d). A recently 
reported consensus statement warns that treatment with new-generation antipsychotics can 
cause a rapid increase in body weight that may not reach a plateau even after 1 year of 
treatment (American Diabetes Association et al. 2004).  Hyperglycaemia, exacerbation of 
existing diabetes, treatment-emergent type 2 diabetes and even diabetic ketoacidosis have 
been associated with clozapine and olanzapine, and some of the other new generation 
antipsychotics (Newcomer et al. 2002c). The risk of hyperglycemia does not appear to be 
dose dependent, it is reversible on cessation of treatment, and reappears on reintroduction of 
these agents (Lindenmayer et al. 2001). Also, hyperglycaemia cannot be explained purely on 
the basis of antipsychotic-induced weight-gain (Newcomer et al. 2002b).  
 
The topic of antipsychotic-induced weight gain and its relationship to glucose metabolism is 
understudied, and there are few well-controlled trials in the literature. The purpose of our 
study was to compare the long-term effects of a new generation antipsychotic, quetiapine and 
a conventional antipsychotic, haloperidol on body weight and glycaemic control in patients 
with schizophrenia. While weight gain and glucose intolerance appear to be more common 
with olanzapine and clozapine, the risk in patients taking quetiapine is less clear (American 
Diabetes Association et al. 2004). There is little published information on the effect of 
quetiapine on weight and glucose metabolism, and results have been conflicting. The 
Canadian National Outcomes Measurement Study in Schizophrenia reported that weight gain 
(i.e. > 7% of baseline weight) was observed in 55.6% of patients treated with quetiapine, 
compared with 24.1% of olanzapine and 23.7% of risperidone-treated patients (McIntyre et al. 
2003). This contrasts with a cross-sectional study in outpatients receiving risperidone, 
olanzapine, quetiapine or haloperidol for at least 4 weeks, where the proportion of patients 
with clinically relevant (≥7%) weight gain was highest with olanzapine (45.7%) followed by 
risperidone (30.6%) and haloperidol (22.4%). Five quetiapine treated patients (13.5%) had 
some degree of weight gain, although this was not clinically relevant. However, data for 
quetiapine were not conclusive because of the short duration of treatment (Bobes et al. 
2003b).  In a long-term, open label extension trial in 10 adolescents, quetiapine treatment was 
associated with a non-significant increase in mean weight and body mass index after 64 
weeks (McConville et al. 2003). Haloperidol has not generally been associated with excessive 
weight gain, although it may have a direct effect on glucose metabolism (Lindenmayer et al. 
2003c). 
 
 
 
Method 
 
Participants 
The sample comprised in- and out-patients aged 18 - 65 years with a diagnosis of 
schizophrenia or schizo-affective disorder according to the criteria of the Diagnostic and 
Statistical Manual of Mental Disorders, fourth edition (DSM-IV) (American Psychiatric 
Association 1994), whose psychiatric condition was judged to be clinically stable. All 
participants had received a stable dose of antipsychotic medication for at least 30 days before 
entry. They also had tardive dyskinesia, as this formed an additional part of the study (Emsley 
et al. 2004). Exclusion criteria included another Axis I DSM-IV diagnosis, significant or 
unstable general medical condition, and patients currently receiving clozapine. The University 
of Stellenbosch Ethics Committee approved the study protocol, patient information and 
consent procedures.  All of the subjects provided written, informed consent to participate. The 
study adhered to International Conference on Harmonisation Guidelines for Good Clinical 
Practice (International Conference on Harmonization 1996). 
 
Study design 
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This was a randomised, investigator-blinded, parallel-group comparison of flexible doses of 
quetiapine and haloperidol. After an initial screening visit, subjects were tapered from all 
psychotropic medication over a 2 week period (although a shorter time was allowed if there 
was concern regarding the clinical status of the patient during this period). They were then 
randomised to receive either quetiapine or haloperidol for a 52-week treatment period. The 
dose of medication was titrated over seven days to the starting dose (haloperidol 10 mg/day, 
quetiapine 400 mg/day). Thereafter, flexible dose adjustment was allowed at the discretion of 
the investigator, up to a maximum dose of haloperidol 20mg/day and quetiapine 800mg/day.  
Haloperidol was adjusted in 2.5mg increments and quetiapine in 100mg increments. 
Medication compliance was assessed by ‘pill counts’ at each visit. Concomitant 
benzodiazepines were allowed for agitation or insomnia, and anticholinergic agents for 
extrapyramidal symptoms. 
 
Assessments  
Subjects were weighed, and blood samples were collected for glycosylated haemoglobin 
(HbA1c) and serum prolactin measurement at the screening visit (week 0) and at weeks 10, 
22, 34, 46 and 54. A minor haemoglobin component of human red blood cell haemolysate, 
HbA1c is a product of the non-enzymatic reaction of glucose with the alpha-amino groups of 
the valine residues at the N-terminus of the beta-chains of human haemoglobin. Expressed 
as a percentage of total haemoglobin in whole blood, HbA1c measures average glycaemic 
control in individuals during the preceding 6-8 weeks (Dhatt et al. 2003). It is a highly specific 
and convenient alternative to fasting plasma glucose for diabetes screening (Rohlfing et al. 
2000). HBA1c assays were performed on a Beckman Coulter CX-S synchron analyser. 
Values of ≥6.1% are regarded as mildly abnormal and ≥7% as severely abnormal (Davidson 
et al. 1999). Height was measured at the screening visit. Body mass index (BMI) was 
calculated as the weight in kilograms divided by the square of height in meters. BMI is widely 
accepted as the 'gold standard' for determining whether a patient is underweight or 
overweight, and is strongly predictive of changes in glucose regulation (Resnick et al. 1998).  
 
Clinical assessments were conducted at two-weekly intervals for the first 6 weeks, and 
thereafter 4 weekly, until the completion of the trial (52 weeks of active treatment). Patients 
were assessed by means of the Positive and Negative Syndrome Rating Scale (PANSS) (Kay 
et al. 1987) and Extrapyramidal Symptom Rating Scale (ESRS) (Chouinard et al. 1980).  
 
 
Data analyses 
The main analysis was conducted on observed cases (OC). We also performed an analysis 
on the intent to treat (ITT) population, using the method of last observation carried forward 
(LOCF) to deal with missing values due to dropouts. The a priori primary outcome measures 
were change in BMI and change in HBA1c from baseline to endpoint. Treatment groups were 
compared at each time point using Student’s t test. Repeated measures analysis of variance 
(RANOVA) was performed including all of the assessment points, and because of 
considerable variance in the data, we also used non-parametric bootstrap re-sampling 
techniques to calculate confidence intervals for the means at the various time points. 
Bootstrap analysis makes no prior assumptions regarding the data provides less biased 
estimates of confidence intervals in highly skewed data (Pollack et al. 1994). To control for the 
effects of factors known to affect BMI and glucose metabolism, we performed an analysis of 
covariance with change in BMI and change in HBA1c as dependent variables (separately), 
treatment group, gender and race as categorical variables and age as covariate. For 
correlations between pairs of numeric variables we used the Pearson product moment 
correlation coefficient. Significance tests were performed at a two-sided alpha level of 0.05. 
Results are expressed as mean±SD. Analyses were performed with Statistica version 6 
(Statsoft, Inc.) software package. 
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Results 
 
Of 47 participants entered into the study, two were excluded (one withdrew before reaching 
the target treatment dose, and one had unrelated medical illness). The analysis was therefore 
conducted on 22 patients in the quetiapine group and 23 in the haloperidol group. Baseline 
demographic and clinical details were similar for the two treatment groups (Table 1). All of the 
subjects had been receiving conventional antipsychotics before entry into the study. The 
majority were receiving depot fluphenazine, flupenthixol or clopenthixol. Ten subjects from the 
quetiapine group failed to complete the study, for the following reasons: worsening of 
psychosis (n=7); non-compliance (n=1); withdrawal of consent (n=1); and pregnancy (n=1). 
Eight subjects in the haloperidol group did not complete the study, due to worsening of 
psychosis (n=4); non-compliance (n=1); withdrawal of consent (n=1); severe, persistent 
dystonia (n=1); and disallowed concomitant treatment (n=1). For the OC analysis the sample 
sizes for quetiapine and haloperidol were, respectively, 22 and 23 at week 10, 16 and 18 at 
week 22, 13 and 16 at week 34, 13 and 15 at week 46 and 12 and 15 at week 54.  The 
mean±SD endpoint doses were 400±147.7mg/day for quetiapine and 8.5±5.6mg/day for 
haloperidol. 
 
The sample was not overtly obese - the mean baseline BMI for the entire group was 25.5±6.3 
kg/m2  and 20 subjects (43%) had a baseline BMI > 25 
kg/m2 (overweight). However, there was evidence of abnormal glucose metabolism at 
baseline in a larger than expected proportion of the patients. The mean baseline HBA1c for 
the entire group was 6.7±1.9%, with 22 subjects (48%) having at least mildly elevated values 
(HBA1c >6.1%) and 9 (19%) markedly elevated values (HBA1c >7%) (Davidson et al. 1999).  
 
Effect of treatment on BMI and HBA1c 
Neither treatment group exhibited significant changes from baseline in BMI, and there were 
no between-group differences at any of the time points (Figure 1). There was a non-significant 
increase in BMI at 10 weeks for the quetiapine treated subjects, but this returned to below 
baseline values at subsequent visits. RANOVA reported a significant time-treatment current 
effect (F=2.64, p=0.03) but the 95% confidence interval estimated by bootstrap methods 
found no between group differences.   HBA1c results for the two groups are given in Figure 2. 
There were no differences at any of the time points between the groups.  Similarly, both the 
RANOVA and bootstrap showed no significant differences between the two groups (F=1.17, 
p=0.3). Both groups showed a reduction in HBA1c values from baseline to endpoint which 
reached significance for the haloperidol (-1.5%; p=0.04), but not for the quetiapine treated 
patients (-0.3%; p=0.5).  The number of subjects with elevated HBA1c values (>6.1%) 
decreased from 12 (52%) at baseline to 7 (30%) at endpoint in the haloperidol group, and 
from 11 (50%) at baseline to 9 (41%) at endpoint in the quetiapine group.  None of the 
subjects with elevated baseline HBA1c values (i.e. HBA1c >6.1%) showed deterioration of 
glycaemic control during the study. In fact, HBA1c values in these subjects also decreased 
from baseline to endpoint in both groups, with the reduction being statistically significant in the 
haloperidol treated patients (-1.9%, p=0.04), but not for the quetiapine group (-0.6, p=0.5).  
There were highly significant differences in the prolactin levels between the two groups, with 
quetiapine patients levels being reduced, and haloperidol treated patients levels increased 
from baseline (RANOVA F=7.02, p=0.00001). 
 
There was a significant ethnic difference in baseline BMI (Caucasian 21.4±2.6 kg/m2, mixed 
descent 26.3±6.5 kg/m2, p=0.04), but not in HBA1c values or prolactin levels. There were 
considerable gender differences in baseline measures. Women had greater BMI’s (29.3±6.8 
kg/m2 vs 23.3±4.7 kg/m2, p=0.02), higher HBA1c levels (7.6±2.9% vs.6.3±8.2%, p=0.03) and 
higher prolactin levels (29.3± 25.6 ng/ml vs. 15.2±10.7ng/ml, p=0.01). Age was not 
significantly correlated with baseline BMI, HBA1c or prolactin levels. The analysis of 
covariance for the primary efficacy measures found that the change in BMI was not 
significantly influenced by gender, race, age or treatment group (F=3.19, p=0.08), although 
there was a slight trend in women of mixed descent toward increased BMI with quetiapine 
treatment  and decreased BMI with haloperidol treatment. However, for change in HBA1c 
there was a significant effect for gender, race and treatment group (but not age), with 
haloperidol-treated Caucasian females showing the greatest HBA1c reductions (F=11.93, 
p=0.001). 
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We found a significant correlation between baseline PANSS negative subscale scores and 
change in BMI (r=0.44, p=0.04). There were no other significant correlations between 
symptoms of psychosis (PANSS total and subscale scores) or extrapyramidal symptoms 
(ESRS subscale and total scores) and BMI or HBA1c.  There was an indication of an 
interaction between prolactin and HBA1c levels. Baseline prolactin levels correlated 
significantly with HBA1c at week 10 (r=0.51, p=0.03), and change in prolactin was negatively 
correlated with HBA1c at week 10 (r= -0.55, p=0.02); week 22 (r= -0.52, p=0.03); week 34 (r= 
-0.58, p=0.02), week 46 (r= -0.52, p=0.03); and week 54 (r= -0.53, p=0.03). i.e. Persistently 
high prolactin levels were associated with less reduction in HBA1c values. 
 
Results of the ITT LOCF analyses were essentially the same as the OC analyses reported 
above. 
 
 
 
Discussion 
 
This is one of very few prospective, controlled studies comparing the effect of a new 
generation antipsychotic with a conventional antipsychotic on body mass and glucose 
metabolism. Moreover, we are not aware of other controlled studies that have investigated the 
long-term effects of antipsychotics on body mass and glucose metabolism. Our results 
indicate that, in stable schizophrenic patients previously on conventional antipsychotics, long 
term treatment with both quetiapine and haloperidol is not associated with persistently 
increased adiposity, or worsening of glycaemic control.  Furthermore, these agents may be 
safe for patients with existing glucose intolerance, as the subjects with elevated HBA1c at 
baseline showed no evidence of exacerbation of glycaemic control with either of these 
treatments. Given the importance of glycosylation in the genesis and development of diabetic 
microvascular and neuropathic complications, (Davidson et al. 1999) these findings are of 
considerable clinical significance. 
 
The absence of significant body weight gain in the quetiapine-treated patients contradicts the 
findings of the Canadian National Outcomes Measurement Study in Schizophrenia, (McIntyre 
et al. 2003) and is more in line with those of the cross-sectional study in outpatients of Bobes 
et al. (Bobes et al. 2003a) and the open label extension trial in adolescents of McConville et 
al. (McConville et al. 2003). An explanation for the greater degree of weight gain with 
quetiapine in the McIntyre et al study (McIntyre et al. 2003) is not immediately forthcoming, 
although theirs was an uncontrolled study permitting concomitant medication, the sample was 
diagnostically heterogeneous and the quetiapine sample was significantly smaller (n=23) than 
the other groups.  The absence of a deleterious effect on glucose metabolism with haloperidol 
is in contrast to an earlier study reporting a significant increase in fasting blood glucose levels 
after 8 weeks of treatment with haloperidol (Lindenmayer et al. 2003b). One possible 
explanation for this discrepancy is that the effect with haloperidol could be dose related. 
Patients were treated with haloperidol 20mg/day in the Lindenmayer et al (Lindenmayer et al. 
2003a) study, while the mean endpoint dose in our trial was considerably lower (8.5mg/day).  
 
The high incidence of pre-existing glucose dysregulation in this relatively non-obese cohort 
gives cause for alarm, and once again highlights the fact that patients with schizophrenia are 
at high risk for developing glucose intolerance and type 2 diabetes. The fact that this occurred 
even in the absence of obesity, together with a lack of significant correlations between BMI 
and HBA1c provides further evidence that glucose intolerance is not necessarily secondary to 
weight-gain in antipsychotic-treated schizophrenic patients (Newcomer et al. 2002a;Ryan et 
al. 2003a).  
 
Various, and possibly multiple mechanisms may be responsible for glucose intolerance with 
antipsychotic treatment. Weight gain is one of the mechanisms involved, and considerable 
evidence suggests that antipsychotic-induced weight gain is at least partly related to the 
blocking effects on serotonin- and histamine-mediated neurotransmission (Koponen et al. 
2002) resulting in altered hunger and satiety (American Diabetes Association et al. 2004).   
Patients receiving an antipsychotic for the first time experience substantial deposition of both 
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subcutaneous and intra-abdominal fat, reflecting a loss of the normal inhibitory control of 
leptin on body mass. Along with fat deposition, there is an increase in the levels of fasting 
lipids and non-fasting glucose (Zhang et al. 2004)  However, other mechanisms independent 
of weight gain  may also lead to elevation of serum leptin and insulin resistance (Lean and 
Pajonk 2003). Serotonin (5-HT2) receptor activation influences glycogenolysis and blood 
glucose levels (Darvesh and Gudelsky 2003) so that this may be a mechanism in the case of 
the new generation antipsychotics. Agents that influence monoaminergic neurotransmission 
have been shown to have an effect on glucose regulation. Peripheral blood glucose 
concentration was found to be significantly correlated with cerebrospinal fluid concentrations 
of dopamine and noradrenaline metabolites (Umhau et al. 2003) This may be pertinent with 
the conventional antipsychotics, with their more pronounced effect on dopaminergic 
neurotransmission (Meltzer et al. 1989) Finally, an association between glucose metabolism 
and prolactin has also been described. Prolactin induces glucose intolerance, 
hyperinsulinemia and insulin resistance (Tuzcu et al. 2003) This could be a relevant 
mechanism with patients receiving risperidone and the high potency conventional 
antipsychotics such as haloperidol. In this regard, our finding of a relationship between 
HBA1c and prolactin levels is of interest. The association between high baseline prolactin and 
high HBA1c levels at 10 weeks, as well as higher HBA1c values in patients with persistent 
prolactin levels is indeed what would be anticipated by the findings of Tuzcu et al (Tuzcu et al. 
2003) Unlike another study investigating the relationships between prolactin and weight gain 
in antipsychotic-treated subjects, we did not find an association between prolactin and BMI 
(Baptista et al. 2001b). 
 
 
 
The greater BMI’s and higher HBA1c levels in women in our study are in keeping with a 
previous finding that women treated with conventional antipsychotics displayed more insulin 
resistance than healthy controls, thereby predisposing them to excessive weight gain 
(Baptista et al. 2001a), and suggests that female gender is a risk factor for diabetes in 
subjects treated with antipsychotic medication. Age and ethnicity were not identified as risk 
factors for glucose intolerance in our sample although non-caucasians had greater BMI’s.  
The finding that patients with higher baseline negative symptom scores showed less 
reduction of BMI over the treatment period is of interest, in view of previous reports of an 
association between weight gain and treatment response. However, previous studies reported 
either no association, or improvement in symptoms together with weight gain (Meltzer et al. 
2002).  It has been suggested that the effects of the antipsychotic on neurotransmitters which 
influence weight gain, may also contribute to the improvement in psychopathology (Meltzer et 
al. 2002). Our result could be explained on the basis that subjects with negative symptoms 
display more sedentary behaviour. 
 
This study is limited by its relatively small sample, and the findings cannot be generalised to 
other populations such as medication-naïve first-episode patients. In fact, our sample may be 
particularly at risk for disorders of glucose metabolism, as an association between diabetes 
and TD has recently been reported in elderly patients (Caligiuri and Jeste 2004).  Also, while 
HBA1c is a useful measure, other means of assessing glucose metabolism such as fasting 
blood sugar and oral glucose tolerance tests were not performed on our subjects. These 
additional measures would be necessary in order to diagnose diabetes mellitus according to 
World Health Organisation criteria (World Health Organisation 1980). 
 
This study highlights the high incidence of unrecognised glucose intolerance in patients with 
schizophrenia receiving antipsychotic treatment. Our findings suggest that switching from a 
conventional antipsychotic to quetiapine treatment does not further impair glucose 
metabolism, even in the long term. Quetiapine may be a relatively safe treatment option in 
patients at risk for diabetes mellitus. While haloperidol is also safe in this regard, its well 
documented neurotoxic effects would preclude its use where alternative treatment is available 
(Joy et al. 2001). 
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Table 1. Baseline demographic and clinical details of the two treatment groups (mean±SD). 
 Quetiapine (n=22) Haloperidol (n=23) 
Male : female 14:8 15:8 
Age (Yrs)  49.2±14.5 50.1±8.6 
Weight (Kg) 71.9±21.3  66.6±11.7  
BMI (%) 26.4±7.0 24.5±5.4 
HBA1c (%) 6.4±1.1 7.0±2.5 
Prolactin (ng/ml)  25.4±23.3 15.2±9.2 
PANSS total score 55.5±12.7 57.0±14.1 
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Summary 
Background:  The introduction of a new generation of atypical antipsychotic agents has 
raised difficult economical and ethical questions, particularly in lower-income countries. The 
reported tolerability and efficacy advantages of the atypical antipsychotics over their 
conventional predecessors have to be weighed against their higher acquisition costs. 
Pharmaco-economic studies conducted in Western countries consistently report cost-
advantages or cost-neutrality for these new agents. However, considerable differences in 
health-care service provision make it difficult to generalize these findings to South Africa. 
Method:  We compared the direct costs (private and public sector) of treating schizophrenia 
with an atypical antipsychotic quetiapine, with a conventional antipsychotic haloperidol, by 
adapting a decision-analytic pharmacoeconomic model for South African circumstances. The 
sample comprised patients partially responsive to antipsychotics, who had participated in a 
multinational randomized controlled trial comparing the efficacy and safety of quetiapine 
versus haloperidol. 
Results:  The estimated total direct cost for the treatment with quetiapine in South Africa was 
slightly less than for haloperidol for various models in both the private and the public sector. 
Conclusions:  Significant differences in health-care provision make pharmacoeconomic 
studies conducted in other countries invalid for South African circumstances. Quetiapine 
treatment previously did not result in direct cost savings in South Africa. However, the recently 
introduced legislation to establish single exit prices for medications has resulted in the cost of 
quetiapine treatment declining by 36.7% and that of haloperidol by 13%. This has translated 
into an overall direct cost-saving for quetiapine in both the private and public sector models.  
This, together with additional indirect advantages of the atypical antipsychotics such as 
improved quality of life and better social and vocational functioning, argues strongly from both 
an economic and ethical perspective for the use atypical antipsychotics in treating 
schizophrenia in South Africa. 
 
 
 
The costs of schizophrenia 
 
Schizophrenia is one of the most important diseases affecting humankind, costly in both 
social and financial terms.1  It imposes a disproportionately large economic burden on 
patients and their families, health care systems and society, because of its early onset, 
devastating effects, and usually lifelong course,2 and it is the most costly illness that 
psychiatrists treat.3  In 1993 the disease consumed an estimated $33 billion in the United 
States of America ($18 billion in direct costs and $15 billion in indirect costs). This constituted 
2.5% of the annual total health care allocations.4  In England, the identifiable direct and 
indirect costs suggest an annual total cost of £2.6 billion (this figure omitted some indirect 
costs).5  In South Africa (SA), the costs are not known.  The direct costs of schizophrenia 
include aspects such as hospitalisation, day care, residential accommodation, medication, 
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special investigations and disability grant payments. Examples of indirect costs are lost 
employment, reduced productivity and family costs (e.g. household expenditure, travel costs, 
lost earnings).6  
 
In the current worldwide cost-cutting climate in health services, the focus has fallen on 
economizing the delivery of health care.  Yet decreasing expenditures on drugs for severe 
illnesses such as schizophrenia may be a false economy, as drugs account for only a small 
proportion of the total costs.1 In the case of schizophrenia, the acquisition costs of medication 
comprise a very small portion of the total costs of the illness – at least in the developed world. 
For example, the costs of antipsychotic medication have been estimated at 4% of the direct 
costs in the United Kingdom (UK),7 5.6% in France,8 and 1.1% in the Netherlands.9   
 
The introduction of the atypical antipsychotics has had a major impact upon the way we treat 
patients with schizophrenia. Evidence is accumulating to show that these drugs hold 
significant advantages over their predecessors in terms of both tolerability (although other 
side-effect concerns have emerged) and efficacy. In particular, it has been shown that these 
agents have a reduced propensity to induce acute extrapyramidal symptoms (EPS),10 
previously a major obstacle to the effective treatment of schizophrenia. There is now a 
considerable literature indicating other advantages of these drugs.  These advantages include 
improved efficacy in treatment-refractory patients,11 in patients with negative symptoms12 and 
depressive symptoms,13;14 reduced levels of suicidality,15 less neurocognitive impairment,16 
better subjective quality of life,17 reduced incidence of tardive dyskinesia,18 decreased 
likelihood of relapse19 and improved overall outcome.20  Although often modest, these 
advantages often make a substantial difference to patients in terms of improved social and 
vocational functioning and a better quality of life. The clinical advantages of these drugs are 
greatest close to the onset of the illness, and they are increasingly regarded as first-choice 
agents.21  However, because of their much greater acquisition costs, their availability in lower-
income countries in regions such as Africa, Latin America, Asia and the Pacific, is extremely 
limited.   
 
 
Pharmacoeconomic studies generally show the atypical antipsychotics to be cost-effective or 
cost-neutral in treating schizophrenia. But it is not clear to what degree these findings 
(conducted in the Western world) can be generalised to other countries, where other factors 
need to be considered. For example, schizophrenia reportedly runs a different course in 
developing countries,22 and a cost-effectiveness study in Nigeria indicated that the 
antipsychotic drugs accounted for 52.8% of the cost of treating schizophrenia!23 This was 
because most patients are cared for by their families at no direct cost to the state, and 
residential care, when available, had low staff and infrastructure expenditure. 
  
The ideal pharmacoeconomic study would be a prospectively designed trial in a large sample, 
and conducted over a long study period. Such a study would however be very difficult to 
conduct, and extremely expensive. A less dependable but easier attainable alternative is to 
construct a pharmacoeconomic model specifically for South African conditions. This study 
attempts to quantify the direct costs involved in treating a large group of patients with 
schizophrenia in SA. It will hopefully provide guidance to clinicians and decision makers alike 
regarding both private and public health sector costing.  
 
 
 
 
Method 
 
This study incorporated the clinical findings of a randomized controlled trial in a 
pharmacoeconomic model adapted for SA circumstances. The model estimated outcomes 
and direct costs over 5 years for quetiapine and haloperidol in treating partially responsive 
patients with schizophrenia. Persistent positive symptoms occur in many patients treated with 
conventional antipsychotics,24;25 and this population has been referred to as ‘partial 
responders’.26 They are an important patient group, as they represent the majority of patients 
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with schizophrenia, and their treatment is problematic. Consequently, disproportionately more 
resources are likely to be allocated to these patients. 
 
Patients and study design 
The study that we utilized for the analysis was a multicentre, double-blind, randomised trial 
comparing quetiapine and haloperidol in patients with a partial response to conventional 
antipsychotic treatment. Although multinational, many of the participants were in SA.  A 
detailed description of the study design, patient selection criteria, and efficacy and safety 
measures has been reported elsewhere,27 and so will only be briefly described here. Patients 
meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) 
diagnostic criteria for schizophrenia and who had a history of only partial response to 
conventional antipsychotics were entered into a 4-week active run-in treatment phase with 
fluphenazine (20 mg/day). Those patients showing either no response, or only a partial 
response to the fluphenazine treatment (defined as <30% reduction in the Positive and 
Negative Symptom Scale (PANSS) total score), were then randomised to receive either 
quetiapine (600 mg/day) or haloperidol (20 mg/day). As these patients were envisaged to be 
difficult to treat, the quetiapine and haloperidol dosages were towards the upper end of their 
recommended dosage ranges, namely 600 mg/day and 20 mg/day, respectively. Current 
clinical practice with quetiapine has moved towards the use of considerably higher doses. In 
fact, 600mg/day is usually the target dose for most patients, not just those considered difficult 
to treat.  Doses were titrated over a 7-day period, and then fixed for the next 7 weeks. Key 
exclusion criteria included severe resistance to conventional antipsychotics, known non-
responders to clozapine and an acute psychotic exacerbation within the past 3 months. 
 
The results of the analysis of the intent-to-treat (ITT) population indicated that both quetiapine 
and haloperidol were associated with significant mean reductions in PANSS total scores. The 
reduction was numerically greater with quetiapine than that observed with haloperidol, but the 
difference did not reach statistical significance. However, the treatment response rate was 
significantly greater for quetiapine (52% vs 38%, p=0.04). (Treatment response was defined 
as a reduction in PANSS total score of ≥20% from week 4 to week 12.)  Further analysis on 
the ITT population indicated that a decrease in PANSS total score of ≥30% from week 4 to 
week 12 was also in favour of quetiapine (29% vs 16%, p=0.01). This can be seen as a good 
level of clinical response.28 The results of the safety analysis indicate that the proportion of 
patients who were using anticholinergic medication at the end of the trial (after eight weeks on 
either quetiapine or haloperidol) was significantly lower in the quetiapine group than the 
haloperidol group (32% vs 53%, respectively, p = 0.001). Other measures of EPS occurrence 
consistently indicated a lower incidence of EPS in the quetiapine group when compared to the 
haloperidol group. 
  
 
The pharmaco-economic model 
We adapted a study that was previously conducted on this sample for UK circumstances.29 
Medical resource utilisation and unit costs were obtained for SA private and public sectors. 
For the model, a decision-analytic model with Markov processes was constructed, 
incorporating the consequences of treatment with regard to both the treatment response and 
the incidence of EPS. The Markov model has been extensively used in pharmacoeconomic 
studies.30 Costs are computed on the basis of assumptions about service utilisation that are 
derived from the results of a randomized, controlled trial, the pattern of resource use assumed 
in SA and from information provided by SA psychiatrists. Five groups of patients are advanced 
through a Markov process of eleven health states in cycles of 3 months over a period of five 
years, based on the likely sequelae of relapse and non-response. These groups have 
different responses to medication and/or incidence of EPS. The sequelae for these groups 
are driven mainly by the probabilities of compliance to medication and relapse (determined 
from a literature review and advice from a panel of SA psychiatrists). The Health States of the 
Markov model are as follows: PANSS Improvement > 30% (without EPS); PANSS 
Improvement > 30% (with EPS); PANSS Improvement > 20% but < 30% (without EPS); 
PANSS Improvement > 20% but < 30% (with EPS); No treatment response (PANSS 
improvement <20%); First relapse; Post-relapse (quetiapine treatment): Response (PANSS> 
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30%); Post-relapse (haloperidol treatment): Response (PANSS > 30%); Post-relapse: No 
response (PANSS <30%); Subsequent relapse(s); Suicide. 
 
 
Results 
The original model for the UK found the total treatment costs of quetiapine to be lower than 
for haloperidol. While the cost of medication was higher for quetiapine treated patients, 
substantial cost savings were achieved by a reduction in the use of health care services. It 
cost £244 less per patient over the five year period for the quetiapine treated patients than 
those treated with haloperidol (£38,106 vs. £38,350).29 However, these findings cannot be 
generalized to SA as substantial differences exist between psychiatric service delivery in the 
UK and both the private and public sector in SA. Health care costs obtained in August 2004 
for the private and public sector in SA are provided in Tables 1 and 2, respectively. Medication 
costs subsequent to August 2004  in SA are provided in Table 3. Costs between countries do 
not only differ in terms of fee structures of specific items, but also regarding their nature. For 
example, general practitioners and community nurses are much less frequently involved in 
treating patients with schizophrenia in the private sector in SA than in the UK. Also, day-care 
and residential care facilities are less available in both the private and public sector. Thus, 
although these costs are saved in the SA system, the absence of these services increases 
the likelihood of relapse and lengthens the duration of hospitalization. On the basis of 
information obtained from a panel of SA psychiatrists from both the private and public sector, 
we made certain assumptions regarding these differences, and calculated the following 
solutions:  
(a) ‘Baseline’ situation: This was a direct transposition of SA private sector costs in the 
original model without making other assumptions about differences in health care 
provision between the UK and SA. 
(b) ‘Private sector 1’ situation: Assumed a 5% increase in hospitalization and risk of relapse 
for private health care services in SA 
(c) ‘Private sector 2’ situation: Assumed a 10% increase in hospitalization and risk of relapse 
for private health care services in SA.   
(d) ‘Public sector 1’ situation: Assumed a 5% increase in hospitalization and risk of relapse 
for public health care services in SA 
(e) ‘Public sector 2’ situation: Assumed a 10% increase in hospitalization and risk of relapse 
for public health care services in SA.  
 
The results of the cost-effectiveness analysis for each of the five situations in terms of the 
main outcomes of cost-effectiveness, including the aggregate financial costs are listed in 
Table 4. The proportion of total direct costs for quetiapine was considerably higher in SA than 
in the UK. Thus, for private sector situations 1 and 2 quetiapine made up 14.2% and 13.9% of 
the total costs respectively, and for public sector situations 1 and 2 the figures were 16.5% 
and 16.2% respectively. (For private sector situations 1 and 2 haloperidol made up 1.7% and 
1.7% of the total costs respectively, and for public sector situations 1 and 2 the figures were 
2.1% and 2% respectively.)   
 
 
The results of the sensitivity analysis (not reported here) showed that quetiapine remains less 
costly than haloperidol in almost all cases under the baseline and private 1 situation. In the 
case of situation public 1, where the cost differential was the smallest (R684 per patient over 
a five-year period), changes in assumptions that saw treatment costs decline in almost all 
cases resulted in quetiapine patients being more costly to treat than haloperidol patients. Yet, 
the cost differential was relatively small where quetiapine was not cost saving and ranged 
from R0.93 (assumed no relapse patients to be hospitalized compared to 60% in baseline 
situation) to R121.52 (assumed non-response and relapse health state costs to decline by 
50% compared to public 1 situation) per patient per month. 
 
The results of the conservative estimates (i.e. situation 1) for the private and public sectors 
are depicted graphically in Figures 1 and 2, respectively. It can be seen that, over a five year 
period, while the acquisition costs of the two treatments differ substantially, the total direct 
costs are very similar.  
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Discussion: 
The results of our study show that, as in the UK, the direct costs are slightly less for 
quetiapine than for haloperidol for all of our situations in both the private and public sectors. 
Although the medication acquisition costs were higher for quetiapine, substantial savings 
were achieved by a reduction in the use of health care services. Cost-savings per patient over 
5 years amounted to R2,641 in the baseline situation; R3,058 and R3,625 in private situations 
1 and 2; and R684 and R1,197 in public situations 1 and 2, respectively. The cost differences 
however are not great – for the private sector models they translate into a saving of R51 
(private 1) or R60 per month (private 2) for quetiapine, and for the public sector models R11 
(public 1) or R20 (public 2) per month. 
 
 
We conducted our initial analysis using medication prices that were in effect prior to the 
recently introduced legislation that has resulted in significant cost-cuts. In this analysis 
treatment with quetiapine did not result in cost savings compared to haloperidol. However, in 
view of the fact that recent legislation to introduce single exit prices has significantly cut costs 
of medication in South Africa,31, we decided to re-analyse the data using the prices introduced 
in August 2004. The new prices resulted in a reduction of 36.7% in the cost of quetiapine and 
13% for haloperidol. As a result, quetiapine treatment is now 3.7 times more expensive than 
haloperidol treatment compared to the 5-fold difference in price assumed in our original 
model. The daily cost of the drugs used for atypical antipsychotics (15mg olanzapine and 6mg 
risperidone) increased marginally (1.3%), while the daily cost of anticholinergic treatment 
(4mg akineton) declined by 7.5%. Consequently, the results of the cost-effectiveness analysis 
based on these new drug prices saw quetiapine patients being less costly to treat than 
haloperidal patients in all five situations. Although the cost of medication was higher for 
quetiapine, substantial cost savings were achieved by a reduction in the use of health care 
services. Cost-saving over 5 years amounted to R2,889 in the baseline situation. Cost-saving 
for private situations one and two amounted to R3,370 and R3,981, and R2,040 and R2,579 
for public situations one and two, respectively.  
 
The analysis we used adopted a conservative approach, so that, where data were not 
available, it was assumed that there were no differences between the treatments. This is 
unlikely to be the case however, as improved side-effect profile34 and better patient 
acceptance32 with quetiapine are likely to improve compliance and reduce the relapse rate 
and resource utilization in the long-term. Also, the model does not take some direct, and all 
indirect costs into account. These latter costs are likely to be considerable.  For example, only 
12% of persons with schizophrenia were found to be employed in a full-time capacity in the 
United States,33 and the illness is associated with poor physical health – patients with the 
illness are more likely to eat poorly, smoke and drink alcohol to excess, thus necessitating 
additional health-resource utilisation.34 Also, family members spend on average 15 hrs per 
week35 and an estimated $3,500 per year36 looking after a family member with schizophrenia 
 
Our findings cannot necessarily be generalized to other samples, need to be interpreted with 
caution, due to a number of limitations. First, the entire model is based on indirect estimates 
in the absence of a prospective pharmacoeconomic study. Second, the lack of good data on 
costs of care in both the private and public sector in SA make estimates difficult. The cost 
estimates employed in this study were derived from tariffs, which are unlikely to represent the 
true opportunity cost of resources in the absence of perfectly competitive markets37 and may 
substantially underestimate the direct cost of treatment, thus possibly translating into greater 
cost savings than those reported here. Third, the inclusion in this analysis of the cost of 
suicide or attempted suicide (excluded here for the sake of simplicity and due to absence of 
good estimates of the cost of suicide in SA), which is likely to be substantial,38 may also have 
translated into considerable resource savings, thus resulting in quetiapine being even more 
cost saving. Fourth, relative costs of care differ substantially in developed and developing 
country settings. For example, comparative costs per bed day and outpatient visit compiled by 
the World Health Organisation (available at http://www.who.int/evidence/cea) show estimates 
for a country such as SA to represent a quarter or less of the cost estimates for developed 
countries such as Canada, the US and United Kingdom.39 More importantly, in terms of this 
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study, it shows how higher relative costs are more likely to translate into cost-effectiveness, as 
noted by Drummond and Pang.40 This emphasizes how the relatively lower cost of health care 
in a developing country such as SA is less likely to translate into cost-effectiveness where the 
main cost savings result from the lower relapse rates and subsequent hospitalization and 
resource use under the alternative treatment. Finally, considerable variation in intensity and 
nature of care exists in SA in both the private and public sectors. 
 
Notwithstanding these limitations, as far as we are aware, this study provides a first attempt at 
quantifying costs in treating schizophrenia in SA. Hopefully, it will focus attention on this often 
neglected group of patients, and encourage further research in the area. We also hope that it 
will provide guidance to health care costing decision makers in both the private and public 
domains in South Africa. While costs ultimately play a large role in deciding what medications 
should be made available, other considerations are no less important. Particularly, from an 
ethical point of view it should be argued that every individual has the right to good medical 
care. There is now overwhelming evidence of neurotoxic effects of haloperidol, so that even a 
traditionally conservative Cochrane meta-analysis recently concluded that “given no choice of 
drug, use of haloperidol to counter the damaging and potentially dangerous consequences of 
untreated schizophrenia is justified. If a choice of drug is available, however, people with 
schizophrenia and clinicians may wish to start another antipsychotic with less likelihood of 
causing parkinsonism, akathisia and acute dystonias. For countries where haloperidol is not 
widely used, it should not be a control drug of choice for randomised trials of new 
antipsychotics.”41 This study provides economic support to add to the ethical argument for 
more extensive use of the atypical antipsychtics in both the private and public sectors in 
treating schizophrenia in South Africa. 
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Table 1.  Private Psychiatric Care Costs in South Africa. 
 
Item  Cost per day 
Hospital admission bed day (acute stay) Pr58 R 725.60 
Hospital admission bed day (long stay) Pr55 R 681.10 
Residential care (1 day) R 130.00 
Psychiatrist consultation (25 minutes) R 214.10 
GP consultation R 117.20 
Psychiatric nurse visit (1 hour) R  73.40 
Day care R 486.00 
Outpatient visit R 255.90 
 
 
Data provided by Old Mutual Health Group, and based on previous Board of Healthcare 
Funders tariffs. August, 2004 
 
 
 
 
 
 
 
 
Table 2. Public psychiatric care costs in South Africa. 
 
Item Cost per day 
Inpatient care (acute stay)  R 680.00 
Inpatient care (long stay)  R 460.00 
Psychiatrist visits (25 minutes)  R180 
Outpatient visits  R180 
Community psychiatry visits  R125 
GP (clinic) visits  R125 
 
Source: Uniform Patient Fee Schedule for externally funded patients attending public 
hospitals of the Provincial Administration of the Western Cape, 1 January 2004.
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Table 3.  Medication costs in South Africa 
 
Product 
Trade Price 
(ex. Vat) 
Pack 
Size dose/day Cost/day 
Quetiapine 300mg R 1,017.54 60 600mg R 33.92 
Haloperidol 5mg (Serenace)  R 229.04 100 20mg R 9.16 
Olanzapine 10mg  R 965.78 28 20mg R 68.98 
Risperidone 4mg R 928.12 30 8mg R 61.87 
Clozapine 100mg R 682.56 100 600mg R 40.95 
Artane 2mg R 62.28 100 2mg R 0.62 
Akineton 2mg R 86.21 50 2mg R 1.72 
Akineton 5mg/ml R 121.35 5 5mg/ml R 24.27 
Fluoxetine 20mg (Prozac) R 193.85 30 20mg R 6.46 
Lilly-Fluoxetine (generic) R 72.10 28 20mg R 2.58 
 
Source: Pharmaceutical Computer Data, August 2004. 
Prices are Trade Prices Excluding VAT and pharmacy costs. 
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Table 4.  Estimated total costs of different health care situations for SA. 
 
AGGREGATE 
COSTS: Baseline Private 1 Private 2 Public 1 Public 2 
Medical resource Quetiapine  Quetiapine Quetiapine Quetiapine Quetiapine 
Total cost of study 
medication 28,939,380 29,152,857 29,429,104 29,152,857 29,429,104
Total cost of other 
medications 15,649,003 15,460,448 15,223,802 15,460,448 15,223,802
Total cost of 
inpatient services 117,528,542 124,027,492 129,995,166 97,955,878 103,218,503
Total cost of 
outpatient services 37,716,091 36,620,807 36,451,731 34,095,682 33,981,457
Total treatment 
costs 199,833,016 205,261,604 211,099,802 176,664,865 181,852,866
      
Medical resource Haloperidol Haloperidol Haloperidol Haloperidol Haloperidol 
Total cost of study 
medication 3,689,974 3,632,504 3,596,363 3,632,504 3,596,363
Total cost of other 
medications 30,884,712 31,130,841 31,312,363 31,130,841 31,312,363
Total cost of 
inpatient services 127,389,903 134,305,158 140,780,433 106,121,337 111,828,356
Total cost of 
outpatient services 40,508,846 39,251,527 39,035,591 36,465,297 36,312,806
Total treatment 
costs 202,473,435 208,320,030 214,724,750 177,349,978 183,049,888
      
Medical resource Difference Difference Difference Difference Difference 
Total cost of study 
medication 25,249,406 25,520,353 25,832,741 25,520,353 25,832,741
Total cost of other 
medications -15,235,709 -15,670,393 -16,088,561 -15,670,393 -16,088,561
Total cost of 
inpatient services -9,861,361 -10,277,666 -10,785,267 -8,165,459 -8,609,853
Total cost of 
outpatient services -2,792,754 -2,630,721 -2,583,860 -2,369,615 -2,331,349
Total treatment 
costs -2,640,419 -3,058,426 -3,624,947 -685,113 -1,197,022
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Figure 1. Total estimated direct costs per patient treated in the Private Sector in South 
Africa 
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Figure 2. Total estimated direct costs per patient treated in the Public Sector in South 
Africa 
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